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The two regulatory RI subunits of cAMP-dependent protein kinase (PKA) form 
interprotein disulfides during oxidative stress which is associated with kinase 
activation. PKA classical activation involves cAMP binding to the regulatory subunits 
causing release of catalytic subunits which phosphorylate substrates. Presence of 
substrate sensitises Type I PKA to cAMP. PKA subcellular localisation is determined 
by regulatory subunits binding A-kinase anchoring proteins (AKAPs), with RI 
oxidation enhancing their binding. I assessed whether thioredoxin (Trx) redox recycles 
disulfide RI back to its reduced state. In adult rat ventricular myocytes (ARVMs) pre-
treatment with diamide (inducing disulfide) potentiated isoprenaline-induced cardiac 
Troponin I phosphorylation. Inhibition of monoamine oxidase (MAO), which 
metabolises monoamines to generate hydrogen peroxide (H2O2), blocked monoamine-
induced RI oxidation. Echocardiography revealed that RICys17Ser „redox-dead‟ 
knock-in (KI) mouse (which I verified cannot form disulfides) hearts had larger left 
ventricles during diastole and systole and demonstrated systolic dysfunction. Cytosolic 
RI disulfide translocated to membrane and myofilament in isolated WT hearts in 
response to oxidant. Dual-specificity AKAP (D-AKAP) 1, D-AKAP2, AKAP220 and 
/  tubulin were not co-purified with WT or KI RI after cAMP-affinity capture. LC-
MS/MS showed that the PKA substrates, alpha-enolase and ChChd3 did co-purify, but 
the AKAPs associated with these (myomegalin and sphingosine kinase interacting 
protein, respectively) were not co-captured. Trx recycled disulfide RI back to its 
reduced state shown by an RI-dependent decrease in NADPH fluorescence and RI 
disulfide accumulation in ARVMs treated with Trx reductase inhibitors. In conclusion, 
whilst monoamines classically elevate cAMP to activate PKA, their degradation by 
MAO generates H2O2 which induces disulfide formation. Disulfide RI translocates 
from cytosol to membrane and myofilament in response to oxidant, but whether this is 
due to an increased affinity for AKAPs remains unclear. Disulfide-induced sensitisation 
of PKA to cAMP is consistent with the idea it increases RI affinity for AKAPs, so 
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HCl     hydrochloric acid 
HET     heterozygous 
His     histidine 
H2O     water 
H2O2     hydrogen peroxide 
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HRP     horse radish peroxidase 
IP     intraperitoneally 
IQGAP1    IQ domain GTPase-activating protein 1 
IU     international unit 
IVS     intraventricular septal width 
JNK     c-Jun N-terminal kinase 
KCl     potassium chloride 
KDa     kilodalton 
Kg     kilogram 
KH     K-homology 
KH2PO4    potassium dihydrogen sulphate 
KI     knock-in 
KO     knock-out 
L     litre 
LC-MS/MS    liquid chromatography-tandem mass spectrometry 
LD50      lethal dose, 50% 
LTCC     L-type Ca
2+
 channel 
LVAW    left ventricular anterolateral wall 
LVID     left ventricular internal dimension 
LVP     left ventricular pressure 
LVDP     left ventricular developed pressure 
LVPW     left ventricular posterior wall 
m     metre 
M     molar 
mAKAP    muscle-specific AKAP 
MAO     monoamine oxidase 
List of Abbreviations 
19 
 
MAPK     mitogen-activated protein kinase 
mg     milligram 
MgCl2     magnesium chloride 
MgSO4.7H2O    magnesium sulfate heptahydrate 
min     minutes 
ml     millilitre 
mm     millimetre 
mmHg     millimetres of mercury 
M-mode    motion-mode 
mM     millimolar 
Mn     manganese 
mRNA     messenger ribonucleic acid 
ms     millisecond 
m / s     metres per second 
MSK-1    mitogen- and stress-activated protein kinase 1 
Mw     molecular weight 
N     nitrogen 
Na
+     
sodium ion
 
NaCl     sodium chloride 
NAD
+ 
    oxidised nicotinamide adenine dinucleotide 
NADH     reduced nicotinamide adenine dinucleotide 
NaHCO2    sodium hydrogen carbonate 
NFκB nuclear factor kappa-light-chain-enhancer of 
activated B cells 
NHE-3     Na+ / H+ exchanger 3 
NHERF(-1/ -3)   Na+ / H+ exchanger regulatory co-factor(-1 /-3) 
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NKA     Na+ / K+ ATPase 
nM     nanomolar 
No.     number 
NO     nitric oxide 
NOS     nitric oxide synthase 
NOX     NADPH oxidase 
O / O2     oxygen 
O2
•- 
    superoxide 
OD     optical density 
OH
•
     hydroxyl radical 
ONOO
•
    peroxynitrite 
OPA1     optic atrophy 1 
P     phosphorus 
PAP7     PKA-associated protein 7 
PBR     peripheral-type benzodiazepine receptor 
PBS     phosphate buffered saline 
PBS-T     phosphate buffered saline with 0.1 % Tween-20 
PCR     polymerase chain reaction 
PDE     phosphodiesterase 
PDE4D3    phosphodiesterase 4D3 
PDGF     platelet-derived growth factor 
PDK     phosphoinositide-dependent protein kinase 
PI3K     phosphoinositide-3 kinase 
PKA     protein kinase A/ cAMP-dependent protein kinase 
PKa     acid dissociation constant 
PKC     protein kinase C 
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PKD     protein kinase D 
PKG     protein kinase G, cGMP-dependent protein kinase 
PLB     phospholamban 
PLC     phospholipase C 
PLM     phospholemman 
PP1     protein phosphatase 1 
PP2A     protein phosphatase 2A 
Pro     proline 
Prx     peroxiredoxin 
Pt     platinum 
PTP     protein-tyrosine phosphatase 
PVDF     polyvinylidene fluoride 
Rcf     relative centrifugal force 
Ref-1     redox factor 1 
RFU     relative fluorescence units 
RI     regulatory subunit I 
RNS     reactive nitrogen species 
ROS     reactive oxygen species 
rpm     revolutions per minute 
RVXF     arginine-valine-any residue-phenylalanine 
RyR     ryanodine receptor 
s     systolic 
S     sulphur 
S-AKAP84    spermatid A-kinase anchoring protein 84 
SDS     sodium dodecyl sulphate 
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SDS-PAGE sodium dodecyl sulfate polyacrylamide gel 
electrophoresis 
secs     seconds 
SeCys     selenocysteine 
SEM     standard error of the mean 
Ser     serine 
SERCA    sarcoplasmic reticulum Ca
2+
-ATPase 
SFRS17A    splicing factor arginine / Ser-rich 17A 
sGC     soluble guanylate cyclase 
SphK     sphingosine kinase 
SPHKAP    sphingosine kinase interacting protein 
SR     sarcoplasmic reticulum 
Srx     sulfiredoxin 
StAR     steroidogenesis acute regulatory protein 
TAE     tris acetate buffer with EDTA 
TEMED    tetramethylethylenediamine 
Thr     threonine 
TnC     troponin C 
TNF     tumour necrosis factor 
Trx     thioredoxin 
TrxR     thioredoxin reductase 
TXNIP    thioredoxin interacting protein 
Tyr     tyrosine 
U     units 
V     volts 
VLCD     very long-chain specific acyl-CoA dehydrogenase 
List of Abbreviations 
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WT     wild-type 
w / v     mass / volume 
XDH     xanthine dehydrogenase 
XO     xanthine oxidase 
Zn     zinc 
ºC     degrees celcius 
º     degrees 
µl     microlitre 
%     percent 
5-HT     5-hydroxytryptamine, serotonin  
8-Br-cAMP     8-bromoadenosine 3′,5′-cyclic monophosphate 
8-AEA-cAMP-agarose (2- aminoethylamino) adenosine- 3', 5'- cyclic 
monophosphate immobilized on agarose 
3-UTR     the three prime untranslated region 
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1 GENERAL INTRODUCTION 
1.1 Generation of reactive oxygen species and reactive nitrogen species  
Reactive oxygen species (ROS) is a catch-all term for a variety of free radicals (species 
with unpaired electrons) and molecules derived from molecular oxygen (O2) that are 
generated through a sequence of reduction reactions. As shown in Figure 1.1, one 
electron reduction of O2 generates superoxide (O2
•-
), which can then undergo further 
sequential one electron reduction steps to hydrogen peroxide (H2O2), the hydroxyl 
radical (OH
•
) and then water (H2O). ROS and species derived from nitric oxide (NO) 
can react to form secondary reactants known as reactive nitrogen species (RNS). For 
example, peroxynitrite (ONOO
•
) forms when NO and OH
•
 react. In addition, NO can be 














Figure 1.1 Generation of ROS and RNS.  
O2 can be sequentially reduced to superoxide (O2•-), hydrogen peroxide (H2O2), the 
hydroxyl radical (OH
•





 generation from O2 can be catalysed by multiple enzyme systems including 
NADPH oxidases (NOX), xanthine oxidase (XO) and the electron transport chain. 
Superoxide dismutase (SOD) catalyses reduction of O2
•- 
to H2O2 which can then be 
further reduced to OH
•
 during the Fenton reaction. H2O2 can also be decomposed to H2O 
by antioxidant enzymes such as glutathione peroxidase (Gpx) and catalase. OH
•
 reacts 
with nitric oxide (NO
•-
) to form peroxynitrite (ONOO
•
) or is reduced to the nitroxyl ion (NO).   
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ROS generation has been studied extensively in phagocytic cells where NADPH 
oxidase (phox) is activated during engulfment of microbes to generate the „oxidative 
burst‟. Phox consists of a membrane-bound flavocytochrome b558, which is a complex 
made up of a flavin and haem-binding glycoprotein (gp91phox) and another subunit 
p22phox, several cytosolic regulators (p47phox, p67phox and p40phox) and also a 
small GTPase, Rac1 or Rac2.[1] Upon stimulation, the cytosolic subunits translocate to 
the membrane and interact with membrane-associated subunits leading to the transfer of 
an electron from NADPH to molecular O2, forming O2
•-
 which can then dismutate to 
H2O2, as explained below.[2] Various homologues of gp91phox have been identified in 
humans, designated as the NADPH oxidase (NOX) family, although the precise 
composition of NOX enzymes and their physiological roles are still being determined. 
The family consists of NOX1, NOX2 (formerly termed gp91phox), NOX3, NOX4, 
NOX5 and the dual oxidases, DUOX1 and DUOX2, which have an N-terminal 
extracellular peroxidase-like domain and a gp91phox-like oxidase portion.[1] Platelet-
derived growth factor (PDGF) binds to the PDGF receptor causing autophosphorylation 
of tyrosine (Tyr) 740 and Tyr751 of the receptor and the binding and consequent 
activation of phosphoinositide 3-kinase (PI3K). The products of PI3K activity, 
phosphatidylinositol (3,4,5) trisphosphate and phosphatidylinositol 3,4-bisphosphate, 
bind to Pix, a guanine nucleotide exchange factor, which catalyses the exchange of 
guanosine diphosphate (GDP) for GTP, required for Rac activation and consequent 
NOX1 activation.[3] Epidermal growth factor also activates NOX1 via PI3K, Pix and 
Rac,[4] and generates H2O2.[5] Other stimuli for NOX activation include the pro-
inflammatory cytokines interleukin-1 or interferon- γ,[6] and the vasoconstrictor 
angiotensin II which causes increased O2
•-
 production in vascular smooth muscle 
associated with development of hypertension.[7]  
As already considered, H2O2 may be generated by dismutation of O2
•-
 involving its 
single electron reduction, which can occur spontaneously or through catalysis by 
superoxide dismutase (SOD), as shown below in reaction A. There are three 
mammalian isoforms of SOD; copper (Cu) / zinc (Zn) SOD (SOD1) located in the 
cytosol, manganese (Mn) SOD (SOD2) located in the mitochondria, and extracellular 
SOD (SOD3). In addition to producing H2O2, SOD enzymes also protect against O2
•-
 





 reacts rapidly with NO to form ONOO
•
, potentially attenuating NO 
bioavailability and signalling.[8] ONOO
•
 also reacts with select Tyr residues to generate 
nitrotyrosine, which may also mediate dysfunction. This may also explain why in part 
increased NOX activity (producing O2
•-
) is associated with impaired NO-mediated 
endothelial function, and increased risk of atherosclerosis, a condition in which the 
artery wall thickens and hardens due to accumulation of fatty materials.[9, 10] 
(A) 2 H
+
 + 2 O2
•-
           H2O2 + O2 
H2O2 can be further reduced to OH
•
 by the Fenton reaction,[11] (shown below in 
reaction B) which, for example in the mitochondria, can be catalysed by reduced 
transition metals present in the electron transport chain complexes (described later). The 





















             Fe
2+
 + O2 
Another major source of ROS is the xanthine oxidoreductase system, which consists of 
two forms, xanthine dehydrogenase (XDH) and xanthine oxidase (XO), which are 
interconvertible by proteolysis. Both forms degrade purines by metabolising 
hypoxanthine to xanthine and xanthine to uric acid. The difference is that XO only 
reduces O2, whereas XDH reduces O2 and also NAD
+
, having a higher affinity for 
NAD
+
. Oxidation of reduced XO yields H2O2 as well as O2
•-
.[12] Both increased XO 
activity and reduced SOD3 activity have been shown to contribute to increased 
oxidative stress and consequent endothelial dysfunction in patients with congestive 
heart failure.[13]  
O2
•-
 may be generated during aerobic respiration when single electrons leak from the 
mitochondrial electron transport chain and react with molecular O2. The mitochondrial 
electron transport chain couples the transfer of electrons from NADH or succinate to 
molecular O2 (reducing it to H2O) with the transfer of H
+
 ions across the membrane. 
The transmembrane proton gradient provides the energy required for phosphorylation of 
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adenosine diphosphate (ADP) to ATP by ATP synthase. As shown in Figure 1.2, the 
electron transport chain is made up of four electron-transporting complexes (I – IV) and 
one H
+
-translocating ATP synthetic complex. Complex I (the NADH ubiquinone 
oxidoreductase) and complex III (the ubiquinol-cytochrome c oxidoreductase) are 
considered to be the major sources of O2
•-
 in the chain,[14] as illustrated in Figure 1.2. 
Complex III releases O2
•-
 to both sides of the inner mitochondrial membrane, whereas 
complex I only releases O2
•-
 into the mitochondrial matrix.[15] The one electron transfer 
to molecular O2 to generate O2
•-
 is mediated by electron carriers present in the 
complexes of the electron transport chain. The electron carriers present in complex I are 
the flavin mononucleotide (FMN), the iron-sulfur (Fe-S) centers (N1a, N1b, N2, N3, 
N4, N5), and an unknown number of semiquinones. There is controversy about the 
source of O2
•-
 in complex I, with evidence for it being fully reduced FMN,[16, 17] Fe-S 
centres N1a,[18] or N2,[19] the ubisemiquinones which are spin-coupled with Fe-S 
centre N2,[20] or both FMN and a semiquinone.[21] The electron carriers in complex 
III are the Rieske Fe-S center, cytochromes bL, bH and c1 and the semiquinones at 
centers “i” and “o” and investigators agree that the source of O2
•-
 in complex III is the 












Figure 1.2 Generation of O2
•-
 at complex I and III of the mitochondrial electron 
transport chain (adapted from Schaffer et al.[24]). 
NADH is oxidised to NAD
+
 transferring its electrons to complex I followed by coenzyme Q 
(ubiquinone) forming ubiquinol (Q). Electron carriers in complex I can also transfer 
electrons to molecular O2 to form O2
•-
. Succinate may also be oxidised to generate 
electrons for complex II (via flavin adenine dinucleotide (FAD)) followed by ubiquinone. 
Electrons are removed from ubiquinol and transferred to complex III, another major 
source of O2
•-
, followed by cytochrome c (Cyt c). Electrons are then transferred to 
complex IV, which transfers the electrons to molecular O2 to form H2O. Whilst electrons 
are transferred along the chain, protons are pumped into the intermembrane space 
creating a proton gradient across the membrane. This gradient provides the energy to 
drive production of ATP by ATP synthase.   
 
 
H2O2 can be reduced to H2O and O2 by catalase (as shown in reaction D below), or it 
can be reduced to H2O by glutathione peroxidase (Gpx), a process fuelled by reduced 
glutathione (GSH) which is oxidised to GSSG, as shown in reaction E below. Catalase 
is localised in mitochondria and peroxisomes and Gpx is also localised in mitochondria 
as well as the cytosol suggesting that H2O2 generated in the mitochondria, for example, 
may be reduced in the mitochondria itself or diffuse across the membrane into the 
cytosol for reduction there.[14, 25, 26] Peroxiredoxins (Prxs) are also peroxidases that 
decompose H2O2 but they are reduced by thioredoxin (Trx) rather than GSH (as is the 
case for Gpx), which will be discussed in detail later.  
(D) 2 H2O2          H2O + O2 
(E) H2O2 + 2 GSH         2 H2O + GSSG 
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Catalase, SOD, Gpx and 2-Cys Prxs (explained later) are all examples of antioxidant 
enzymes which are able to compete with other oxidisable substrates to inhibit or slow 
the oxidation of these substrates. Non-enzymatic antioxidants include -tocopherol, -
carotene, GSH and ascorbate (vitamin C).[27] 
NO synthase (NOS) enzymes catalyse the oxidation of L-arginine to L-citrulline 
generating NO. NO biosynthesis also requires the reducing agent (6R)-5, 6, 7, 8 - 
tetrahydro-L-biopterin (BH4) and NADPH. Electrons are transferred from NADPH to 
the heme in the amino-terminal oxygenase domain of NOS via flavin adenine 
dinucleotide (FAD) and FMN in the carboxy-terminal reductase domain of the enzyme. 
There are three isoforms of NOS namely endothelial NOS (eNOS), inducible NOS 
(iNOS) or neuronal NOS (nNOS), all of which are dimeric. Healthy cardiac myocytes 
express eNOS and nNOS whilst iNOS expression is induced during inflammation in 
conditions such as heart failure. eNOS is the dominant form of NOS in the vasculature 
and NO generation can be stimulated by circulating factors such as acetylcholine, 
bradykinin, and adenosine or shear stress due to flowing blood. NO is important in 
activation of cGMP-dependent protein kinase (PKG) for endothelium-dependent 
vasodilation and blood pressure regulation (as explained later), and is also important in 
platelet activation, inflammation and thrombosis.[28-30] 
All three isoforms of NOS are susceptible to „uncoupling‟ where O2
•-
 is generated rather 
than NO. eNOS uncoupling can occur due to depletion of the cofactor BH4, as a result 
of its oxidation / degradation by ONOO
• 
to form cofactor-inactive pterins.[31] 
Uncoupling of eNOS can also result from oxidation of its Zn-thiolate complex by 
ONOO
•
. The Zn-thiolate complex stabilises the dimer interface of eNOS,[32] but 
interaction with ONOO
•
 releases Zn from the complex and promotes formation of 
disulfides between the subunits, reducing dimer stability and causing uncoupling of 
eNOS resulting in O2
•-
 production.[33] Other mechanisms for eNOS uncoupling are 
depleted L-arginine levels, or increased levels of the endogenous eNOS inhibitor 
asymmetric dimethyl-L-arginine.[34] S-glutathionylation (formation of a mixed 
disulfide with glutathione (GSH), explained later) of eNOS also uncouples the enzyme 
producing O2
•-
.[35] Uncoupled eNOS and therefore the consequential reduced NO 
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bioavailability results in endothelial dysfunction and is associated with conditions such 
as atherosclerosis,[28] and hypertension.[36]  
1.2 Redox signalling 
If ROS levels increase or levels of antioxidant „defences‟ such as catalase, Gpx, Trx or 
SOD decrease, redox homeostasis is no longer maintained and there is a shift towards 
pro-oxidising conditions commonly known as oxidative stress. At high levels, ROS can 
damage proteins,[37] nuclear and mitochondrial deoxyribonucleic acid (DNA) resulting 
in accelerated cell death and unregulated cell proliferation,[38] as well as lipids 
resulting in altered cell membrane permeability.[39] Oxidative stress has been widely 
implicated in ageing,[40] cancer,[41, 42] and cardiovascular diseases such as 
hypertension,[43] injury during ischaemia and reperfusion,[44] as well as progression to 
hypertrophy and heart failure.[45] However, it is now known that oxidants are also 
produced in healthy tissue, where controlled levels play a key role in redox signalling 
(summarised in Figure 1.3). 
Redox signalling may be defined as „a regulatory process where the signal is delivered 
by redox chemistry‟ and this signalling can induce functional responses such as 
increased expression of antioxidant enzymes or altered activity of antioxidants, such as 
Prx as discussed later to sustain redox homeostasis and protect the cell from oxidative 
damage.[27] Redox signalling can also play regulatory physiological roles other than 
protection against oxidative stress, as considered below when the redox regulation of 
3′,5′-cyclic monophosphate (cAMP)-dependent protein kinase (PKA) and cGMP-
dependent protein kinase (PKG) are discussed. These crucial regulatory roles of 
oxidants may help explain why antioxidant therapies have been generally unsuccessful 
or even dangerous in some cases,[37, 38] as these reducing molecules may intercept the 
oxidants and prevent them from „hitting‟ their regulatory targets and achieving their 
important homeostatic roles.  




Figure 1.3 Schematic showing consequences of low and high levels of oxidants. 
Low levels of oxidants play a key role in redox signalling which involves reversible 
oxidative protein modifications and can lead to altered protein activity. As the level of 
oxidants increases oxidative stress occurs and very high unregulated levels of oxidants 
can result in oxidative damage and irreversible protein modifications leading to ageing, 
disease and cell death.  
 
1.3 Oxidative modifications of Cysteine thiols 
Redox signalling can involve post-translational oxidative protein modifications 
allowing the transduction of an oxidant signal into a response (Figure 1.3). Methionine 
is an amino acid that can be reversibly oxidised to methionine sulfoxide by a range of 
ROS as well as be irreversibly oxidised to methionine sulfone.[39] Tyr can be nitrated 
by ONOO
•
 to form nitrotyrosine, with some evidence that this can be reversed by a 
denitrase.[40] As these amino acid modifications can be reversed, there may be 
potential for post-translational regulation.  
Cysteine (Cys) contains a thiol group (S-H) on its side chain which is potentially 
reactive with oxidants. Oxidants such as H2O2 only react efficiently with thiols when 
they are deprotonated to the thiolate anion (S
-
) state. The redox properties of a protein 
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thiol depend on its surrounding tertiary structure and its solvent environment. For 
example, the presence of adjacent positively charged amino acid lowers the acid 
dissociation constant (pKa) of the thiol because these basic residues deprotonate it to S
-
. 
These low pKa thiols are likely to be principal targets for H2O2 at physiological pH.[41] 
Likewise, an „acid-base‟ motif of flanking acidic (aspartic acid, glutamic acid) and basic 
(arginine, histidine (His), lysine) residues has been shown to be predictive of Cys thiols 
susceptible to S-nitrosylation (described below).[42] The side chain thiol of a typical 
Cys thiol has a pKa of 8.0 meaning at physiological pH (~7.3) essentially none of it is 
ionised to the S
-
 state and so it is not reactive with oxidants. However, when in a 
deprotonating environment the pKa of the thiol decreases. If the thiol pKa lowers to 7.3, 
50 % of it will be in the reactive state at physiological pH. The dependence of a Cys 
thiols reactivity on its pKa means that some thiols are oxidant reactive whilst indeed 
most Cys thiols are not. This provides a basis for selective oxidant signalling. In 
summary, most proteins do not have Cys residues that react efficiently with 
physiological concentrations of oxidants whereas certain redox-active proteins do.  
Figure 1.4 focuses on some examples of oxidative modifications of Cys thiols. H2O2 
reversibly reacts with S
-
 to form a sulfenic acid (Protein-SOH) which can then be 
further irreversibly oxidised to sulfinic acid (Protein-SOOH) and then sulfonic acid 
(Protein-SO2OH).[43] Under mild oxidising conditions, a sulfenic acid intermediate can 
react with a second reduced thiol to form a disulfide (Protein-S-S-Protein). This is 
reversible, and the disulfide can be either interprotein or intraprotein (i.e. between thiols 
in two proteins or between thiols in one protein respectively).[44] Similarly, mixed 
disulfides can form between a protein thiol and a thiol on a small Cys containing 
molecule such as GSH, which is known as S-glutathionylation.[43] Disulfide formation 
is important in preventing irreversible oxidation of thiols to the sulfinic / sulfonic acid 
forms. As already mentioned, the addition of the NO moiety to a Cys thiol produces an 
S-nitrosothiol (SNO) and this is known as S-nitrosylation (also referred to as S-
nitrosation). The NO moiety may be provided by NO itself, nitrosothiols, nitrite or 
metal NO complexes, and de-nitrosylation can be performed by Trx,[42] as discussed in 
Chapter 6. S-nitrosylated proteins, like sulfenates, can also react with additional thiols 
to yield disulfides. 






Figure 1.4 Examples of oxidative modifications of the Cys thiol.  
Cys thiols may be S-nitrosylated to an S-nitrosothiol by addition of the nitric oxide (NO) 
moiety, reversibly oxidised to sulfenic acid, irreversibly oxidised to sulfinic or sulfonic 
acids or react with other protein thiols such as glutathione (GSH, known as S-
glutathionylation) to form disulfides (intraprotein (between thiols of the same protein) or 
interprotein (between thiols of different proteins)). The unbroken line represents reversible 
modifications by Trx or glutaredoxin, whereas the broken line represents irreversible 
modifications. 
 
1.4 Reversal of oxidative Cys thiol modifications 
As already mentioned, some thiol modifications such as disulfides and S-nitrosothiols 
can be reversed enzymatically. Glutaredoxin (Grx) is able to reduce disulfides using two 
mechanisms (Figure 1.5). One mechanism uses the two Cys thiols in its active site, 
whereby one of the Cys thiols forms an interprotein disulfide with the oxidised substrate 
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disulfide in Grx (step 2). GSH then reduces this disulfide to form a mixed disulfide 
(step 3), which is then further reduced by GSH to form glutathione disulfide (GSSG) 
and regenerate reduced Grx (step 4). GSH is then regenerated by glutathione reductase 
using NADPH (step 5). The second mechanism for reduction of disulfides by Grx 
involves the thiol in the more N-terminal active site Cys of Grx being S-
glutathionylated and then reduced by GSH (steps 6 and 4).[45] Trx is a universal 
disulfide reductase that catalyses thiol-disulfide exchange reactions by a similar 
mechanism that will be discussed in more detail in Chapter 6. 
 
 
Figure 1.5 Mechanisms of protein disulfide reduction by Grx. 
(1) Grx forms an interprotein disulfide with the oxidised substrate protein. (2) This is 
attacked by the resolving Cys thiol to form an intraprotein disulfide in Grx and reduced 
substrate protein. (3) GSH then forms a mixed disulfide with Grx. (4) Another GSH 
reduces this disulfide to regenerate reduced Grx and form GSSG. (5) GSH is regenerated 
from GSSG by glutathione reductase using NADPH. (6) Grx can also reduce protein 
disulfides by using one of its active site Cys thiols and forming a mixed disulfide which 
can then be reduced by GSH (same as (4)).   
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1.5 Examples of proteins modified by Cys thiol oxidation 
Oxidant-reactive Cys thiols are found widely in many types of proteins including ion 
channels, signalling molecules and structural proteins, enabling their redox regulation. 
Numerous oxidation-sensitive proteins have been identified and some examples are 
shown in Table 1.1, which focuses specifically on signalling proteins that are regulated 





















Table 1.1. Table of example signalling proteins modified by thiol oxidation.  
The table shows the type of Cys thiol oxidative modification that occurs in the protein and 
functional consequences and references to support these.  
Protein Modification Result References 
2-Cys Prx sulfinic acid inactivation [46] 
MEKK1 S-glutathionylation inactivation [47] 
p38 interprotein disulfide p38phosphorylation [48] 




































PKA catalytic domain 

















































Yap1/Gpx3 interprotein / 
intraprotein disulfide 
Yap1 activation [70, 71] 
OxyR intraprotein disulfide activation [72-74] 
c-Jun S-glutathionylation inhibition [75, 76] 














inhibition of IKK activation  
inhibition of IKK 
inhibition of NFkB gene 
transcription 
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A number of signalling proteins have been identified as being responsive to H2O2 but 
the molecular mechanism has not always been clearly established (i.e. the specific post-
translational oxidative modification). A functional response is often not defined. For 
example, Yang et al.,[84] showed that H2O2 induced Akt activation, but there was no 
molecular insight as to how H2O2 did this; this being a common scenario. In contrast, 
the molecular structural basis for the redox regulation of some redox-regulated proteins, 
such as Prx, PKG and PKA are at least in part understood as discussed in more detail 
below. 
Prxs: Prx enzymes are ubiquitous thiol-containing Trx peroxidase antioxidant enzymes 
which reduce H2O2 to H2O. Mammals have three classes which differ in the number and 
location of their Cys residues: typical 2-Cys (PrxI - PrxIV), atypical 2-Cys (PrxV) or 1-
Cys Prxs (PrxVI),[46] but all isoforms contain a redox sensitive Cys which is termed 
the peroxidatic Cys.[85]  
The first step in the catalytic cycle (Figure 1.6) for all isoforms is the oxidation of the 
peroxidatic Cys thiol to a sulfenic acid by reacting with H2O2. Typical 2-Cys Prxs exist 
as homodimers,[85] and contain a conserved NH2-terminal Cys and a COOH-terminal 
Cys,[86] so following sulfenic acid formation, the resolving Cys thiol at the COOH-
terminal of the adjacent monomer of the homodimer reacts with the sulfenic acid 
intermediate to form an interprotein disulfide. This disulfide is stable and can be 
reduced by Trx. In contrast, atypical 2-Cys Prxs are monomeric and so intraprotein 
disulfide bonds form between Cys thiols within the same polypeptide, again via a 
sulfenic acid intermediate. 1-Cys Prxs only have the conserved peroxidatic Cys but no 
resolving protein thiols. Instead the sulfenic acid form is resolved by the thiol in 
GSH,[85] forming an S-glutathiolate, an adduct that is reduced by Grx. 
2-Cys Prxs can be inactivated by hyperoxidation of the peroxidatic Cys thiol to a 
sulfinic acid. For this hyperoxidation to occur, Prx must be turning over its catalytic 
cycle i.e. Trx must be present as well as H2O2. The Trx system may be required to 
expose or destabilise the Cys sulfenic acid for hyperoxidation by H2O2.[87] 2-Cys Prxs 
are believed to be more sensitive to hyperoxidation than other Prx classes because of 
interaction between the conserved YF and GGLG motifs. This interaction inhibits attack 
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of the Cys sulfenic acid by the resolving Cys thiol, slowing the rate of disulfide 
formation and increasing the probability of further oxidation by H2O2 to a Cys sulfinic 
acid.[85] Inactivation of 2-Cys Prxs by H2O2 allows accumulation of H2O2 and so H2O2-
mediated signalling.[46] 2-Cys Prxs therefore function as „flood gates‟ which, when 
active keep basal levels of H2O2 low, but when inactivated by increased levels of H2O2 
during oxidative stress, this enables potentiated H2O2-mediated signal transduction.[85] 
However, it is unclear why other peroxidases not inactivated by this hyperoxidation 
mechanism do not prevent the „gates‟ opening, providing an argument against the 
floodgate hypothesis.  
Cys sulfinic acid formation is generally considered to be irreversible in most proteins, 
but the activity of 2-Cys Prxs after inhibitory sulfinic acid formation specifically can be 
restored by an enzyme known as sulfiredoxin (Srx).[86] Srx takes the γ-phosphate of 
ATP and transfers it to Prx sulfinic acid.[46, 88, 89] Transfer of the phosphate to Prx 
leads to phosphorylation and formation of a sulfinic acid phosphoryl intermediate in 
Prx,[46, 88] which then forms an interprotein thiosulfinate intermediate with Cys99 of 
Srx,[90, 91] or thiols such as GSH.[88] This thiosulfinate is then reduced by GSH or 
Trx.[89] In mammals, sestrin 2, a member of a protein family whose expression is 
regulated by p53, has been identified as another enzyme that can reverse hyperoxidised 
PrxI.[92] Reversal of sulfinic acid formation allows the termination of H2O2-mediated 
signalling and restores peroxidase activity, lowering H2O2 levels and so „shuts-off‟ 
oxidant signalling.[86] This background information about the redox regulation of 2-
Cys Prx enzymes is potentially useful in understanding PKA RI. This is because RI 
is also an antiparallel homodimer that forms a double disulfide during oxidative stress, 
as discussed below. 





Figure 1.6 Oxidation of Prx and reduction of the sulfinic acid product by Srx 
(adapted from Jonsson et al. 2008,[89, 91]). 
The catalytic cycle (in blue) of typical 2-Cys Prxs involves oxidation of the thiol (SpH) of 
the peroxidatic Cys by H2O2 to a sulfenic acid (SpOH) intermediate. This intermediate is 
then resolved by the thiol (SRH) of a Cys on the adjacent monomer to form a disulfide 
bond which is reduced by Trx.[85] Some Prxs are sensitive to hyperoxidation by H2O2 and 
so the sulfenic acid intermediate is further oxidised to sulfinic acid (SpO2
-
, in green).[46, 
87] Srx is able to specifically target this and restore Prx activity. This process involves the 
transfer of a phosphate from ATP to Prx to form a sulfinic acid phosphoryl intermediate 
(Prx-SpO2PO3
2-
, in red).[46, 88, 89] This then forms a thiosulfinate bond with Srx,[90, 91] 
(in pink) or thiols such as GSH (in brown).[88] The complexes are then reduced by Trx or 
GSH forming the Prx sulfenic acid intermediate,[89] and the catalytic cycle can occur.    
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PKG: The classical mode of activation of PKG involves NO binding to the haem group 
of soluble guanylate cyclase (sGC) in smooth muscle, activating the kinase and 
increasing the conversion of GTP to cGMP.[93] The second messenger cGMP then 
binds to and allosterically activates PKG.[94] There are two types of PKG in 
mammalian cells; PKG I and PKG II. PKG I is highly expressed in smooth muscle as 
two isoforms (Iα and Iβ) that have identical catalytic and regulatory domains, but differ 
in their first ~100 amino acids.[95]
 
PKG I exists basally as a parallel aligned 75 kDa 
homodimer with each subunit containing a C-terminal catalytic domain and an N-
terminal regulatory domain. The subunits are held together by a leucine zipper in the 
regulatory domain and aligned PKG I molecules have Cys42 residues in close 
proximity.[96] Members of my research laboratory showed that H2O2 caused the 
formation of an interprotein disulfide linkage between the two Cys42 residues. PKG I 
disulfide formation directly activates PKG I increasing its affinity for substrates. This 
activation is independent of the classical NO-sGC-cGMP pathway, and contributed to 
H2O2-induced vasorelaxation of the coronary vasculature.[60] This oxidant-induced 
activation pathway also contributes to sGC-independent vasorelaxation induced by 
transnitrosylating NO donors.[97] In follow-up studies, a PKG I Cys42Ser „redox-
dead‟ KI mouse was found to be basally hypertensive,[98] and deficient in its 
vasodilatory blood pressure-lowering response to the thiol-oxidising drug 
nitroglycerin.[99] Disulfide formation represents a novel mechanism for direct cGMP-
independent PKG I activation. 
PKA: The structure and activity of PKA can also be regulated by oxidation, and is the 
primary focus of this thesis. After providing an overview of PKA structure and 
regulation, I will review current evidence as to its redox regulation. 
Regulatory subunit isoforms: PKA is a tetramer of two regulatory subunits and two 
catalytic subunits (Figure 1.7). There are two types of regulatory subunit; RI and RII 
and their presence defines Type I and Type II PKA respectively. There are also  and β 
isoforms of RI and RII encoded by different genes on different chromosomes. The open 
reading frames of RI and RI are 75 % identical in nucleotide sequence and both 
proteins are 380 amino acids long and are 82 % identical in amino acid sequence.[100]  











Figure 1.7 Model of the RII holoenzyme based on small angle X-ray scattering 
(adapted from Taylor 2005,[101]).  
All PKA holoenzymes consist of two catalytic subunits and two regulatory subunits. This 
figure also shows the dimerisation / docking (DD) domain important for dimerisation of the 
regulatory subunits and A-kinase anchoring protein (AKAP) binding, which determines 
PKA localisation e.g. allows PKA to anchor to membranes. 
 
Regulatory subunit structure: All isoforms of the regulatory subunit have the same 
domain organisation (Figure 1.8). They have two C-terminal cAMP-binding domains 
(A and B) which couple cAMP binding to kinase activation and a linker region which 
contains phosphorylation sites. They also have SH3 binding domains and a 
pseudosubstrate inhibitor region which binds to the active site of the catalytic subunit, 
preventing it from phosphorylating substrates. Type II PKA can be autophosphorylated 
in its inhibitor region whereas Type I PKA cannot as the phosphorylated serine (Ser) 
residue is replaced with alanine (Ala). The regulatory subunits also have an N-terminal 
dimerisation / docking (DD) domain which dimerises RI or RII, and also determines 
PKA localisation via its binding to A-kinase anchoring proteins (AKAPs), as discussed 





















Figure 1.8 Domain organisation of PKA regulatory subunit.  
It consists of a dimerisation / docking (DD) domain, which is important in dimerising the 
regulatory subunits and binding to A-kinase anchoring proteins (AKAPs) to determine 
PKA localisation, as well as a pseudosubstrate inhibitor site (IS) and cAMP-binding 
domains (A and B).  
 
The DD domain refers to residues 12 - 61 in RI, 14 - 62 in RIβ and 1 - 44 in RII/ β. 
The DD domain of RI (Figure 1.9) contains two Cys residues, RIβ contains three and 
there are none in the RII or β isoforms. I am primarily interested in RI because it 
forms a disulfide dimer during oxidative stress,[57] and is constitutively expressed in 
the heart, whereas RIβ is restricted to neural tissue,[100] and the alignment of the Cys 
residues doesn‟t allow for disulfide formation. Solution nuclear magnetic resonance 
revealed that the DD domain of both RII and RI is an X-type four helix bundle,[102] 
(as shown in Figure 1.9) where each subunit contains two helices (helix 1 and helix 2) 
separated by a turn.[103] As discussed later, each subunit contains two Cys residues 
(Cys16 and Cys37) which form disulfides during oxidative stress.[57] Dual-specificity 
AKAPs (D-AKAPs, explained in Chapter 5) bind at the region directly flanked by the 
two Cys residues, so as part of my PhD studies I assessed the logical possibility that 



















Figure 1.9 DD domain of RI.[104]  
The DD domain of both RII and RI is an X-type four helix bundle as each subunit 
contains two helices (helix 1 and helix 2) separated by a turn. Each subunit contains two 
Cys residues (Cys16 and Cys37) which form disulfides during oxidative stress. D-AKAPs 
bind at the region flanked by the Cys residues so it is possible that disulfide formation 
may modulate AKAP binding to RI. 
 
Classical mode of PKA activation: As shown in Figure 1.10, the classical mode of PKA 
activation involves ligands binding to GS-coupled receptors, e.g. catecholamines 
binding to β adrenoceptors. This causes the conversion of GDP to GTP which then 
activates adenylate cyclase which converts ATP to cAMP. cAMP binds to cAMP-
binding domain B of PKA regulatory subunits causing a conformational change that 
allows cAMP to access cAMP-binding domain A. cAMP binding to domain A induces 
dissociation of catalytic subunits which catalyse the transfer of a phosphates to Ser / 
threonine (Thr) residues of substrates.[105] PKA signalling continues until 
phosphodiesterases hydrolyse cAMP, the catalytic subunit is inhibited by protein kinase 
inhibitor peptide,[106] or phosphatases dephosphorylate PKA substrates to return their 
activity to basal. GS-coupled receptors, G-proteins and adenylate cyclase are also 
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compartmentalised to regulate where PKA signalling occurs. PKA itself is 
compartmentalised by binding to specific AKAPs, which help enable co-ordinated 
signalling by this kinase, explained in Chapter 5.  
 
Figure 1.10 Classical mode of PKA activation.  
GPCR activation e.g. catecholamine stimulation of the β1 adrenoceptor leads to 
conversion of GDP to GTP which activates adenylate cyclase to catalyse the conversion 
of ATP to cAMP. cAMP binds to the regulatory (R) subunits of the PKA tetramer, causing 
dissociation of the catalytic (C) subunits and phosphorylation of substrates. PKA 
signalling can be regulated by PDEs which break down cAMP, and phosphatases which 
dephosphorylate PKA substrates. 
 
PKA catalyses the phosphorylation of a number of proteins involved in regulating a 
highly diverse range of physiological processes. A prominent example is glycogen 
metabolism in the liver, whereby PKA is activated by glucagon causing it to 
phosphorylate and activate glycogen phosphorylase kinase. This then phosphorylates 
and activates glycogen phosphorylase, which phosphorylates glycogen resulting in its 
breakdown to yield glucose. PKA also phosphorylates and inhibits glycogen synthase 
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resulting in inhibited glycogen synthesis contributing to increased glucose levels. PKA 
is therefore important in maintaining glucose homeostasis.[107] PKA also plays a role 
in promoting cell survival,[108] or promoting apoptosis,[109] depending on the cell-
type. For example, in lymphoid cells, induction of the pro-apoptotic protein BimEL is a 
key event in cAMP-mediated apoptosis,[109] and the mechanism for this was shown to 
be PKA regulatory subunits binding to BimEL positioning it close to PKA catalytic 
subunits for catalysis of BimEL phosphorylation and therefore protection from 
proteosomal degradation.[110] Inhibition of apoptosis by PKA was observed in 
neuronal cells,[108] as well as endothelial cells during ischaemic late 
preconditioning.[111] Preconditioning is repeated intermittent short episodes of 
ischaemia that protects the myocardium against a subsequent longer otherwise injurious 
ischaemic insult and it is classed into early phase (lasting 2 - 3 hours) then late phase 
(lasting 2 - 3 days).[112] Phosphorylation of Akt (which then stimulates eNOS activity) 
by PKA and PI3K is important in protecting cells against ischaemia-induced cell death 
during late preconditioning.[111] My particular focus in this thesis, which will become 
evident later, is PKA‟s role in increasing the force and rate at which the heart beats, to 
elevate cardiac output. PKA achieves this by phosphorylating a number of Ca
2+
-
handling and sarcomeric proteins. These events and their redox regulation will be 
discussed in detail in Chapter 4. 
Catalytic subunit oxidation: The catalytic subunit of PKA contains Cys thiols at 
positions 199 and 343. Cys199 is located in the activation loop but is not involved in 
catalysis and is protected from modification when the catalytic subunit is bound to 
regulatory subunits. At physiological pH, Cys199 is more reactive than Cys343, which 
is located in the C-terminus outside the catalytic domain.[58] Diamide, a thiol selective 
oxidant that induces disulfides, inhibited PKA activity,[58, 106] but recombinant 
catalytic subunit mutants with a Cys199 to Ala mutation (Cys199Ala) were resistant to 
this diamide-induced inhibition, suggesting Cys199 oxidation was responsible for the 
inactivation. In wild-type (WT) catalytic subunits inhibition could be reversed by 
dithiothreitol (DTT) suggesting that a disulfide bond was involved, which was 
identified as an internal disulfide between Cys199 and Cys343 (Figure 1.11).[58]  
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In the presence of diamide and GSH, the catalytic subunit forms a disulfide with GSH 








Figure 1.11 PKA catalytic subunit.[113]  
Phosphorylation sites in the catalytic subunit are indicated by red circles (Ser338 and 
Thr197) and the Cys residues are indicated by two yellow circles. An intraprotein disulfide 
forms between Cys199 and Cys343, sensitising the catalytic subunit to 
dephosphorylation.   
 
The catalytic subunit contains regulatory phosphorylation sites; Thr197 (in the 
activation loop) and Ser338 (near the C-terminus). Phosphorylation of Thr197, most 
probably by  phosphoinositide-dependent protein kinase (PDK),[114, 115] is essential 
for optimal PKA activity involving the generation of a stable binding surface for 
RI.[113] Cys199Ala catalytic subunit mutants were inactivated by phosphatases, 
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whereas WTs were resistant to the inactivation. This demonstrates that Cys199, located 
proximal to the phosphate on Thr197, is involved in the resistance to 
dephosphorylation. Also, re-phosphorylation of PKA by PDK-1 was preferential when 
the catalytic subunit was reduced, suggesting that the redox state of PKA may 
determine its phosphorylation state.[113]      
Regulatory subunit oxidation: Initially, the RI dimer was thought to contain a 
constitutive double disulfide.[116] However, previous studies from my research 
laboratory showed, using diagonal electrophoresis with proteomic analysis, the 
disulfides only form in cellular RI in response to oxidants.[57] Disulfides also are not 
necessary for dimerisation.[117] However, RI prepared in vitro and kept in the 
absence of reducing agents does contain the disulfide due to air-mediated oxidation. RII 
also exists as a dimer but does not form disulfides consistent with the absence of Cys 
residues in the DD domain.  
Diamide induced a biphasic response to PKA agonists in HeLa cells. Up to 100 M 
diamide reversibly enhanced agonist-induced PKA activity, but this increase in activity 
did not involve increased adenylate cyclase activity (i.e. changes were independent of 
cAMP levels), or direct activation of PKA by diamide. The enhanced PKA activity was 
suggested to be a result of inactivation of a phosphatase that dephosphorylates PKA 
substrates.[106] H2O2 added exogenously or generated endogenously in adipocyte cell 
membranes via insulin stimulation caused Cys97 in the RII subunit and Cys199 in the 
catalytic subunit to form an interprotein disulfide. This modification prevented PKA 
activation upon cAMP addition and inhibited lipolysis.[59]  
Previously, work from my research laboratory demonstrated that in adult rat ventricular 
myocytes (ARVMs) and isolated rat hearts, elevated levels of H2O2 caused the two RI 
subunits of PKA to form interprotein disulfides,[57] (shown in Figure 1.12) as did the 
transnitrosylating NO donor nitrocysteine.[97] As shown in Figure 1.12, RI subunits 
lie antiparallel to each other in the dimeric complex,[118] so Cys17 of one monomer is 
positioned opposite Cys38 of the other monomer. I do not know for certain whether 
Cys17 is the sensing thiol (i.e. the thiol that is oxidised first by H2O2), but this is 
rational in the context of the peroxidatic Cys in 2-Cys Prxs (as described above, see 
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Figure 1.6). The sensing thiol of one subunit (Cys17 in Figure 1.12) is likely oxidised to 
a sulfenic acid intermediate, which is then attacked by the resolving Cys thiol of the 
other subunit (Cys38 in Figure 1.12) to form an interprotein disulfide dimer. If this 
occurs on both Cys thiols of each RI subunit, a double disulfide will form. 
Figure 1.12 Proposed mechanism for RIdisulfide formation
This schematic shows the DD domains of the RI subunits (residues 12 - 61) lying 
antiparallel to each other so Cys38 and Cys17 are opposite each other. H2O2 causes the 
sensing thiol (e.g. Cys17, S-H) to form a sulfenic acid intermediate (S-OH) which is then 
resolved by the opposite Cys (e.g. Cys38) thiol to form interprotein disulfides (S-S). 
  
Recombinant RI disulfide in vitro is highly resistant to reduction with concentrations 
of 50 mM DTT or more required for significant reduction. Furthermore, adding urea to 
unfold the protein does not lower the concentration of DTT required. This suggests that 
the disulfides are well shielded from the cell‟s reducing environment.[117] Also, 
mutating Tyr19 or His23, which are in close proximity to the disulfide, interferes with 
disulfide formation so these residues may help stabilise the disulfide.[119]  
In isolated rat hearts, disulfide dimerisation of RI induced translocation to the 
myofilament compartment and the nucleus, potentially positioning PKA closer to its 
substrates. RI disulfide formation seemed to activate PKA, independently of cAMP, as 
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demonstrated by increased phosphorylation of PKA substrates and increased myocyte 
contractility. However, these phosphorylation events were not blocked efficiently by the 
PKA inhibitor H89. Also, no „simple‟ in vitro demonstration of disulfide-activation of 
the kinase was provided.[57]  
Interestingly, neither intraprotein disulfide formation or S-glutathionylation of the 
catalytic subunit of PKA, nor interprotein disulfide formation between the regulatory 
subunits and catalytic subunits of PKA have been observed in cardiac tissue samples 
prepared by members of my research laboratory. These oxidative modifications have 
not been identified using multiple screening approaches for cardiac proteins susceptible 
to Cys-targeted oxidation.[120-123] These observations that seemingly contradict those 
in the literature,[58, 59] may be a result of different model systems. In addition, 
perhaps, RI oxidation serves to first activate the kinase, with subsequent catalytic 
subunit inactivation serving as a regulatory „off-switch‟. This would avoid chronic PKA 
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1.6 Primary aims of this thesis  
PKA RI disulfide formation during cardiovascular oxidative stress warrants further 
study as we do not fully understand the physiological significance of this process. 
Consequently the over-arching goal of my PhD studies is to increase our knowledge of 
this oxidation event. My work addresses some of the many remaining questions with 
regards to the biochemistry, cell biology and implications for cardiovascular physiology 
that ensue as a result of disulfide oxidation of PKA RI.  
Comparisons will be made between hearts from a novel Cys17Ser RI „redox-dead‟ 
knock-in (KI) mouse line which, in theory, will not form a disulfide in response to 
oxidative stress, and hearts from WT mice to determine the contribution of this 
oxidative event to function of PKA specifically and function of the heart in general. 
I plan to use the mutant KI mouse, biochemical and cell biological approaches to 
address the following, which will be discussed in more detail in subsequent chapters: 
1. Whether the Cys17Ser RI KI mouse, which is unable to form a disulfide, has a 
cardiac phenotype   
2. Whether RI disulfide formation synergises or counteracts the classical mode of 
PKA activation by cAMP 
3. Whether there are AKAPs that selectively bind disulfide-oxidised RI 
4. Whether the Trx system reverses RI disulfide back to the reduced thiol state 
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2 GENERAL METHODS & DEVELOPMENT OF 
METHODS 
2.1 GENERAL METHODS 
2.1.1 Reagents 
Unless stated otherwise, reagents were obtained from Sigma Aldrich. 
2.1.2 Generation of a novel ‘redox dead’ Cys17Ser RI knock-in (KI) mouse 
Mice constitutively expressing RI Cys17Ser (knock-in, KI) were generated for us on a 
pure C57BL/6 background by TaconicArtemis. A targeting vector was constructed, 
which involved polymerase chain reaction (PCR) amplification of the murine Prkar1 
region, introducing the Cys17Ser mutation into exon2 (the translation initiation codon) 
by site directed mutagenesis and inserting an FRT-flanked neomycin selection marker 
(to allow for selection of transfected embryonic stem cells) close to the mutation to 
favour homologous recombination. Then screening by Southern blot was carried out to 
identify if homologous recombination had occurred followed by validation of the 
positive clones. Embryonic stem cell transfection was then carried out followed by 
chimera generation. The chimeras were directly bred with an Flp deletor for the in-vivo 
deletion of the selection marker. As the embryonic stem cells always go germline, 
chimeras can be directly bred to the deletor in order to obtain germline transmission and 
selection marker deletion at the same time. 
2.1.3  Breeding of mice 
Mice were set up as heterozygous : heterozygous breeding pairs to generate wild-type 
(WT) or KI mice. Mice were bred at 6 - 7 weeks old and able to breed for ~6 months. 
Gestation lasted ~3 weeks and then the mice were weaned at 3 weeks old.  
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2.1.4 Genotyping of mice 
The genotype of each mouse was determined by isolating deoxyribonucleic acid (DNA) 
from a small piece of mouse ear tissue using the Qiagen DNAeasy tissue kit. PCR was 
then performed followed by DNA electrophoresis. 
Ear-clipping: Ears of mice were clipped to provide the tissue for DNA isolation and 
clipped in such a way that each mouse could be identified i.e. each mouse was 
numbered and then either right, left or right and left ear-clipped etc. The clipping was 
stored in the freezer until DNA isolation was carried out. 
DNA isolation: The standard protocol provided in the Qiagen DNAeasy tissue kit was 
followed. All the DNeasy mini spin columns, collection tubes and buffers (of an 
undisclosed proprietary composition) were provided in this kit (unless stated otherwise).  
The mouse ear clipping was placed in an Eppendorf tube. 180 µl ATL buffer and 20 µl 
proteinase K were added. The mixture was vortexed and incubated at 55 ºC on a shaker 
(1000 rpm) overnight. The next morning, the samples were removed from the incubator 
and vortexed. 400 µl buffer AL - ethanol (1:1 ratio, Fisher Scientific) mixture was 
added to each sample and vortexed. The mixture was then pipetted into the DNeasy 
mini spin column placed in a new collection tube and centrifuged at 10000 rpm for 1 
min. The flow-through was then discarded and the spin column was placed in a new 
collection tube. 500 µl buffer AW1 was then added to each sample and centrifuged at 
10000 rpm for 1 min. The flow-through was then discarded and the spin column placed 
in a new collection tube. 500 µl Buffer AW2 was then added and the sample centrifuged 
at 10000 rpm for 3 min. The flow-through was then discarded and the spin column 
placed into a 1.5 ml Eppendorf tube. 200 µl of buffer AE was then pipetted onto the 
DNeasy membrane and after 1 min incubation at room temperature was centrifuged at 
10000 rpm for 1 min. The DNA elute (flow-through) was now ready for PCR.  
PCR: The genotype of each mouse was identified by first using a PCR reaction 
developed by TaconicArtemis (Figure 2.1). The volume of each reagent required for one 
reaction (i.e. one sample) is shown in Table 2.1. A master-mix was made where these 
volumes (except that of DNA) were multiplied by the number of samples to be analysed 
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and added to an Eppendorf tube on ice. The master-mix was then split into the number 
of samples to be analysed (36 µl) and the DNA was added (4 µl). The samples were 
then placed in the thermal cycler (Eppendorf) and the program detailed in  selected and 
started. When the program was finished, the samples were held at 4 ºC.  
Reagent Volume for one PCR reaction (µl) 
5 x green GoTaq flexi buffer (Promega) 10 
25 mM MgCl2 (Promega) 4 
10 mM dNTPs (Promega) 1 
5 µM PKA primer 1 (Invitrogen) 
GCT TTC CTT TAC CAA GCA GG 
1 
5 µM PKA primer 2 (Invitrogen) 
GTC TGT GAG TCA CAC TGA CC 
1 
Taq (5 U / µl) (Promega) 0.4 
nucleotide free H2O 35.6 
DNA elute 4 
Table 2.1 Volumes of reagents required for one PCR reaction.  
First a master-mix was made which had all the reagents present except DNA and then 36 




Figure 2.1 Details of PCR reaction program.  
Temperatures and period the reagents were incubated at each temperature are shown. 
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DNA electrophoresis: After PCR, the genotype of the mouse was determined by 
carrying out DNA electrophoresis. 4 g agarose and 200 ml 1 x tris acetate buffer with 
ethylenediaminetetraacetic acid (EDTA) (TAE) (50 x TAE (1 l): 242 g Tris base, 57.1 
ml glacial acetic acid, 18.6 g EDTA) was heated in microwave for ~2 min to make a 5 
% agarose gel and then 5 µl of GelRed
TM
 Nucleic Acid Gel Stain (Biotium) (stains 
DNA) was added. The mixture was poured into the electrophoresis tank and allowed to 
set. 1 x TAE was then poured over the gel. The PCR products were loaded (15 µl of 
each) on the agarose gel and in the first lane the 100 bp DNA step ladder (Promega) was 
loaded (5 µl). The gel was run at 160 V for 30 min or until the samples had run far 
enough through the gel.  
Analysis of PCR products: The gel was removed from the tank and placed in the 
GelDock system which imaged and photographed the gel. Fragments were expected at 
385 bp for WT, 548 bp for KI and both 385 bp and 548 bp for heterozygous genotypes 




Figure 2.2 Agarose gel showing size of PCR products for identifying WT, KI and 
HET mice.  
The upper band (548 bp) represents knock-in (KI), the lower band (385 bp) represents 
wild-type (WT) and both bands represent a heterozygous (HET) mouse. 
 
2.1.5  Langendorff heart perfusion 
Mouse heart excision: WT and KI mice (14 - 16 weeks old) were anaesthetised with 
pentobarbital (45 mg / kg intraperitoneally (IP)) and anti-coagulated
 
with heparin (1000 
IU / kg IP). Hearts were rapidly excised and placed in cold Krebs-Henseleit bicarbonate 
buffer (K-HB) (described below).  
Heart cannulation: The aorta was located and cut just below the aortic arch. The heart 
was then „hung‟ by inserting a cannula (connected to the perfusion rig and made from a 
548bp (KI)
385bp (WT)
ladder WT HET WT KI WT HET
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20-gauge blunted needle) into the aorta, tying it on securely. This meant that the heart 
was retrogradely perfused. The pressure of the perfusion medium in the aorta closes the 
aortic valve so it flows into the ostium and the coronary vessels.  
Perfusion medium: Hearts were perfused with K-HB. This contained 118.5 mM NaCl, 
25 mM NaHCO3, 4.7 mM KCl, 1.2 mM MgSO4.7H2O, 1.2 mM KH2PO4, 11 mM 
glucose and 1.4 mM CaCl2. It was gassed with 95 % O2 and 5 % CO2 and maintained at 
37 ºC by the heated water jacket around the buffer reservoir (Figure 2.3). The K-HB 
was circulated around the system and passed through a heated glass coil to maintain the 
K-HB at 37 ºC. 
Parameters measured during perfusion: After the heart was cannulated, the coronary 
flow was increased (driven by a peristaltic pump) until a coronary
 
perfusion pressure 
(CPP) of 80 mmHg was reached. CPP was continuously measured by a pressure 
transducer and maintained at 80 mmHg throughout the perfusion period by the 
computer-driven peristaltic pump controller (Figure 2.3). After the CPP was set, the left 
atrium was removed from the heart and a small hole made so that a small balloon (made 
of cling-film, Figure 2.4A) could be inserted into the left ventricle (Figure 2.4B). This 
was then inflated by filling with water via a Hamilton syringe. The balloon was also 
connected to a pressure transducer so left ventricular pressure (LVP) could be measured 
(Figure 2.4C).  End diastolic pressure (EDP) and left ventricular developed pressure 
(LVDP) were also calculated. Hearts were paced at 600 bpm via a pacing wire 
connected to a pacing box. All parameters were recorded on the computer using 
LabChart 7 (ADInstruments). 
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Figure 2.3 Set-up for Langendorff mouse heart perfusion.  
Heated reservoirs were filled with K-HB which then flowed through a peristaltic pump (to 
control coronary flow rate) to the heart. The heart was immersed in a water bath to 
maintain its temperature at 37 ºC. The CPP was set to 80 mmHg (measured by pressure 
transducer) and a balloon was inserted into the left ventricle and inflated. As the heart 
contracts and relaxes, pressure changes are measured by the pressure transducer 
connected to the balloon and LVP was recorded on the computer. The heart was also 














Figure 2.4 Measuring LVP in the Langendorff mouse heart.  
(A) A small balloon was made out of cling-film (B) After the heart was cannulated and 
perfusion pressure set to 80 mmHg, the balloon was inserted into the left ventricle (C) 
The balloon was inflated (using Hamilton syringe) and LVP was recorded by a pressure 
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Stability period: Hearts were perfused with K-HB for a total period of 40 min. During 
the first 20 min adjustments were made when needed, such as inflating the balloon to 
maintain EDP. During the subsequent 20 min stabilisation period no adjustments were 
made and function should have been stable. This approach was used to make sure that 
WT and KI hearts were stable.  
Inclusion criteria: In initial training experiments I checked that I was able to perfuse 
hearts with similar criteria to those recommended by others,[124] (Figure 2.5). Thus 
after a 20 min stabilisation period, to be included in a study, individual hearts had to 
have a coronary flow of 1 - 5 ml / min, an EDP of 4 - 10 mmHg and an LVDP above 60 
mmHg. I achieved these criteria during my training before moving on to studies using 
WT and KI hearts. During training I also checked there was no „changing the line 
effect‟. By no changing the line effect I mean that when the line supplying the heart 
with K-HB is switched to another line also supplying the heart with K-HB there is no 
change in function (Figure 2.6). If there was a changing the line effect the coronary flow 
rate through each line and their temperatures were re-checked (they should be the 
same), and then if nothing seemed to resolve the problem, the perfusion setup was 
washed with 10 % hydrochloric acid (HCl) and then boiling water. Hearts were 
included in the study if they weren‟t „cycling‟ during the stability period. By „cycling‟ I 
mean a cyclical pattern of increasing and decreasing function as shown in Figure 2.7, 
where the LVDP, EDP and coronary flow change. Other laboratories,[124, 125] have 
also reported this in mouse hearts. The severity and duration of the cycling can vary and 
its occurrence is unpredictable. A possible reason for contractile cycling is a substrate 
deficiency as addition of pyruvate (a substrate for the heart to produce energy) to the K-
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  (A) 
    
(B) 
     
  (C) 
     
  (D) 
 
Figure 2.5 Stability of Langendorff-perfused C57BL/6 mouse hearts over a 40 min 
period.   
(A) Adjustments, such as balloon inflation, were only made during the first 20 min of 
aerobic perfusion after which no adjustments were made; the hearts must stabilise. (B) 
Graph of average coronary flow during the 40 min perfusion period (n=9 ± SEM) (C) 
Graph of average LVDP (D) Graph shows average EDP. In my hands, during the stability 
period, coronary flow was 3 - 4 ml / min, LVDP was 60 - 80 mmHg and EDP was 6 - 9 
mmHg and these are all within the recommended inclusion criteria. 






































































Figure 2.6 ‘Changing the line effect’.  
Hearts were perfused with K-HB for 40 min and then the line was changed so that the 
heart was perfused with K-HB from a different reservoir. LabChart traced LVP during the 
stability period and then after the line was changed. (A) Changing the line has no effect 
on LVP (B) Changing the line caused a decrease in LVP. This must be rectified before 






























Figure 2.7 ‘Cycling’ in the Langendorff-perfused mouse heart.  
LabChart traced LVP, coronary perfusion pressure (CPP), coronary flow, heart rate, EDP 
and LVDP over 40 min in the Langendorff-perfused heart. This representative part of a 
trace shows that coronary flow, EDP and LVDP are all increasing then decreasing again 
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2.1.6 Tissue homogenisation 
Organs such as heart (after excision or Langendorff perfusion studies) or other tissues 
were stored in liquid nitrogen until subsequent analysis. Typically it was weighed and 
then 10 ml of homogenisation buffer was added per g tissue. The homogenisation buffer 
was 100 mM Tris-HCl pH 7.4 with 100 mM maleimide, 200 µM 
phenylmethanesulfonylfluoride (PMSF, a protease inhibitor), phosphatase inhibitor 
cocktail 2 (1:100) and 100 µM EDTA. Tissue was homogenised on ice using a Polytron 
grinder until all tissue was fully homogenious. The homogenate was then added to an 
equal volume of non-reducing SDS sample buffer (100 mM Tris HCl pH 6.8, 4 % SDS, 
20 % glycerol, bromophenol blue) with 100 mM maleimide or reducing SDS sample 
buffer (i.e. supplemented with 5 % β-mercaptoethanol).  
2.1.7 SDS-polyacrylamide gel electrophoresis (PAGE)  
SDS polyacrylamide gels were made with a stacking gel on top of a resolving gel (see 
Table 2.2). The volume of acrylamide was adjusted according to the percentage gel 
required. For proteins of a low molecular weight a higher percentage resolving gel was 
used. Samples were centrifuged at 25000 rcf for 2 min before loading. Unless stated 
otherwise, 10 μl of each sample was loaded into the wells of the gel.  The gels were 
placed into two gel or four gel electrophoresis tanks (BioRad) filled with 1 x running 
buffer (10 x running buffer (1 l): 30 g tris base, 144 g glycine) with 0.1 % SDS, and run 
at a constant voltage of 180 - 210 V until the protein had run off the gel (shown by the 
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 5 % resolving 
gel (ml) 
10 % resolving 
gel (ml) 




30 % acrylamide 1.67 3.33 5 0.9 
Water 4.33 2.67 1 4 
TEMED 0.01 0.01 0.01 0.01 
10 % SDS (w / v) in 
water 
0.1 0.1 0.1 0.1 
1 M Tris HCl, pH 8.8 3.8 3.8 3.8 - 
10 % (w / v) APS in 
water 
0.09 0.09 0.09 0.07 
1 M Tris HCl, pH 6.8 - - - 0.72 
 
Table 2.2. Composition of different percentage resolving gels and the stacking gel.  
The volume of acrylamide and water in the resolving gel was adjusted for different 
percentage gels but the composition of the stacking gel did not change.   
 
2.1.8 Western blotting 
PVDF membranes were soaked in methanol for 5 min followed by transfer buffer (100 
ml transfer buffer : 10 ml 10 x running buffer, 0.1 ml 10 % SDS, 20 ml methanol, make 
up to 100 ml with water). The protein was then transferred from the gel to the 
membrane using a semi-dry transfer blotter (BioRad). This was achieved by making a 
„sandwich‟ as shown in Figure 2.8. Transfer was for 38 min at a constant voltage of 10 
V and 0.25 A per gel being transferred in the blotter. The membrane will now be 
referred to as a blot. 
 




Figure 2.8 Western blotting set-up.  
To transfer protein from the gel to the membrane after SDS-PAGE, a ‘sandwich’ is made 
where six sheets of blotting paper soaked in transfer buffer are placed on the anode of 
the blotter, the membrane soaked in transfer buffer is placed on top of this then the gel is 
placed on top of the membrane. Another six sheets of blotting paper soaked in transfer 
buffer are placed on top of the gel. Air bubbles are rolled out of the sandwich. Finally, the 
lid (cathode) coated in transfer buffer is placed on the sandwich and the voltage set at 10 




Blots were typically blocked overnight at 4 ºC on a shaker in 5 % milk in PBS with 0.1 
% Tween-20 (PBS-T). The blot was then incubated with 10 ml primary antibody 
(diluted in 5 % milk in PBS-T), washed for 1 hour (four 15 min washes) in PBS-T and 
then incubated with horse radish peroxidase (HRP)-linked secondary antibody (1:1000 
in 5 % milk in PBS-T, 10 ml) for 1 hour, followed by another wash for 1 hour. Details 
of the primary and secondary antibodies will be described in the specific methods 
section for each chapter. 
2.1.10 Enhanced chemiluminescence 
Proteins were visualised by incubating the blots with enhanced chemiluminescence 
reagent (GE Healthcare) for 1 min, placing them in a cassette and then, in a dark room, 
exposing hyperfilm to them.     




The film was scanned and the maximum optical density (OD) of each band on the film 
was calculated using Gel Pro-Analyzer 3.1.  
2.1.12 Coomassie Brilliant Blue staining of proteins on the PVDF membrane 
After the proteins were visualised on the blot and the film was labelled, the blot was 
washed in de-ionised water and then immersed in Coomassie Brilliant Blue stain (0.2 % 
Coomassie Brilliant Blue R-250, 7.5 % acetic acid, 50 % ethanol) for 5 min on a shaker. 
This stains all protein bands on the blot. The Coomassie Blue was replaced with de-
staining solution (50 % methanol, 1 % acetic acid), which was changed regularly. The 
blot was de-stained until the proteins were more visible. This procedure was performed 
to check that protein transfer from the gel to blot was efficient and also to check loading 
was similar between lanes, so an accurate comparison could be made between different 
samples loaded on the same gel.   
2.1.13 Heart fractionation 
Protocol: 500 μl of heart homogenate (without SDS sample buffer present) was added 
to an Eppendorf tube, and centrifuged at 25000 rcf for 5 min at 4 °C. The supernatant 
(cytosol-enriched fraction) was then removed and added to 500 μl non-reducing (with 
100 mM maleimide) or reducing (with 5 % β-mercaptoethanol) SDS sample buffer. The 
pellet was then re-suspended in 500 μl homogenisation buffer with 1 % Triton X-100 
and centrifuged at 25000 rcf for 5 min at 4 °C. The supernatant (membrane-enriched 
fraction) was removed and added to 500 μl non-reducing (with 100 mM maleimide) or 
reducing (with 5 % β-mercaptoethanol) SDS sample buffer. The pellet (myofilament-
enriched fraction) was re-suspended in 1000 μl non-reducing (with 100 mM maleimide) 
or reducing (with 5 % β-mercaptoethanol) SDS sample buffer. 
Checking for markers of the heart fractions: To assess whether the fractionation 
protocol was successful, WT hearts were Langendorff-perfused for 45 min with K-HB 
and homogenised and fractionated (as above). SDS-PAGE and Western blotting were 
carried out. Blots were probed for glyceraldehyde 3-phosphate dehydrogenase 
Chapter 2: General Methods & Development of Methods  
66 
 
(GAPDH, marker of cytosol), the 1 subunit of the Na+/K+ ATPase (marker of 
membrane) and telethonin (marker of myofilament) as shown in Table 2.3.  
 
















6F Developmental Studies 
Hybridoma Bank 









mouse 1:1000 overnight at 4 
ºC  
Table 2.3. Antibodies to markers of fractions of heart.  




 ATPase -1 subunit is a marker of 
membrane and telethonin is a marker of myofilament. The table shows the company from 
which the antibody was purchased and the product code, the species the antibody was 
raised in and so the secondary antibody to be used and also the concentration the 
antibody was used at (in 5 % milk in PBS-T) and for how long. 
 
  





ATPase was only present in the membrane and telethonin was only present in 
the myofilament. Therefore the fractionation protocol successfully generated cytosol-, 












Figure 2.9 Confirmation that the heart fractionation protocol was successful.  
WT hearts (n=2) were Langendorff-perfused for 45 min and then homogenised. The 
homogenate was fractionated in cytosol-, membrane- and myofilament-enriched fractions. 










 ATPase 1 was only present in the membrane-enriched fraction and 
telethonin was only present in the myofilament-enriched fraction, as expected, confirming 
that the protocol was successful. 
 
 
2.1.14 Isolation of adult rat ventricular myocytes (ARVMs) 
Adult rat ventricular myocytes (ARVMs) were isolated from adult male Wistar rats by 
Dr. Shiney Reji. In this protocol, hearts were excised, perfused for 5 min with modified 
K-HB solution (Solution A; 130 mM NaCl, 0.4 mM NaH2PO4, 0.75 mM CaCl2, 4.2 mM 
2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid (HEPES), 1.4 mM MgCl, 220 
mM taurine, 4.5 mM KCl, 10 mM creatine and 10 mM glucose, pH 7.3, 37 ºC) and then 
perfused for 4 min with Ca
2+
-free solution A containing 100 µM ethylene glycol tetra 
acetic acid (EGTA). The heart was then perfused for 8 min with solution A containing 
100 µM CaCl2 and 1 mg / ml collagenase. The ventricles were cut into small pieces and 
incubated in 10 ml collagenase solution (gassed with 100 % O2, 37 ºC) for ~ 10 min 
until the digestion was complete. This mixture was then filtered through nylon gauze to 
separate isolated ARVMs from undigested ventricular tissue. The filtrate was then 
allowed to settle for 10 min. The pellet was then re-suspended in 500 µM Ca
2+
 with 1 % 
bovine serum albumin (BSA). ARVMs were again left to settle and the supernatant 
replaced with 30 ml solution A containing 1 mM CaCl2.  
Freshly isolated ARVMs: After the above procedure, ARVMs were left to settle at 
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divided so each aliquot contained ~2 % of the isolation in a 500 µl total volume. After 
treatment, ARVMs were centrifuged at 1000 g for 0.5 min, the supernatant was 
removed and the pellet was re-suspended in 250 μl of SDS sample buffer containing 
100 mM maleimide. 
Overnight-cultured ARVMs: After isolation, ARVMs were left to stabilise at room 
temperature for 30 min before being washed in 50 ml modified M199 containing 100 IU 
/ ml penicillin / streptomycin, 5 mM taurine, 2 mM creatine and 2 mM carnitine. The 
ARVMs were again left to settle before re-suspension in fresh modified M199 
(approximately 25 ml of modified M199 was added to the pellet from ~50 % of a rat 
heart). Laminin (from Engelbreth-Holm-Swarm murine sarcoma basement membrane, 
Sigma, diluted 15 µg / ml in sterile PBS) was added to each well of the culture plate (1 
ml / well for a twelve well plate and 2 ml / well for a six well plate) and left for 1 hour. 
The laminin was then removed and the cell suspension was pipetted into each well (1 ml 
/ well for a twelve well plate or 2 ml / well for a six well plate). The ARVMs were 
incubated at 37 ºC and in 5 % CO2 for 1.5 hours. After this time, the M199 medium was 
removed, to remove any non-adherent ARVMs, and replaced with fresh modified 
M199. The ARVMs were incubated at 37 ºC and in 5 % CO2 overnight before treatment 
studies the following day.   
2.1.15 Statistics 
Mean values are expressed ± SEM. Statistical analyses were carried out using GraphPad 
Prism 5. Unless stated otherwise, differences between two groups were analysed by a T-
test. Differences between three or more groups were analysed using an analysis of 
variance (ANOVA) followed by a T-test. Differences were considered statistically 
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2.2 DEVELOPMENT OF METHODS 
During the studies described in this thesis a number of methodological issues hampered 
my progress. There were significant early issues with identifying an antibody that 
detects both redox states of RI, as well as problems detecting reduced monomeric RI 
after storing samples in the freezer and in ARVMs after overnight culture. The 
experiments carried out to troubleshoot, better-define and overcome these 
methodological issues are described below as well as the results and conclusions. 
2.2.1 Screening for an antibody that detects both redox states of PKA RI 
The PKA RI antibody (Calbiochem) Brennan et al.,[57] used to assess RI disulfide 
formation is no longer available. Therefore, my initial aim was to find an alternative 
antibody that detects both redox states of PKA RI. Previous studies investigating the 
redox regulation of PKG I made us aware that the oxidation state can markedly 
influence the affinity of antibodies. For example, antibodies to PKG I selectively bind 
the reduced form, and others the oxidised form.[126] 
Methods: Freshly isolated ARVMs were left untreated or treated with 1, 100 or 1000 
µM H2O2 for 5 min. Samples were then prepared in non-reducing SDS sample buffer 
containing 100 mM maleimide. SDS-PAGE and Western blotting were carried out and 
then the blots were incubated with the primary antibodies listed in Table 2.4 at the 
concentrations and for the periods stated. The blots were then incubated with an HRP-
conjugated secondary antibody appropriate for the species the primary antibody 
originated from (also listed in Table 2.4) and antibody binding was visualised as 









Table 2.4. Details of anti-PKA RI antibodies screened to identify an antibody that 
detects both redox states of RI
This table shows the company from which each antibody was purchased, its purchase 
code, the species it was raised in (and so the secondary antibody to be used), the 
concentration the antibody was used at and the incubation period. The incubation was at 
room temperature except for overnight incubation, which was at 4 ºC. 
 
 
Results: Figure 2.10 shows that some antibodies simply failed to detect any protein, 
namely Santa Cruz sc-28893 and Santa Cruz sc-18800, and another antibody (Abcam 
ab38936) detected a non-specific band at too high a molecular weight to be disulfide 
dimeric RISome antibodies detected a decrease in monomer with increasing H2O2 
concentration but without a corresponding increase in the anticipated disulfide dimer 
(BD Transduction laboratories 610610, Santa Cruz sc-81641, Biomol International SA-
Antibody name Code Company Species Conc. Incubation time 
PKA I/β reg (H-
90) 
sc-28893 Santa Cruz 
Biotechnology 
rabbit 1:1000 1 hour 
PKA RI 610610 BD Transduction 
Laboratories 
mouse 1:500 overnight 
PKA I reg 
(3546c2a) 
sc-81641 Santa Cruz 
Biotechnology 
mouse 1:1000 3 hours 
PKA RI ab38936 Abcam rabbit 1:1000 3 hours 
PKA RI ab65013 Abcam rabbit 1:1000 overnight 
PKA RI subunit SA-285 Biomol International chicken 1:1000 overnight 
PKA I reg (C-14) sc-18800 Santa Cruz 
Biotechnology 





610165 BD Transduction 
Laboratories 
mouse 1:5000 1 hour 
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285). There was no detectable change in the monomeric RI signal with H2O2 treatment 
for the antibody from Abcam (ab65013), consistent with this not detecting PKA RI. 
However, eventually an antibody (BD Transduction Laboratories 610165) was 
identified that clearly detected both redox states of RI and showed a marked loss of 
monomer and concomitant increase in disulfide dimer with increasing H2O2 
concentration. This was used in subsequent studies monitoring the thiol-disulfide redox 















Figure 2.10 Antibody detection of PKA RI disulfide dimer formation.  
Freshly isolated ARVMs were treated with 0 - 1000 μM H2O2 for 5 min. SDS-PAGE was 
then carried out followed by Western blotting, probing blots with the antibodies described 
above. The PKA R antibody from BD Transduction Laboratories (610165) was the only 
one that detected loss of RI monomer with reciprocal formation of RI disulfide dimer in 
response to treatment with increasing concentration of H2O2 and so was the chosen 
antibody for use in subsequent studies.  
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Conclusions: Commercially available RI antibodies vary immensely in their ability to 
detect both redox states of RI. This may be because oxidative modification of RI 
alters the epitope and so the antibody may not bind oxidised RI protein with the same 
affinity as when it was in the reduced state. Antibody 610165 (BD Transduction 
Laboratories) was primarily used in subsequent studies, unless stated otherwise, when a 
Western blot was probed for PKA RI. 
2.2.2 Effect of sample storage time on detection of RI monomer and dimer 
It is often necessary to re-run samples, and is important that the redox state of RI 
remains the same, or is unaltered during storage which involved freezing at 20 ºC.  
Methods: Samples were prepared in non-reducing SDS sample buffer (with 100 mM 
maleimide) and SDS-PAGE and Western blotting were carried out. The blots were 
probed for PKA RI. The same samples were stored in the freezer (for ~1 or ~2 
months) and then re-analysed using the same procedure. The samples analysed in this 
way were (1) homogenate of hearts excised from C57BL/6 mice and Langendorff-
perfused with K-HB for 45 min or K-HB for 40 min followed by 50 or 100 µM H2O2 
for 5 min or (2) freshly isolated ARVMs left untreated or treated with 0.5 mM diamide 
for 5 min. All methods are described in more detail in section 2.1.  
Results: Figure 2.11A shows that there was both RI monomer and disulfide dimer 
present basally in control hearts; in most cases more monomer than dimer. The 
percentage disulfide increased in hearts when they were perfused with H2O2 (Figure 
2.11Ai). However, after storage of the samples in the freezer for just under a month, the 
blot (Figure 2.11Aii) had to be exposed for a longer time to get the same intensity 
disulfide dimer signal as in Figure 2.11Ai, and even at this higher exposure, there was 
very little reduced RI monomer detected compared to Figure 2.11Ai. Figure 2.11B 
shows that approximately equal amounts of RI monomer and disulfide dimer were 
present in control ARVMs. Treatment with 0.5 mM diamide caused the entire RI pool 
to become disulfide dimeric. However, when the same samples were run approximately 
two months later, for similar signal intensity for RI disulfide dimer, no reduced 
monomer was detected. Even when the exposure time was increased, the signal for RI 
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monomer was blurred and less intense compared to when the samples were run two 
months before. Clearly, storing the sample at -20 ºC for several weeks results in loss of 




























Figure 2.11 Detection of PKA RI redox state in samples after storage in the 
freezer.  
(A) C57BL/6 hearts were perfused for 45 min with K-HB or 40 min with K-HB then 5 min 
H2O2 (50 or 100 μM) (i) Western blot of the samples run on a gel the same day the 
samples were prepared probed for PKA RI (ii) Western blot of the same samples run on 
a gel a month later (B) Freshly isolated ARVMs were left untreated or treated with 0.5 mM 
diamide for 5 min. Top blot shows PKA RI in samples run on a gel on the same day the 
samples were prepared and middle and bottom blots are for the same samples run on a 
gel ~ two months later and film was exposed for 1 min or 5 min. Less RI monomer was 
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Conclusions: The detection of reduced monomeric RI redox state was hampered by 
time-dependent changes in the sample during storage in the freezer. This was not 
because of oxidation to the disulfide dimer form as there was still a difference in dimer 
abundance between untreated control and oxidant-treated samples after time in storage. 
It also was not sample-type specific, as this reduced detection of monomeric RI was 
demonstrated in both heart homogenate and freshly isolated ARVM samples. A possible 
explanation is that the RI antibody (BD Transduction Labs 610165) may have a higher 
affinity for disulfide dimeric RI than reduced monomeric RI and this may be 
exacerbated by the presence of maleimide in the SDS sample buffer. Time in storage 
may allow maleimide in the SDS sample buffer to react with the RI thiols and the 
antibody may not detect the alkylated monomer as well as the non-alkylated monomer. 
Due to this finding, samples were typically analysed within a few days of preparation. 
2.2.3 Effect of overnight culture on RI disulfide in ARVMs 
RI redox state in freshly isolated ARVMs and overnight-cultured ARVMs 
Methods: ARVMs were isolated and aliquoted into two groups. One group was 
cultured overnight as described in section 2.1, and the other left for 2 hours before 
experimental treatments and were considered „freshly‟ isolated cells. ARVMs in both 
groups were left untreated or treated with 0.5 mM diamide for 5 min. Samples were 
then prepared by adding non-reducing sample buffer containing 100 mM maleimide. 
SDS-PAGE and Western blotting were carried out as described in 2.1. Blots were 
probed for PKA RI.  
Results: Figure 2.12 shows a clear difference in redox state of RI between overnight-
cultured and freshly isolated ARVMs. As expected, in untreated freshly isolated 
ARVMs there was approximately equal abundance of RI monomer and disulfide 
dimer present. 0.5 mM diamide caused the entire pool of RI to shift to the disulfide 
dimer form. However, unexpectedly, in untreated control overnight-cultured ARVMs 
there was only RI disulfide dimer present; no reduced monomer. 0.5 mM diamide 
increased the signal for disulfide dimeric RI but as there was no monomeric RI 
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present in overnight-cultured control ARVMs suggests an increase in RI protein 
abundance. This blot clearly illustrates that culturing ARVMs overnight causes a loss of 






Figure 2.12 PKA RI in overnight-cultured and freshly isolated ARVMs.  
ARVMs were left untreated or treated with 0.5 mM diamide for 5 min. SDS-PAGE and 
Western blotting were carried out and blots were probed for PKA RI. RI monomer was 
absent in control overnight-cultured ARVMs unlike in control freshly isolated ARVMs, 
which had equal amounts of RI monomer and disulfide dimer.  
 
 
Conclusions: Reduced RI monomer was detected in freshly isolated ARVMs but not 
in overnight-cultured ARVMs. An increase in RI disulfide in response to oxidant 
treatment was still observed in overnight-cultured ARVMs, similar to in freshly isolated 
ARVMs, suggesting an increase in RI protein expression in overnight-cultured 
ARVMs. This de novo protein synthesis is difficult to explain and has not been 
observed in other model systems. After further investigation, the „changing the medium‟ 
step in the culture protocol appeared to cause the complete loss of reduced monomer in 
overnight-cultured ARVMs and an associated decrease in total RI protein. Expression 
of the kinase PKG I has been shown to be suppressed in cultured vascular smooth 
muscle cells resulting in a dedifferentiated phenotype.[127] Alternatively, perhaps RI 
is exiting the cell so total RI protein decreases. There is evidence that cells can secrete 
PKA into the extracellular space.[49] Maleimide in the sample buffer, as discussed with 
time in storage, is not the reason why I do not observe the monomeric form of RI in 
ARVMs cultured overnight as all samples were analysed within 24 hours of preparation. 
Another possible explanation is that RI disulfide dimerisation may be important in 
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adhesion of ARVMs to the laminin coated plate so non-adhered cells (which have RI 
present as monomer) are removed when the culture medium is changed, leaving RI 
disulfide dimer only present in adherent cells. Another explanation may be anoikis, 
which is programmed cell death induced when anchorage-dependent cells detach from 
the extracellular matrix. When the culture medium is changed the cells may detach and 
RI may dimerise and then the cells may die.  
The explanation for absence of monomer is complicated and could be a combination of 
the factors above. A solution to this issue is to use another cell type or using freshly 
isolated ARVMs for experiments, which was the solution of choice in my studies in this 
thesis. Examples highlighting this problem of absence of RImonomer in overnight-
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3 INITIAL CARDIAC CHARACTERISATION OF A 
NOVEL PKA RI KNOCK-IN MOUSE 
3.1 Introduction 
RI homozygous null mutant embryos have developmental abnormalities and so die 
early in embryogenesis. They have increased basal PKA activity due to lack of 
regulatory inhibition of the catalytic subunit, but can be partially rescued by deletion of 
the  isoform of the catalytic subunit (C).[128] In RI knockout (KO) animals on a 
C KO background the total abundance of catalytic subunit was reduced and so 
catalytic activity was more controlled and basal or 3′,5′-cyclic monophosphate (cAMP)-
stimulated PKA activity was lower. This resulted in improved development but the 
genotype was still lethal.[129] Similarly, C homozygous null mice survive through 
embryogenesis but die early after birth.[130] 
Carney complex (CNC) is a multiple endocrine neoplasia characterised by spotty skin 
pigmentation typically on the face together with Schwannomas, which are benign 
tumours made up of Schwann cells of the peripheral nervous system. Myxomas 
(tumours of the heart) are also characteristic and a major cause of mortality. Endocrine 
tumours may also form, most commonly occurring in the adrenal glands.[131, 132] In 
~75 % of patients with CNC, a mutation in PRKAR1A that inactivated PKA RI was 
the cause.[133] Most of the mutations in PRKAR1A result in a premature stop codon 
leading to messenger RNA (mRNA) instability and degradation.[132, 134] Many of the 
CNC mutations are located in the dimerisation / docking (DD) domain (Figure 
3.1),[132] a region in RI that contains the pair of disulfides that form during oxidative 
stress.[57] Consequently the cysteine 17 serine (Cys17Ser) mutation present in the KI 
mouse I investigated in these studies is located within the DD domain. In tumours with 
these RI inactivating mutations, basal PKA activity was shown to be unaltered but 
activity induced by cAMP was enhanced i.e. the tumours were more sensitive to 
cAMP.[135] 




Figure 3.1 Location of mutations in PRKARIA in patients with CNC.[132]  
Each circle represents one family unit with a mutation in that region. Of particular note is 
the number of families with mutations in the DD domain which is where the Cys17 
mutated in the KI mouse is located. NMD= nonsense-mediated mRNA decay. 
 
 
A number of mouse models have been developed to study CNC. Kirschner et al. 
showed that heterozygous mutations in PRKARIA resulted in tumourigenesis 
highlighting PKA RI‟s role as a tumour suppressor. Mice with a mutation in exon 2 of 
PRKAR1A, a modification frequently seen in CNC patients, develop Schwannomas and 
bone lesions with similar histology to those seen in human CNC. Similarly, mice with 
facial neural crest tissue-specific KO of PRKAR1A also develop Schwannomas.[136] 
Pituitary-specific KO mice also develop tumours, although with a long latency.[131] 
Mice with cardiomyocyte-specific ablation of PRKAR1A die during embryogenesis due 
to aberrant cardiac development. Their hearts have myxomas and they also have 
elevated total and free PKA activity, which results in down-regulation of transcription 
factors required for cardiogenesis.[137] The increase in activity was found to be due to 
uncontrolled catalytic subunit activity which is normally suppressed by RI.[131]  
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In my studies, the influence of RI disulfide formation on cardiac „function‟ was 
investigated primarily by the characterisation of a novel Cys17Ser RI „redox-dead‟ KI 
mouse line. I refer to this mouse line as „redox dead‟ as Cys17 in each RI subunit has 
been mutated to a Ser (Figure 3.2) so theoretically the regulatory subunits cannot form 
disulfides in response to oxidative stress.  
 
Figure 3.2 Diagram of Cys17Ser ‘redox-dead’ KI RI.  




I hypothesised that Cys17Ser mutant mice that cannot form RI disulfides would still 
be regulated by classical stimulation of PKA by cAMP. This was reasoned because 
disulfide RI is not generally present in tissues under basal conditions as an oxidant is 
required, but the PKA is responsive to  agonist-induced PKA activation via elevated 
cAMP.[57] Furthermore, the anti-parallel dimeric RI state is not disrupted by mutating 
either or both Cys residues involved in disulfide formation.[116]  
My research laboratory chose to solely mutate Cys17, as opposed to both Cys17 and 
Cys38, when generating the transgenic mouse. This was because a single amino acid 
change is more conservative compared to a two amino acid change. Furthermore, at the 
time of choosing which RI „redox dead‟ mouse to generate, the effect of mutating the 
redox-sensitive Cys thiols in the DD domain of RI on binding to dual-specificity A-
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kinase anchoring proteins (D-AKAPs) had been investigated. As discussed in more 
detail in Chapter 5, D-AKAP1 and D-AKAP2 are proteins that bind to the DD domain 
of RI and RII subunits and determine PKA localisation with substrates PKA 
phosphorylates. AKAP binding is crucial to the coordination of PKA function. Banky et 
al. showed that mutating both Cys17 and Cys38 to alanine abolished D-AKAP1 binding 
to RI,[116] and Huang et al. showed this double mutation also abolished D-AKAP2 
binding to RI[138] suggesting that the dual amino acid change caused a 
conformational change that itself altered normal PKA function. Therefore, a dual 
mutant mouse was not considered to be a viable option. Similarly, the same research 
group (Taylor‟s laboratory) showed that mutation of Cys38 to histidine (His) had a 
more marked effect on the conformation of RI (such that it attenuated D-AKAP1 / D-
AKAP2 binding to RIthan solely mutating Cys17 to His, which did not alter binding 
to the D-AKAPs.[116, 138] In addition, mutating Cys to Ser in the KI mouse was 
envisaged not to have a marked effect as both side chains of these amino acids are 
hydrophilic and of a similar size. Overall the transgenesis to produce a Cys17Ser RI 
KI mouse line introducing a single atom (sulfur to oxygen) alteration was considered 
the best option.  
The primary aim of this chapter was to characterise the novel Cys17Ser RI KI mouse 
which was achieved by addressing the following: 
1. Whether KI RI forms the disulfide bonds a wild-type (WT) does during oxidative 
stress. I hypothesise it will not because Ser17 cannot be oxidised so cannot form a 
disulfide with the adjacent Cys38.  
2. Whether the Cys17Ser mutation in RI causes any compensatory changes in 
expression of other PKA subunits or protein kinases. It is important to establish whether 
the abundance of proteins is the same in WT and KI mice allowing me to dis-count such 
potential changes as a reason for any differences I may identify between genotypes. For 
this reason it was also important to determine whether there were any compensatory 
changes in abundance of other PKA subunits in the KI mouse. The abundance of 
cGMP-dependent protein kinase (PKG) Iwas also analysed as this is also activated by 
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oxidation to a disulfide form,[60] and has roles in excitation-contraction coupling and 
smooth muscle relaxation by phosphorylating some of the same substrates as PKA. The 
abundances of the following enzymes were also compared between genotypes: p38 
mitogen-activated protein kinase (MAPK), protein kinase C (PKC) (ε, , δ), protein 
kinase D (PKD)Akt, cyclooxygenase-2 (COX-2) and extracellular signal-regulated 
kinase (ERK).  
3. Whether the inability to form RI disulfide results in a compensatory increase in RI 
abundance in the heart and other organs (kidney, liver, lung, brain and pancreas). The 
Cys17Ser RI mutation is global and PKA has roles in multiple tissues (Chapter 4). At 
the outset, I don‟t anticipate the expression of RI to be different between WT and KI 
organs. 
4. Whether RI disulfide alters basal cardiac and coronary vascular function. RI 
disulfide has been associated with increased PKA activity and increased 
phosphorylation of cardiac proteins.[57] I hypothesise that there will be a difference in 
basal function between WT and KI hearts because there may be some RI disulfide in 
WT basally but RI will all be reduced in KI. I therefore expect PKA activity to be 
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3.2  Methods 
3.2.1 In vitro treatment of heart homogenate with diamide 
Male and female hearts were perfused with K-HB for 45 min and then homogenised as 
described in Chapter 2.1. The homogenate was treated with 0.5 mM diamide (a thiol-
specific oxidant that selectively induces disulfide formation) for 5 min or left untreated 
for 5 min (control). The homogenate was then added to an equal volume of non-
reducing (with 100 mM maleimide) or reducing (i.e. with 5 % β-mercaptoethanol) SDS 
sample buffer. 
3.2.2 Ex vivo treatment of heart homogenate with H2O2 
Male and female WT and KI hearts were perfused with K-HB for 40 min followed by 
50 µM H2O2 for 5 min and then homogenised and added to non-reducing SDS sample 
buffer (with 100 mM maleimide) as described in Chapter 2.1. 
3.2.3  Excising organs and analysis of RI abundance 
After the heart was excised for Langendorff perfusion, the lung, kidney, liver, pancreas 
and brain were removed, homogenised as the heart was (described in Chapter 2.1) and 
added to reducing SDS sample buffer. SDS-PAGE and Western blotting were carried 
out with blots probed for PKA RI. The relative expression of RI in WT and KI was 
assessed by comparing pairs of samples. This approach was used as analysis was carried 
out on different days, which precludes absolute quantitative analysis. 
3.2.4  Probing for specific proteins in WT and KI heart homogenate 
Homogenates of Langendorff-perfused (K-HB for 45 min) male WT and KI hearts were 
analysed for abundance of different enzymes and PKA subunits by adding reducing 
SDS sample buffer (i.e. with 5 % β-mercaptoethanol) to the homogenate and carrying 
out SDS-PAGE and Western blotting. Blots were probed with the antibodies shown in 
Table 3.1.   
 





















PKCε (C-15) sc-214 Santa Cruz 
Biotechnology 
rabbit 1:1000 1 
PKC (C-20) sc-208 Santa Cruz 
Biotechnology 
rabbit 1:1000 1 
PKC (C-17) sc-213 Santa Cruz 
Biotechnology 
rabbit 1:1000 1 
PKA RII 06-411 Upstate cell 
signalling 
solutions 
goat 1:1000 1 
PKD/PKCµ #2052 Cell Signalling 
Technology 
rabbit 1:1000 3 
PKA catalytic 
subunit 
610980 BD Biosciences mouse 1:1000 1 
Akt #9272 Cell Signalling 
Technology 
rabbit 1:1000 1 
COX-2 160126 Cayman 
Chemical 
mouse 1:1000 3 
ERK 1/2 
(p44/42 MAPK) 
#9102 Cell Signalling 
Technology 
rabbit 1:1000 2 
PRKAR1B WH000557
5M5 
Sigma Aldrich mouse 1:1000 1 
Table 3.1. Antibodies to different proteins used to compare their abundance in 
male WT and KI hearts.  
The table shows the name of the antibody, the company from which it was purchased 
(and product code) and the species it was raised in. The table also shows the 
concentration of antibody the blot was probed with and the incubation period at room 
temperature. 
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3.2.5 Measuring heart weight 
After the heart was excised it was placed in cold K-HB and weighed on a zeroed 
weighing balance (fresh heart weight). In some studies, the heart was frozen in liquid 
nitrogen after Langendorff perfusion and then weighed (frozen heart weight).  
3.2.6 Echocardiography 
An echocardiogram uses sound waves to give a two-dimensional picture of the heart 
enabling measurement of cardiac dimensions and cardiac function. This was carried out 
by Dr. Oleksandra Prysyazhna. Six WT and six KI male mice of ~26 g in body weight 
were anaesthetised by placing in a box supplied with isoflurane (~4 %, 0.75 % O2). 
They were then removed, weighed and a mask supplying isoflurane (~2.5 %) was 
placed on the mouse. Heart rate was monitored and maintained at ~520 bpm. The mouse 
was placed on a heated table and temperature of the mouse was monitored and 
maintained at approximately 37 ºC. Hair was removed from the chest and abdomen and 
ultrasound transmission gel was applied on to which the probe was placed. The long and 
short axes of the heart were imaged in different modes, as outlined below.  
The long axis of the heart (axis of heart is horizontal) was measured when the aorta was 
positioned to the right opposite the apex and one papillary muscle was visible (Figure 
3.3). This was visualised using motion-mode (M-mode) which produces a one-
dimensional view of the cardiac structures moving over time. The short axis of the heart 
was visualised by rotating the probe 90º from the long axis position so the biggest 
ventricular lumen could be visualised. Ideally, both papillary muscles were visible 
(Figure 3.4).  
Transmission gel was applied to the right side of the mouse‟s chest and the probe placed 
on the chest such that the ultrasound beam was parallel with the direction of flow of 
blood through the aorta (white dotted line on Figure 3.5). A vertical line was drawn on 
the image (red line in Figure 3.5) near to the first vessel of the aortic arch and so that it 
had a slope of ~50 º to the white dotted line which enables measurements of blood flow. 
This is called Doppler mode and assesses blood flow velocity by measuring the change 
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in frequency between transmitted sound waves and sound waves reflected from blood 
cells moving away from or towards the probe.  











Figure 3.3 Long axis of the heart.  
(A) The heart is positioned so that the aorta is positioned to the right opposite the apex 
(B) The heart is also positioned so that one papillary muscle is visible (top right). The 
representative M-mode echocardiogram of a WT heart shows a trace is created of 
dimension (mm) v time (ms) showing boundaries of the heart contracting and relaxing 
with time. Various parameters are measured including ejection fraction, fractional 
shortening, systolic and diastolic volume and (a) systolic and (b) diastolic dimension. The 
program itself calculates an average of three different measurements for systolic and 
diastolic dimension (red and green lines) and we can calculate the dimensions ourselves 
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 (A)   
 (B)  
Figure 3.4 Short axis of the heart.  
(A) The heart was positioned so that both papillary muscles were visible. (B) The 
representative M-mode echocardiogram of the short axis of a WT heart shows a trace of 
dimension (mm) vs time (ms). Parameters measured in this mode include left ventricular 
anteriolateral and posterior wall thicknesses during diastole and systole as well as left 












anterior papillar  
muscle 










Figure 3.5 Representative Doppler mode echocardiogram of a WT heart.  
A trace of velocity (m / s) v time (ms) is created. Parameters measured include aortic root 











3.3.1 Confirmation that KI mouse RI does not form disulfide in vitro or ex vivo 
The novel Cys17Ser RI „redox-dead‟ KI mouse, in theory, should not form disulfides 
in response to oxidative stress. Therefore this was assessed in vitro and ex vivo by 
comparing the KI RI response to oxidant to that of RI in WT littermates.  
In vitro RI disulfide formation: To assess RI disulfide formation in vitro, perfused 
WT or KI hearts were homogenised and treated with 0.5 mM diamide for 5 min. Figure 
3.6A (male hearts) and Figure 3.6B (female hearts) show that in homogenates prepared 
from WT perfused hearts, both monomer and disulfide dimer were present. In cardiac 
samples from males the basal disulfide dimer was ~60 % of the total RI pool, which 
was similar to females (~65 %). Treatment of WT homogenates with 0.5 mM diamide 
caused complete loss of monomer and a corresponding increase in RI disulfide dimer. 
There was ~40 % increase in disulfide dimer in male which was statistically significant 
(p<0.05) and ~20 % increase in female which was not statistically significant. When 
reducing agent was added to the preparation (from either sex) in SDS sample buffer, as 
anticipated the disulfide was fully reduced and so RI ran at its monomeric weight. In 
control and diamide-treated male KI heart homogenate there was only reduced 
monomeric RI present and no disulfide dimer at all, as anticipated. In females, there 
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           (B) 
Figure 3.6 Effect of diamide on RIα redox state in WT and KI hearts in vitro.  
(A) Male hearts were Langendorff-perfused for 45 min, homogenised and treated for 5 
min with or without (control) 0.5 mM diamide. Representative blot shows RI monomer 
and dimer and graph presents average percentage RI disulfide dimer for n=4, n=3 ± 
SEM. * p<0.05 compared to untreated WT, # p<0.05 with -mercaptoethanol compared to 
without. (B) As above but female hearts were studied. Diamide increased disulfide 
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Ex vivo RI disulfide formation: To establish ex vivo whether KI mice fail to form 
RI disulfide, WT and KI hearts were perfused with K-HB for 40 min followed by 50 
μM H2O2 for 5 min. Monomer and disulfide dimer were present in perfused WT hearts. 
There was ~25 % disulfide dimer in female hearts (Figure 3.7A) and ~20 % in male 
hearts (Figure 3.7B) and perfusion with H2O2 increased RI disulfide in males and 
females by ~70 %. However, there was no disulfide dimer present at all in female or 




















Figure 3.7 PKA RI redox state in WT and KI hearts Langendorff-perfused with K-
HB or H2O2.  
(A) Female hearts were Langendorff-perfused with K-HB for 45 min or K-HB for 40 min 
followed by 5 min with or without (control) 50 µM H2O2. The representative blot was 
probed for PKA RI and graph shows average percentage RI disulfide for n=6 ± SEM. 
(B) Same as above but in male hearts. In both male and female, 50 µM H2O2 caused a 
significant increase in RI disulfide formation in WT which was not seen in the KI where 
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3.3.2 RIα abundance in female and male WT and KI organs  
To further characterise the novel KI mouse the abundance of PKA RI in various 
organs of female (Figure 3.8) and male mice (Figure 3.9) was examined and compared 
to those in WT of the same sex respectively. KI kidneys had more RI than WT; with 
~3 times more in females and ~4 times more in males. Female KI livers had ~2 times 
more RI than WT, and in males there was ~3 times more. However, in lungs, hearts 
and brains the abundance of RI was similar between genotypes in both males and 
females. WT pancreas expressed the same amount of RI as KI in females; whereas in 
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Figure 3.8 RI abundance in organs from female WT and KI mice.  
Organs were homogenised and added to reducing SDS sample buffer. SDS-PAGE and 
Western blotting were carried out. Top, representative blot showing RI present in female 
WT and KI kidney, liver, lung, heart, brain and pancreas. Bottom, graphical representation 
(kidney n=4 pairs, liver n=5 pairs, lung n=5 pairs, heart n=5 pairs, brain n=3 pairs, 
pancreas n=4 pairs ± SEM) of the average ratio of RI present in WT organ compared to 
KI organ. Lung, heart, brain and pancreas show comparable abundance of RI in WT 
and KI but KI kidney and liver has more RI present than WT.  




Figure 3.9 Abundance of RI in organs from male WT and KI mice.  
Organs were homogenised and added to reducing SDS sample buffer. SDS-PAGE and 
Western blotting were carried out. Top, representative blot showing RI present in WT 
and KI kidney, liver, lung, heart, brain and pancreas. Bottom, graphical representation of 
the average ratio of RI present in WT organ compared to KI organ (kidney n=4 pairs, 
liver n=6 pairs, lung, brain, pancreas n=4 pairs, heart n=5 pairs ± SEM). Lung, heart, 
brain showed comparable abundance of RI in WT to KI but KI kidney, liver and 
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3.3.3 Protein expression in male WT and KI hearts 
I am primarily interested in PKA but it was important to determine whether the 
abundance of other proteins, such as kinases and other PKA subunits are different 
between WT and KI. Any such compensatory changes could be responsible for any 
physiological or biochemical difference observed between the genotypes. Figure 3.10 
shows the abundance of selected kinases in the hearts of WT and KI mice. It was 
evident from Western blots and quantitative analysis that there was no statistically 
significant difference in the abundance of p38 MAPK, PKG I, PKCε, PKC, PKCδ, 
PKD, ERK, COX-2 or Akt between WT and KI. The abundance of other PKA subunits 
was also analysed (Figure 3.11); the PKA catalytic subunit and RII were also not 
different between WT and KI hearts. PKA RI could not be detected in WT or KI hearts 
(results not shown). With a long exposure a band was observed at ~42 kDa perhaps 
corresponding to PKA RI but there were also a lot of additional non-specific bands 



















































































































































   
   
   
Figure 3.10 Abundance of proteins in WT and KI hearts.  
(A) Langendorff-perfused WT and KI hearts were homogenised. SDS-PAGE and Western 
blotting were performed and blots probed with antibodies to p38 MAPK. Graph shows 
average max OD for WT and KI hearts (n=3) ± SEM (B) PKG I (C) PKC (D) PKC(E) 
PKCδ (F) PKD (G) ERK (H) COX-2 (I) Akt. There were no differences in protein 
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Figure 3.11 Abundance of PKA subunits in WT and KI hearts.  
WT and KI hearts were Langendorff-perfused and homogenised. Western blots were 
probed with antibodies to PKA catalytic subunit and PKA RIIGraphs show average max 
OD for WT and KI hearts (n=3) ± SEM. There was no difference in abundance of any of 
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3.3.4 Heart weight: body weight ratios for WT and KI mice 
To further characterise the KI mouse, the body weights and heart weights of KI mice 
were compared to WT littermates (Figure 3.12). There was no difference in average 
body weight between WT and KI mice (28.9 ± 2.4 g and 28.7 ± 2.5 g respectively). In 
some studies, hearts were weighed after Langendorff perfusion and freezing in liquid 
nitrogen. Average frozen heart weight to body weight ratio for KI was similar to WT 
(8.8 ± 0.2 mg / g and 8.6 ± 0.3 mg / g respectively). In other studies hearts were 
weighed before Langendorff perfusion. Average fresh heart weight to body weight 


























































































Figure 3.12 Average body weight and heart weight to body weight ratios for WT and 
KI mice.  
Body weights of WT and KI mice (14 - 17 weeks old, WT n=42, KI n=38) were measured 
as were frozen and fresh heart weights. The ratios of frozen heart weight to body weight 
(n=33) and fresh heart weight to body weight (WT n=22, KI n=21) were calculated ± SEM. 
There was no difference in body weight or frozen or fresh heart weight : body weight 
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3.3.5 Stability of Langendorff-perfused male WT and KI hearts 
The influence of RI disulfide on cardiac function was analysed in Langendorff-
perfused WT and KI hearts. Coronary flow, LVDP and EDP were measured over a 40 
min stabilisation period. Figure 3.13 shows these parameters during the last 20 min of 
this period, during which no adjustments to the preparation were made. Coronary flow 
(Figure 3.13A) was similar in WT and KI hearts and stayed at ~4 ml / min. The EDP 
(Figure 3.13B) was different between genotypes for the first 7 min after which it 
stabilised at ~8 mmHg in both genotypes. Overall, there was not a statistically 
significant difference in EDP over the 20 min period between WT and KI. There was a 
trend for average LVDP (Figure 3.13C) in the KI hearts to be ~10 mmHg lower than 
WT throughout the 20 min period. As the EDP was similar between WT and KI hearts 
the lower LVDP in KI hearts may be explained by a lower end systolic pressure in KI 
















Figure 3.13 Stability of male WT and KI hearts during Langendorff perfusion.  
(A) WT and KI hearts were Langendorff-perfused for 40 min. Graph shows average 
coronary flow during the last 20 min of the stability period (n=6 ± SEM) (B) EDP (C) 
LVDP. Coronary flow and EDP were similar in WT and KI hearts, but KI hearts showed a 
trend for a slightly lower LVDP than WT hearts.  
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3.3.6 Echocardiography in WT and KI mice  
Body weights were not different between WT (25.5 ± 0.9 g) and KI (25.1 ± 0.5 g) mice 
used for echocardiography. The echocardiography software also calculated the left 
ventricular mass and Figure 3.14 shows that average left ventricular mass: body weight 
ratios were also not significantly different between genotypes (WT, 3.9 ± 0.1 mg / g and 






















































Figure 3.14 Average body weight and left ventricular mass to body weight ratios for 
WT and KI mice used in echocardiography.  
Mice were weighed before they were echocardiographed and the ratio of left ventricular 
mass to body weight was calculated by the echocardiography software (n=6 ± SEM). 
There were no statistically significant differences in these measurements between WT 
and KI.  
 
 
Echocardiographic analysis of WT and KI mice revealed that KI mice had a larger left 
ventricular internal dimension during systole (~0.3 mm in M-mode long axis (p<0.05, 
Figure 3.15 and Table 3.2) and ~0.22 mm in M-mode short axis (p<0.05, Figure 3.16 
and Table 3.3)). Figure 3.15 shows that the left ventricular dimension was ~0.4 mm 
larger in KI compared to WT during systole and the left ventricular volume was ~9 µl 
larger in KI compared to WT too, both significant differences (p<0.05). KI left 
ventricles had a ~10 µl larger volume than WT during diastole, and a ~0.2 mm larger 
dimension, both statistically significant (p<0.05). However, the left ventricular internal 
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dimensions were not different between WT and KI mice during diastole. 
Intraventricular septal widths and left ventricular posterior wall thicknesses were similar 
in WT and KI mice during diastole or systole. The cardiac output was similar in WT 
and KI mice, although ejection fraction and fractional shortening were significantly 
(p<0.05) smaller in KI mice compared to WT mice (~7 % smaller and ~6 % smaller 
respectively). Doppler mode (Figure 3.17 and Table 3.4) revealed no differences in 
aortic root velocity time integral or aortic valve peak velocity.      
 
Figure 3.18 presents a schematic which summarises these observations. KI hearts 
displayed contractile dysfunction as their left ventricular dimensions and volumes were 
significantly (p<0.05) larger in KI than WT during systole. Despite these larger 
dimensions in the KI, their hearts had the same cardiac output as WT explained by a 





Figure 3.15 M-mode long axis analysis of WT and KI hearts.  
Representative M-mode images of the long axis of WT and KI hearts showing that KI left 








Parameter WT KI 
 
intraventricular septal width (IVS): diastole (d) (mm) 0.82 ± 0.03 
 
0.93 ± 0.06 
 
left ventricular internal dimension (LVID): d (mm) 3.95 ± 0.09 
 
4.11 ± 0.05 
 
left ventricular posterior wall (LVPW): d (mm) 0.87 ± 0.06 
 
0.85 ± 0.09 
 
IVS: systole (s) (mm) 1.32 ± 0.04 
 
1.28 ± 0.07 
 
LVID: s (mm) 2.57 ± 0.04 
 
2.9 ± 0.09* 
 
LVPW: s (mm) 1.29 ± 0.05 1.21 ± 0.06 
dimension; s (mm) 2.38 ± 0.08 2.76 ± 0.08* 
dimension; d (mm) 3.88 ± 0.08 4.11 ± 0.07* 
volume; s (μl) 20.00 ± 1.53 28.78 ± 1.98* 
volume; d (μl) 65.23 ± 3.05 74.94 ± 3.00* 
stroke volume (μl) 45.24 ± 1.96 46.16 ± 1.53 
ejection fraction (%) 69.49 ± 1.47 61.78 ± 1.49* 
fractional shortening (%) 38.60 ± 1.16 32.89 ± 1.03* 
cardiac output (ml / min) 23.91 ± 1.07 25.19 ± 0.99 
heart rate (bpm)   543.17 ± 7.32 545.3 ± 6.22 
Table 3.2. M-mode long axis analysis of WT and KI hearts.  
Average values for various echocardiographic parameters in WT and KI mice (n=6 ± SEM 
*p<0.05 compared to WT) in M-mode long axis. Left ventricular dimension and volume 
during systole and diastole were significantly larger in KI compared to WT whilst the 
ejection fraction and fractional shortening were significantly lower in KI than WT. 
 





Figure 3.16 M-mode short axis analysis of WT and KI hearts  
Representative M-mode images of the short axis of WT and KI hearts showing that the KI 
left ventricle was larger than the WT left ventricle during diastole and systole.  
 
Parameter WT KI 
 
left ventricular anterolateral 
wall (LVAW): diastolic (d) 
(mm) 
0.82 ± 0.04 0.9 ± 0.05 
left ventricular internal 
dimension, diastolic (LVID): 
d (mm) 
3.96 ± 0.04 4.03 ± 0.07 
left ventricular posterior 
wall, diastolic (LVPW): d 
(mm) 
0.87 ± 0.05 0.84 ± 0.07 
LVAW: systolic (s) (mm) 1.39 ± 0.03 1.31 ± 0.06 
LVID: s (mm) 2.55 ± 0.06 2.77 ± 0.06* 
LVPW:s (mm) 1.26 ± 0.04 1.18 ± 0.07 
Table 3.3. M-mode short axis analysis of WT and KI hearts  
Average values for various echocardiographic parameters in WT and KI mice (n=6 ± SEM 
*p<0.05 compared to WT) in M-mode short axis are shown. Systolic left ventricular 
internal dimension was significantly larger in KI than WT. 
WT 
KI WT 




Figure 3.17 Doppler mode analysis of WT and KI hearts.  
Representative images of WT and KI hearts in Doppler mode showing that blood flow 




Parameter WT KI 
 
aortic root velocity time 
integral 
1737.31 ± 59.50 1857.27 ± 120.25 
aortic valve peak velocity 5.79 ± 0.40 6.11 ± 0.53 
Table 3.4. Doppler mode analysis of WT and KI hearts.  
Average values for various echocardiographic parameters in WT and KI mice in Doppler 









Figure 3.18 Schematic diagram to show the phenotype of WT and KI hearts.  
The results of echocardiography suggest that, compared to WT, KI left ventricles were 
larger in volume and dimension during diastole and systole. However, the cardiac output 
was the same in both genotypes because KI hearts had a lower ejection fraction and 








In this chapter I confirmed that KI RI does not form disulfide basally or in response to 
oxidant, unlike in WT, as anticipated. This was observed in in vitro and ex vivo 
experimental preparations; although basal WT RI disulfide was higher in vitro than ex 
vivo. This is probably because the in vitro heart homogenate was not prepared with 
maleimide to prevent air oxidation, whereas the ex vivo heart homogenate was. 
Maleimide was absent from the homogenisation buffer used in in vitro studies because 
this alkylates Cys thiols and so would have blocked any disulfide dimerisation induced 
by the diamide treatment. However, both in vitro and ex vivo results confirm that the 
novel Cys17Ser RI KI mouse is a valid tool for investigating the influence of RI 
disulfide on PKA activity and cardiovascular function, as PKA RI in the tissue of 
these mice does not form disulfides.  
Mutations or KO of PKA regulatory subunits can result in up-regulation of other 
regulatory subunit isoforms, as well as alter expression of the catalytic subunit. For 
example, neural specific deletion of the RIβ gene results in a compensatory increase in 
RI protein with no change in RII or catalytic subunit protein. When the RIIβ gene is 
deleted from white adipose and brown adipose tissue of mice, RI protein increases and 
catalytic subunit protein reduces slightly. There is no change in RI mRNA levels 
however, so the increased protein is likely due to increased stability of RI by 
incorporation into Type I PKA holoenzyme.[139] However, the Cys17Ser mutation did 
not alter the abundance of the PKA RI, RII or catalytic subunits in the heart. PKA RI 
was not detected in the heart, concurring with others who suggest it is only found in the 
brain and testes.[100] In addition, the abundance of other selected kinases was similar 
in WT and KI hearts. Of course, I have not analysed the expression of every kinase 
known but a number of kinases linked to PKA were assessed and no statistically 
significant differences were observed between genotypes. I can therefore, be reasonably 
confident that any physiological differences observed between WT and KI were due to 
RI disulfide formation.  
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Interestingly, RI abundance was much higher in KI kidney compared to WT kidney in 
both male and female mice. This was also the case in liver but to a lesser degree. A 
reason for this may be compensation for the absence of RI disulfide. RI disulfide 
may play a more significant role in the kidney and liver than in the heart, for example so 
RI expression was increased in kidney and liver and not in heart. If RI disulfide is 
associated with PKA activation, perhaps KI kidney and liver express a higher 
abundance of RI (but without disulfide) to achieve the same amount of activity 
achieved by the WT which basally has a small amount of disulfide present.  
The kidney plays a key role in Na
+
 balance and regulating blood volume and 
extracellular fluid volume and so ultimately arterial pressure and hypertension.[140] 










 exchanger regulatory co-factor (NHERF, which binds to the 
A-kinase anchoring protein D-AKAP2,[142] which determines PKA localisation as 
discussed in Chapter 5) and the anchoring protein ezrin are also required for this 
inhibition.[143] NHE-3 preferentially exchanges extracellular Na
+
 for intracellular H
+
 
and is important in intravascular volume maintenance and pH homeostasis as 
demonstrated in NHE-3 null mice which have decreased blood pressure, acidic plasma 
pH and diarrhoea.[144] In light of this, the higher abundance of RI in KI mouse 
kidney could alter blood pressure and this could be investigated in vivo by 
radiotelemetry and with isolated blood vessels using myography. However, the adaptive 
change in RI expression in the KI kidney could complicate such studies. Fortunately, 
no such compensatory expression changes occur in the heart, which is the focus of my 
studies.  
Echocardiography was performed on WT and KI hearts to gain insight into any 
differences in the structure and function of KI hearts. KI hearts demonstrated some 
systolic dysfunction, and had a larger left ventricular volume and dimension compared 
to WT during systole and diastole. The cardiac output was however similar in WT and 
KI hearts. This was because the KI hearts, despite a larger ventricle, had lower 
fractional shortening and ejection fraction compared to WT. This could represent an 
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adaptive response resulting from the chronic inability of RI in KI to form a disulfide. 
An alternative is this subtle variation between genotypes could represent a difference in 
signalling, such that the KI has a deficit in its basal PKA activity, perhaps resulting in 
the under-phosphorylation of a target protein involved in cardiac contractile function. If 
the latter explanation was correct, the KI phenotype might be recapitulated in WT if all 
the basal disulfide could be removed, perhaps pharmacologically with reducing agents. 
However, such interventions would not be selective for RI, limiting the information 
such an approach would provide. The ventricular posterior wall thickness during systole 
and diastole was not different between WT and KI. Furthermore, the heart weight to 
body weight ratios were similar between the hearts of either genotype so no hypertrophy 
was evident in KI hearts.   
Langendorff perfusion illustrated that KI hearts had a trend for a lower LVDP than WT 
hearts. This trend may become statistically significant with a higher n number. The EDP 
was not significantly different between WT and KI hearts but it was slightly lower in KI 
than WT, despite altering the balloon volume during the first 20 min of the perfusion 
protocol to repeatedly set the EDP at ~7 mmHg. Frank-Starling‟s Law states that the 
greater the preload (pressure in the ventricle at the end of diastole) the greater the 
contractile force during systole. Therefore a small decrease in EDP can have a marked 
effect on lowering end systolic pressure and therefore LVDP and this may be what I am 
observing. I therefore cannot safely say, from these results, that there is a contractile 
deficit in KI hearts but clearly the LVDP is lower. However, in Chapter 4 I demonstrate 
that KI LVDP was significantly lower than WT LVDP during the last 5 min of the 
stabilisation period. Biochemically, a lower LVDP in KI could be due to a basal 
turnover of RI disulfide in WT hearts that cannot occur in KI, resulting in higher PKA 
activity in WT compared to KI. This would occur if thiol oxidants are produced basally 
in hearts, which is likely as such products are generated in many biochemical 
processes,[27, 145] and explains the resting disulfide in WT hearts. Whether this small 
functional change in the KI heart would mean anything in the whole animal is difficult 
to say and would be something to investigate further. Other methods for assessing 
contractile function include Frank-Starling curves which demonstrate the relationship 
between EDP and LVDP in the Langendorff-perfused heart and pressure-volume loops 
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which, using the Millar ARIA system, measure simultaneous left ventricular pressure 
and volume. 
In conclusion, these results suggest that RIdisulfide may be important in basal heart 
contractile function, but oxidative stress is likely required for a more pronounced 
phenotypic difference between WT and KI to be observed. Indeed, a differential 
response of the two genotypes to oxidative stress is the subject of Chapter 4.  
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4 RI DISULFIDE AND cAMP-MEDIATED PKA 
ACTIVATION 
4.1 INTRODUCTION 
4.1.1 Adrenergic signalling  
Monoamine neurotransmitters are compounds with one amino group connected to an 
aromatic ring by a two carbon chain (Figure 4.1). Examples include norepinephrine 
(noradrenaline), epinephrine (adrenaline), phenylephrine and serotonin as well as the 
drug isoprenaline. Norepinephrine and epinephrine are also classed as catecholamines 
as they are compounds with a catechol (benzene with two hydroxyl side groups) and a 
side-chain amine. 
Norepinephrine, phenylephrine and epinephrine target the G-protein coupled 
adrenoceptors,  (1A, 1B, 1D, 2) and  (1, 2, 3), with different affinities and link 
the sympathetic nervous system to the cardiovascular system. 1, 2, 3 and 1 
adrenoceptors are present in cardiomyocytes. 1 and 2 are linked to Gs proteins which 
activate adenylate cyclase causing the production of 3′,5′-cyclic monophosphate 
(cAMP). cAMP then binds to the regulatory subunits of cAMP-dependent protein 
kinase (PKA), enabling catalytic activity and so phosphorylation of PKA substrates 
(examples described later). The accepted view is that under physiological conditions, 
catecholamines cause positive inotropy (increased contractility), lusitropy (increased 
rate of relaxation) and chronotropy (increased heart rate) by 1 adrenoceptor activation 
and PKA signalling,[146, 147] but there is also evidence that persistent stimulation of 
1 adrenoceptors activates Ca
2+ 
/ calmodulin-dependent kinase II independent of PKA 
activation. This increases intracellular Ca
2+
 and causes myocyte contraction and leads to 
apoptosis and maladaptive remodelling.[148, 149] 2 adrenoceptors are linked to both 
Gs and Gi, which activate and inhibit adenylate cyclase respectively. The switch from Gs 
to Gi occurs with prolonged stimulation of the 2 adrenoceptor and this has a 
cardioprotective effect.[150] 3 adrenoceptors appear to be responsible for the negative 
inotropic effects of catecholamines.[151] Isoprenaline is structurally similar to 
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epinephrine and is a non-selective  adrenoceptor agonist routinely used as a positive 
control for activation of PKA. 
1 receptors are associated with Gq proteins and coupled to several signalling pathways 
such as protein kinase C (PKC), protein kinase D (PKD), mitogen activated protein 
kinase (MAPK), phospholipase C (PLC), Ca
2+
 channels and phospholipase D.[146, 147] 
Activation of 1 receptors is important in smooth muscle contraction,[152] positive 
inotropy,[153] and negative inotropy.[154, 155] Studies have shown that the outcome of 
1 receptor stimulation depends on extracellular Ca
2+
 concentration which may explain 
the conflict in the literature over whether adrenoceptor stimulation increases or 
reduces myocardial contraction. For example, high extracellular Ca
2+
 can activate PKC 
which opposes 1 adrenoceptor-induced positive inotropy.[146, 156]  
5-hydroxytryptamine (5-HT, also known as serotonin) is also a monoamine but signals 
through a different receptor. 5-HT receptors are coupled to various signalling pathways 
including the PLC pathway. PLC increases inositoltrisphosphate and triggers 
intracellular Ca
2+
 release and formation of diacylglycerol which activates PKC. This 
then stimulates the nitric oxide (NO) synthesis pathway generating cGMP which 
activates cGMP-dependent protein kinase (PKG).[157] In the heart, serotonin causes 
positive chronotropy and inotropy and mitogenesis (induction of mitosis, the process of 
cell division) and is a vasoconstrictor or vasodilator depending on the species, blood 
vessel type or the state of the endothelium cell layer.[158] 
4.1.2 Metabolism of monoamines by monoamine oxidases 
Monoamine oxidase (MAO) enzymes are located in the outer mitochondrial membrane 
and catalyse the oxidative deamination (catabolism) of monoamines. There are two 
types; MAO-A and MAO-B, each having different specificities for substrates and 
pharmacological inhibitors.[159, 160] Serotonin, norepinephrine and epinephrine are 
the preferred substrate for MAO-A.[161] The monoamine must first be transported into 
the cell to be metabolised, as shown in Figure 4.1. An aldehyde intermediate is formed 
and H2O2 is produced as a by-product.[162, 163] The intermediate may then be further 
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metabolised to an acid by aldehyde dehydrogenase. Metabolism of monoamines is 

















Figure 4.1 Mechanism of MAO-catalysed metabolism of monoamines.  
The amine is removed from the monoamine (norepinephrine in this example) and 
ammonia (NH4
+
) and H2O2 are produced as by products as well as the aldehyde 




4.1.3 Mechanism of activation of Type I PKA  
As explained in Chapter 1, cAMP binding to the regulatory subunits of PKA causes 
dissociation of the catalytic subunits which then catalyse the phosphorylation of PKA 
substrates. Substrate has been shown to sensitise Type I PKA but not Type II PKA to 
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low concentrations of cAMP. cAMP-induced dissociation of Type I PKA but not Type 
II was enhanced by substrate and the rate of re-association of the RI subunit with 
catalytic subunit was inhibited by substrate (which was not the case with RII and 
catalytic subunit) prolonging PKA activity induced by a given concentration of 
cAMP.[164-166] The pseudosubstrate inhibitor site and cAMP binding domain A of RI 
bind to the catalytic subunit,[167] whereas the inhibitor site and both cAMP binding 
domains (A and B) of RII bind to the catalytic subunit.[168] Vigil et al. showed that 
both substrate and cAMP were required for full activation of Type I PKA. They 
proposed a mechanism for Type I activation whereby cAMP binds to cAMP binding 
domain A of RI causing dissociation of some catalytic subunit, then the substrate 
competes with the pseudosubstrate inhibitor site of the RI subunit for the catalytic 
subunit causing full dissociation of regulatory subunit-bound catalytic subunits.[165] In 
comparison, Type II PKA is not sensitised to cAMP by substrate but 
autophosphorylation of Type II PKA causes RII to have a lower binding affinity for 
catalytic subunit which increases the dissociation of catalytic subunit caused by 
cAMP.[166, 169] A role for RI disulfide in substrate-induced PKA activation is shown 
in Figure 4.3. 
4.1.4 Excitation-contraction coupling 
Excitation-contraction (EC) coupling is the series of events that happen from the 
electrical excitation of the myocyte to contraction of the heart. Ca
2+ 
enters the cell 
during the action potential via depolarization-activated Ca
2+ 
channels such as L-type 
Ca
2+




 exchanger (NCX, considered to be in reverse mode 
when pumping Ca
2+
 into cell). This triggers Ca
2+ 
release from the sarcoplasmic 
reticulum (SR) via ryanodine receptors (RyRs). These together raise intracellular 
concentration of Ca
2+ 
which then directly binds to troponin C (TnC) in the myofilament. 
This causes a conformational change in the troponin complex (TnC together with TnI 
and cTnT, which anchors the troponin complex to the actin filament). TnI moves away 
from the myosin binding site of actin so myosin can now bind strongly to actin 
generating force and causing contraction. To allow relaxation to occur, the intracellular 
Ca
2+ 
concentration must be lowered. This occurs via the NCX (which switches to the 
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forward mode to extrude Ca
2+
 from the cell), the SR Ca
2+
-ATPase (SERCA) 2A which 
pumps Ca
2+
 into the SR, and mitochondrial Ca
2+
 uniport. This lowering of cytosolic 
Ca
2+
 means less of the ion binds to TnC, allowing the Tn complex to move back to its 
inactive conformation, blocking the binding of myosin to actin.  
Substrates for PKA in EC coupling: Increased circulatory demand leads to  
adrenergic stimulation, activation of PKA (considered in more detail in Chapter 1) and 
enhanced inotropy, lusitropy and chronotropy. PKA achieves this by phosphorylating a 
number of Ca
2+
-handling and sarcomeric proteins involved in EC coupling (Figure 4.2). 
These include the L-type Ca
2+
 channel, the RyR, phospholamban (PLB), 
phospholemman (PLM), the thin filament protein cardiac TnI (cTnI) and the thick 
filament protein cardiac myosin binding protein C (cMyBP-C).  
PKA phosphorylates and activates L-type Ca
2+
 channels causing Ca
+ 
influx.[170] PKA 
also phosphorylates RyR2, in which two potential PKA phosphorylation sites have been 
identified; Ser2030 and Ser2808. There is some controversy over the major 
phosphorylation site upon activation of PKA in response to  adrenergic stimulation. 
Xiao et al.,[171] showed that Ser2030 is the major site and Wehrens et al.,[172] used 
RyR2-Ser2808Ala mice to show that Ser2808 is the major site. Phosphorylation of 
RyR2 results in activation of the channel,[173] and so Ca
2+
 release from the SR into the 
cytosol. 
PLB inhibits SERCA which prevents SERCA‟s function of transporting Ca2+ into the 
lumen of the SR from the cytosol, hydrolysing ATP to drive this uptake. 
Phosphorylation of PLB by PKA at Ser16 reduces its affinity for SERCA, reversing its 
inhibition on the pump,[174] and so increasing the rate of Ca
2+
 re-uptake into the SR 
and rate of relaxation.[175]  





 ATPase (NKA). PKA phosphorylates PLM at Ser68 which activates the NKA 
reducing intracellular Na
+
.[176] The NKA transports three Na
+ 
ions out in exchange for 
two K
+
 ions in which is important in generating the resting membrane potential and 
maintaining the transmembrane Na
+
 gradient which in turn regulates activity of other 
Chapter 4: RI Disulfide and cAMP-mediated PKA Activation 
116 
 
ion transporters. These include the NCX which, as already mentioned, is important in 
regulating the intracellular Ca
+ 
concentration and so myocardial contraction. PLM is 
important in limiting Na
+
 overload at the expense of reduced contraction during  
adrenergic stimulation, helping limit arrhythmias and progression to heart failure.[177-
179] 
As already mentioned, during systole intracellular Ca
2+ 
directly binds to TnC in the 
myofilament. This causes a conformational change in the troponin complex so TnI 
moves away from the myosin binding site of actin enabling myosin to bind strongly to 
actin forming cross-bridges and generating force and causing contraction. During 
diastole, lowering of cytosolic Ca
2+
 means less of the ion binds to TnC, allowing the 
troponin complex to move back to its inactive conformation, blocking the binding of 
myosin to actin. PKA phosphorylates cTnI at Ser23 and Ser24. This was shown when 
cTnI was replaced with slow skeletal (ss) TnI. The ssTnI does not contain the N-
terminal region of cTnI that contains the phosphorylatable Ser residues,[180] allowing 
the role of cTnI phosphorylation to be determined. Phosphorylation of cTnI by PKA 
results in reduced myofilament Ca
2+
 sensitivity and an increased rate of Ca
2+
 
dissociation from TnC contributing to increased rate of relaxation.[181-183] PKA 
phosphorylation also increases cross-bridge cycling rate,[184] and sarcomere shortening 
velocity,[185] which is important in increasing rate of relaxation as well as positive 
inotropy. However, the consequence of cTnI phosphorylation by PKA is controversial 
as some have failed to show these effects occur.[186, 187] In addition, PKA also 
phosphorylates cMyBP-C at Ser282, Ser302 and Ser273,[188] which has been shown to 
play a role in reducing myofilament Ca
2+
 sensitivity,[189] and increasing rate of cross-
bridge cycling,[190, 191] although the relative contribution of PKA-mediated cTnI and 
cMyBP-C phosphorylation to these outcomes is controversial.[192] 
PKA also has a role in vascular smooth muscle relaxation and vasodilation, although the 
mechanism is not fully understood. To achieve this role, PKA phosphorylates and 
activates the ATP-sensitive K
+
 channels (involved in K
+
 efflux) at multiple sites,[193] 
and a 20 kDa heat shock-related protein HSP20 at Ser16. HSP20 is an actin binding 
protein so its phosphorylation may modulate its binding to contractile elements to cause 
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vasorelaxation.[194-196] PKA also phosphorylates and inhibits RhoA, a protein that 
indirectly inhibits de-phosphorylation of the myosin light chain by myosin light chain 
phosphatase, resulting in smooth muscle contraction. Inhibition of RhoA by PKA 
enables de-phosphorylation of myosin light chain and smooth muscle relaxation.[197]  
 
 
Figure 4.2 Substrates for PKA in cardiomyocytes.  
PKA phosphorylates PLM which relieves its inhibition of NKA activity which is important in 
preventing intracellular Na
+ 
overload. PKA phosphorylates L-type Ca
2+
 channels and 
RyRs potentiating Ca
2+ 
influx into the cytosol increasing intracellular Ca
2+
 which induces 
contraction. PKA phosphorylates PLB releasing its inhibitory effect on SERCA, which 
increases Ca
2+ 
uptake into the SR and enhances rate of relaxation. PKA also 
phosphorylates the myofilament proteins cTnI and cMyBP-C.  
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4.1.5 Other substrates for PKA 
PKA is also able to phosphorylate a number of proteins not directly associated with EC 
coupling. Glycogen synthase kinase (GSK) 3 is important in cell proliferation, gene 
expression and cell survival,[198] and has two isoforms,  and  PKA phosphorylates 
and inhibits GSK3 at Ser21,[199] and GSK3 at Ser9.[199, 200] PKA also 
phosphorylates the transcription factor cAMP response element-binding protein (CREB) 
at Ser133 stimulating transcription of target genes,[201, 202] although one study has 
demonstrated PKA does not phosphorylate CREB at Ser133 in the mouse heart.[203] 
Phosphorylation of CREB increases binding of its cofactor, CREB-binding protein 
which is important for CREB activity.[204]  
This chapter focuses on the important issue of the potential inter-relationship of RI 
disulfide formation with classical cAMP-dependent PKA activation. For example, they 
may be mutually-exclusive events or potentially could synergise. The order in which 
oxidation or cAMP binding occur could also impact on the precise functional 
consequence of the kinase. The Cys17Ser RI KI mouse cannot form a disulfide in 
RIin response to oxidative stress (discussed in Chapter 3), and so is potentially of 
immense value in addressing these complexities. The specific aims of this chapter were 
to address the following: 
1. Whether RI disulfide sensitises PKA to cAMP, which I hypothesise may be the case 
because others have shown that substrate sensitises Type I but not Type II PKA to 
cAMP,[164, 165] and Type I can form disulfide but Type II cannot. As considered in 
detail in Chapter 5, disulfide formation may increase the affinity of RI for A-kinase 
anchoring proteins (AKAPs), targeting PKA close to its substrates where the process of 
substrate-induced activation may then occur (Figure 4.3). Therefore, disulfide may 
potentiate PKA activity caused by a given concentration of cAMP. 




Figure 4.3 Schematic of substrate-induced PKA activation.  
RI disulfide may increase affinity of RI for AKAPs causing translocation of PKA from 
the cytosol and targeting of PKA close to its substrates where substrate can sensitise 
PKA to cAMP. Upon cAMP binding to regulatory subunits, catalytic subunits are released 
which can phosphorylate target substrates. 
 
2. Whether cAMP modulates RI disulfide formation which I hypothesise may be the 
case, as cAMP binding to RI may cause a conformational change that could alter 
oxidant-induced disulfide formation. However, whether this is an increase or decrease 
in disulfide formation is difficult to say. 
3. Whether the classical mode of PKA activation by cAMP and potential disulfide-
mediated activation of PKA are integrally linked by MAO-mediated breakdown of 
monoamines. I propose this because catecholamines signal via adrenoceptors to elevate 
cAMP, but also enter cells to be metabolised by MAO to generate H2O2 which may 
induce RI oxidation. Thus, monoamines potentially trigger dual events that converge 
at RIas shown in Figure 4.15.  
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4. Whether RI disulfide dimerisation modulates cardiac function. I hypothesise this 
may occur as RI disulfide is associated with PKA activation,[57] which is associated 
with positive inotropy, chronotropy and vasorelaxation. Thus cardiac functional 
responses to oxidants such as H2O2 may be different in wild-type (WT) and Cys17Ser 
RI KI mice.  
5. Whether disulfide-oxidised PKA phosphorylates the same substrates as cAMP-
activated PKA, which may occur as RI disulfide formation has previously been shown 



















4.2.1 Dose-response to isoprenaline in Langendorff-perfused WT mouse hearts 
Any differences in sensitivity to cAMP between WT and KI hearts were compared by 
assessing their respective responses to isoprenaline. One of the classical responses to 
isoprenaline is an increase in heart rate. Therefore hearts weren‟t paced at a constant 
heart rate of 600 bpm which otherwise is my standard procedure when assessing the 
function of Langendorff-perfused mouse hearts. The rationale was that I could monitor 
and compare heart rate in WT and KI hearts basally and then after isoprenaline 
treatment. Another modification to the standard Langendorff procedure in these studies 
was that K-HB was superfused over the right atrium of the heart, which contains the 
sinoatrial node (the pacemaker tissue of the heart) that is poorly perfused by normal 
retrograde perfusion. The standard set-up shown in Chapter 2 was modified so that there 
were two separate lines emerging from each buffer reservoir rather than one. Each line 
passed through a peristaltic pump to control coronary flow, with glass heating coils in 
place to maintain the K-HB at 37 ºC (Figure 4.4A and B). One line from each reservoir 
supplied K-HB to the heart via a cannula (made from a 20-gauge blunted needle) placed 
in the aorta (as described in Chapter 2) and the other line from each reservoir superfused 
the atrium via another cannula placed over the right atrium (Figure 4.4C). Supply to the 
heart could be switched from one reservoir to another by opening and closing-off lines 
using clamps.  
A pilot study was carried out in WT hearts only to first determine whether a dose-
response to isoprenaline could indeed be achieved in un-paced hearts. WT hearts were 
Langendorff-perfused for 40 min as described in Chapter 2 but were un-paced and the 
right atrium was superfused, as described above. First, stability of the Langendorff-
perfused and atrial-superfused preparation was determined in WT hearts, so that 
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(A) Each of the two buffer 
reservoirs supplied two 
lines, which passed through 
a peristaltic pump to control 
coronary flow (CF) and 
heating systems to maintain 
temperature at 37 ºC. (B) 
Schematic of set-up for 
heart perfusion and atrial 
superfusion. (C) The heart 
was perfused by inserting a 
cannula into the aorta of the 
heart and the right atrium 
was superfused by a 
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One buffer reservoir contained K-HB and the other contained isoprenaline in K-HB 
(prepared immediately before use). Langendorff-perfused and atrial-superfused WT 
hearts were stabilised for 40 min and if they satisfied the inclusion criteria determined 
(as described above) they were then simultaneously Langendorff-perfused / atrial-
superfused with 0.1 nM isoprenaline for 5 min. The isoprenaline was then washed out 
of the heart by perfusing with K-HB for 5 min. During this „wash-out‟ period, 0.1 nM 
isoprenaline was drained out of the buffer reservoir and replaced with a higher 
concentration of 1 nM isoprenaline. The heart was then Langendorff-perfused / atrial-
superfused with 1 nM isoprenaline for 5 min followed by another 5 min K-HB „wash-
out‟. The heart was then Langendorff-perfused / superfused with 10 nM isoprenaline for 
5 min followed by another 5 min wash-out with K-HB and then 100 nM isoprenaline for 
5 min.    
4.2.2 Assessing the effect of RI disulfide on activation of PKA by cAMP  
The effect of RI disulfide formation on the cellular response to isoprenaline treatment 
was investigated in adult rat ventricular myocytes (ARVMs). 
Treatment of overnight-cultured ARVMs with diamide then isoprenaline: ARVMs 
were cultured overnight as described in Chapter 2 and then left untreated or pre-treated 
with diamide (0.1 or 0.5 mM) for 5 min followed by no further treatment or isoprenaline 
(10 nM or 1 μM) for 1, 5 or 10 min. The treatment medium was then removed and the 
cells scraped into SDS sample buffer containing 100 mM maleimide. SDS-PAGE was 
carried out followed by Western blotting with blots probed for PKA RI or phospho-
PLM (Ser68) as described in Table 4.1.   
Treatment of freshly isolated ARVMs with H2O2 then isoprenaline: ARVMs were 
isolated and left to settle as described in Chapter 2. The ARVMs were then left 
untreated or treated with 10 - 1000 μM H2O2 for 10 min and then left without further 
treatment or treated with 10 nM isoprenaline for a further 5 min. Samples were prepared 
in SDS sample buffer containing 100 mM maleimide and SDS-PAGE and Western 
blotting were carried out. Blots were probed for PKA RI to determine if isoprenaline 
(C) 
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altered RI disulfide formation. They were also probed for phospho-cTnI (Ser23/24), a 
representative PKA substrate, as described in Table 4.1. 
4.2.3 Treatment of ARVMs with 8-Br-cAMP and H2O2 to determine whether 
disulfide formation is effected by cAMP  
The classical mode of PKA activation involves cAMP binding to the regulatory 
subunits of PKA causing dissociation of the catalytic subunits from the PKA tetramer. I 
wanted to establish whether cAMP-dependent activation of PKA altered oxidant-
induced RI disulfide dimerisation.  
ARVMs were isolated and left to settle as described in Chapter 2. They were then left 
untreated or treated with 100 µM 8-Br-cAMP (a PKA activator which is a cell-
permeable cAMP analog with greater resistance to hydrolysis by phosphodiesterases 
than cAMP itself) for 15 min followed by 0 - 1000 µM H2O2 for 15 min. Samples were 
prepared in SDS sample buffer containing 100 mM maleimide after treatment. SDS-
PAGE and Western blotting were carried out and blots were probed for PKA RIas 
described in Chapter 2). 
4.2.4 Treatment of ARVMs with monoamines and MAO inhibitor 
MAO-catalysed breakdown of monoamines is an endogenous source of H2O2,[163] and 
this may potentially cause RI disulfide dimerisation. To determine if this is so, 
ARVMs were isolated and left to settle as described in Chapter 2. The ARVMs were 
left untreated or treated with 10 μM MAO inhibitor, Clorgyline, for 30 min at 37 ºC 
followed by monoamine (epinephrine, serotonin, phenylephrine or norepinephrine) at 1, 
10, 100 or 500 μM for 30 min. For epinephrine, treatment with a vehicle control (0.5 
mM HCl (VWR)) was also carried out. Samples were prepared in SDS sample buffer 
containing 100 mM maleimide after treatment. SDS-PAGE and Western blotting were 
carried out and the blots were probed for PKA RI (as described in Chapter 2) to 
determine whether treatment with a MAO inhibitor blocked any RI disulfide 
dimerisation induced by monoamine treatment. 
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4.2.5 Measuring phosphorylation of PKA substrates in control and H2O2-treated 
hearts  
Brennan et al.,[57] showed that oxidation of RI was associated with increased activity 
of PKA i.e. increased substrate phosphorylation in freshly isolated and overnight-
cultured ARVMs only. Therefore, I determined if this also occurs in isolated WT mouse 
hearts and whether there was any differential response between WT and KI hearts, so 
determining whether RI disulfide formation was associated with or indeed caused 
PKA activation in this ex vivo model system.    
WT and KI hearts were Langendorff-perfused with K-HB for 45 min or K-HB for 40 
min (stabilisation period) followed by 50 µM H2O2 for 5 min (see Chapter 2 for more 
details). Phosphorylation of PKA substrates in the hearts was analysed by incubating 
Western blots with specific antibodies; described in Table 4.1. To detect 
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Table 4.1. Phospho-PKA substrate antibodies used in studies.  
This table shows the antibodies used to measure phosphorylation of specific PKA 
substrates in untreated or H2O2-treated WT and KI hearts. The table shows the company 
from which the antibody was purchased and its product code, the species it was raised in 








4.3.1 Cardiac function in un-paced and atrial-superfused Langendorff hearts 
In order to determine the effects of isoprenaline on heart rate, the preparation was not 
paced, as mouse hearts are conventionally. During the last 20 min of the 40 min 
stabilisation period in un-paced hearts, the average EDP remained relatively stable at ~8 
mmHg and the LVDP stabilised at ~70 mmHg. However, the heart rate decreased from 
380 bpm to 300 bpm and the coronary flow decreased from 2.4 ml / min to 1.8 ml / min 
(Figure 4.5). Although this lack of stability as a result of not pacing is not ideal, it 
enables the heart rate response to isoprenaline to be determined. Some hearts were 
atrial-superfused during the stabilisation period in addition to normal Langendorff 
coronary perfusion to determine if this attenuated the decline in coronary flow or heart 
rate observed in un-paced hearts. Indeed atrial superfusion helped maintain heart rate 
which was ~440 bpm at the end of the 20 min stabilisation period. Heart rate was 
significantly (p<0.05) higher in the Langendorff-perfused and atrial-superfused heart 
compared to the un-paced Langendorff-perfused preparation. LVDP stabilised at ~80 
mmHg in atrial-superfused hearts which was higher than in un-paced hearts (but this 
was not statistically significant). Atrial superfusion did not affect EDP or coronary flow 
in un-paced hearts (stabilised at ~6 mmHg and ~3 ml / min respectively) (Figure 4.5). 
These results suggest that atrial superfusion improved function of un-paced hearts, 
especially in terms of increasing heart rate. This was important for future studies 













Figure 4.5 Effect of atrial superfusion on function of un-paced Langendorff-
perfused WT mouse hearts.  
(A) The function of the un-paced WT heart in Langendorff mode with (n=6) or without 
atrial-superfusion (n=2) was analysed. Graph shows average (± SEM for superfused) 
heart rate during the last 20 min of the stabilisation period. *p<0.05 AUC not superfused 
compared to superfused (B) Graph shows average EDP (C) Graph shows average LVDP 
(D) Graph shows average coronary flow. Atrial superfusion maintained a significantly 
higher heart rate over the 20 min period compared to when there was no superfusion. It 
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4.3.2 Dose-response to isoprenaline in Langendorff-perfused WT hearts with or 
without atrial superfusion 
A pilot study was carried out to establish whether a dose-response to isoprenaline could 
be achieved in the Langendorff-perfused and atrial-superfused WT mouse hearts before 
experiments were performed using a KI heart preparation.  
Figure 4.6 shows a representative trace from LabChart 7 for a WT heart concomitantly 
Langendorff-perfused and atrial-superfused with K-HB for 40 min followed by 
successive doses of 0.1, 1, 10 and 100 nM isoprenaline for 5 min with 5 min K-HB 
„wash-outs‟ in between each concentration. Left ventricular pressure (LVP) was 
relatively stable in the hearts before treatment, although there were a few arrhythmias. 
However, when 0.1 nM isoprenaline, 1, 10 or 100 nM isoprenaline was administered the 
heart became highly arrhythmic with a variable heart rate, EDP and LVDP making 
reliable analysis and therefore quantification of function in these hearts impossible. The 
periods when isoprenaline was washed out during the protocol reduced the number of 
arrhythmias but this was accompanied by decreased LVDP which progressively 
lowered with each successive wash. Indeed, the LVDP was eventually lower than 
during the stabilisation period making the baseline for LVDP different for each 
isoprenaline concentration. This lowering of the LVDP together with high incidence of 




 concentration in the K-HB was reduced from 1.4 mM to 0.7 mM to assess if 
this reduced the number of arrhythmias during isoprenaline treatment as Ca
2+ 
plays a 
role in arrhythmogenesis.[206] Figure 4.7 shows a representative trace from LabChart 7 
for a WT heart Langendorff-perfused and atrial-superfused with K-HB containing 0.7 
mM Ca
2+
 for 40 min followed by successive doses of 0.1, 1, 10 and 100 nM 
isoprenaline for 5 min, with 5 min wash-out periods with K-HB in between each 
concentration. During the 40 min stabilisation LVDP, EDP, coronary flow and heart 
rate stabilised with very few arrhythmias. LVDP was lower compared to when 1.4 mM 
Ca
2+
 was present in the K-HB, which is perhaps expected due to the lower extracellular 
trigger Ca
2+
. However, arrhythmias were still induced by isoprenaline, although less so 
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than with 1.4 mM Ca
2+
. The wash-outs, again, reduced the number of arrhythmias 
present compared to during isoprenaline treatment. EDP, coronary flow and heart rate 
returned to their basal level observed during the stabilisation period, but LVDP again 
decreased to below baseline. The high incidence of arrhythmias and consequential 
unstable function, together with the decrease in LVDP with each successive wash-out, 
again precluded reliable analysis and quantification of these hearts. Ultimately, this 
meant I could not undertake studies comparing the functional response of the heart in 
WT and KI mice which had been a primary aim. 
 
Figure 4.6. Dose-response to isoprenaline in Langendorff-perfused WT mouse 
heart.  
Un-paced hearts were Langendorff-perfused and atrial-superfused for 40 min with K-HB 
(containing 1.4 mM Ca
2+
) and then isoprenaline (0.1 - 100 nM) for 5 min with 5 min K-HB 
wash-outs in between each concentration of isoprenaline. Representative LabChart 
traces show LVP, perfusion pressure, coronary flow, heart rate, EDP and LVDP during 
the experiment. LVDP decreased with each successive wash making the baseline 
different for each isoprenaline concentration. The unstable function and decrease in 
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Figure 4.7. Effect of K-HB Ca
2+ 
concentration on dose-response to isoprenaline.  
Un-paced hearts were Langendorff-perfused and atrial-superfused for 40 min with K-HB 
(containing 0.7 mM Ca
2+
) and then isoprenaline (0.1 - 100 nM) for 5 min with 5 min K-HB 
wash-outs in between each concentration of isoprenaline. Representative LabChart 
traces show LVP, perfusion pressure, coronary flow, heart rate, EDP and LVDP during 
the experiment. 0.7 mM Ca
2+
 did not reduce the number of arrhythmias during 
isoprenaline treatment and LVDP still decreased with each successive wash making the 
baseline different for each isoprenaline concentration. The unstable function and 
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4.3.3 Isoprenaline and RI disulfide formation ex vivo 
The effect of isoprenaline on RI disulfide formation when perfused through the 
Langendorff mouse heart preparation was assessed. 100 nM isoprenaline treatment for 5 
min did not significantly alter the percentage RI disulfide in WT hearts compared to 
controls, and as expected there was no RI disulfide present in KI hearts (Figure 4.8). 




































Figure 4.8 Effect of isoprenaline on RI disulfide in Langendorff-perfused WT and 
KI hearts.  
Hearts were perfused with K-HB for 45 min (control n=3) or K-HB for 40 min followed by 
100 nM isoprenaline for 5 min (WT n=4, KI n=2). Western blots were probed for PKA RI. 
Top, representative blot (broken line represents a cut in the film) shows RI monomer 
and disulfide dimer and bottom, graphical representation of average percentage RI 
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4.3.4 Effect of diamide on isoprenaline-induced phosphorylation of PLM in 
overnight-cultured ARVMs 
Other research groups,[164, 165] have demonstrated that substrate sensitises Type I, but 
not Type II, PKA to cAMP. I wanted to determine whether RI disulfide sensitised 
PKA to cAMP because the disulfide can form in Type I PKA but not Type II. Disulfide 
may increase affinity of RI for AKAPs, which would position it close to substrate and 
potentially enable substrate-induced sensitisation to cAMP. The RI protein used in the 
studies,[164] would have almost certainly been in the disulfide state because of the 
absence of reducing buffers and the presence of oxygen in the air. The presence of the 
disulfide may therefore be integral to this sensitisation phenomenon (Figure 4.3). 
Perhaps if the studies had been carried out with reduced RI then substrate-induced 
sensitisation would have been absent, as in the RII preparation. This hypothesis was 
initially investigated using a cell-based approach. Overnight-cultured ARVMs were 
treated with diamide (to cause disulfide formation) and then isoprenaline (to produce 
cAMP and classically activate PKA). PKA RI disulfide formation was assessed as 
well as PLM phosphorylation, as a measure of PKA activity. If the disulfide does 
sensitise PKA to cAMP then I would expect more PLM phosphorylation for a given 
cAMP concentration when diamide pre-treatment was used compared to control without 
it. Figure 4.9 shows that the level of basal RI monomer varies between different cell 
isolations (A, B or C). The level of disulfide dimer in untreated control cells is higher 
than expected based on previous work from this lab,[57] and the total signal for RI 
does not add up between treatment groups. 0.5 mM diamide induced the anticipated 
disulfide dimerisation (Figure 4.9A) and caused PLM phosphorylation to a level 
comparable to isoprenaline (Figure 4.9B), suggesting PKA activation. However, pre-
treatment with diamide did not alter the level of isoprenaline-induced PKA activation.  
As 0.5 mM diamide caused such a high level of phosphorylation, I assessed the effect of 
a lower concentration of diamide on isoprenaline-induced PLM phosphorylation. 0.1 
mM diamide caused minimal RI disulfide dimerisation and did not induce PLM 
phosphorylation whereas 10 nM isoprenaline did induce PLM phosphorylation, as 
expected (Figure 4.9C). Diamide had a differential effect on isoprenaline-induced PLM 
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phosphorylation with time where 1 min diamide appeared to reduce phosphorylation 
induced by isoprenaline, 5 min diamide increased the phosphorylation induced by 
isoprenaline and 10 min diamide reduced phosphorylation induced by isoprenaline. It 
should be noted that this experiment was not replicated because of the variable levels of 
basal RI monomer between different cell isolations. The variation in RI redox state 
and total RI expression between different isolations (see discussion on this in Chapter 
2.2) made it impossible to establish whether disulfide dimerisation effects activation of 





































































































Figure 4.9 Effect of RI disulfide on isoprenaline-induced PLM phosphorylation.  
(A) Overnight-cultured ARVMs were left untreated or pre-treated with 0.5 mM diamide for 
5 min. No further treatment or 1 μM isoprenaline was then added (1, 5 or 10 min). 
Western blots were probed for PKA RI (B) Same as (A) but in a different ARVM 
isolation. Western blots were also probed for phospho-PLM (Ser68) (C) Overnight-
cultured ARVMs were pre-treated with 0 - 0.1 mM diamide (5 min) and then treated with 
10 nM isoprenaline (1, 5 or 10 min). Western blots were probed for PKA RI or phospho-
PLM (Ser68). RI abundance varied between treatments and presence of RImonomer 
varied between isolations making analysis difficult.  
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4.3.5 Effect of RI disulfide on isoprenaline-induced phosphorylation of cTnI in 
freshly isolated ARVMs 
As discussed in section 2.2 and section 4.3.4, there are problems with using overnight-
cultured ARVMs. To avoid these issues, the effect of RI disulfide on response to 
isoprenaline was investigated in freshly isolated ARVMs. Treatment with increasing 
concentrations of H2O2 (10 - 100 µM) caused a trend towards an increase in 
phosphorylation of cTnI, although 1000 µM caused no increase in phosphorylation 
compared to isoprenaline alone (Figure 4.10A). Treatment of ARVMs with 10 nM 
isoprenaline alone caused an increase in cTnI phosphorylation compared to control 
untreated. This was the positive control to confirm that the ARVMs were responding to 
this concentration of isoprenaline. Pre-treatment with 10 - 100 µM H2O2 potentiated 
isoprenaline-induced cTnI phosphorylation and caused a trend towards an increase in 
phosphorylation with increasing concentration of H2O2. However, pre-treatment with 
1000 µM caused a reduction in isoprenaline-induced phosphorylation of cTnI. Figure 
4.10B confirms that treatment of freshly isolated ARVMs with increasing 
concentrations of H2O2 (10 - 1000 µM) caused a trend towards an increase in 
percentage RI disulfide dimer, and treatment with isoprenaline after H2O2 did not alter 
this trend. Total RI protein was similar between treatments unlike in overnight-
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Figure 4.10 Effect of RI disulfide on response to isoprenaline in freshly isolated 
ARVMs.  
(A) ARVMs were left untreated or treated with 10 - 1000 μM H2O2 (10 min) and then left 
untreated or treated with 10 nM isoprenaline (5 min). Representative Western blot probed 
for phospho-cTnI (Ser23/24) and quantification of phospho-cTnI normalised to 
phosphorylation with 10 nM isoprenaline alone (n=4) ± SEM are shown. H2O2 caused a 
trend towards an increase in cTnI phosphorylation and concentrations up to 100 μM 
potentiated isoprenaline-induced phosphorylation of cTnI. *p<0.05 curve for cTnI 
phosphorylation with isoprenaline compared to without (2-way ANOVA with repeated 
measures) (B) Western blots were probed for PKA RIQuantification of percentage RI 
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4.3.6 Effect of cAMP on RI disulfide formation 
The classical mode of Type I PKA activation involves cAMP binding to the RI 
subunits. I wanted to determine whether this event sensitised RI to disulfide 
dimerisation. Treatment of freshly isolated ARVMs with increasing concentrations of 
H2O2 up to 1000 µM increased the percentage RI disulfide dimer, with ~35 % 
disulfide dimer basally and ~95 % disulfide dimer in 1000 µM H2O2-treated ARVMs 
(Figure 4.11). Pre-treatment of ARVMs with 100 µM Br-cAMP (to activate PKA) 
caused a trend towards potentiation of the H2O2-induced RI disulfide formation when 
the vehicle control had no effect. The potentiation was statistically significant (p<0.05) 













Figure 4.11 Effect of cAMP on RI disulfide dimerisation.  
Freshly isolated ARVMs were left untreated or pre-treated with Br-cAMP (100 μM, 15 
min) followed by 0 - 1000 μM H2O2 (10 min). Western blots were probed for PKA RI. 
Representative blot shows RIdisulfide dimer and reduced monomer. Graph shows 
quantification (n=6 ± SEM) of percentage RI disulfide. Increasing concentrations of H2O2 
caused an increase in RI disulfide dimerisation and pre-activation of PKA by cAMP 






























































Chapter 4: RI Disulfide and cAMP-mediated PKA Activation 
139 
 
4.3.7 MAO as a source of H2O2 for RI disulfide formation 
Members of my research laboratory found that monoamines caused PKG I disulfide 
dimerisation and that a MAO inhibitor blocked this effect (unpublished). These 
observations were consistent with breakdown of monoamines by MAO to yield H2O2 
which then oxidises PKG I to disulfide dimer.[60] I therefore hypothesised that 
monoamines may have the same effect on PKA RI disulfide dimerisation.  
Treatment of freshly isolated ARVMs with increasing concentration of epinephrine up 
to 10 µM (Figure 4.12A) caused a trend towards a small decrease in the percentage of 
RI disulfide (~50 % to ~40 %). However, treatment of ARVMs with epinephrine at 
higher concentrations (100 µM and 500 µM) increased RI disulfide over control 
untreated ARVMs, albeit this was not statistically significant. The vehicle for 
epinephrine had no effect on basal RI oxidation. Another monoamine phenylephrine, 
did not cause RI disulfide formation in ARVMs at concentrations below 500 µM, with 
percentage RI disulfide remaining at ~40 %, although 500 µM phenylephrine caused a 
small increase (~15 %, not statistically significant) which was inhibited by pre-
treatment with the MAO inhibitor Clorgyline (Figure 4.12B). Treatment of ARVMs 
with increasing concentrations of norepinephrine (1 - 500 µM) caused a clear trend 
towards an increase in RI disulfide formation compared to control untreated (~25 % 
increase at  500 µM), and this increase was blocked by pre-treatment with the MAO 
inhibitor (Figure 4.12C). This was also observed with serotonin treatment where 100 
µM or 500 µM serotonin increased RI disulfide formation by ~10 % or ~20 % 
respectively and this was blocked by Clorgyline (Figure 4.12D). There was a significant 
difference (P<0.0001) between the curve for RI disulfide formation with increasing 
concentration of serotonin and the curve for disulfide formation with increasing 
concentration of serotonin and Clorgyline pre-treatment. In all these experiments, 
treatment with diamide caused ~100 % RI disulfide dimer formation so ARVMs were 
responding as expected. 
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 (A)                                                                 (B)    
 (C)                                                                        (D) 
Figure 4.12 Monoamines and PKA RI disulfide dimer formation.  
(A) Freshly isolated ARVMs were left untreated or pre-treated with MAO inhibitor (10 μM, 
30 min) followed by 0 - 500 μM epinephrine for 30 min. Western blots were probed for 
PKA RI Representative blot shows RI monomer and disulfide dimer and graphs 
present average percentage RI disulfide dimer for n=5 experiments (± SEM). (B) 
ARVMs were treated with the monoamine phenylephrine. (C) ARVMs were treated with 
norepinephrine. (D) ARVMs were treated with serotonin. There was a trend towards an 
increase in RI disulfide dimer with increasing concentrations of epinephrine or 
norepinephrine or serotonin but not phenylephrine and inhibition of MAO blocked the 
increase in disulfide formation. This effect was statistically significant for serotonin 
(*P<0.05 curve for RI disulfide with MAO inhibitor compared to without, 2-way ANOVA 
with repeated measures). 
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4.3.8 Effect of RI disulfide on Langendorff function  
Western blotting studies confirmed KI Cys17Ser RI does not form disulfide basally or 
in response to oxidative stress (Chapter 4). Therefore, by comparing the responses of 
WT and KI littermates basally and after oxidative stress (which induces RI disulfide in 
WTs), I may be able to determine the role of this single oxidative modification in 
various cardiovascular „functional‟ parameters. Consequently, the isolated heart model 
was used to assess how H2O2 alters coronary flow, LVDP and EDP in WT and KI 
hearts. A concentration of H2O2 was required that had an effect, but was not un-
necessarily high. 50 µM H2O2 was chosen as the concentration to perfuse WT and KI 
hearts with to determine the role of RI disulfide on cardiac function. 50 µM was 
chosen because results from a pilot study in C57BL/6 mice showed that this 
concentration altered coronary flow and LVDP similarly to 100 µM H2O2 and also 
increased EDP, albeit to a lesser degree than 100 µM H2O2 (data not shown). 
Figure 4.13 shows coronary flow, EDP and LVDP in male WT and KI hearts 5 min 
before and 5 min after 50 μM H2O2 Langendorff-perfusion. Basal coronary flow (Figure 
4.13A) was similar in WT and KI hearts (~3.9 ml / min). KI hearts showed a 
statistically significant (p<0.05) increase of ~0.4 ml / min in coronary flow with H2O2 
and in WT hearts, there was an initial trend towards an increase in coronary flow (~0.2 
ml / min) when H2O2 was perfused, but this decreased again.  
Basal EDP (~7 mmHg, Figure 4.13B) was similar in WT and KI hearts, with H2O2 
causing a statistically significant (p<0.05) increase in both genotypes. However, the 
increase was more pronounced in WT hearts (~8 mmHg) compared to KI (~4 mmHg). 
H2O2 caused a statistically significant (p<0.05) decrease in LVDP (Figure 4.13C) in 
both WT (~77 mmHg to ~56 mmHg) and KI (~64 mmHg to ~59 mmHg) hearts but the 
effect was less pronounced in the latter. However, this may be because KI hearts also 
had a significantly (p<0.05) lower basal LVDP compared to WT hearts. 
 
 




      (B) 
(C) 
Figure 4.13 Effect of H2O2 on function of Langendorff-perfused WT and KI hearts.  
(A) WT and KI hearts were Langendorff-perfused with K-HB for 40 min followed by 5 min 
50 μM H2O2. Graph shows average coronary flow (WT n=6, KI n=7 ± SEM) during the last 
5 min of the stabilisation period and then during 5 min perfusion with H2O2. * p<0.05 area 
under curve (AUC) for parameter during 5 min H2O2 perfusion compared to parameter 
during 5 min aerobic perfusion. (B) Graph shows average EDP. (C) Graph shows 
average LVDP. # p<0.05 for AUC of LVDP in KI compared to WT. H2O2 caused a 
significant increase in coronary flow and significant decrease in EDP and LVDP in both 
WT and KI hearts. 
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4.3.9 RI disulfide and phosphorylation of PKA substrates in WT and KI hearts  
Previous work in our laboratory showed that phosphorylation of PKA substrates 
increased following H2O2 treatment in both freshly isolated ARVMs as well as 
overnight-cultured ARVMs. The H2O2-induced phosphorylation was associated with 
RI disulfide formation,[57] but this was not investigated in isolated Langendorff-
perfused hearts exposed to H2O2. 
Phosphorylation of selected PKA substrates (at their established PKA phosphorylation 
sites) was compared between untreated WT and KI hearts (which cannot form RI 
disulfide) to see if RI disulfide affected basal phosphorylation levels. Some basal 
differences in PKA activity may have been anticipated as WT hearts contain some basal 
disulfide dimerised RI (Figure 4.8). However, Figure 4.14 shows that there were no 
significant differences in the phosphorylation of any of the PKA substrates (phospho-
PLM (Ser68), phospho-PLB (Ser16), phospho-cTnI (Ser23/24), phospho-MyBP-C 
(Ser302/Ser282), phospho-CREB (Ser133) or phospho-GSK3 (Ser9)) analysed 
between WT and KI hearts.  
In WT hearts phosphorylation of PLB at Ser16 was significantly decreased by 50 µM 
H2O2. There was also a trend for a decreased phosphorylation of cTnI at Ser23/24 and 
cMyBP-C at Ser282 or Ser302 with H2O2 in both WT and KI hearts. No other substrates 
studied altered their phosphorylation status in WT or KI hearts exposed to H2O2. 
Both WT and KI hearts responded to 100 nM isoprenaline, as demonstrated by 
increased phosphorylation of PLM at Ser68, PLB at Ser16, cMyBP-C at Ser282 and 
Ser302, GSK3β at Ser9 and cTnI at Ser23/24 compared to untreated controls. However 
unexpectedly, isoprenaline did not cause phosphorylation of CREB at Ser133 in WT or 










Figure 4.14 Phosphorylation of PKA 
substrates in untreated and H2O2-treated 
WT and KI hearts.  
(A) Male hearts were Langendorff-
perfused with K-HB (WT, KI n=6) or K-HB 
followed by 50 μM H2O2 (WT, KI n=6) or 
100 nM isoprenaline (WT, KI n=2). 
Western blots were probed for phospho-
cMyBP-C (Ser282) (B) phospho-cMyBP-C 
(Ser302) (C) phospho-CREB (Ser133) (D) 
phospho-GSK3β (Ser9) (E) phospho-PLM 
(Ser68) (F) phospho-PLB (Ser16) (G) 
phospho-cTnI (Ser23/24). Graphs show 
average percentage phosphorylation of 
the substrate normalised to the first 
control of each set of samples run on the 
same gel ± SEM. * p<0.05 compared to 
untreated WT. RI disulfide formation was 
associated with a significant reduction in 
PLB phosphorylation at Ser16. 







- + - + - - 50M H2O2
100nM
Isoprenaline













































- + - + - - 50 M H2O2
100 nM
Isoprenaline














































- + - + - - 50 M H2O2
100 nM
Isoprenaline















































- + - + - - 50 M H2O2
100 nM
Isoprenaline
















































- + - + - - 50 M H2O2
100 nM
Isoprenaline

















































- + - + - - 50M H2O2
100 nM
Isoprenaline













































- + - + - - 50 M H2O2
100 nM
Isoprenaline












































142 kDa 142 kDa 
43 kDa 47 kDa 
  24 kDa 
15 kDa 6 kDa 




This chapter focused on whether the classical mode of PKA activation by cAMP is 
effected by, or indeed affects oxidant-induced RI disulfide formation. The cAMP 
binding sites and the Cys residues where disulfides form are relatively close to each 
other in RI. Certainly cAMP binding causes substantial structural changes (as might a 
disulfide) and so hypothesising that these events synergise or are mutually exclusive is 
rational. This is an important issue and trying to better understand the interplay between 
cAMP binding and RI disulfide formation may provide insight into the redox 
regulation of PKA.  
Isoprenaline was studied as a positive control for PKA activation as it binds 1 
adrenoceptors causing production of cAMP which activates PKA. Isoprenaline did not 
cause RI disulfide formation when perfused through WT hearts. It also failed to induce 
disulfide dimerisation in freshly isolated ARVMs, whereas other monoamines tested 
did. Epinephrine, serotonin and norepinephrine all induced RI disulfide formation and 
this is likely explained by their metabolic decomposition by MAO, during which H2O2 
is generated.[162, 163] This scenario is supported by the observation that the MAO 
inhibitor Clorgyline blocked monoamine-induced RI disulfide formation, consistent 
with such treatment blocking H2O2 production.   
Western blotting showed that phenylephrine did not induce RI disulfide until high 
concentrations were applied despite being a substrate for MAO.[207] Phenylephrine 
could be coupling RI oxidation to disulfide even at low concentrations but not 
accumulating due to rapid redox recycling by the thioredoxin (Trx) system. Studies in 
Chapter 6 demonstrate that inhibition of TrxR by auranofin or cisplatin caused 
accumulation of RI disulfide showing that even basally that there must be an oxidant 
stress that couples to RI oxidation. However, redox cycling prevents us observing this. 
With higher concentrations of phenylephrine, the disulfide may accumulate because of 
enhanced H2O2 production which overwhelms the cardiac Trx reducing system and so 
oxidation of RI is „unveiled‟.  
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500 µM was the highest concentration of monoamine that ARVMs were exposed to, 
which is far beyond the physiological low nanomolar level. It is possible that I would 
observe RI disulfide accumulation at lower concentrations of monoamine, if the Trx 
system was inhibited to prevent reduction of the disulfide (discussed in Chapter 6). 
Isoprenaline is not a substrate for MAO and is instead metabolised by catechol-O-
methyl transferase which involves O-methylation (addition of CH3 to O) of 
isoprenaline.[208, 209] Therefore, H2O2 is not produced during its metabolism which 
explains why it did not cause RI disulfide dimerisation.  
I hypothesised that RI disulfide may sensitise PKA to cAMP as others,[164, 165] 
showed that Type I, but not Type II, PKA is sensitised to cAMP by substrate. One of 
the differences between Type I and Type II is that Type II cannot form regulatory 
subunit disulfides as it does not have the N-terminal Cys residues required for this. As 
described in Chapter 5 and shown in Figure 4.3, disulfide may increase RI affinity for 
AKAPs, which may serve to target PKA close to its substrate which would facilitate the 
substrate-induced activation mechanism, which does not occur in RII. This may provide 
a mechanism for sensitisation of PKA to cAMP. It is difficult to replicate such a model 
in a test tube with just RI and substrate because the AKAP may not be needed as the 
RI and substrate are already together. In contrast, in the cell RI would have to 
translocate via AKAP binding due to RI oxidation. I had anticipated Langendorff-
perfused WT and KI mice would differentially respond to given concentrations of 
isoprenaline (which induces cAMP production) with WT hearts having a larger increase 
in LVDP and coronary flow and a larger decrease in EDP for a given concentration of 
isoprenaline compared to KI. This was anticipated as the KI would lack the sensitisation 
that the disulfide would potentially provide. However, I was unable to construct a dose-
response curve to isoprenaline in un-paced Langendorff-perfused WT hearts that could 
be analysed accurately. This was because the heart became highly arrhythmic during 
isoprenaline perfusion making analysis inaccurate and unreliable. These arrhythmias 
were likely caused by Ca
2+
-overload induced by isoprenaline. A decrease in LDVP was 
also observed between concentrations of isoprenaline (during the wash-out period) 
which was not expected and made analysis essentially impossible. This decrease in 
LVDP has been observed by others in this department and may occur because the heart 
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is working hard when isoprenaline is administered. Therefore, the heart may become 
stressed with repeated isoprenaline stimulation and unable to recover during the wash-
out period. A dose-response to isoprenaline in un-paced mouse hearts has been achieved 
by others,[210, 211] but they do not show how stable the un-paced hearts were before 
isoprenaline treatment. These authors also perfused hearts with isoprenaline in 
increments rather than having wash-out periods between final isoprenaline 
concentrations. This may be an alternative protocol for comparing WT and KI heart 
whereby a dose-response to isoprenaline is given, but due to time constraints I did not 
attempt such studies. 
Another approach to assessing cAMP sensitivity would be to treat vascular aortic rings 
with different concentrations of isoprenaline. Dose-relaxation response curves (as 
performed by others,[212]) for WT and KI aortic rings could then be compared to assess 
any difference in cAMP-sensitivity between genotypes. Also, myocytes could be 
isolated from WT and KI hearts and treated with different concentrations of 
isoprenaline, comparing the phosphorylation responses of PKA substrates between 
genotypes. EC coupling experiments could be performed measuring contractile function 
and Ca
2+
 transients. These studies are being carried out in the Laboratory of Professor 
Maier (Goettingham, Germany). In addition, the difference in cAMP-sensitivity with 
RI disulfide may be investigated using pure WT and KI Cys17Ser RI protein in in 
vitro kinase assays. 
H2O2 has been reported to modulate the response to isoprenaline.[213, 214] Pre-
treatment of Langendorff-perfused rat hearts with 200 or 500 µM H2O2 for 10 min 
attenuated their response to 1 µM isoprenaline due to depression of adenylate cyclase 
activity.[213] A biphasic response to isoprenaline has been shown in rat heart 
membranes with increasing concentrations of H2O2 where low concentrations of H2O2 
(100 and 200 µM) increased isoprenaline-induced adenylate cyclase activity and high 
concentrations decreased the enzymes activity.[214] 
I assessed the influence of RI disulfide on response to isoprenaline in ARVMs. This 
experiment could only be carried out in freshly isolated ARVMs as the total RI protein 
abundance varied between treatments in overnight-cultured ARVMs, as discussed in 
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Chapter 2.2. Increasing the amount of RI disulfide via treatment with H2O2 potentiated 
isoprenaline-induced phosphorylation of cTnI, with this eventually reaching a peak 
where-after the phosphorylation level returned to that with isoprenaline alone. There 
was also a trend towards an increase in cTnI phosphorylation in ARVMs treated with 10 
- 100 µM H2O2 alone (no isoprenaline present). Although the amount of RI disulfide 
increased with 1000 µM H2O2 the amount of phosphorylation did not increase above 
that at 100 µM H2O2. This could be due to cell death caused by the higher H2O2 
concentration and isoprenaline together. However, oxidation of PKA catalytic subunit 
has been shown by others with 100 µM diamide, inhibiting PKA activity.[58] 
Consequently, the higher concentrations of H2O2 used in my experiments perhaps cause 
PKA catalytic subunit oxidation, perhaps acting as an off-switch to prevent chronic 
PKA activation resulting from RI disulfide formation. As discussed in Chapter 1, the 
catalytic subunit can also be modified by Cys-targeted oxidation. Humphries et al. 
showed that, during oxidative stress, the catalytic subunit was sensitive to inhibition by 
intraprotein and interprotein disulfide formation.[58, 113] I have not assessed whether 
these modifications occur in my samples but my research laboratory has previously 
screened for proteins susceptible to Cys-targeted oxidation,[120-123] and the PKA 
catalytic subunit was not identified, although they could have missed it due to low 
abundance.  
Schröder et al. suggest that application of 10 µM to 1 mM H2O2 is physiological and 
ARVMs may be treated with these concentrations of H2O2 for hours before there is any 
detrimental effect.[215] Therefore the treatment conditions used in my experiments are 
potentially physiologically relevant, although the physiological concentration range of 
H2O2 is a matter of debate.  
Results in freshly isolated ARVMs showed a trend towards cAMP pre-treatment 
potentiating H2O2-induced RIdisulfide formation suggesting that cAMP sensitises 
RI to disulfide formation. This may be because cAMP binding causes a 
conformational change that alters the Cys thiols such that they are more readily 
oxidised. RI disulfide may be redox-cycled to the reduced state by the Trx system at 
low oxidant concentrations so less of a potentiation by isoprenaline is observed.  
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One of the aims of this chapter was to establish whether oxidation of RI to disulfide 
induces phosphorylation of substrates and alters cardiac function similarly to when PKA 
is classically activated by cAMP binding to RI. In terms of contractile function as a 
comparative read-out of function ex vivo this was not readily apparent. For example, I 
found that H2O2 decreases LVDP and increases EDP in WT and KI hearts. If RI 
disulfide is directly activating PKA,[57] as occurs via mechanisms that couple to cAMP 
elevation, I would expect an increase in LVDP and a decrease in EDP in WT hearts. 
However, one confounding issue is that H2O2 will concomitantly activate PKG I. 
Burgoyne et al.,[97] showed that isoprenaline-induced activation of PKA increased 
LVDP in rat hearts and this then slowly decreased with time. This isoprenaline-induced 
increase in LVDP declined more rapidly, however, when PKG I was activated by S-
Nitroso-N-Acetyl-D,L-Penicillamine (SNAP)-generated NO. Burgoyne also showed 
that H2O2 did not affect LVDP in rat hearts but when PKG I was inhibited a transient 
increase in LVDP occured. These results suggest that PKG I overrides PKA effects 
and this may also be occurring in my studies. PKG may override PKA by 
phosphorylating the L-type Ca
2+
 channels to attenuate trigger Ca
2+
 influx and so 
decrease contractile function.[216] In the future, perfusing hearts with a PKG inhibitor 
may help confirm this. Another explanation could be H2O2-induced inhibition of 
adenylate cyclase,[213] as already mentioned, and this would mean that cAMP is not 
generated to activate PKA despite RI oxidation promoting sensitisation to the second 
messenger. 
The increase in EDP induced by H2O2 perfusion was more significant in WT than KI 
hearts. KI hearts therefore appear to be partially resistant to the diastolic dysfunction 
induced by H2O2. This may, however, be explained by results from echocardiography 
(see Chapter 3) showing that KI left ventricle volume was larger than WT during 
diastole, thus at the end of diastole the pressure on a certain sized balloon inserted into 
the ventricle will be less in KI hearts than WT hearts.    
Interestingly, basal LVDP was significantly lower in KI hearts which could be 
explained by a basal turnover of disulfide in WT hearts that cannot occur in KI, 
resulting in higher basal PKA activity in WT compared to KI. This would occur if thiol 
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oxidants are produced basally in control hearts, which is likely as such products are 
generated in many biochemical processes. As mentioned, I investigated this idea of RI 
disulfide turnover by assessing reversal of the RI disulfide by the Trx system (see 
Chapter 6).     
H2O2, like cAMP, induced coronary vasorelaxation but RI disulfide did not play a role 
as coronary flow increased to the same extent in both genotypes. Activation of smooth 
muscle PKG is a principal mechanism of vasorelaxation and blood pressure lowering. 
As the 1 isoform of PKG is directly activated by H2O2,[60] this may explain the 





 channels through the phospholipase A2 / arachidonic acid 
signalling pathway to cause vasorelaxation.[217, 218] The literature on responses to 
H2O2 in the isolated mouse heart is relatively sparse but several studies have been 
reported in the isolated rat heart with H2O2 (180 µM, 10 min) reversibly increasing 
coronary flow, decreasing LVDP and increasing EDP.[219] The dysfunction with H2O2 





which increases intracellular Na
+
 leading to Ca
2+
 overload.[220, 221] 
As discussed above, I found some evidence of increased cTnI phosphorylation with 10- 
100 µM H2O2 in freshly isolated ARVMs after-which there was no further effect on 
cTnI phosphorylation by H2O2. Increased phosphorylation of cTnI in response to 100 
µM H2O2 was also observed by Brennan et al.[57] Others have also shown increased 
phosphorylation of cTnI in response to H2O2, but provided evidence that this was PKC-
dependent.[222] I wanted to determine if H2O2 increased substrate phosphorylation ex 
vivo in WT and KI hearts and whether there was any difference between genotypes. The 
only significant difference was in PLB phosphorylation; H2O2 decreased Ser16 
phosphorylation of PLB in WT but not KI. PLB inhibits sarcoplasmic reticulum (SR) 
Ca
2+
-ATPase (SERCA) and phosphorylation of PLB at Ser16 relieves this inhibition. 
Decreased phosphorylation of PLB after H2O2 would attenuate SERCA activity 
resulting in reduced Ca
2+
 uptake into the SR. This would result in elevated cytosolic 
Ca
2+
, causing the heart to relax less during diastole. This may also explain the potential 
increase in EDP observed in WT compared to KI with H2O2 perfusion. Sulakhe et 
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al.,[223] have shown that the hydroxyl radical decreases phosphorylation of PLB in 
response to  adrenergic stimulation. The mechanism by which H2O2 reduces 
phosphorylation of PLB is unclear but perhaps activation of phosphatases such as 
protein phosphatase (PP) 2A ,[224] could be responsible. Protein tyrosine phosphatases 
can be reversibly inhibited by H2O2 unlike Ser / threonine phosphatases such as PP2A 
whose activity was not altered.[225]  
Basal substrate phosphorylation was not significantly different between WT and KI 
hearts which may be expected in the absence of oxidative stress although some basal 
level of oxidant production is likely. However, yet unpublished studies by Professor 
Maier‟s group at the University of Goettingen, Germany found in collaboration studies 
that SR Ca
2+
 content was lower and diastolic Ca
2+
 concentration was higher in myocytes 
isolated from the KI mouse compared to WT at baseline. They suggest this may be 
because oxidant-dependent PKA activation is important for PLB phosphorylation. 
Although my results suggest there was not a statistically significant difference in PLB 
phosphorylation between control perfused WT and KI hearts, there was a clear 
indication of a trend towards lower phosphorylation in KI than WT. These findings 
conflict with my results in Langendorff-perfused hearts where H2O2 significantly 
decreased PLB phosphorylation at Ser16 in WT but not KI. However, this could be 
because H2O2 may be activating other signalling pathways in the Langendorff heart that 
over-ride PKA‟s actions, such as PKG (as discussed above). Brennan et al.,[57] showed 
PLB phosphorylation at Ser16 was increased by H2O2 in ARVMs which agrees with the 
unpublished work from Maier‟s laboratory. As discussed in Chapter 5, RI redox state 
could modulate its interaction with a PLB-associated AKAP, namely AKAP7γ,[226] 
potentially enabling targeting of PKA to its substrate PLB for phosphorylation.        
Although H2O2 did not cause any significant differences in phosphorylation of any PKA 
substrates other than PLB, the large errors in these measurements may mask any 
disparate responses. The large errors could be due to the Langendorff mouse heart being 
highly stress-sensitive which could activate kinases to elevate basal phosphorylation of 
substrates. There was, however, a trend for a decrease in phosphorylation of cMyBP-C 
and cTnI with H2O2 in both genotypes, which may contribute to the decline in 
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contractile function with H2O2 ex vivo. Therefore, it seems RI disulfide did not affect 
PKA activity in the same way as cAMP in terms of PKA substrate phosphorylation in 
isolated hearts. KI hearts still responded to cAMP, as shown by similar amounts of 
substrate phosphorylation in both genotypes in response to isoprenaline. Unexpectedly, 
CREB was not phosphorylated at Ser133 in response to isoprenaline in either genotype 
consistent with Li et al.,[203] who found that 100 nM isoprenaline did not cause CREB 
to be phosphorylated at Ser133. They concluded that PKA does not phosphorylate 
cardiac CREB at Ser133 after isoprenaline treatment, unlike in other tissues, whereas 
PKCε does after phorbol 12-myristate 13-acetate stimulation. 
Experiments using freshly isolated ARVMs generally provide more clear-cut 
understandable results than the Langendorff mouse heart model in terms of the effect of 
RI disulfide on substrate phosphorylation and cAMP sensitisation.  
As shown in Figure 4.15, results in ARVMs suggest MAO-catalysed metabolism of 
monoamines appears to be a source of H2O2 for RI disulfide dimerisation. These 
monoamines also target  adrenoceptors linked to Gs proteins which activate adenylate 
cyclase and generate cAMP. Therefore, monoamines have a dual input and may 
synergise to activate PKA. Disulfide may increase RI affinity for AKAPs (see Chapter 
5) targeting RI close to its substrate for substrate-induced activation. This potentially 
increases PKA sensitivity to a given concentration of cAMP and so RI disulfide is 
associated with PKA activation. Results suggest cAMP itself sensitises RI to disulfide 
dimerisation induced by H2O2. The observed increase in substrate phosphorylation to a 
peak suggests that the above cycle of events lead to increased RI disulfide formation 
and PKA activity until a maximum when PKA activity returns to baseline. This 
suggests there is an off-switch. This off-switch may be catalytic subunit oxidation,[58] 
or recycling of RI disulfide by the Trx system (see Chapter 6). It may be interesting to 
test what happens in cells or a heart exposed to chronic or extreme acute oxidative stress 
when the system is really pushed as the off-switch could fail. This could be detrimental 
similarly to when the  adrenergic system is overstimulated in heart failure.[227]  
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Ex vivo results are more difficult to explain because I expected to observe an increase in 
contractility and substrate phosphorylation with H2O2 in WT hearts associated with 
increased PKA activity but instead observed decreased contractility and unaltered or 
decreased substrate phosphorylation. This could be due to activation of other signalling 
pathways in the Langendorff-perfused heart that are not activated in freshly isolated 
ARVMs as there are other cell types present but also the heart may just be more 
sensitive to the effects of H2O2 as a whole organ rather than isolated cells. 
 
Figure 4.15 Summary of results in freshly isolated ARVMs.  
Monoamines target  adrenoceptors which activate adenylate cyclase (AC) generating 
cAMP which activates PKA. These monoamines are also metabolised by MAO to produce 
H2O2 which oxidises RI to disulfide, associated with PKA activation. These monoamines 
therefore have two mechanisms for PKA activation which may synergise. In addition, cAMP 
sensitises RI to disulfide formation and RI disulfide sensitises PKA to cAMP resulting in 
increased PKA activity. The Trx system may be important in recycling RI disulfide and 
preventing chronic PKA activation. Serotonin (which targets the 5-HT receptor) metabolism 
by MAO is also a source of H2O2 for disulfide formation. 
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5 A ROLE FOR RI DISULFIDE IN A-KINASE 
ANCHORING PROTEIN (AKAP) BINDING 
5.1 INTRODUCTION 
Subcellular localisation of 3′,5′-cyclic monophosphate (cAMP)-dependent protein 
kinase (PKA) can be determined by its association with scaffolding proteins known as 
A-kinase anchoring proteins (AKAPs). A 14 - 18 amino acid amphipathic helix in the 
AKAP interacts with the dimerisation / docking (DD) domain of the PKA regulatory 
subunit.[228] The AKAP contains a targeting domain (involving protein-protein or 
protein-lipid interactions) which targets PKA to specific locations.[229, 230] PKA is 
therefore positioned close to its target substrate and upon cAMP binding to regulatory 
subunits, catalytic subunits are released and can catalyse phosphorylation of the 
substrate. AKAPs also form complexes with different cAMP effectors such as 
phosphodiesterases (PDEs) and phosphatases. PDE‟s hydrolyse cAMP to terminate 
activation of PKA and phosphatases dephosphorylate PKA substrates. Therefore, 
targeting PKA and these cAMP effectors allows specific regulation of cAMP signalling 
(see reviews [231-233]). AKAPs can also integrate cAMP signalling with other 
signalling pathways, as shown in the following example.  
Muscle-specific AKAP (also known as mAKAP or AKAP6 (Figure 5.1)) forms a 
complex with Type II PKA and phosphodiesterase 4D3 (PDE4D3).[234] 
Phosphorylation of serine (Ser) 13 of PDE4D3 by PKA increases its affinity for 
mAKAP,[235] and phosphorylation of Ser54 of PDE4D3 by PKA leads to its 
activation.[236] PDE4D3 also recruits extracellular-regulated kinase (ERK) 5 and 
exchange protein directly activated by cAMP (Epac1) to the mAKAP complex. ERK5 
phosphorylates and suppresses PDE4D3 activity and Epac1 is a cAMP acceptor that 
suppresses ERK5 activity.[237] Ryanodine receptors (RyRs) and protein phosphatase 
(PP) 2A can also be recruited to the mAKAP-PKA complex. These RyRs may be 
phosphorylated by mAKAP-targeted PKA and dephosphorylated by mAKAP-targeted 
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PP2A, providing a mechanism for regulation of RyR activity. mAKAP targets this 













Figure 5.1. mAKAP complex.  
mAKAP is tethered to the nucleus. It associates with PKA as well as the RyR and PP2A. 
When PKA is activated by cAMP it phosphorylates the RyR which is deactivated by PP2A-
catalysed dephosphorylation. mAKAP also associates with epac1 and PDE4D3, which 
recruits ERK5 to the complex. cAMP binds to and activates epac1 which can suppress ERK5 
activity which then can inhibit PDE4D3, preventing cAMP hydrolysis. The formation of this 
complex is important in regulating cAMP signalling as well as ERK signalling.    
 
PKA RII is considered to be non-cytosolic due to binding to AKAPs.[239, 240] RI is 
generally considered to be soluble and cytosolic but there have been reports of RI in 
other locations. Upon T-cell activation RI translocates from the cytoplasm to the T-
cell receptor-CD3 complex,[241] and H2O2 induces translocation of RI from cytosol to 
myofilament in cardiac tissue.[57] RI has also been identified tightly bound to the 
membrane of erythrocytes,[242] and bound to the growth factor receptor-bound protein 
2.[243] RI has also been shown to be localised at the neuromuscular junction in 
skeletal muscle.[244]  
This introduction discusses some examples of AKAPs that only bind Type I or Type II 
PKA, as well as those with dual specificity for the kinase. As mentioned in Chapter 1 
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and above, the DD domains of RI and RII are each comprised of two helix-turn-helix 
motifs which dimerise to form a conserved X-type four helix bundle. The amphipathic 
helix of the AKAP binds across the DD domain. As shown in Figure 5.2, the DD 
domain of RI is precisely flanked by the disulfides formed between cysteine (Cys) 16 
and Cys37 (Cys17 / Cys38 in mouse) in response to oxidant and so these disulfides may 








Figure 5.2. Amphipathic helix of D-AKAP 2 binding to DD domain of RI.[119]  
Antiparallel subunits are each made up of two helices (0 and 1) and form an X-type four 
helix bundle. The DD domain of each subunit contains two Cys residues (Cys16 and Cys37) 
which form disulfides during oxidative stress (shown by black arrows). D-AKAPs bind at the 
region flanked by the two Cys residues and mutating Cys16 or Cys37 has been shown to 
reduce D-AKAP2 binding.   
 
Despite both RI and RII DD domains being X-type four helix bundles, RII provides a 
shallow hydrophobic surface at its DD domain for the amphipathic helix to bind,[104, 
245] whereas RI provides a compact deep cleft. This is because each RI subunit has 
an additional short helix (helix N-1) at its N-terminus shifting the DD domain further 
from the N-terminus. This helix N-1 folds back on to the X-type four helix bundle 
altering the protein shape and reducing accessibility to residues for protein interaction 
and reducing hydrophobicity compared to RII.[102] As shown in Figure 5.3, RI and 
RII therefore provide different surfaces for protein-protein interaction which may 
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explain differences in AKAP specificity and affinity between the regulatory subunit 
isoforms. Some dual-specificity AKAPs (D-AKAPs) also have an RI specifier region 
(RISR) outside the amphipathic helix which acts in synergy with the amphipathic helix 
to enhance RI binding.[246]  
Figure 5.3 Comparison of RI and RII AKAP docking domains.[232]  
The DD domain of RI provides a deep cleft and the DD domain of RII provides a shallow 
hydrophobic groove. Accessibility to the AKAP binding domain is more restricted in RI due 
to the helix at the N-terminal which is absent in RII. This may explain differences in AKAP 
specificity and affinity between the regulatory subunit isoforms. 
 
5.1.1 Type II PKA binding AKAPs 
An example of an AKAP that binds to RII (Type II PKA) in the heart is AKAP7γ (also 
known as AKAP18δ) which also co-localises with phospholamban (PLB) and 
sarcoplasmic reticulum Ca
2+
 ATPase (SERCA) 2. PLB inhibits SERCA2 activity and 
phosphorylation of PLB at Ser16 by PKA relieves this inhibition.[174] The PKA-
mediated phosphorylation of PLB and consequent increased SERCA2 activity is 
dependent on AKAP18δ function.[226]  
Studies with AKAP5 (also known as AKAP79, 150 or 75) knock-out (KO) mice have 
helped demonstrate that this AKAP targets PKA to the L-type Ca
2+ 
channel (LTCC) but 
protein kinase C (PKC) is also in the complex. The association allows phosphorylation 
of the 1C subunit of the channel by PKA and therefore channel opening.[247] In 
ventricular myocytes, AKAP5 associates with adenylate cyclase, PKA RII, 
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calcineurin,  adrenoceptors and caveolin-3-associated LTCCs and is important in 
enhancing Ca
2+ 
transients upon  adrenergic stimulation. During stimulation, only 
caveolin-3-associated LTCCs are phosphorylated by PKA. However, in AKAP5 KO 
mice adenylate cyclase fails to associate with AKAP5 with the result that non-caveolin-
3-associated LTCCs are also phosphorylated upon  adrenergic stimulation. 
Phosphorylation of RyR2 and PLB is also reduced as a result of AKAP5 deletion even 
though these proteins do not directly associate with AKAP5 but this may be due to 
absence of the microdomain of cAMP created by the AKAP complex.[248]  
5.1.2 D-AKAPs 
D-AKAPs bind both RI and RII, although in most cases they have a higher affinity for 
the latter.[228] D-AKAP1 binds PKA RI, RII and RIIβ but not RIβ.[249] For RII to 
bind to D-AKAP1, the DD domain itself is adequate but for RIto bind to D-AKAP1, 
the DD domain and residues in regions peripheral to this domain are also required.[116]  
S-AKAP84,[250] AKAP121,[251] and D-AKAP1a, b, c and d,[252] are splice variants 
of the D-AKAP1 gene in mice and AKAP149 is the human homologue.[253] As shown 
in Figure 5.4, these all have a common 525 amino acid core containing the PKA-
binding site but differ at the N-terminus and C-terminus. They also vary in their tissue 
expression and subcellular localisation. D-AKAP1a, D-AKAP1c, S-AKAP84 and 
AKAP121 variants have a shorter N-terminus which targets the AKAP to mitochondria 
whilst D-AKAP1b and D-AKAP1d have a longer N-terminus sequence, containing an 
additional thirty-three residues, that suppresses mitochondrial targeting and instead 
targets the AKAP to the endoplasmic reticulum.[254] Asp31 has been identified as 
essential for this switch from mitochondrial targeting to endoplasmic reticulum 
targeting.[252] AKAP149 and the longer forms of D-AKAP1 also have a K homology 
(KH) domain at the C-terminus,[252, 253] which is an ribonucleic acid (RNA) binding 
motif, discussed in more detail below.  




Figure 5.4 Isoforms of D-AKAP1 (modified from Ma et al.[252])  
The PKA-binding domain (AKB) is common to all isoforms. Isoforms differ at the N-terminus, 
where some isoforms have the thirty residue mitochondrial (mitochondria) targeting domain 
(N0) or this region and an additional region of thirty-three residues (N1) that target the AKAP 
to the ER. The localisation of each AKAP is shown on the right. Isoforms also differ at the C-
terminus where they may have KH and Tudor domains, which are RNA binding motifs. 
 
 
AKAP149 is a trans-membrane protein in the endoplasmic reticulum and nuclear 
envelope, with most of the protein positioned in the cytosol. At the nuclear envelope, 
upon nuclear assembly after mitosis, AKAP149 binds PKA by its amphipathic helix and 
protein phosphatase 1 (PP1) by its arginine-valine-any residue-phenylalanine (RVXF) 
motif.[255] The AKAP149-PP1 complex dephosphorylates B-type lamins promoting 
laminin formation and nuclear assembly.[256] In adipocytes, PKA-associated D-
AKAP1 binds to the catalytic subunit of PP1 which may regulate PKA‟s role in lipid 
metabolism.[257] The RVXF motif in AKAP149 is flanked by Ser residues, which are 
phosphorylated by PKC to cause dissociation of PP1 and also PKA, although this does 
not cause dissociation of PP1 and the role of this modification remains unknown.[258]  
AKAP121 tethers PKA to the mitochondrial membrane possibly via AKAP121 binding 
to  tubulin.[259] AKAP121 targeting of PKA (Figure 5.5) enhances PKA signalling in 
the mitochondria and protects cells from apoptosis through PKA-dependent 
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phosphorylation of BAD and inhibition of cytochrome c release.[260] AKAP121 is also 
found in a complex with Src (a tyrosine kinase) and protein-tyrosine phosphatase (PTP) 
D1. PTPD1 promotes dephosphorylation of Src which increases the kinase‟s activity. 
Src phosphorylates the epidermal growth factor (EGF) receptor and leads to increased 
EGF signalling but binding of AKAP121 to PTPD1 down-regulates this signalling.[261] 
However, others have shown that AKAP121 increases Src signalling and PKA 
signalling in the mitochondria, leading to increased phosphorylation of mitochondrial 
substrates such as cyclooxygenase (COX) and ultimately increased ATP synthesis.[262]  
As already mentioned, AKAP149 and the longer forms of D-AKAP1 have a KH 
domain at their C-terminal,[252, 253] which is an RNA-binding motif that may play a 
role in localising RNA to a particular cellular compartment. PKA can phosphorylate the 
KH domain of AKAP121 and increase its binding to the three prime untranslated region 
(3
‟
-UTR) coding for manganese superoxide dismutase (MnSOD), an antioxidant 
enzyme, for example. This results in translocation of MnSOD from the cytosol to the 
mitochondria, which increases its abundance in this cellular compartment.[263] 
AKAP121 and AKAP149 also bind lipoprotein lipase mRNA which inhibits translation 
of the enzyme.[264] Lipoprotein lipase plays a role in triglyceride-rich lipoprotein 
hydrolysis and adipose tissue lipogenesis. 
 
  









Figure 5.5 D-AKAP1 multi-protein complex.  
The amphipathic helix of D-AKAP1 binds to the DD domain of PKA tethering PKA to the 
mitochondrial membrane. PP1 binds to the RVXF motif in D-AKAP1 and mRNA binds to the 




D-AKAP2 (also known as AKAP10) binds RI, RII and RIIβ but not RIβ.[138] For 
RI to bind to D-AKAP2, the DD domain (see Figure 5.2) and regions peripheral to this 
domain are required.[138] D-AKAP2 has regulator of G-protein-signalling (RGS) 
domains (RGS-A and RGS-B) which means it can interact with G proteins.[138] No 
D-AKAP2 binding G proteins have yet been identified, but the GTPases, Rab11 and 
GTP-bound Rab4 directly interact with the RGS domains. This causes D-AKAP2 to 
move from the cytosol to endosomes, regulating recycling of endocytosed proteins back 
to the membrane.[265]  




 exchanger regulator 
factor 1 (NHERF-1) and 3 (NHERF-3 or PDZK1) in proximal tubular cells of the 
kidney.[142] Type II Na
+
-dependent phosphate co-transporters are important in renal 
reabsorption of phosphates. NHERF-1 and PDZK1 regulate expression of the co-
transporters in the apical membrane of proximal tubules,[266] so D-AKAP2 binding 
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AKAP10 also appears to play a role in heart rhythm regulation by altering the 
sensitivity of cardiac cells to cholinergic stimulation. Cardiac cells of mice with a fifty-
one amino acid C-terminal deletion of AKAP10 (removing the PKA-binding site) have 
increased sensitivity to cholinergic stimulation, leading to a slower heart rate and 
increased heart rate variability.[267] 
AKAP220 (also known as AKAP11) is predominately located in the testes, but it is also 
found in heart, brain, lung and kidney.[268] The literature mainly focuses on AKAP220 
binding to PKA RII, but AKAP220 also binds RI.[269] AKAP220 forms a multi-protein 
complex with Type II PKA, PP1,[270] and the PKA substrate glycogen synthase kinase 
(GSK) 3. PKA in the complex can phosphorylate and inhibit GSK3 whereas PP1 can 
dephosphorylate and activate GSK3.[271] AKAP220 inhibits PP1 activity and this 
effect is enhanced by PKA RII.[272] AKAP220 can also bind IQ domain GTPase-
activating protein 1 (IQGAP1) which is a cytoskeletal scaffolding protein that promotes 
cell migration by aiding cytoskeleton remodelling. GSK3 inhibits the interaction 
between IQGAP1 and another protein, CLASP2 by phosphorylating CLASP2. 
Therefore, PKA in the complex may phosphorylate and inhibit GSK3 thereby allowing 
IQGAP1 and CLASP2 to interact promoting cell migration. Ca
2+ 
also increases binding 
of IQGAP1 and AKAP220 or IQGAP1 and CLASP2. Ultimately, AKAP220 recruits all 
these proteins to the leading edge of the cell and promotes cell migration which occurs 
during tissue development and tumour metastasis.[273] AKAP220 also forms a 
complex with PKA and aquaporin 2, a water channel in the collecting ducts of the 
kidney. PKA phosphorylates aquaporin 2 at Ser256 causing its insertion into the apical 
membrane and water reabsorption.[274]  
The splicing factor arginine / Ser-rich 17A (SFRS17A) is located in splicing factor 
compartments of the nucleus. It binds RI and RII with a similar affinity, which is 
atypical for D-AKAPs. SFRS17A binds RI and RII by an amphipathic helix at its N-
terminus which is expected, based on how we know AKAPs interact with regulatory 
subunits (see Figure 5.2 for an example of this). It also binds to RI by the RISR at its C-
terminus. The result is targeting of PKA to splicing factor compartments for a potential 
role in pre-mRNA splicing.[275]  
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The sarcomeric protein cardiac troponin T (cTnT) is also considered a D-AKAP. It‟s 
PKA binding site is an amphipathic helix and displacement of Type II PKA from cTnT 
leads to reduced PKA activity in the myofilament.[276]   
Brefeldin A-inhibited guanine nucleotide-exchange protein 2 (BIG2) is a guanine 
nucleotide-exchange protein (GEP) that is inhibited by brefeldin A, an antibiotic 
produced by fungi. GEP‟s accelerate the release of bound GDP from inactive cytosolic 
adenosine diphosphate (ADP)-ribosylation factor (ARF)-GDP. This promotes binding 
of guanosine triphosphate (GTP) and formation of active membrane-bound ARF-GTP, 
and regulates intracellular vesicular trafficking. BIG2 interacts with PKA RIPKA 
RI as well as PKA RII and has three different binding sites each with different 
specificities for the regulatory subunit isoforms. cAMP has been shown to promote 
translocation of brefeldin A-inhibited guanine nucleotide-exchange protein 1 (BIG1) / 
BIG2 from cytosol to the golgi membrane,[277] where PKA promotes ARF association 
with the golgi membranes.[278] However others have shown that BIG1, BIG2, RI and 
PDE3 form a complex in the cytosol and depletion of PDE3 decreases abundance of 
BIG1 and BIG2 in membrane and increases their abundance in cytosol.[279] In this 
situation, cAMP levels increase (due to a decrease in breakdown by PDE3) leading to 
PKA activation and phosphorylation of BIG1 or BIG2. Phosphorylation decreases GEP 
activity of BIG1 / 2 and reduces the amount of active ARF-GTP.[279, 280] PP1γ also 
binds BIG1 or BIG2. After inhibition by PKA-mediated phosphorylation, PP1 
dephosphorylates BIG1 or BIG2 which restores GEP activity.[280]  Therefore, PDE3, 
PKA and PP1 all appear to regulate BIG1 or BIG2 activity and therefore ARF function. 
5.1.3 Type I PKA binding AKAPs  
Most analyses of PKA-AKAP binding have been with Type II PKA. More AKAPs that 
bind RII have been identified, probably because they can be identified using blot 
overlay (also known as Far Westerns) in work pioneered by Dr. John Scott.[281, 282] 
However, this approach is less successful in identifying RI-binding proteins.[283] This 
is perhaps because during the interaction of AKAPs with RI, the off-rate is faster than 
the on-rate,[284] making the interaction transient and difficult to catch using solid phase 
assays. 
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However, increasingly more AKAPs that only bind RI are being identified. These 
include 4 integrin, which binds to RI via its cytoplasmic tail and is important in cell 
motility,[285] and AKAPCE, a protein found in Caenorhabditis elegans.[286] In 
neurons,/  tubulin forms a complex with RI but not with RII.  and  tubulin can 
form dimers which then form protomers and assemble to form microtubules which are 
important in cell motility, cell movement and mitosis. The /  tubulin-RI complex is 
formed in the cytosol and translocates to the synaptic end. Degradation of this is 
induced by serotonin allowing long lasting PKA activity in the synapse.[287] As 
outlined in Chapter 4, I observed monoamine (including serotonin) -induced RI 
disulfide formation, which may be a prerequisite to degradation of the /  tubulin-RI 
complex. Myosin VIIA is an unconventional myosin located in the outer hair cells of 
the ear. The DD domain of PKA RI binds to the C-terminal 4.1, ezrin, radixin, moesin 
domain of myosin VIIA which may modulate cAMP's regulation of voltage-dependent 
potassium channels in outer hair cells.[288] Peripheral-type benzodiazepine receptor 
(PBR) and PKA-associated protein 7 (PAP7) as the name suggests interacts with PBR 
and PKA RI. Binding of RI to PAP7 may target PKA to the mitochondria where, 
upon cAMP activation, the catalytic subunit is released and can catalyse 
phosphorylation of steroidogenesis acute regulatory protein (StAR). Phosphorylation 
causes cholesterol to be transferred from StAR to PBR, a cholesterol binding protein, 
leading to steroidogenesis.[289]   
Sphingosine is a sphingoid base produced by the deacylation of ceramide, an acylated 
sphingoid base which is a component of the cell membrane. For sphingosine to be 
catabolised it must be phosphorylated. Sphingosine kinase (SPHK) is an enzyme that 
catalyses the phosphorylation of sphingosine producing sphingosine 1 phosphate (S1P). 
S1P is then degraded in the endoplasmic reticulum or can be converted back to 
ceramide. S1P can also act as a second messenger, activating signalling pathways such 
as ERK to promote cell survival.[290] Sphingosine kinase interacting protein (SKIP, 
SPHKAP) interacts with SPHK1 and reduces its activity.[291] SKIP is an RIspecific 
AKAP,[292] and has two binding sites with different affinities for RI dimer so can 
carry two RI dimers at one time.[293] The AKAP is cytosolic and highly expressed in 
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the heart. It is also enriched at the inner mitochondrial membrane where it recruits 
RI and associates with coiled-coil-helix-coiled-coil-helix domain-containing protein 3 
(ChChd3) for phosphorylation by PKA.[293, 294] ChChd3 is a scaffolding protein that 
is important in maintaining mitochondria function and mitochondrial cristae 
structure.[295] 
Most recently, a novel RI-specific AKAP termed small membrane (sm) AKAP has been 
identified in the heart. This AKAP localises at the plasma membrane via potential 
myristoylation / palmitoylation anchors and the filopodia (cytoplasmic projections on 
migrating cells), which could be associated with PKA‟s role in cell migration.[296]   
Table 5.1 summarises AKAPs that bind RI. This chapter focuses on how the 
interaction between some of these AKAPs and PKA RI is potentially altered when 
RI disulfide formation occurs in the heart. This was primarily determined by 
comparing cardiac wild-type (WT) and knock-in (KI) Cys17Ser RI binding to AKAPs. 
This chapter aims to address the following: 
1. Whether disulfide is associated with subcellular translocation of cytosolic RI to the 
membrane or myofilament and so determining RI localisation in mouse hearts. I 
hypothesise this is so because the disulfide may increase RIaffinity for AKAPs,[119] 
and so induce cytosolic RI to move to the AKAPs which may be localised in the 
membrane or myofilament. In addition, Brennan et al. previously showed that 100 µM 
H2O2 caused translocation of PKA RI from the cytosol to the myofilament in rat 
hearts,[57] so it is likely that this occurs in mouse hearts too.  
2. Whether disulfide modulates RI interaction with AKAPs. I initially chose to look at 
RI binding to D-AKAP1, D-AKAP2, AKAP220 and  tubulin as these had been 
studied extensively. I hypothesise that AKAP interaction will be modulated by RI 
redox state because the disulfides precisely flank the AKAP binding site (Figure 5.2) 
and so they may cause a conformational change that acts as a molecular structural 
switch to alter AKAP binding to this region. I hypothesise that disulfide will increase 
binding to AKAPs as Sarma et al. demonstrated that RI disulfide increases its affinity 
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for D-AKAP2,[119] and so this could be applicable to other AKAPs. However, there is 
also the idea that disulfide may reduce the association between RI and some AKAPs. 
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Table 5.1. AKAPs that bind PKA RI
Proteins shown to interact with the AKAP and the functions that have been associated with 
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Lipid metabolism 
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ATP synthesis 
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5.2.1 Fractionation of hearts and analysis of RI and AKAP abundance  
WT and KI hearts were Langendorff-perfused with K-HB for 45 min or K-HB for 40 
min followed by 50 µM H2O2 for 5 min. Hearts were then homogenised and 
fractionated into cytosol-enriched, membrane-enriched and myofilament-enriched 
fractions, as described in Chapter 2. SDS-PAGE and Western blotting were carried out 
and blots were probed for PKA RI. Blots were also incubated with antibodies to 
selected AKAPs that, as described in 5.1.3, have been shown by others to bind RI. 
Blots were also incubated with a ChChd3 antibody for reasons discussed later. ChChd3 
is a PKA substrate associated with an RI AKAP.[293] Antibodies and incubation 
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AKAP220 (L-16) sc6444 Santa Cruz 
Biotechnology 
Goat 1:1000 3 hours 
AKAP10 ab65038 Abcam Rabbit 1:1000 3 hours 
AKAP10 (N-13) sc-109188 Santa Cruz 
Biotechnology 
Goat 1:1000 3 hours 
AKAP149 / 121 (C-
20) 
sc-6439 Santa Cruz 
Biotechnology 
Goat 1:1000 3 hours 
AKAP1 15618-1-AP Proteintech 
Group 
Rabbit 1:1000 3 hours 
/  tubulin #2148 Cell Signalling 
Technology 
Rabbit 1:1000 3 hours 
SPHKAP  GTX101951 GeneTex Rabbit 1:500 3 hours 
SPHKAP GTX101952 GeneTex Rabbit 1:500 3 hours 
Myomegalin [N1], 
N-term 
GTX115270 Genetex Rabbit 1:1000 3 hours 
ChChd3 ab99491 Abcam Goat 1:1000 3 hours 
Table 5.2. Details of anti-AKAP antibodies
This table shows the company each antibody was purchased from and its purchase code, 
the species it was raised in (and so the secondary antibody to be used), concentration the 
antibody was used at (in 5 % milk in PBS with 0.1 % Tween-20) and the incubation period at 
room temperature. D-AKAP1 is also known as AKAP121, AKAP149 and AKAP1. D-AKAP2 
is also known as AKAP10. 
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5.2.2 cAMP affinity capture of cardiac WT and KI RI   
Preparation of heart homogenate: WT and KI hearts were Langendorff-perfused 
(more detail in Chapter 2) with K-HB for 45 min or K-HB for 40 min followed by 50 
µM H2O2 for 5 min and homogenised, as described in Chapter 2. 50 µl of 10 % Triton 
X-100 in homogenisation buffer (100 mM Tris pH 7.4, 1 % Triton X-100, 100 mM 
maleimide, 1 mM ethylene glycol tetra acetic acid (EGTA), 1 mM 
ethylenediaminetetraacetic acid (EDTA), 200 µM phenylmethanesulfonylfluoride 
(PMSF, protease inhibitor) and phosphatase inhibitor cocktail 2 (1:100)) was added to 
450 µl of each homogenate, vortexed and left on ice for 5 min. The homogenates were 
then centrifuged at 25000 rpm for 5 min at 4 ºC. 450 µl of the Triton X-100 soluble 
fraction from each heart was diluted five-fold by adding 1800 µl of homogenisation 
buffer. 100 µl of this was added to 100 µl of non-reducing SDS sample buffer 
containing 100 mM maleimide. This is called the input. 
Incubation of 8-AEA-cAMP-agarose with heart homogenate: 200 µl of 8-AEA-
cAMP-agarose ((2- aminoethylamino) adenosine- 3', 5'- cyclic monophosphate 
immobilized on agarose, Biolog Life Science Institute) was washed in 500 µl 
homogenisation buffer. The mixture was vortexed and centrifuged at 1000 rcf for 0.5 
min. The supernatant was then removed and discarded and the 8-AEA-cAMP-agarose 
was washed twice more in homogenisation buffer. After centrifugation, 200 µl of 
homogenisation buffer was added to the agarose and mixed to give a 50 % slurry. 100 
µl of this slurry was added to four 1.5 ml Eppendorf tubes and then centrifuged at 1000 
g for 0.5 min. The supernatant was removed and discarded. 2 ml of Triton X-100 
soluble fraction from untreated WT, untreated KI, 50 µM H2O2-treated WT or 50 µM 
H2O2-treated KI hearts was added to 50 µl 8-AEA-cAMP-agarose (prepared earlier) and 
incubated overnight (~17 hours) on a rotating wheel at 4 ºC. The next day the samples 
were centrifuged at 1000 g for 1 min at 4 ºC and 100 µl of each supernatant was added 
to 100 µl SDS sample buffer containing 100 mM maleimide. This is called the flow-
through. The remaining supernatant was removed and discarded. 1.5 ml of 
homogenisation buffer was added to the 8-AEA-cAMP-agarose, gently agitated and 
then incubated at 4 ºC on a rotating wheel for 15 min. Following this, the supernatant 
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was removed and discarded and the 8-AEA-cAMP-agarose was washed twice more in 
the same way. Finally, 100 µl of non-reducing SDS sample buffer containing 100 mM 
maleimide was added to the 8-AEA-cAMP-agarose and this is called the capture.    
Optimisation of cAMP affinity capture: The basic method outlined above was 
systematically modified in an attempt to improve efficiency of RI capture with AKAP 
proteins. The first alteration was that 9 ml of diluted Triton X-100 soluble heart fraction 
was incubated with 200 µl 8-AEA-cAMP-agarose rather than 2 ml Triton X-100 soluble 
fraction with 50 µl 8-AEA-cAMP-agarose. The second modification was that the Triton 
X-100 soluble fraction was diluted three-fold rather than five-fold in homogenisation 
buffer with 8 ml of this added to 250 µl 8-AEA-cAMP-agarose. Experiments in which 
these alterations were made will be stated.  
5.2.3  SDS-PAGE, Western blotting and probing for AKAPs 
Input, flow-through and capture samples were analysed by SDS-PAGE and Western 
blotting, as described in Chapter 2. Blots were probed with antibodies to D-AKAP1, D-
AKAP2, AKAP220 and / -tubulin (see Table 5.2). To increase the likelihood of 
detecting the AKAPs in the cAMP affinity capture samples, antibodies were all used at 
a concentration of 1:500 overnight.  
5.2.4 Colloidal Coomassie staining of polyacrylamide gel 
Colloidal Coomassie was made up by mixing 784 ml of Solution A (85 % 
orthophosphoric acid, 0.6 M ammonium sulphate) with 16 ml of Solution B (5 % 
Coomassie Brilliant Blue G-250). 20 % methanol was then added before use. The 
polyacrylamide gel was stained in colloidal Coomassie on a shaker overnight. The gels 
were then de-stained in water until stained bands were clearly observed on the gel 
against a clear background.   
5.2.5 Liquid chromatography-tandem mass spectrometry (LC-MS/MS) 
Sections of the colloidal Coomassie stained polyacrylamide gel were excised and 
analysed by Manuel Mayr and Xiaoke Yin (Kings College, London) who carried out 
LC-MS/MS to identify the proteins in the gel. This method combines liquid 
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chromatography, which is the physical separation of chemicals, with mass spectrometry, 
which involves ionisation of chemicals and determining their mass to charge ratio. In-
gel digestion with trypsin was performed following a protocol previously 
published,[297] with modifications so it could be used with an Investigator ProGest 
(Genomic Solutions) robotic digestion system. A nanoflow LC system on a reverse-
phase column (25 cm C18 PepMap100, Dionex) was used to separate peptides and then 
these were applied to an LTQ Orbitrap XL mass spectrometer (Thermo Scientific). Full 
ion scan mode over the mass-to-charge (m / z) range 300-2000 was used to collect 
spectra. Six independent scans were performed on each ion using dynamic exclusion. 
Proteins were identified using Mascot 2.3.01 search engine and matching against the 
mouse UniProt/ Swiss-Prot (version 57.15) database. These results were then validated 
using Scaffold (version 3.3.1, Proteome software Inc.). Peptide identifications were 
accepted if they could be established at greater than 95.0 % probability (specified by the 
Peptide Prophet algorithm).[298, 299] Protein identifications were accepted if they 
could be established at greater than 99.0 % probability and contained at least two 
identified peptides with ± 10-ppm mass accuracy. A Fishers Exact test was carried out 
to compare the number of assigned spectra in WT and KI hearts and differences were 
considered statistically significant if p<0.05. These statistics were carried out by Manuel 













5.3.1 Localisation of PKA RI in WT and KI hearts basally and after H2O2  
Figure 5.6B shows that control WT hearts predominately contain RI in the reduced 
monomeric state (~60 %) and this is localised in the cytosol-enriched fraction. There 
were also small amounts of disulfide dimer in cytosol- (~20 %), membrane- (~13 %) 
and myofilament- (~7 %) enriched fractions of WT hearts. In comparison, in control KI 
hearts RI was all monomer and present in cytosol- and membrane- enriched fractions 
(~90 % and ~10 % respectively). H2O2 increased total disulfide dimer by ~30 % in WT 
hearts but the increase was not easily observed on Western blots (Figure 5.6A). This 
was because the film needed to be exposed for long periods to detect RI in membrane- 
and myofilament- enriched fractions making the signal for cytosolic RI monomer or 
dimer very dense. Figure 5.6 shows that in WT hearts, H2O increased membrane-
associated disulfide by ~10 % and myofilament-associated disulfide by ~5 %. However, 
H2O2 did not affect RI localisation in KI hearts; RI monomer was still only present in 
cytosol- and membrane- enriched fractions These results suggest a role for RI 










Figure 5.6 Localisation of PKA RI monomer and dimer in control and H2O2 
Langendorff-perfused WT and KI hearts.  
(A) Male WT / KI hearts were Langendorff-perfused with K-HB or 50 µM H2O2 for 5 min and 
fractionated into cytosol-enriched (c), membrane-enriched (m) and myofilament-enriched 
(M) fractions. Redox state of PKA RIwas determined by immunoblotting as shown in the 
representative blot (B) Quantification (n=3 ± SEM) of percentage of total RI abundance in 
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5.3.2 Localisation of PKA catalytic subunit in WT and KI hearts basally and 
after H2O2  
Figure 5.7 shows that, as expected, most PKA catalytic subunit was in the cytosol-
enriched fraction of WT hearts (~50 % of total catalytic subunit in the heart) with 
smaller amounts of catalytic subunit in the membrane- (~40 %) and myofilament- 
enriched (~10 %) fractions. However, in KI hearts, ~25 % more catalytic subunit was 
localised in the cytosol-enriched fraction compared to WT. Consequently, there was 
~10 % less catalytic subunit in the membrane and myofilament fractions of KI hearts 
compared to WT. When RI disulfide was increased by oxidant treatment in WT hearts, 
abundance of catalytic subunit in the cytosol-enriched fraction was not altered. 
However, catalytic subunit localisation in the membrane increased with a corresponding 
decrease in the myofilament such that the difference in catalytic subunit abundance 
between membrane and myofilament fractions now became statistically significant 
(p<0.05, ~40 % compared to ~15 % in control WT hearts). In contrast, oxidant 
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Figure 5.7 Localisation of PKA catalytic subunit in control and H2O2-perfused WT and 
KI hearts.  
Hearts were Langendorff-perfused with K-HB or 50 µM H2O2 for 5 min and fractionated into 
cytosol-enriched (c), membrane-enriched (m) and myofilament-enriched (M) fractions. 
Western blots were probed for PKA catalytic subunit as shown in the representative blot. 
Average percentage of total catalytic subunit in each fraction was calculated for n=3 hearts 
± SEM * p<0.05 compared to membrane-enriched fraction of WT + 50 µM H2O2. The 
catalytic subunit was mostly localised in the cytosol-enriched fraction in all hearts with some 
catalytic subunit in the membrane-enriched fraction. H2O2 caused an increase in catalytic 
subunit abundance in WT membrane but not KI membrane.   
   
5.3.3 Screening for antibodies that detect selected AKAPs  
Screening for an antibody to D-AKAP1: Figure 5.8A shows that antibody sc-6439 
detected a protein at ~149 kDa in control or H2O2-treated WT or KI hearts, as well as in 
liver which was used as a positive control known to abundantly express this AKAP. 
This was the correct molecular weight for D-AKAP1 but non-specific bands were also 
seen at ~135 kDa and ~175 kDa. In WT or KI hearts (control or H2O2-treated) and in 
liver, antibody 15618-1-AP (Figure 5.8B) detected proteins at ~180 kDa, ~90 kDa and 
~149 kDa, the latter corresponding to D-AKAP1. Antibody 15618-1-AP was the chosen 
antibody to probe blots for D-AKAP1 because it generated fewer interfering non-
specific bands near to 149 kDa that might otherwise complicate the detection of D-
AKAP1 at 149 kDa.  














Figure 5.8 Immunoblot detection of D-AKAP1 in male WT and KI hearts.  
(A) WT and KI hearts were Langendorff-perfused with K-HB or H2O2. Western blot was 
probed for D-AKAP1 using antibody sc-6439 which detected a protein at the correct 
molecular weight (149 kDa) for D-AKAP1, as indicated by the arrow. (B) Western blots were 
also incubated with the D-AKAP1 antibody 15618-1-AP which detected a band at the correct 
molecular weight for D-AKAP1 (as indicated by the arrow) and fewer non-specific interfering 
bands near to 149 kDa. Antibody 15618-1-AP was therefore chosen when probing for D-
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Screening for an antibody to D-AKAP2: Figure 5.9A shows that the first antibody 
purchased from Abcam (ab65038) detected proteins at ~50 kDa, ~100 kDa and ~250 
kDa but did not detect a protein at the correct molecular weight for D-AKAP2 (74 kDa) 
in hearts. D-AKAP2 was not detected in lung, kidney, liver or brain either so this was 
not because it is not present in heart but because the antibody did not detect D-AKAP2. 
Antibody sc-109188 (Figure 5.9B) detected the AKAP at 74 kDa in WT or KI hearts 
(control or H2O2-perfused) as well as in lung, kidney and liver. Sc-109188 was therefore 




































































Figure 5.9 Immunoblot detection of D-AKAP2 in male WT and KI hearts.  
(A) WT and KI hearts were Langendorff-perfused with K-HB or 50 µM H2O2 for 5 min. 
Western blots were probed for D-AKAP2 with antibody ab65038 which failed to detect a 
protein at the correct molecular weight (74 kDa) (B) Western blots were incubated with 
antibody sc-109188 which showed the presence of a band at ~74 kDa (indicated by the 
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Screening for an antibody to AKAP220: Figure 5.10 shows that antibody sc6444 to 
AKAP220 detected a band at ~220 kDa in control as well as H2O2-perfused WT or KI 
hearts. This band was also observed in lung, kidney and liver, but not brain and 
corresponded to AKAP220. Therefore, this antibody was to be used in subsequent 







Figure 5.10 Immunoblot detection of AKAP220 in WT and KI hearts.  
WT and KI hearts were Langendorff-perfused for 45 min with K-HB or 40 min with K-HB 
followed by 50 μM H2O2. After SDS-PAGE, the Western blot was probed for AKAP220 (L-
16, sc6444). AKAP220 was detected in all hearts and lung, kidney and liver but not brain, as 




Screening for an antibody to  tubulin: Figure 5.11 shows that antibody #2148 
detected a doublet at ~55 kDa corresponding to  (lower band) and  (upper band) 
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Figure 5.11 Immunoblot detection of /  tubulin in male WT and KI hearts.  
WT and KI hearts were Langendorff-perfused with K-HB or K-HB followed by 5 min H2O2. 
The Western blot was probed for /  tubulin (antibody #2148). (lower band) and (upper 
band) tubulin were present in WT and KI hearts and lung, kidney, liver and brain. 
 
 
5.3.4 Localisation of AKAPs in WT and KI hearts 
Only binding of WT and KI RI to AKAPs localised in the Triton X-100 soluble 
fraction of WT and KI hearts could be assessed using the cAMP affinity capture 
method. Figure 5.12A shows that D-AKAP1 was most abundant in the membrane-
enriched fractions of WT and KI hearts with only small amounts in the cytosol- and 
myofilament- enriched fractions of hearts. In contrast, D-AKAP2 was most abundant in 
the cytosol-enriched fractions of untreated control or H2O2-perfused WT and KI hearts. 
A small amount of the D-AKAP2 localised to myofilament-enriched fractions with even 
less in membrane-enriched fractions (Figure 5.12B). AKAP220 was clearly most 
abundant in cytosol-enriched fractions of control WT and KI hearts and H2O2-perfused 
WT and KI hearts with small variable amounts in membrane- or myofilament-enriched 
fractions (Figure 5.12C).  tubulin was predominately in the cytosol- and 
myofilament- enriched fractions of control and H2O2-treated WT and KI hearts (Figure 
5.12D). In summary, there were no differences in the localisation of any of these 
AKAPs between genotypes or between oxidant-treated and control untreated hearts.   
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Figure 5.12 Subcellular localisation of selected AKAPs in WT and KI hearts.  
(A) Hearts were Langendorff-perfused for 45 min with K-HB or 40 min with K-HB followed by 
5 min with H2O2. They were fractionated into cytosol- (c), membrane- (m) and myofilament- 
(M) enriched fractions. After SDS-PAGE, Western blots were probed for D-AKAP1 as shown 
in the representative blot. Percentage of total AKAP in each fraction (n=3) ± SEM was 
calculated (B) Western blots were probed for D-AKAP2 (C) Western blots were probed for 
AKAP220 (D) Western blots were probed for  tubulin. All of these AKAPs were present 
in the cytosol- or membrane-enriched fractions of WT and KI hearts so their binding to RI 
could be assessed using the cAMP affinity capture method. 
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5.3.5 Role for disulfide in modulation of AKAP binding to RI  
Pilot study to determine whether RI and R-bound AKAPs were ‘captured’: The 
cAMP affinity capture was considered successful if RI abundance was higher in 
capture samples than input samples, with flow-through being depleted of RI. RIin 
the input sample (Figure 5.13A) was monomeric (reduced) in untreated WT heart and 
shifted almost completely to disulfide dimer with H2O2 treatment. In untreated control 
and H2O2-treated KI hearts RI was only present in its reduced monomeric form, as 
expected. No RI was present in flow-through samples and RI signal intensity for all 
capture samples was higher than for their corresponding input sample, demonstrating 
the cAMP affinity capture had worked efficiently. The redox state of control capture 
RI was the same as the input sample so overnight incubation of heart homogenate with 
cAMP-agarose in air did not oxidise WT RIHowever, an increase in monomeric RI 
was observed in the oxidant-treated WT capture sample compared to input which 
lowered percentage disulfide dimer to ~50 % which was unexpected. In addition, more 
RI was observed in the H2O2-treated KI heart compared to the other hearts, which 
would make any differences in AKAP binding between this sample and others difficult 
to analyse. However, this was not a reproducible result. A colloidal Coomassie stained 
polyacrylamide gel containing these capture samples revealed only a couple of faint 
bands in KI capture samples at ~50 kDa (Figure 5.13B, indicated by arrows). Therefore, 
the protocol needed to be optimised so that more proteins bound to RI / RII might be 
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     (A)  







Figure 5.13 cAMP affinity capture of PKA RI.  
(A) The Triton X-100 soluble fraction of WT and KI hearts (Langendorff-perfused with K-HB 
or 50 μM H2O2) was incubated with 8-AEA-cAMP-agarose. Western blotting and probing for 
PKA RIdemonstrated that RI was captured. (B) Capture samples were run on a gradient 
gel and the gel was stained with colloidal Coomassie to show proteins that were bound to RI 
/ RIIHowever, only two bands were identified (indicated by arrow) and were not very 
abundant, generating less signal than the staining achieved by the 100 ng bovine serum 
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‘Capture’ of RI and R-bound proteins after optimisation of the method: The total 
volume of Triton X-100 soluble heart fraction and the volume of 8-AEA-cAMP-agarose 
were increased with the aim of enhancing capture and detection of candidate proteins by 
colloidal Coomassie staining and specific antibodies. In control WT input, RI was ~46 
% dimer and with H2O2 treatment this percentage increased to ~59 % (Figure 5.14A). 
This change was not as large as expected based on previous experiments (for example in 
Figure 5.13). In KI input samples no disulfide dimer at all was present, which was 
expected. The modified capture method was still efficient as there was no RI present 
in flow-through samples. After a 15 min film exposure time, it was evident that there 
was no disulfide dimer present at all in 50 μM H2O2-perfused KI capture but, 
unexpectedly, there was a small amount in control KI capture. It was difficult to see any 
difference in RI disulfide dimerisation with H2O2 in WT hearts but after a shorter film 
exposure time (10 secs), control WT capture had ~13 % disulfide dimer and with H2O2 
treatment this increased to ~41 %, which was a bigger difference than seen in input 
samples. Abundance of RImonomer appeared to stay the same with H2O2 treatment in 
capture WT samples as observed in the previous experiment. The redox state of RI 
was as expected in all capture samples so a comparison of AKAP binding could be 
performed between samples. Another important aspect of the solid-phase cAMP studies 
was the possibility that AKAPs might be captured as determined by immunoblotting. 
This would also allow me to assess whether there were differences in AKAP binding to 
WT or KI RI and whether oxidation to the disulfide modulated this. Figure 5.14B 
shows that D-AKAP1 was only just detectable in input, flow-through and capture 
samples so any differences between genotypes could not be observed. D-AKAP2 and 
AKAP220 were not detected in any of the samples. The Triton X-100 soluble fraction 
was diluted 5-fold before incubation with the 8-AEA-cAMP-agarose overnight so this 
dilution would explain why the AKAPs were not detected in these samples, but were in 
Figure 5.12. /  tubulin was present in the input samples and flow-through samples, 
but were absent from capture samples suggesting that RI / RII did not bind to /  
tubulin. Capture samples were also run on a polyacrylamide gel which was then 
colloidal Coomassie-stained to reveal proteins bound to RI / RII. Figure 5.14C shows 
that some proteins were detected in the capture samples at amounts of ~100 ng or less. 
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The most prominent band was at ~50 kDa, which was probably RI and some bands 
were seen below 50 kDa but were very faint so the changes to the protocol did not 
significantly improve detection of regulatory subunit-bound proteins by Coomassie 





























Figure 5.14 cAMP affinity capture of PKA RI.  
(A) The Triton X-100 soluble fraction of WT and KI hearts Langendorff-
perfused for 45 min with K-HB or 40 min with K-HB followed by 5 min with 50 
μM H2O2 were incubated with 8-AEA-cAMP-agarose. The success of the 
capture was shown by SDS-PAGE followed by Western blotting and probing 
for PKA RI (B) Samples were also probed for D-AKAP1, D-AKAP2, 
AKAP220 and / tubulin. / tubulin and D-AKAP1 were detected in the 
input, flow-through and capture samples. (C) The capture samples were also 
concentrated down and run on a gradient gel which was then stained with 
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‘Capture’ of RI and R-bound proteins after further optimisation of the method: 
The total volume of Triton X-100 soluble heart fraction and the volume of 8-AEA-
cAMP-agarose were increased with the aim of enhancing the capture (and therefore 
detection of candidate proteins as assessed by immunoblotting) that leads into 
proteomic studies. 
In Triton X-100 soluble input samples (Figure 5.16A) RI was present as ~35 % 
disulfide dimer in control WT and ~40 % disulfide dimer in H2O2-treated WT. As 
expected, KI RI was 100 % monomer in control and H2O2-treated input samples. RI 
was absent from the flow-through samples. RI redox state in capture samples was 
similar to that for input samples, but a faint band was detected at ~100 kDa in KI hearts. 
To determine if this was a PKA catalytic subunit (42 kDa) bound to a PKA RI subunit 
(50 kDa) the blot was probed with an antibody specific for PKA catalytic subunit 
(Figure 5.16B). The antibody indeed detected a band at ~100 kDa in the capture 
samples, which may provide some evidence for this complex forming between the RI 
subunit and a catalytic subunit. Blots were also probed for specific candidate AKAPs 
(Figure 5.16A). D-AKAP1 was present in all input samples but abundance was lower in 
control WT compared to other samples. There was no D-AKAP1 in the flow-through 
suggesting this protein bound to RI / RII and capture samples suggest that D-AKAP1 
bound to the regulatory subunit in H2O2-treated WT, control KI and H2O2-treated KI 
hearts. However, there was no evidence for D-AKAP1 binding to the regulatory subunit 
in control WT heart but this was probably because of the lower abundance of D-AKAP1 
in the control WT input sample. Despite this, these results suggest that RI disulfide is 
not involved in D-AKAP1 binding as the amount of D-AKAP1 pulled out was similar 
in H2O2-treated WT and H2O2-treated KI capture samples. D-AKAP2 and AKAP220 
were present in flow-through samples but not capture samples suggesting that these 
AKAPs did not bind RI / RII. However, the band intensities for potential D-AKAP2 and 
AKAP220 were weak and limit confidence in them being RI / RII AKAPs, although of 
course we know from the literature that they are indeed RI / RII binding proteins.  /  
tubulin was detected well in input samples and was present in flow-through samples 
suggesting  /  tubulin is not an RI / RII AKAP, consistent with results in Figure 
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5.14B. Colloidal Coomassie staining revealed a number of proteins bound to RI 
(Figure 5.16B); more than identified in Figure 5.14C. Again, a prominent band was seen 
at ~50 kDa, which was probably PKA RI and other prominent bands (more than 100 
ng) were seen at ~25 kDa, ~37 kDa and ~150 kDa. 
Overall increasing the volume of Triton X-100 soluble fraction and 8-AEA-cAMP-
agarose did increase detection of some selected AKAPs by antibodies and proteins 
bound to RI RII by colloidal Coomassie staining but the results were still inconsistent 























Figure 5.15 cAMP affinity capture of PKA RI.  
(A) 8-AEA-cAMP-agarose was incubated with the Triton X-100 soluble fraction of WT and KI 
hearts Langendorff-perfused with K-HB or 50 μM H2O2. Western blotting and probing for 
PKA RIshowed that RI was captured.(B) Western blots were incubated with a PKA 

















Figure 5.16 cAMP affinity capture of PKA RI.  
(A) Western blots were probed for D-AKAP1, D-AKAP2, AKAP220 and / tubulin to see if 
these were captured. Only D-AKAP1 was identified in capture samples (B) Capture samples 
were also run on a gradient gel which was then stained with colloidal Coomassie but only faint 
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5.3.6 Proteomics analysis by LC-MS/MS 
Preparation of colloidal Coomassie stained gel bands for analysis by LC-MS/MS: 
Figure 5.16B shows only a few weakly-stained bands and certainly the pattern is 
virtually identical between groups and so staining provides no evidence that RI redox 
state modulates the presence of RI binding proteins such as AKAPs. Proteomic 
methods are hampered by the high abundance proteins, that are often non-specific 
proteins or proteins that bind but are not modulated by RI oxidation state. However, it 
is possible that there is a sub-proteome „below‟ these dominant bands that cannot be 
detected by Coomassie. As LC-MS/MS is more sensitive, it may be used to detect and 
identify these proteins. If this could be achieved the samples could be re-analysed using 
immunoblotting to examine the relative abundance of these proteins. Indeed the MS 
provides some information about the abundance of these proteins, as measured by 
spectral counting. Figure 5.17 shows the bands cut out of the colloidal Coomassie 
stained gel (previously shown in Figure 5.16B) for analysis by LC-MS/MS. As already 
stated, there were only a few prominent bands stained on the gel and due to restrictions 
on the length of time the mass spectrometer could be used for, areas of the gel where 
these stained bands could be observed were prioritised for analysis. 
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Figure 5.17 Bands cut out of a colloidal Coomassie stained gel to be analysed by LC-
MS/MS.  
Capture samples were run on a SDS polyacrylamide gradient gel which was stained with 
colloidal Coomassie. The bands cut out are outlined and were labelled according to which 
lane (A, B, C or D) and molecular weight level (1, 2, 3, 4, 5 or 6) they were cut from. A total 
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RI / RII-binding proteins identified by LC-MS/MS: LC-MS/MS identified 158 RI / 
RII binding proteins (see Appendix A). The data was also analysed for any proteins in 
which there was a trend for the spectral count to increase or decrease with H2O2 in WT 
but not KI, as shown in Appendix B. A Fishers Exact test was performed to identify 
statistically significant differences (p<0.05) in the abundance of the identified proteins 
between WT and KI captures. Appendix C summarises the proteins of which abundance 
was significantly different between WT and KI captures. Finally, Table 5.3 below 
summarises some of these proteins that are of particular interest due to their potential 
association with PKA or an AKAP as described in the literature. Very long chain 
specific acyl-CoA dehydrogenase, SERCA2, ChChd3, alpha-enolase, D-AKAP1 and D-
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Table 5.3. Proteins of particular interest identified by LC-MS/MS.  
The table shows the number of assigned spectra for each protein in capture samples from control or 50 µM H2O2-perfused (5 min) WT or KI hearts. p 
values are given for a Fishers Exact test comparing WT and KI hearts (statistically significant if p<0.05). The function of each protein, whether it is a 
PKA substrate or associated with a PKA substrate and whether it is an AKAP or associated with an AKAP are also described.    
Genotype/ 
treatment 




   
Identified protein Fishers 
Exact Test 
(p value) 
A B C D Function Substrate for PKA? AKAP association? 
Alpha-enolase 0.013 12 12 9 3 glycolysis enzyme no but it is phosphorylated by Src,[300] 
which is a PKA substrate (Ser17).[301] 
in a complex with myomegalin isoform 
4 (an AKAP) and PKA RI.[302] Src 
signalling is linked to D-AKAP1.[262] 
ChChd3 0.024 13 13 5 8 forms protein complexes important in 
maintaining crista architecture and 
protein import.[295] 
yes (Thr10).[294]  
 
interacts with SKIP which is an RI 
AKAP.[293] 
D-AKAP2 0.27 0 13 6 8 anchoring protein for PKA No yes (see 5.1.2) 
D-AKAP1 0.25 12 23 18 18 anchoring protein for PKA No yes (see 5.1.2) 




 entry into 
the sarcoplasmic reticulum. 
no  but it is inhibited by PLB which is a 
PKA substrate (Ser16).[174] 
in a complex with PKA RII, AKAP18 





0.00039 8 4 17 16 fatty acid  oxidation and lipid 
metabolism 
yes (Ser586).[303] No 




5.3.7 Determining whether disulfide modulates RIbinding to candidate proteins 
identified from LC-MS/MS  
SKIP, ChChd3 and RIcomplex: ChdChd3, a protein identified in LC-MS/MS, is a 
novel substrate for PKA,[294] that has been identified in a complex with SKIP and 
RI.[293] SKIP is an AKAP for Type I PKA and present in the heart.[292, 293] The 
spectral count for ChChd3 in WT capture samples was significantly higher than for KI 
capture samples suggesting more ChChd3 was captured in the WT than KI samples. 
Therefore, RI disulfide could be important in binding of RI to SKIP, potentially 
serving to position PKA close to ChdChd3 to enable targeted phosphorylation.   
An antibody to SKIP was required in order to determine its subcellular localisation in 
the heart and to determine a potential association with RI and ChChd3. Antibody 
GTX101952 detected a protein at ~183 kDa consistent with the predicted molecular 
weight of SKIP, but there were several additional non-specific bands present (Figure 
5.18A). Antibody GTX101951 detected proteins at ~80 kDa and ~183 kDa in cardiac 
samples, the latter being consistent with the detection of SKIP (Figure 5.18B). 
Therefore, GTX101951 was the chosen antibody when probing blots for SKIP as there 
were less non-specific bands that could complicate detection of SKIP at 183 kDa. 
SKIP was present in the Triton X-100 insoluble fraction and ChChd3 was present in the 
Triton X-100 soluble fraction of WT and KI hearts (Figure 5.19). This is consistent with 
the LC-MS/MS identification of ChChd3 in Triton X-100 soluble capture samples. 
There was also a hint of more ChChd3 in the Triton X-100 insoluble fraction of WT 
hearts exposed to H2O2 but fractionation of WT and KI hearts revealed that SKIP was 
only present in the myofilament-enriched fraction of H2O2-treated WT hearts even after 
long film exposures times. ChChd3 was predominately localised in membrane-enriched 
fractions and only after long film exposures times were small amounts observed in 
cytosol- and myofilament-enriched fractions (Figure 5.20). Therefore, SKIP and 
ChChd3 may potentially interact with disulfide RI in the myofilament (but not reduced 
monomeric RIas this is not present in the myofilament (Figure 5.6. 




    
Figure 5.18 Screening for an antibody to SKIP.  
(A) WT hearts were Langendorff-perfused for 45 min with K-HB or 40 min with K-HB 
followed by 5 min with 50 μM H2O2. A Western blot was probed for SKIP with antibody 
GTX101952. This detected a protein at ~183 kDa corresponding to SKIP but also a lot of 
non-specific bands (B) A Western blot was incubated with SKIP antibody GTX101951 which 
detected a significant band at ~183 kDa (indicated by the arrow) corresponding to SKIP and 











































Figure 5.19 Localisation of SKIP and ChChd3 in WT and KI hearts.  
Langendorff-perfused (K-HB for 45 min or K-HB for 40 min followed by 50 μM H2O2 for 5 
min) WT and KI hearts were homogenised, separated into Triton X-100 soluble and Triton 
X-100 insoluble fractions and added to SDS sample buffer. SDS-PAGE and Western 
blotting were performed and blots were probed for SKIP or ChChd3. SKIP was only present 
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Figure 5.20 Localisation of SKIP and ChChd3 in WT and KI hearts.  
(A) Langendorff-perfused WT and KI hearts were fractionated into cytosol-, membrane- and 
myofilament- enriched fractions. Western blots were probed for SKIP as shown in the 
representative blot. Average percentage of total SKIP in each fraction was calculated for 
n=3 hearts ± SEM. (B) Western blots were probed for ChChd3, as shown in the 
representative blot. Average percentage of total ChChd3 in each fraction was calculated for 
n=3 hearts ± SEM. SKIP was only present in the myofilament-enriched fraction and ChChd3 
was mainly in the membrane.  






























































Alpha-enolase, myomegalin and RI complex: Human isoform 4 of myomegalin is 
an AKAP that associates with PKA RI and RII as well as cardiac troponin I (cTnI), 
alpha-enolase (enolase 1) and enolase 2.[302] LC-MS/MS (by spectral counting) 
revealed alpha-enolase was significantly more abundant in WT than KI capture 
samples. Therefore myomegalin (isoform 4) could serve to localise PKA RIwith 
alpha-enolase, a process that could be regulated by RI disulfide status altering its 
interaction with myomegalin. LC-MS/MS did not identify myomegalin but I found 
myomegalin (isoform 4, molecular weight of 267 kDa) was predominately localised in 
the myofilament-enriched fraction (Triton X-100 insoluble fraction) of hearts (Figure 
5.21) which may explain this. There is potential for oxidation status of RI to modulate 
its binding to myomegalin, as RI is only present in the myofilament in WT hearts and 
not KI hearts (Figure 5.6). However, results suggest myomegalin, RI and alpha-
enolase cannot associate as LC-MS/MS revealed alpha-enolase was in the Triton X-100 









Figure 5.21 Myomegalin localisation in WT and KI hearts.  
WT and KI hearts were Langendorff-perfused with K-HB or 50 µM H2O2. Western blots were 
incubated with myomegalin antibody (GeneTex) as shown in the representative blot. 
Average percentage of total myomegalin in each fraction was calculated for n=3 hearts ± 
SEM. Myomegalin was predominately localised in myofilament-enriched fraction of all 






























































This chapter focused on the role of RI disulfide in modulating binding to AKAPs and 
determining RI localisation. As the disulfides that can form in RI precisely flank the 
AKAP-binding domain of the kinase, I thought it is highly likely that the interaction 
between RI and the AKAP will be modulated by disulfide formation. Heart 
fractionation and immunoblotting studies demonstrated that RI was mostly cytosolic 
and this was regardless of its redox state. This is consistent with the historical view that 
RI is soluble and cytosolic,[304] with the RII isoforms being in the particulate fraction 
due to association with AKAPs.[239, 240] The percentage RIdisulfide in WT hearts 
basally was higher than expected based on previous work,[57] and Western blots in 
Chapter 4 illustrating basal disulfide abundance in WT hearts but this may be a partial 
over-estimation due to the long film exposure times required to detect RI in other 
fractions of the heart.  
Others have also observed RI in the membrane fraction of cardiac ventricular 
tissue,[305] and associated with the cardiac myocyte sarcolemma.[306] A small amount 
of RI was present in the membrane-enriched fraction of WT and KI hearts basally. 
Boeshans et al.,[307] used MS to determine whether RI is membrane-associated 
because of a post-translational modification such as palmitoylation, which is the 
covalent attachment of fatty acids to Cys, Ser or threonine residues.[308] They 
concluded that there were no structural differences between cytosolic and membrane 
associated RI that could explain the membrane localisation rather than cytosolic 
localisation of RI. They did discover that membrane-associated RI had a higher 
abundance of disulfide than cytosolic RIThis is consistent with more RI monomer 
than disulfide dimer in the cytosol and mostly disulfide dimer in the membrane of WT 
hearts. However, I found that KI heart tissue also had monomeric RI in the membrane 
but this could be non-specific as the membrane-enriched fraction was not washed after 
separation from the cytosol-enriched fraction so there could be a small amount of RI 
remaining from the cytosol fraction.  




Increased localisation of PKA RI at membrane and myofilament was associated with 
increased PKA RI disulfide in response to oxidant and suggested translocation. It 
appears that only disulfide dimeric RI can translocate to the membrane (consistent 
with Boeshans et al.,[307]) or myofilament. Translocation of RI to the membrane- and 
myofilament-enriched fractions in response to H2O2 has been observed by others in rat 
hearts.[57] Peroxiredoxins (Prxs), which like PKA RIform double disulfides during 
oxidative stress also translocate from cytosol to membrane in response to H2O2, with 
Prx peroxidative thiol hyperoxidation to the sulfinate state causing translocation to the 
myofilament.[309]  
The PKA catalytic subunit has been shown to translocate to the nucleus.[310, 311] I did 
not observe catalytic subunit translocation concomitant with RI disulfide dimer to the 
myofilament. However, I have evidence to suggest that catalytic subunit translocated to 
the membrane in response to oxidant. Western blotting analysis suggested that the 
catalytic subunit translocated from the myofilament to the membrane, however. This is 
inconsistent with RI translocation, which was from cytosol to membrane. When RI 
and the catalytic subunit are both localised in the membrane they may first associate to 
form the inactive PKA tetramer. Following disulfide dimer formation there may be an 
increase in RIaffinity for membrane-associated AKAPs which may serve to position 
the PKA tetramer close to its substrates for substrate-induced sensitisation of PKA to 
cAMP, of which I have provided some evidence in Chapter 4 (Figure 5.22). This would 
increase release of catalytic subunits from the PKA tetramer leaving AKAP bound RI. 
Others have shown that membrane-associated RI is unbound to catalytic subunit,[305, 
306] which would support this hypothesis. I would therefore expect increased 
phosphorylation of membrane-associated PKA substrates with H2O2. However, as 
discussed in Chapter 4, increased phosphorylation of membrane-associated PKA 
substrates such as phospholemman (PLM) and PLB was not observed in oxidant-
perfused WT hearts. Disulfide may also reduce RI affinity for some AKAPs, which 
may explain the significant reduction in PLB phosphorylation observed in oxidant-
treated WT hearts, as discussed further below. In addition, binding of RI to some 




AKAPs may not be altered by disulfide as may be the case for the membrane-associated 
substrate, PLM, the phosphorylation state of which was not altered by H2O2.  
 
Figure 5.22 Schematic of substrate-induced PKA activation.  
RI disulfide may increase affinity of RI for AKAPs causing translocation of PKA from the 
cytosol and targeting of PKA close to its substrates where substrate can sensitise PKA to 
cAMP. Upon cAMP binding to regulatory subunits, catalytic subunits are released and can 
phosphorylate target substrate. 
 
I found that AKAP220 was predominately a cytosol-associated AKAP which agrees 
with another study,[274] but another study shows that it is membrane-associated.[273] I 
also demonstrated that D-AKAP2 was predominately cytosolic with a small amount in 
the membrane and others have also shown that D-AKAP2 is primarily cytosolic but can 
associate with membranes of endosomes,[265] and is also mitochondrial.[312] I 
observed a high abundance of  tubulin in the cytosol which is consistent with 
another study illustrating that  tubulin is cytosolic.[313] I demonstrated that D-




AKAP1 was predominately membrane-associated with small amounts in the cytosol in 
WT or KI hearts which agrees with a study showing D-AKAP1 is on the cytosolic 
surface of the mitochondrial membrane.[252] It is likely that RIpredominatelybinds 
to cytosol-associated AKAPs such as AKAP220, D-AKAP2,  tubulin or D-AKAP1 
under control conditions as it is predominately localised in the cytosol. A smaller 
amount of RI may also bind to membrane-associated AKAPs such as D-AKAP1 and 
D-AKAP2 as a small amount of RI is also localised here. However, when RI is 
oxidised to the disulfide form its affinity for membrane- and myofilament-associated 
AKAPs may increase inducing the observed translocation to the membrane and 
myofilament. As already mentioned, D-AKAP1 and D-AKAP2 were found in the 
membrane so are candidate AKAPs responsible for translocation of RI to membrane 
from cytosol. Small amounts of D-AKAP1, D-AKAP2 and  tubulin were found in 
the myofilament-enriched fraction so these are candidate AKAPs responsible for the 
observed translocation of RI to myofilament.  
A solid-phase cAMP affinity capture method was implemented to assess whether 
disulfide increases RI affinity for membrane-associated AKAPs, which could underlie 
the translocation of RIfrom the cytosol. A similar approach has been used 
successfully by others,[275, 312] for analysis of AKAP binding. A variety of cAMP 
analogues with different affinities for RI and RII AKAPs have been used to identify RI / 
RII-specific AKAPs and D-AKAPs.[314] This method relies on the premise that WT or 
KI PKA RI / RII (with bound AKAPs) will bind to cAMP so that captured AKAPs can 
be identified using antibodies to specific AKAPs. This method could only be used to 
analyse AKAPs in the Triton X-100 soluble fraction (cytosol-enriched and membrane-
enriched fractions) of the heart. If AKAPs are not Triton X-100 soluble (i.e. in the 
myofilament-enriched fraction) this precludes their detection using this approach. In the 
pioneering work of Dr. Scott,[281, 282] AKAPs were identified using radiolabelled RII 
in blot overlays and of course the entire cell / tissue fraction is present, including the 
Triton X-100 insoluble fraction. Unfortunately, as discussed elsewhere, capturing RI 
AKAPs in this way is more difficult. This cAMP affinity capture method, therefore, 




excludes AKAPs responsible for oxidant-induced translocation of WT PKA RI to 
myofilament. 
The cAMP affinity captures generated variable results which may be explained by a 
number of issues encountered. Firstly, not all the antibodies purchased to assess the 
presence of AKAPs were specific; antibodies to D-AKAP1, D-AKAP2 and AKAP220 
detected other proteins of variable molecular weights which were most likely to be 
splice variants, which are highly prevalent in AKAPs,[232, 252] but regardless 
complicated interpretation of results. Some of the antibodies, namely the AKAP220 and 
D-AKAP2 antibodies, were not sensitive enough either. Even when the antibody 
concentration was increased and longer incubation periods were used, D-AKAP2 and 
AKAP220 were not easily detected in many input samples. Often the film had to be 
exposed for long periods, leading to high background signal; this particularly made the 
detection of D-AKAP1 unreliable. This AKAP detection issue may be because the 
affinity capture studies used diluted heart homogenates; although the idea was that if 
they were indeed captured by the cAMP-agarose the AKAPs would be enriched and so 
easily detected by immunoblotting.  
Another issue was that the cAMP affinity capture process appeared to chemically 
reduce RI disulfide. Hearts where RI was mostly disulfide dimer in input samples 
then had similar amounts of disulfide dimer and monomer in capture samples consistent 
with reduction of RI. This decrease in percentage disulfide in H2O2-treated hearts may 
result in less of a difference in AKAP binding between control and H2O2-treated hearts 
as the difference in percentage disulfide is smaller. In some examples, there also 
appeared to be an increase in total RI protein because of this reduction to monomer 
which is difficult to explain as there is no sensible basis for de novo protein synthesis.  
Another issue was that a band at ~100 kDa (the same mass as RI disulfide dimer) was 
observed in some KI capture samples. KI RI cannot form RI disulfide so this was not 
expected and was not observed previously. I have provided some evidence that this 
could be the PKA catalytic subunit bound to RI subunit (shown to occur with RII and 




catalytic subunit,[59]) but as this was only explored in one experiment it is possible that 
the 100 kDa band in the KI hearts is an artefact from over-exposure of the film as it is 
not observed on a shorter exposure that is adequate to generate a strong RI signal.  
I expected to see a number of significantly stained bands on colloidal Coomassie-
stained gels of capture samples. It is unclear why only a few faint bands were observed 
as the affinity capture appeared to work well in terms of capturing RI. Although 
optimisation of the protocol was attempted, perhaps further optimising is required to 
increase the amount of RI captured and so RI-bound proteins. Although it is possible 
that AKAPs are in insufficient abundance to generate Coomassie stained bands even if 
captures are highly efficient. For this reason and because of lack of success with 
specific AKAP antibodies, LC-MS/MS was used to identify AKAPs in the cAMP-
agarose capture samples. This was considered a more sensitive technique.  
LC-MS/MS identified a number of cAMP-binding proteins captured in similar 
abundance between genotypes and with oxidant treatment. These could be RII-specific 
binding proteins or targets simply not effected by RI disulfide formation. Western 
blotting demonstrated that AKAP220 and /  tubulin were both in the Triton X-100 
soluble fraction of WT and KI hearts but they were not identified by LC-MS/MS. 
However, they may not have been detected by LC-MS/MS because they were present in 
the part of the colloidal Coomassie stained gel that was not analysed or the LC-MS/MS 
was not sensitive enough to detect them. AKAP220 was difficult to detect in input 
samples using antibodies but where visible was not detected in capture samples, which 
agrees with LC-MS/MS results that AKAP220 does not bind RI / RII. However, this 
conflicts with a study showing it binds RI and RII.[269]  /  tubulin was easily 
detected in input samples but was generally not detected in capture samples. This 
further conflicts with literature showing RI binds tubulin specifically.[287] Possible 
explanations for this are considered below. 
ChChd3 is a substrate for PKA,[294] and forms a complex with SKIP, an AKAP that 
binds Type I PKA.[293] LC-MS/MS identified significantly more ChChd3 was 




captured for WT compared to KI. I hypothesised that there was more ChChd3 in WT 
because WT RI can form disulfide that may increase binding to SKIP. ChChd3 was 
localised in the membrane-enriched fraction of WT and KI hearts which agrees with 
others who found ChChd3 is located in the inner mitochondrial membrane.[295] They 
show it may be synthesised in the cytosol and associated with HSP70 to keep it in its 
reduced form before being transported to the mitochondria. Therefore, ChChd3 can 
potentially be phosphorylated by membrane-localised PKA. Perhaps ChChd3 
phosphorylation is increased in oxidant-treated WT hearts as a result of translocation of 
RI disulfide and so catalytic subunit to the membrane. However, there is no antibody 
to phospho-ChChd3 (Thr10) available commercially and the one generated by Taylor‟s 
lab (San Diego, USA) is no longer available. Future studies could implement the Phos-
tag method,[315] to assess phosphorylation status or immunoprecipitation of ChChd3 
with subsequent probing with a pan-specific PKA phospho-substrate antibody may be 
valuable.  
SKIP was not identified by LC-MS/MS but this could be for reasons already mentioned; 
because it was present in the part of the colloidal Coomassie stained gel that was not 
analysed or the LC-MS/MS was not sensitive enough to detect it. Fractionation revealed 
SKIP was located in the myofilament-enriched fraction of WT and KI hearts whereas 
others have reported SKIP localisation to the cytosol.[292] This conflict in results may 
be due to differences in sample preparation although I am confident with my 
fractionation protocol as I showed presence of respective marker proteins that are 
indicative of each fraction (shown in Chapter 2). If SKIP is localised in the 
myofilament, it would not have been detected by LC-MS/MS because the capture 
sample analysed was only the Triton X-100 soluble fraction of the heart.   
Overall, the reason for increased ChChd3 binding to WT RI does not appear to be due 
to increased RI binding to SKIP. I reason this is because SKIP is only in the Triton X-
100 insoluble fraction of the heart whereas ChChd3 is predominately present in the 
Triton X-100 soluble fraction. ChChd3 is a scaffolding protein that forms complexes 
with proteins other than PKA including the inner mitochondrial membrane proteins, 




mitofilin and optic atrophy 1 (OPA1) and the outer mitochondrial membrane protein 
Sam50. These are GTPases involved in mitochondrial fusion (merging of mitochondria 
before division).[295] Interestingly, OPA1 has been identified as a D-AKAP that has a 
slightly higher specificity for RI than RII. It has been shown to localise with PKA (Type 
I or Type II) and perilipin in lipid droplets. Perilipin is a PKA substrate and its 
phosphorylation regulates access of lipases and so formation of this complex is 
important in control of lipolysis.[316] Therefore OPA1 may also function as a D-AKAP 
in mitochondria and form a complex with ChChd3 and RI and disulfide may alter the 
interaction of RI with OPA1.  
AKAP7γ (also known as AKAP18δ) binds PKA RI and RII and is located in the 
cytoplasm and nucleus.[317] It forms a multi-protein complex with PLB, SERCA2 and 
PKA RII. However, the presence of PKA RI in this complex was not analysed despite 
AKAP7γ being a D-AKAP. Lygren et al. demonstrated that the interaction between 
AKAP7γ and PLB was inhibited by phosphorylation of PLB at Ser16, a known PKA 
phosphorylation site. AKAP7γ interaction with PLB was necessary to recruit PKA for 
phosphorylation of PLB and Ca
2+
 re-uptake into the SR.[226] LC-MS/MS identified 
SERCA2 as a protein that bound KI RI more than WT RI. This may suggest that RI 
disulfide reduces binding of PKA RI to an AKAP (e.g. AKAP7γ) and so reduces 
complex formation with SERCA2 and PLB too. I found (see Chapter 4) that 
phosphorylation of PLB, the inhibitory protein for SERCA2, was significantly 
decreased by oxidant treatment in WT but not KI. This is consistent with the hypothesis; 
if AKAP binding is reduced in response to oxidant, less PKA is anticipated to associate 
with its substrate PLB, so phosphorylation of PLB would be less. This highlights the 
possibility that disulfide may reduce RI-AKAP binding as well as increase it. Reduced 
AKAP binding may be a mechanism to increase the amount of free RI in the cytosol- / 
membrane- enriched fractions of the heart so it can then translocate to myofilament. 
Alpha-enolase is a glycolysis enzyme present in the cytosol as well as on the cell 
membrane where it can function as a plasminogen receptor.[318] LC-MS/MS revealed 
this bound more to WT RI than KI RI. Although it is not a substrate for PKA there is 




evidence it may be a substrate for Src,[300] which as mentioned in 5.1.2, is associated 
with D-AKAP1. Work by Banky et al.,[116] showed that mutating Cys16 did not affect 
D-AKAP1 binding to RI. LC-MS/MS demonstrated an increase in D-AKAP1 
abundance in the WT capture sample with H2O2 but not in the KI. D-AKAP1 was 
detected in capture samples using a D-AKAP1 antibody and its binding appeared to 
increase with oxidant treatment in both genotypes. This is interesting but the n number 
for both these analyses needs to be increased to form a confident conclusion on whether 
disulfide alters RI binding to D-AKAP1.  
Isoform 4 of myomegalin interacts with PKA RI and RII and also alpha-enolase.[302] 
Perhaps RI disulfide increases binding to myomegalin which recruits alpha-enolase. 
However, the function of this complex formation is unclear as alpha-enolase is not an 
established PKA substrate. Absence of myomegalin in capture samples could indicate it 
was present in the Triton X-100 soluble fraction of the heart but doesn‟t bind RI / RII, it 
was present in the section of the colloidal Coomassie stained gel that was not analysed 
or the LC-MS/MS was not sensitive enough to detect the protein. However, Western 
blotting showed it to be abundant in the myofilament-enriched fraction of WT and KI 
hearts which is consistent with studies showing its presence in the sarcomere,[302] so 
its detection by LC-MS/MS would not be expected. Overall, I am unable to suggest a 
specific AKAP linking PKA RI and alpha-enolase in the cytosol and membrane as this 
is not an area well studied. 
Very long-chain specific acyl-CoA dehydrogenase (VLCD) is an enzyme involved in 
fatty acid oxidation and lipid metabolism. Ser586 of VLCD is phosphorylated by 
PKA. A VLCD Ser586 mutant has increased apoptosis, increased reactive oxygen 
species production and decreased enzyme activity.[303] VLCD preferentially bound to 
redox-dead RI suggesting that disulfide may reduce binding of RI to this AKAP. It 
may be interesting in further work to determine whether VLCD phosphorylation is 
increased in KI hearts to further test the idea that RI redox status regulates its 
interaction with this dehydrogenase. There are, however, no commercially available 
antibodies to monitor phosphorylation status of this site. Kabuyama et al.,[303] 




produced their own antibody, which could be sought in future studies. The literature 
does not describe any specific AKAPs associated with VLCD but there may be a novel 
AKAP associated with this protein that recruits PKA to VLCD to coordinate its 
phosphorylation.  
The effect of mutating the Cys residues flanking the DD domain in RIon binding to 
D-AKAP2 has been studied by others. Huang et al.,[138] showed that mutating Cys17 
in RI did not affect D-AKAP2 binding, whereas mutating Cys38 abolished D-AKAP2 
binding. Sarma et al. found that mutating Cys17 reduced RI-D-AKAP2 binding 3-fold 
compared to WT protein, and mutating Cys38 reduced binding 16-fold. They suggest 
D-AKAP2 binding may be reduced because disulfide bond formation decreases 
flexibility of the N-terminal helix N-1 of RI so the structure is more ordered and so 
residues critical for D-AKAP2 binding are positioned in close proximity to the AKAP 
for improved binding.[119] D-AKAP2 was identified in cAMP affinity capture samples 
by LC-MS/MS and there was a trend for an increase in spectral count with H2O2 in WT 
capture but not KI. Unfortunately, D-AKAP2 was not detected or only weakly detected 
in input samples or flow-through samples using a D-AKAP2 specific antibody. The 
work of others showed mutating Cys17 did not have as big an effect on D-AKAP2 
binding as mutating Cys38.[119] This may be why I am unable to detect any difference 
between WT and KI, as Cys17 was mutated in the KI mouse rather than Cys38. In 
addition, the apparent chemical reduction of the RI disulfide to reduced monomer by 
the cAMP affinity capture process (described earlier) may compromise the ability to 
assay the effect of H2O2 on RI redox state in WT hearts. This may also prevent a 
difference being observed between WT and KI in terms of AKAP binding and may 
apply to the other AKAPs assessed too. Perhaps when this chemical RI reduction by 
the cAMP affinity capture method happens, AKAP binding that occurred previous is 
lost so I am unable to observe it.  
LC-MS/MS was only carried out on one sample of each band from each genotype and 
each treatment so the n number should be increased in the future to gain more 
information on RI disulfide and AKAP binding. Inconsistencies in results could also 




be due to some of the complexities of the cAMP affinity capture method, some of which 
have already been discussed above. The method is artificial as the concentration of 
cAMP is very high and so not physiological. This may affect binding of AKAPs to RI 
but even if it was low and physiological the same issues could be present. The effect of 
cAMP and H2O2 together on RI binding to AKAPs is not known and which order these 
events happen in physiologically is not known. In addition, PKG can bind cAMP,[319] 
so may bind directly to the cAMP agarose. This kinase has its own binding proteins that 
may then be identified in capture samples, complicating results. LC-MS/MS showed 
that PKG I was significantly more abundant in KI than WT capture samples and there 
was a trend for an increase with oxidant treatment in both genotypes. The difference 
between genotypes is difficult to explain as the PKA RI mutation should not alter 
PKG I interaction with cAMP. However, PKG I forms disulfide in response to 
H2O2,[60] so this may increase its affinity for cAMP and explain the increase in its 
abundance in H2O2-treated capture samples for both genotypes.   
There are alternative methods that may be used to demonstrate the influence of disulfide 
on AKAP binding which avoid the use of AKAP specific antibodies and the numerous 
complexities of cAMP affinity capture. One example is adding a FLAG tag to the 
specific AKAP in WT and KI heart homogenate, isolating the immune complexes by 
FLAG agarose and then carrying out SDS-PAGE and Western blotting and probing for 
PKA RI. The cAMP affinity capture method is a solid-phase binding assay similar to 
Far Westerns which do not identify RI AKAPs as easily as RII AKAPs; one reason 
being that the RI-AKAP binding off-rate is faster than the on-rate,[284] making the 
interaction transient and difficult to catch using solid phase assays. Susan Taylor‟s 
group showed that WT disulfide RI has increased D-AKAP2 affinity by surface 
plasma resonance.[119] This most probably worked because it involves real time 
monitoring of AKAP binding and release. Therefore, this is a method that could be used 
in my studies. Another method that could be used is confocal microscopy, to show co-
localisation of RI and specific AKAPs. 




Although I was unable to determine any association between RI disulfide and AKAP 
binding I did identify a number of proteins that potentially interact with RI. I have 
attempted to provide links between some of these proteins and AKAPs described in the 
literature but there may be novel AKAPs that we do not know about yet that may 
explain some of the results. In conclusion, disulfide causes translocation of RI to the 













The thioredoxin (Trx) system is important in maintaining a reduced intracellular state. 
In this chapter I assessed whether Trx has a role in reduction of PKA RI disulfide. Trx 
was originally identified in Escherichia coli (E. coli), as a hydrogen donor for 
ribonucleotide reductase.[320] It is also known as adult T-cell leukaemia-derived factor 
because a Trx-homologue was identified in the supernatant of human T-lymphotropic 
virus-I-infected T cells.[321] Trx is a 12 kDa protein that catalyses the reduction of 
protein disulfides and S-nitrosothiols,[322] as discussed below.  
Forms of Trx and their structure: Mammalian cells contain Trx1 and Trx2 which are 
encoded by different genes.[323] Trxs from archaea to humans show 27 - 69 % 
sequence identity to Trx from E.coli. All Trxs have the same overall 3D structure,[324] 
and have the same structural motif called the „Trx fold‟. This consists of a four stranded 
β-sheet and three flanking α-helices or more specifically, an N-terminal βαβ motif and a 
C-terminal ββα motif connected by a loop of residues making up another α helix. The 
active site motif is Cysteine (Cys) - Glycine (Gly) - Proline (Pro) - Cys and this redox 
active dithiol, which interacts with the disulfide of the target protein, is located at the N-
terminus of the α1 helix.[325] Human Trx1 has the two Cys residues (Cys32 and 
Cys35) located in the active site, and an additional three Cys residues located outside of 
the active site; Cys62, Cys69 and Cys73. 
There is less information on Trx2 than Trx1. Trx2 contains the Trx fold and the 
conserved active site Cys residues but not the structural Cys residues that Trx1 has in its 
C-terminus.[326] This makes it resistant to oxidation (which occurs in Trx1 as 
discussed below). It also has a sixty amino acid extension at the N-terminal that is 




involved in mitochondrial translocation and contains a protease cleavage site where 
cleavage produces the mature protein.[327] 
Localisation and expression of  Trx: Trx1 is mostly cytosolic but can also be found in 
the  nucleus.[321] Phorbol 12-myristate 13-acetate (PMA), ultra-violet radiation and 
tumour necrosis factor (TNF) α are examples of stimuli that cause Trx1 translocation 
from the cytoplasm to the nucleus.[328] In contrast, Trx2 is mitochondrial.[327, 329]  
Trx is ubiquitous in all living cells but a comparison of expression of Trx1 and Trx2 
reveals differences in their abundances in various organs.[327]. Expression of Trx can 
be altered by a variety of stresses. Taniguchi et al.,[330] showed that oxidant stresses 
such as diamide (5 µM for 6 hours), or H2O2 (1 - 100 µM for 6 hours) increased Trx 
gene expression in Jurkat cells. Trx1 expression was also increased in endothelial cells 
by low doses of H2O2 (10 or 50 µM) and short term shear stress.[331] Expression of 
Trx1 was reduced after ischaemia and reperfusion and adaption to the ischaemic stress 
(by short preconditioning episodes of ischaemia and reperfusion) followed by ischaemia 
and reperfusion resulted in an increase in Trx1 expression.[332] In contrast, it has also 
been shown in human umbilical vein endothelial cells that H2O2 (100 µM or 200 µM for 
6 hours) can induce degradation of Trx1 and apoptosis.[333] 
How Trx reduces its substrate and is regenerated by Trx reductase: Trx does not 
target and reduce all disulfide proteins. It has selective substrates due to specific 
protein-protein interactions. The crystal structures of human Trx1 and human Trx2, both 
reduced and oxidised states have been described.[326, 334, 335] Trx is generally 
thought to interact with its substrates in its reduced monomeric form, but there is also 
evidence for a reduced dimeric Trx1 species where the two monomers of the dimer are 
linked by a hydrogen bond and the linkage stabilised by a disulfide between Cys73 
residues of each monomer. The reduced dimer may be Trx‟s inactive state as it is not a 
substrate for Trx reductase (TrxR), perhaps acting as a regulatory mechanism.[335] As 
mentioned, Trx2 does not contain Cys73, but has Ala73 in its place which precludes 




disulfide formation. There is evidence, however, that Trx2 can still form a dimer due to 
hydrophobic interactions and hydrogen bonds.[326] 
As mentioned, Trx has a consensus redox-active dithiol (Cys32-Gly-Pro-Cys35) in its 
active site. The Cys thiol at the N-terminal (Cys32 in human Trx) has a reduced pKa 
(~6.3 compared to ~8.7 in a „typical‟ Cys thiol).[335] This thiol therefore exists in the 
deprotonated thiolate state at physiological pH and reacts with the target protein 
disulfide, becoming disulfide-linked to the target. This interprotein disulfide is short-
lived because it is rapidly reduced by the C-terminal thiol (Cys35 in human) of Trx. 
Overall this results in formation of a reduced target protein, and intraprotein disulfide in 
the active site of Trx between Cys32 and Cys35. This Trx intraprotein disulfide is 
reduced by TrxR using NADPH, as explained in more detail below.[336] The 
mechanism of Trx-catalysed reduction is shown in Figure 6.1.  
The crystal structure of human Trx complexed with TrxR1 has been solved and shows 
that TrxR1 has a flexible C-terminal arm, which enables the transfer of electrons to 
Trx.[337] Trx can only be reduced by TrxR, no other enzyme has been identified that 










Figure 6.1 Mechanism of reduction of a target protein disulfide by Trx and 
regeneration of Trx by TrxR.  
(1) Reduced Trx interacts with the target protein disulfide. An interprotein disulfide forms 
between one of the active site Cys residues of Trx and a Cys in the target protein. (2) The 
other Cys residue in the active site of Trx then reduces this disulfide. The target protein 
disulfide is fully reduced and an intraprotein disulfide forms in Trx. (3) The disulfide is then 
reduced by TrxR using NADPH.  
 
Functions of Trx and its substrates: Enzymes that form a disulfide during their 
catalytic cycle were the first substrates described for Trx1. These include peroxiredoxin 
(Prx, described in Chapter 1),[339] ribonucleotide reductase,[340] and methionine 
sulfoxide reductase.[341] 
The function of Trx1 has been well-studied, but less is known about the functions of 
Trx2, so unless stated otherwise I am specifically referring to Trx1 from here on. Trx is 
not only important for its reducing activity and protecting cells from oxidative stress, 
but also has an important role in redox signalling, as considered below. Trx interacts 
with and reduces proteins important in cell growth and proliferation, apoptosis and gene 
expression. In addition to these well studied functions, Trx has more recently been 
shown to be important in cardiac muscle contraction and cardiac energy dynamics by 








pore, important in supplying ATP to the heart.[342] Further examples of the substrates 
and functions of Trx are provided below.  
Trx in cell growth and survival: Knockout Trx mice die early in embryogenesis 
suggesting an essential role for Trx in morphogenesis and differentiation of the embryo 
and highlighting a crucial role in cell growth.[343] Trx has been shown to be excreted 
by normal and transformed cells such as monocytes, fibroblasts and airway epithelial 
cells,[344] and exhibit chemo-attractant properties.[345] It has also been described as a 
growth factor stimulating growth of lymphocytes, fibroblasts and some tumour cell 
lines, and it is overexpressed in a number of tumours.[346] Trx inhibits apoptosis by 
targeting a number of proteins such as p53 and apoptosis signal-relating kinase (ASK-
1).  
ASK1 is a mitogen activated protein kinase (MAPK) kinase kinase (MAPKKK) 
activated by reactive oxygen species (ROS), Fas and TNF. Its downstream targets 
include p38 MAPK and c-Jun N-terminal kinase (JNK) which induce apoptosis.[347] 
Under normal conditions, ASK1 is found in the cytoplasm and forms a complex with 
Trx1.[348] Reduced Trx1 inhibits ASK1 activity by binding to ASK1 at its N-
terminus,[349] with amino acids 46 - 277 of ASK1 being necessary and sufficient for 
this interaction.[350] Cys250 in ASK1 has been shown to be particularly important for 
binding to Trx1,[50] as has another single Cys (Cys35 or Cys32) in Trx.[351] Binding 
of Trx to ASK1 prevents the TNF receptor associated factor 2 (TRAF2) binding to 
ASK1 which is important in TNF-induced activation of ASK1.[352] Trx also inhibits 
the homophilic interaction (ASK1 binding to ASK1) of ASK1 at its N-terminal which 
was shown to be necessary for H2O2-induced ASK1 activation,[350] and induces ASK1 
ubiquitination / degradation.[351] When Trx is oxidised by H2O2, it dissociates from 
ASK1, leading to ASK1 activation and apoptosis.[349, 351, 352] ASK1 may also be 
oxidised directly by H2O2 to form a disulfide linked multimer (up to tetramer), which is 
then reduced by Trx. Oxidation of ASK1 to the multimer was required after dissociation 
of Trx from ASK1 (ASK1 activation) for full activation of ASK1‟s downstream target 
JNK and ultimately H2O2-induced apoptosis.[353] ASK1 is not only located in the 




cytoplasm but is also located in the mitochondria. Under resting conditions, reduced 
Trx1 is bound to ASK1 in the cytoplasm (as already stated) and reduced Trx2 is bound 
to ASK1 in the mitochondria. Cys30 in ASK1 is important for binding to Trx2. Stimuli 
such as ROS and TNF cause dissociation of Trx1 and Trx2 leading to mitochondrial-
dependent apoptosis.[348] Trx1 and Trx2 can work cooperatively to inhibit ASK1-
induced apoptosis. This is because when Trx1 dissociates from cytoplasmic ASK1, 
activation of a JNK-dependent apoptotic pathway occurs, involving activation of JNK, 
BID cleavage and Bax translocation. When Trx2 dissociates from mitochondrial ASK1 
at the same time as dissociation of Trx1 from cytoplasmic ASK1, activation of a JNK-
independent apoptotic pathway occurs. Both apoptotic pathways merge at cytochrome c 
release (Trx2 interacts with cytochrome c),[323] and result in caspase 3 activation and 
apoptosis.[348]  
Trx in gene expression: Trx enhances the deoxyribonucleic acid (DNA) binding of 
transcription factors important in the response to apoptosis, oxidative stress and 
tumorigenesis.[354] Activator protein 1 (AP-1), nuclear factor kappa-light-chain-
enhancer of activated B cells (NFB) and p53 are examples of substrates involved in 
this function of Trx. 
AP-1 is a dimeric transcription factor composed of members of the Fos, Jun, activating 
transcription factors and Jun dimerisation partners families. AP-1 has important roles in 
cell proliferation, apoptosis and neoplastic transformation.[355] The binding of Fos and 
Jun to the AP-1 DNA sequence motif is regulated by oxidation and reduction. The 
reduction of a conserved Cys residue in the DNA binding domains of Fos and Jun 
increases DNA binding activity.[356] Certain stimuli cause Trx translocation from the 
cytoplasm to the nucleus where it directly associates (through Cys residues in the active 
site of Trx) with a protein called redox factor 1 (Ref-1).[357] Ref-1 then stimulates 
DNA binding activity of AP-1 by reduction, although the mechanism is poorly 
understood.[358, 359] There is evidence for and against Cys65 / Cys64 (human / 
mouse) being the redox catalytic site in Ref-1.[360, 361] More recently, Ref-1 has been 
described as a „redox chaperone‟ that, independently of its Cys residues, facilitates the 




chemical reduction of various transcription factors by GSH and Trx. AP-1 is suggested 
to be one of these transcription factors.[362]   
NFB is a dimeric transcription factor composed of members of the Rel family 
including p50, p65 and p52. Inactive NFB is present in the cytoplasm bound to an I 
kappa B (IB) inhibitory protein. Stimuli such as TNF trigger an intracellular kinase 
cascade resulting in phosphorylation and proteosomal degradation of IB. This means 
the p50 - p65 heterodimer can translocate to the nucleus, bind to DNA and activate 
transcription of target genes involved in functions such as inflammation, nitric oxide 
(NO) production, apoptosis and proliferation.[363] NFB DNA binding is regulated by 
reduction and oxidation of the p50 subunit. p50 subunits form disulfide dimers and 
formation is dependent on Cys62. Oxidation abolishes DNA binding whereas reduction 
by Trx stimulates DNA binding.[364, 365] Direct physical interaction between an 
oligopeptide from the p50 DNA-binding loop and Trx has been shown.[366] Ref-1 can 
act as a „redox chaperone‟ to facilitate the reduction of NFB by Trx,[362] as well as 
act alone to reduce Cys62 of the p50 subunit.[367] As mentioned earlier, Trx can 
translocate from the cytoplasm to the nucleus under certain conditions. Cys62 of the 
p50 subunit is strongly reduced in the nucleus and highly oxidised in the 
cytoplasm.[367] Hirota et al. suggest that Trx in the cytoplasm and nucleus have 
opposing effects on NFB activity. Trx in the cytoplasm blocks the degradation of IB 
and Trx in the nucleus increases NFB‟s DNA binding activity by direct 
association.[328]   
Functions of Trx2: The mitochondrial respiratory chain is a major source of ROS, so 
mitochondrial antioxidant systems (including the Trx2 system, manganese superoxide 
dismutase (MnSOD) and Trx peroxidase) are important in preventing irreversible 
oxidative damage.[348] Trx2 is essential for embryonic development and cellular 
respiration,[368] and plays a role in protection against oxidant-induced apoptosis, as 
already discussed.[369, 370]  




The role of Trx in de-nitrosylation and S-nitrosylation: In addition to reducing 
protein disulfides, Trx promotes S-nitrosylation and de-nitrosylation of target proteins 
depending on the redox state of the cell. The mechanism of de-nitrosylation of a protein 
involves trans-S-nitrosylation of Cys32 of Trx, intraprotein disulfide formation between 
Cys32 and Cys35 in Trx and release of nitroxyl (HNO). Reduction of disulfide Trx by 
TrxR and NADPH follows. In addition, the intraprotein disulfide form of Trx may be S-
nitrosylated at Cys62, 69 or 73 (in human) and under certain conditions, S-nitrosylated 
Trx may trans-S-nitrosylate other proteins.[322, 371-373] This mechanism is presented 
in Figure 6.2. 
 
Figure 6.2 Mechanism of protein de-nitrosylation and S-nitrosylation by Trx1.  
Trx1 de-nitrosylates its target protein (RSNO to RSH) by being S-nitrosylated itself at 
Cys32. Cys35 then forms an intraprotein disulfide with Cys32 releasing nitroxyl (HNO). 
Under certain conditions i.e. when the intraprotein disulfide in Trx1 cannot be reduced, 
Cys62, 69 or 73 of Trx1 (not in active site) is S-nitrosylated. Trx1 can then S-nitrosylate 
other protein thiols (protein-SH) such as GSH.    
 
 




Substrates for Trx1-mediated denitrosylation and S-nitrosylation have been identified. 
Prx-1 was a substrate for trans-S-nitrosylation but not denitrosylation. Glyceraldehyde 
3-phosphate dehydrogenase (GAPDH) and α-tubulin were substrates for both S-
nitrosylation and denitrosylation.[374] Cys163 of caspase 3, a mitochondrial enzyme, is 
a target for S-nitrosylation by Trx-Cys73 and this leads to inactivation of caspase 3 and 
inhibition of apoptosis.[375, 376] Denitrosylation of S-nitrosylated caspase 3 is induced 
by stimulation of the Fas receptor (death receptor) and this is mediated by Trx2 / TrxR2. 
Denitrosylation is required for full activation of caspase 3 and apoptosis.[377]    
Trx interacting protein: Trx interacting protein (TXNIP) is also known as vitamin D3-
upregulated protein and Trx binding protein 2. It‟s only known function is to bind and 
inhibit Trx. When TXNIP is oxidised it forms an intraprotein disulfide between Cys63 
and Cys247. TXNIP then interacts with reduced Trx, with Cys247 of TXNIP forming 
an interprotein disulfide with Cys32 of Trx.[378] Overexpression of TXNIP has been 
shown to reduce Trx activity and its nuclear translocation, inhibit proliferation,[379] 
enhance ROS production and attenuate cardiac hypertrophy.[380] Knockdown of 
TXNIP also abolishes high glucose-induced apoptosis and ASK1 activation.[381] 
6.1.2 Thioredoxin reductase 
Members of the TrxR family: TrxR was first cloned and sequenced from E.coli in the 
late 1980s.[382, 383] In the late 1990s a human TrxR (named TrxR1) was cloned and 
sequenced from placenta. Human TrxR1 has a molecular mass of 54 kDa and only has 
31 % sequence identity with prokaryotic TrxRs. It is bigger than prokaryotic TrxRs and 
lower eukaryotic TrxR enzymes due to the dimer interface domain (explained 
later).[384] Bovine TrxR1 and rat liver TrxR1 have also been purified,[385, 386] and 
sequenced.[387] TrxR1 is cytosolic.[388] 
The identification of a mitochondrial Trx2 (as described in earlier) prompted work 
investigating the existence of a mitochondrial TrxR. Cloning and expression of 
complementary deoxyribonucleic acid (cDNA) for a mitochondrial human TrxR, 
TrxR2, with a molecular weight of 56 kDa have been described. TrxR2 cDNA had 56 % 




identity to TrxR1 and there was 84 % similarity at the amino acid level.[389] Cloning 
and expression of cDNA for mouse and rat TrxR2 have also been described.[390, 391]  
Another member of the TrxR family is Trx - oxidised glutathione (GSSG) reductase 
(TR2 or Txnrd3). This demonstrates specificity for both the Trx system and GSSG 
system as it can reduce Trx, GSSG and a GSH-linked disulfide.[392] A partial sequence 
for Txnrd3 cDNA has been identified in humans,[393] and the full sequence for mouse 
Txnrd3 cDNA has been identified. This showed 88 % identity to the partial human 
sequence, 73 % identity to human TrxR1 and 56 % identity to human TrxR2. This form 
of TrxR is found mainly in the testis.[392] 
Structure of members of the TrxR family: TrxR1, TrxR2 and Txnrd3 are members of 
the pyridine nucleotide-disulfide oxidoreductase family. Other members of this group 
include lipoamide dehydrogenase, mercuric ion reductase, glutathione reductase and 
NADH peroxidase. Members of this group are homodimeric (except NADH peroxidase 
which is a homotetramer) and each monomer has a redox-active disulfide and FAD 
protein bound.[394] TrxR also contains an NADPH-binding domain.[338] E.coli TrxR 
does not contain the dimer interface domain i.e. the site of interaction between subunits 
found in mammalian TrxR. This explains why mammalian TrxR is larger than E.coli 
TrxR.[384] The structure of mammalian TrxR can be seen in Figure 6.3.  
 





Figure 6.3 Ribbon representation of rat TrxR.  
The two subunits are shown in light or dark colours, respectively. (Red = FAD binding 
domain; yellow = NADP binding domain; blue = interface domain. NADP = orange ball-and-
stick model and bound FAD = red ball and stick model.[394] 
 
Mammalian TrxR contains an active site with the sequence; Cys-Val-Asn-Val-Gly-Cys, 
which is located in the FAD binding domain.[394] In E.coli this sequence is located in 
the NADPH-binding domain and has a two amino acid bridge between the Cys residues 
rather than the four amino acid bridge seen in mammalian TrxR1.[384] Mammalian 
TrxR also contains a C-terminal extension with the unique sequence Gly-Cys-SeCys-
Gly,[395] where SeCys is selenocysteine. This is where the S has been replaced with Se 
which lowers the pKa, which is essential for the enzymes catalytic mechanism.[338, 
396] 
TrxR2 has a similar structure to TrxR1 with a conserved active site, FAD-binding and 
NADPH-binding domains but also has a thirty-three amino acid extension at the N-
terminus which when removed abolishes mitochondrial translocation.[389] Txnrd3 
contains the TrxR1 domains and an N-terminal glutaredoxin (Grx) domain.[392] 




Mechanism of TrxR-catalysed reduction of its substrates: The NADPH and FAD 
domains of E.coli TrxR are positioned so that when NADPH binds it is not in close 
contact with FAD, preventing electrons being transferred from NADPH to FAD. This is 
not the case in other members of the pyridine nucleotide-disulfide oxidoreductase 
family. To overcome this issue of the NADPH and FAD domains not being close 
together, a conformational change occurs where the NADPH domain is rotated 66 º with 
respect to the FAD domain. Now when NADPH binds to the NADPH domain it is in 
close contact with FAD so electrons can be transferred from NADPH to FAD. 
Following this, reduction of the active site disulfide of TrxR can occur. The 
conformational change also exposes the reduced active site dithiol of TrxR so it can 
reduce Trx. During reduction of Trx, an active site disulfide is formed in TrxR, allowing 
TrxR to move back into its original conformation and the catalytic cycle can start 
again.[338, 397-399]   
The mechanism for mammalian TrxR catalysis relies on a head-to-tail orientation of the 
homodimer so that the C-terminal Cys497-SeCys498 (in rat, absent in E.coli TrxR) 
residues of each subunit are opposite the N-terminal active site dithiol (Cys59 and 
Cys64 in rat) of the other subunit of the dimer.[400] In oxidised TrxR, Cys497 and 
SeCys498 form a selenenylsulfide and the active site Cys59 and Cys64 residues form an 
intraprotein disulfide. The active site disulfide is reduced by NADPH via FAD. 
Electrons from NADPH are then transferred to the selenenylsulfide to form a 
selenolthiol.[394, 400-402] Tyrosine (Tyr)116 (its side chain is located above SeCys) is 
also important in the reduction of selenenylsulfide.[403] The resulting selenolthiol then 
acts as the active site for reduction of substrates such as Trx.[394, 400-402] Electrons 
may be offered to the final substrate by movement of the reduced C-terminal arm away 
from the catalytic site to the surface.[394, 404] SeCys498 forms a mixed 
selenenylsulfide with Trx which is then reduced by Cys497 in the C-terminal active site 
to form a selenenylsulfide between Cys497 and SeCys498. The cycle then starts 
again,[394] as shown schematically in Figure 6.4.  
 






Figure 6.4 Postulated mechanism of reduction of Trx by mammalian (example is rat) 
TrxR.  
(1) The mammalian TrxR homodimer is in a head-to-tail orientation so the active site Cys59 
and Cys64 and the C-terminal Cys497-SeCys498 are close to each other. The active site 
Cys residues are oxidised to a disulfide and the C-terminal Cys residues are oxidised to a 
selenenylsulfide. (2) NADPH transfers its electrons to the active site disulfide via FAD 
reducing this disulfide. (3) The C-terminal selenenylsulfide is then reduced and the active 
site Cys residues form a disulfide. (4) Oxidised Trx forms an interprotein disulfide with 
SeCys498 of TrxR which is then reduced by Cys497 to form the oxidised TrxR homodimer 
again (1) and reduced Trx.      
 
Substrates for TrxR: Although knock-out (KO) TrxR1 mice die during 
embryogenesis, interestingly mice with a heart-specific KO of TrxR1 develop 
normally.[405] Mice lacking functional TrxR2 also die during embryogenesis with mice 
with a heart-specific inactivation of TrxR2 dying soon after birth from dilated 
cardiomyopathy and congestive heart failure. This shows the importance of TrxR2 in 
heart development and function. Overall TrxR1 and TrxR2 appear to have non-
redundant functions.[406]  
(1) (2) 
(3) (4) 




In addition to being bigger than E. coli TrxR, mammalian TrxRs have a different and 
wider substrate specificity; reducing proteins other than just Trx.[385] The endoplasmic 
reticulum proteins protein disulfide isomerase, Ca
2+
 binding protein 1 (CaBP1) and Ca
2+
 
binding protein 2 (CaBP2) are also substrates and these have Trx-like activity.[407, 
408] TrxR can also reduce non-disulfide substrates such as lipid hydroperoxides and 
H2O2.[409]  
If RI disulfide formation is a form of redox regulation of PKA then I would anticipate 
that it can be reversed, and most probably this would be enzymatically. This chapter 
investigates whether the Trx system is indeed capable of reducing RI disulfide. I 
hypothesise that the Trx system does reduce oxidised RI because bands at ~62 kDa 
and ~75 kDa have been observed on some non-reducing Western blots,[57] consistent 
with RI monomer and one Trx or RI monomer and two Trx‟s, respectively (Figure 
6.5). Consequently, this chapter aims to address the following:  
1. Whether the Trx-TrxR-NADPH system reduces PKA RIdisulfidehis will be 
assessedby monitoring NADPH consumption indexed by measuring a decrease in 
NADPH fluorescence. I hypothesise that PKA RIdisulfideis a substrate for the Trx 
system and so I anticipate an increase in Trx-TrxR activity and consequent increase in 
NADPH consumption.  
2. Whether 3′,5′-cyclic monophosphate (cAMP) modulates Trx-TrxR dependent 
reduction of RI disulfide. cAMP binding to RI may cause a conformational change in 
RI that may reduce or increase Trx‟s access to RI disulfide and so Trx-mediated 
reduction of disulfide. The altered activity of Trx in turn alters the amount of oxidised 
Trx present and therefore amount of substrate for TrxR thereby altering TrxR activity.  
3. If pharmacological inhibition of TrxR alters basal RI redox state or RI disulfide 
formation in response to a low concentration of oxidant. Inhibition of TrxR will cause 
an accumulation of oxidised Trx, which then can‟t reduce its substrates. I hypothesise 




that PKA RIdisulfide is a substrate for Trx and so I expect to observe an accumulation 







Figure 6.5 Brennans,[57] Western blot probed with anti - PKA RI.  
Isolated perfused rat hearts were perfused with 0 - 10000 μM H2O2 (5 min). I hypothesise 
that the two bands indicated by arrows for hearts perfused with 1000 and 10000 μM H2O2 
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6.2.1 NADPH fluorescence  
RI protein is expensive to purchase, so to determine if the Trx system (TrxR, Trx, 
NADPH) reduced RI disulfide a method was used that was sensitive enough such that 
only a small amount of RI was required. This approach also keeps the concentration of 
proteins and reducing molecules at concentrations similar to what they are in the cell. 
As fluorescence spectroscopy is suitably sensitive, a method based on NADPH which is 
intrinsically fluorescent was chosen. The reduced form of NADPH is fluorescent but the 
non-reduced form is not. Therefore if RI disulfide is reduced by Trx-TrxR, NADPH 
would be consumed as a substrate and therefore oxidised and so I would expect to 
observe a decrease in NADPH fluorescence (Figure 6.6).  
 
Figure 6.6 NADPH fluorescence.  
Schematic showing that reduced NADPH, but not oxidised NADP
+
, fluoresces at a 340 nm 
excitation (ex.) wavelength and a 450 nm emission (em.) wavelength.    
  
 
Construction of a NADPH standard curve and determining assay sensitivity: First, 
a standard curve was constructed. 20 μl of each NADPH standard concentration (0.05, 
0.1, 0.5, 1, 2.5, 5, 7.5, 10, 12.5, 25 and 50 µM in 100 μM diethylene triamine 
pentaacetic acid (DTPA) in 100 mM Tris pH 7.4) was added in duplicate to wells of a 
black 384-well optical bottom plate. The plate was placed in a fluorescence reader 
(FLUOstar Omega (BMG Labtech)) set at 37 ºC and a 340 nm excitation wavelength 
and a 450 nm emission wavelength. Fluorescence readings were recorded every minute 
for 5 min. An NADPH standard curve was then constructed using average values at 5 




min. A low concentration of NADPH that was detected by the reader but with little 
error was then selected for studies assessing RI disulfide reduction. A low 
concentration of NADPH was chosen to sensitise the fluorescence experiment assessing 
Trx-dependent RI reduction, as a limited amount of recombinant RI was available. 
RI or Prx-1 modulated NADPH consumption by Trx-TrxR: To determine if the 
Trx system was involved in RI disulfide reduction, NADPH fluorescence was 
measured as above. The assay mixture in a final volume of 20 µl comprised of 5 μM 
NADPH, 635 nM TrxR (purified from rat liver), 150 nM recombinant human Trx1 
(R&D Systems) and 1.4 μM PKA RI (human recombinant, Biaffin GmbH & Co KG) 
or 1.5 μM recombinant human Prx-1 (Sigma Aldrich) in 100 µM DTPA in 100 mM Tris 
pH 7.4. A 5 min stability period with just Trx, TrxR and NADPH was carried out first 
before RI or Prx-1 was added. Fluorescence of a blank (100 µM DTPA in 100 mM 
Tris pH 7.4) was also measured throughout so that this value could be subtracted from 
the values for the other reaction mixtures to give normalised values. The intrinsic 
fluorescence of each component (Trx, TrxR, RI or Prx-1) was measured to check 
whether these interfere with NADPH fluorescence measurements. 
Effect of cAMP on RI-modulated NADPH fluorescence: I assessed whether cAMP 
altered Trx-dependent RI reduction. cAMP binding to RI may cause a 
conformational change which may enhance or inhibit Trx1 binding to RI and therefore 
alter RI disulfide reduction. NADPH fluorescence was measured as above. In addition, 
NADPH fluorescence in the presence of cAMP-saturated RI was measured. RI was 
incubated with 150 µM cAMP before both being added to the reaction mixture.  
6.2.2 Monitoring disulfide RI or disulfide Prx-1 reduction by Western 
immunoblotting 
The redox status of RI or Prx-1 in the samples from the fluorescence assays (described 
above) was analysed by immunoblotting. 20 µl SDS sample buffer (with 100 mM 
maleimide) was immediately added to the samples at the end of the fluorescence assay 




and SDS-PAGE and Western blotting were carried out as described in Chapter 2. Blots 
were probed for RI or Prx-1. The Prx-1 antibody (ab41906, Abcam) was incubated 
with the blots for 1 hour at 1:1000 in 5 % milk in PBS with 0.1 % Tween-20 (PBS-T) at 
room temperature then washed for an hour and incubated with anti-rabbit secondary 
antibody for 1 hour at room temperature.  
6.2.3  Adult rat ventricular myocyte treatment with TrxR inhibitors: auranofin 
and cisplatin 
Another method for determining whether Trx1 reduced RI disulfide involved treating 
adult rat ventricular myocytes (ARVMs) with the TrxR inhibitors, cisplatin or 
auranofin. As described in Chapter 2, ARVMs were isolated from male Wistar rats and 
either cultured overnight and treated or left to settle at room temperature for two hours 
(freshly isolated) then treated.   
Treatment of overnight-cultured ARVMs: Pilot experiments were carried out in 
overnight-cultured ARVMs. ARVMs were left untreated or pre-treated with a TrxR 
inhibitor (20 nM auranofin or 100 μM cisplatin) or vehicle (ethanol for auranofin and 
dimethyl sulfoxide (DMSO) for cisplatin) for 5 min. ARVMs were then left untreated or 
treated with 0.5 mM diamide for a further 1, 5 or 10 min. The culture medium was then 
removed and 300 µl SDS sample buffer with 100 mM maleimide was added to the wells 
and the cells were scraped off the plate using a cell scraper. The mixture was then 
pipetted into an Eppendorf tube. 
Treatment of freshly isolated ARVMs: Myocytes were aliquoted into Eppendorf 
tubes and left untreated or treated with auranofin (50, 250 or 500 nM) or its vehicle (500 
nM ethanol) or cisplatin (20, 50 or 75 μM) or its vehicle (75 μM DMSO) for 30 min at 
37 ºC. Treatment with diamide (1, 5, 10 or 50 μM) for 5 min then followed. Samples 
were centrifuged at 1000 g for 0.5 min, the supernatant was removed and then the pellet 
was re-suspended in 250 μl SDS sample buffer containing 100 mM maleimide. In 
additional experiments, ARVMs were treated with 150, 300, 500 or 750 μM cisplatin or 




750 nM, 1, 2 or 3 μM auranofin or the vehicles for 30 min using the same protocol 
described.  
6.2.4 Monitoring redox status of PKA RI, cGMP-dependent protein kinase I 
and Prx-1 in freshly isolated ARVMs treated with TrxR inhibitors  
The redox state of PKA RI in auranofin / cisplatin treated ARVMs was determined by 
SDS-PAGE and Western blotting and probing the blots for PKA RI, as described in 
Chapter 2. cGMP-dependent protein kinase (PKG) I redox state was also determined 
by incubating the blots with cGKI (E-17) (sc-10338, Santa Cruz) for 1 hour (1:1000) 
followed by a one hour wash and incubation with anti-goat secondary (1:1000 in 5% 
milk in PBS-T) for 1 hour at room temperature.  The redox state of Prx-1 was also 
determined by probing the blot for Prx-1 (as described in 6.2.2).  
6.2.5  Determining redox state of Prx-1 in Langendorff-perfused wild-type mouse 
hearts by Western immunoblotting 
Wild-type (WT) hearts were Langendorff-perfused for 40 min with K-HB and then 
homogenised. SDS-PAGE and Western blotting were carried out (as described in 











6.3.1 NADPH fluorescence as a measure of RI disulfide reduction by the Trx 
system 
NADPH fluorescence standard curve and stability of NADPH fluorescence over 
time: A standard curve was constructed for NADPH fluorescence at 5 min (Figure 
6.7A). From the standard curve, a low concentration of NADPH was chosen that gave a 
relatively small error but a relatively high relative fluorescence units (RFU) value as 
this allows the RI reduction assay to be sensitive. After magnification of the standard 
curve between 0 and 10 µM NADPH (Figure 6.7B), 5 µM NADPH was chosen which 
fluoresced at ~27000 relative fluorescence units (RFU). Figure 6.8 shows that 
fluorescence for all concentrations of NADPH stayed quite stable over the 5 min period 
which was important when assessing how other proteins affect NADPH fluorescence 
over time. Fluorescence for 5 µM NADPH only changed from 49000 ± 8200 RFU at 0 
min to 48000 ± 8400 RFU at 5 min. 
 
















































Figure 6.7 Standard curve for NADPH fluorescence.  
(A) 0 - 50 µM NADPH standards were prepared and fluorescence (RFU) was read after 5 
min. Values are normalised where the RFU value for the blank (0 µM) was subtracted from 
each value. Graph shows average fluorescence values ± SEM where n=9/10 (B) The graph 
was magnified between 0 – 10 µM NADPH.  
(A) 
(B) 







































































Figure 6.8 Stability of NADPH fluorescence over time.  
(A) 0 - 50 µM NADPH standards were prepared and fluorescence (RFU) was measured 
over 5 min. Graphs show average fluorescence (raw values) ± SEM where n=9/10 (B) 
Magnification of average fluorescence over 5 min for 0 - 7.5 µM NADPH. Fluorescence was 
stable over 5 min. 
(A) 
(B) 




Effect of assay components on NADPH consumption: It was important to check that 
the individual components of the Trx system (Trx alone, TrxR alone) and RI itself did 
not affect NADPH fluorescence over time. This allows me to be sure that any effect 
seen when all the components were incubated together was definitely due to the 
presence of substrate. Prx-1 was used as a positive control to verify the assay was 
working, being selected as it is a known substrate for Trx.[410] Therefore, the effect of 
Prx-1 alone on NADPH fluorescence was also analysed.  
Trx caused a trend for an increase in NADPH fluorescence over time, but this was not 
significantly different from fluorescence for NADPH alone at any time point (Figure 
6.9A). This increase was not expected. It is difficult to explain NADPH production but 
perhaps Trx auto-fluoresces under these conditions. TrxR caused NADPH to be 
consumed and this was significantly different (p<0.05) from NADPH consumption for 
NADPH alone at each time point (Figure 6.9B). This may be due to auto-oxidation of 
TrxR in air requiring reduction by NADPH and so NADPH to be consumed. Prx-1 did 












































































Figure 6.9 Effect of Trx or TrxR on NADPH consumption.  
(A) Fluorescence of 5 µM NADPH alone (n=7) or with 150 nM Trx (n=6) was measured over 
5 min. Graph shows the change in fluorescence (NADPH consumption) from time = 0 min 
(minus blank) ± SEM. (B) Fluorescence of 5 µM NADPH alone (n=7) or with 635 nM TrxR 
(n=5) was measured over 5 min. 
*
p<0.05 compared to NADPH alone. Trx caused a trend for 



































































      (A)  
     (B)  
Figure 6.10 The effect of oxidised Prx-1 or oxidised RIon NADPH consumption.  
(A) Fluorescence of 5 µM NADPH alone (n=6) and with 1.5 μM Prx-1 (n=7) was read over 5 
min. Graph shows change in fluorescence (NADPH consumption) from time = 0 min (minus 
blank) ± SEM (B) Fluorescence of 5 µM NADPH alone (n=6) and with 1.4 μM RI (n=5). 









Effect of RI and Prx-1 on NADPH consumption by Trx-TrxR: In order to 
determine whether the Trx system reduces RI disulfide, the effect of oxidised RI on 
NADPH consumption by Trx-TrxR was analysed over 5 min. NADPH fluorescence 
only decreased by 2700 ± 430 RFU when NADPH was mixed with Trx and TrxR for 5 
min (Figure 6.11). This minor time-dependent consumption of NADPH is likely to be 
because Trx and TrxR are auto-oxidised in air to provide a basal activity of TrxR 
(consuming NADPH). Prx-1, a recognised substrate of the Trx system, served as a 
positive control and confirmed that the assay was working. Oxidised Prx-1 caused 3-
fold more NADPH to be consumed compared to the control (significant, p<0.05). 
Oxidised RIsimilarlycaused 3-fold more NADPH to be consumed compared to 
control (significant, p<0.05) consistent with RI being a substrate for the Trx system.  
Figure 6.11 Effect of oxidised Prx-1 or oxidised RI on NADPH consumption by Trx-
TrxR.  
The fluorescence of 5 µM NADPH, 150 nM Trx and 635 nM TrxR alone or together with 1.5 
μM Prx-1 (oxidised) or 1.4 μM RI (oxidised) was read over 5 min. This graph shows the 
change in NADPH fluorescence (NADPH consumption, minus blank) from time 0 min ± 
SEM. Prx-1 (n=8) and RI (n=6) caused a significant (*p<0.05) reduction in NADPH 
fluorescence over 5 min compared to when no substrate was present (n=7). 
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Confirmation that Prx-1 and RI were indeed reduced by Trx-TrxR: Although the 
consumption of NADPH in the assay containing disulfide RI or Prx-1 together with 
Trx and TrxR was consistent with reduction of the substrate, further confirmation of this 
was sought. Consequently, the oxidation state of RI before and after incubation with 
NADPH alone or NADPH, Trx and TrxR was determined by Western immunoblotting. 
Figure 6.12 confirms that Prx-1 was oxidised at the start of the assay. When Prx-1 was 
mixed with NADPH alone for 10 min, it remained in its oxidised form (no monomer). 
However, when mixed with NADPH / Trx / TrxR, more Prx-1 was present in its 
reduced monomeric state, confirming that the Trx system did reduce Prx-1. Figure 6.13 
confirms that RI was also oxidised at the start of the experiments. When RI was 
mixed with NADPH alone, there was a relatively small amount of reduced monomeric 
RI present in comparison to oxidised dimeric RI. When Trx and TrxR were also in 
the reaction mixture, the abundance of reduced monomeric RI did not change, which 
is inconsistent with the fluorescence results suggesting RI disulfide is reduced by the 


























































































































Figure 6.12 Reduction of Prx-1 by the Trx system.  
5 µM NADPH, 150 nM Trx, 635 nM TrxR and 1.5 μM Prx-1 (non-reduced / oxidised form) 
were incubated together for 5 min. Western blotting was carried out to show Prx-1 redox 
state and average reduced Prx-1 max OD was presented graphically (n=1, 3, 6 ± SEM). 



































































































Figure 6.13 Reduction of PKA RI by the Trx system.  
5 µM NADPH, 150 nM Trx, 635 nM TrxR and 1.4 μM RI (non-reduced form) were 
incubated together for 5 min. Western blot was probed for PKA RIand average max OD of 
reduced RI was calculated (n=1, 3, 6 ± SEM). Reduced RI formed when oxidised RI 
was incubated with NADPH, Trx and TrxR but RI was also unexpectedly reduced when 
incubated with NADPH alone.  
 




6.3.2 Effect of cAMP on RI reduction by the Trx system 
cAMP was added to the fluorescence assay to establish whether this altered Trx-TrxR 
activity induced by oxidised RIα.  
Effect of cAMP on disulfide RI-mediated NADPH consumption: cAMP was now 
an additional component in the assay, and so I needed to determine whether cAMP 
auto-fluorescence interfered with the assay. cAMP alone did not significantly alter 
NADPH fluorescence over 5 min (Figure 6.14A). RIα caused a decrease (5500 ± 1300 
RFU) in NADPH fluorescence over the 5 min period which was significantly different 
(p<0.05) from when substrate was absent (1500 ± 1100 RFU) (Figure 6.14B). When 
cAMP-bound RIα was added to the Trx / TrxR / NADPH mixture a decrease in 
NADPH fluorescence (6300 ± 1100 RFU) occurred which was significantly (p<0.05) 
different from when substrate was absent. This decrease was similar to the decrease in 
NADPH consumption for RI with no cAMP (consistent with results in Figure 6.11). 
Therefore, cAMP did not alter NADPH consumption in an assay assessing RI 
reduction by the Trx system. 
Effect of cAMP on redox state of RIAlthough reduction of RIα by the Trx system 
was not detected by immunoblotting studies (Figure 6.13), I wanted to check this was 
also the case for RIα with cAMP. Figure 6.14C demonstrates, again, that RI with 
NADPH alone is present mainly in its oxidised disulfide dimeric form and the addition 
of Trx / TrxR with or without cAMP did not change RI redox state. Only at a long 
exposure of the immunoblot was any reduced monomeric RI observed, and this was 
minimal compared to RI disulfide dimer. Therefore, again this method could not 
detect RI disulfide reduction by the Trx system.   
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Figure 6.14 Effect of cAMP on NADPH consumption by RI and the Trx system.  
(A) Fluorescence was measured for 5 µM NADPH alone or with 150 µM cAMP for 5 min and 
average change in fluorescence (NADPH consumption) from time = 0 (n=4 ± SEM) was 
calculated. (B) Fluorescence was measured over 5 min for NADPH, TrxR and Trx alone or 
these components with RIor RIand cAMP and average NADPH consumption quantified 
(n=5 ± SEM, * p<0.05 AUC compared to AUC for no substrate). cAMP did not affect the 
significant NADPH consumption caused by oxidised RI. (C) Redox state of PKA RIin 
fluorescence samples was identified by Western blotting but no reduction of RI by the Trx 








6.3.3 Using TrxR inhibitors to assess reduction of RI disulfide by the Trx 
system in ARVMs 
Effect of TrxR inhibition on RI redox state in overnight-cultured ARVMs: 
Experiments were initially carried out in ARVMs cultured overnight for reasons 
discussed in Chapter 2.2.  
Figure 6.15 shows representative blots for overnight-cultured ARVMs treated with 
diamide or the TrxR inhibitors, auranofin (A) or cisplatin (B) for 1 or 5 min. The blots 
illustrate the general finding that the reduced RI monomer was fully absent even in 
control untreated cells. The abundance of RI seemingly varied between treatments 
despite confirmation of equal total protein loading by Coomassie blue staining (not 
shown). This observation of a low abundance of reduced monomeric RI was 
unexpected and complicated studies I had anticipated undertaking. Diamide increased 
RI disulfide compared to control which is consistent with RI monomer being 
oxidised. However, overnight culture caused the „disappearance‟ of the reduced kinase. 
Possible explanations for this are discussed in Chapter 2.2. Consequently, these findings 































































































































































































































Figure 6.15 Effect of TrxR inhibitors (auranofin and cisplatin) on PKA RI redox state in 
overnight-cultured ARVMs.  
 
(A) Overnight-cultured ARVMs were left untreated or pre-treated with vehicle (ethanol) or TrxR 
inhibitor (auranofin) for 5 min. ARVMs were then left untreated or treated with diamide (1 or 5 
 
overnight-cultured ARVMs.  
 
 
Effect of TrxR inhibition on RI redox state in freshly isolated ARVMs: As 
discussed in Chapter 2.2, loss of monomeric reduced RI and variable RI protein 
abundance between samples in overnight-cultured ARVMs appeared to be associated 
with changing the cell culture medium, which is a step routinely carried out when 
culturing ARVMs overnight. In contrast, in freshly isolated ARVMs reduced 
monomeric RI was present and the total RI protein abundance was similar between 
control and treated cells. Therefore, the effect of TrxR inhibition on RI redox state 
could be investigated in freshly isolated ARVMs.  
Figure 6.16 shows representative immunoblots probed for RI with corresponding 
graphs showing the percentage RI disulfide in freshly isolated ARVMs before and 
after treatment with cisplatin. Treatment with concentrations of cisplatin up to 75 µM 
(A) (B) 




(Figure 6.16A) did not alter the percentage RI disulfide, which stayed at ~35 %. When 
this was repeated with diamide pre-treatment, an increase in disulfide RI above basal 
was again not observed. Treatment of freshly isolated ARVMs with higher 
concentrations of cisplatin (150, 300, 500 or 750 µM, Figure 6.16B) caused a trend 
towards an increase in percentage RI disulfide, from 33 ± 6 % to 59 ± 10 %. An 
increase was also seen when these cisplatin-treated ARVMs were pre-treated with 5 µM 
diamide (36 ± 12 % to 75 ± 6 %). This suggests that inhibiting TrxR caused an 
accumulation of RI disulfide.  
Treatment of freshly isolated ARVMs with concentrations of another TrxR inhibitor, 
auranofin (50 - 500 nM) did not alter RI disulfide levels, which was basally ~25 % 
(Figure 6.17A). 50 nM auranofin did not alter RI disulfide in ARVMs pre-treated with 
5 µM diamide (~25 %) but 250 nM and 500 nM caused a small increase to ~40 % and 
~35 % respectively. In comparison, treatment of ARVMs with 750 nM up to 3 µM 
auranofin alone (Figure 6.17B) caused a trend towards an increase in RI disulfide 
formation (29 ± 6 % to 61 ± 7 %). This trend was also observed when ARVMs were 
pre-treated with 5 µM diamide then treated with 750 nM up to 3 µM auranofin (40 ± 10 
% to 68 ± 7 %). When ARVMs were pre-treated with diamide then 1 or 2 µM auranofin 












              (A) 
        (B) 
Figure 6.16 Effect of cisplatin on PKA RI redox state in freshly isolated ARVMs.  
(A) ARVMs were left untreated or treated with cisplatin (0 - 75 μM), vehicle or 0.5 mM 
diamide for 30 min -/+ post-treatment with 5 µM diamide. Blots were probed for PKA 
RIand percentage PKA RI disulfide dimer was calculated (n=5 ± SEM). (B) ARVMs were 
treated with cisplatin (150 – 750 μM), vehicle or diamide -/+ post-treatment with diamide. 
There was a trend towards an increase in RI disulfide with 150 - 750 μM cisplatin with and 
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Figure 6.17. Effect of auranofin on PKA RI redox state in freshly isolated ARVMs.  
(A) ARVMs were treated with auranofin (0 - 500 nM), vehicle or 0.5 mM diamide for 30 
min -/+ post-treatment with 5 µM diamide (5 min). Blots were probed for PKA RIas 
shown in representative blot. Percentage PKA RI disulfide dimer is shown graphically 
(n=5 ± SEM). (B) ARVMs were treated with 0 - 3 μM auranofin, vehicle or 0.5 mM 
diamide (30 min) -/+ post-treatment with 5 µM diamide (5 min). There was a trend 
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PKG I redox state in freshly isolated ARVMs treated with TrxR inhibitors: PKG 
Iα can also be oxidised to a disulfide,[60] (as outlined in Chapter 1). The redox state of 
PKG Iα was determined in the samples previously probed for PKA RI to determine 
whether PKG Iα disulfide was also reduced by the Trx system. There was a trend 
towards an increase PKG I disulfide in ARVMs treated with 0 – 750 µM cisplatin (as 
observed with PKA RIbut it was not statistically significant. The percentage PKG I 
disulfide increased by ~20 % with 750 µM cisplatin treatment (Figure 6.18A). This 
trend also occurred in cisplatin-treated ARVMs then treated with 5 µM diamide. There 
was also a trend towards an increase in percentage PKG I disulfide in ARVMs treated 
with 0 – 3 µM auranofin albeit statistically insignificant (Figure 6.18B), mirroring what 
was observed with PKA RI. Treatment with the maximum auranofin concentration (3 
µM) increased PKG I disulfide by ~13 %. Again, this trend was also observed in 
auranofin-treated ARVMs then treated with 5 µM diamide. 5 µM diamide alone 


















             (B) 
Figure 6.18 Effect of cisplatin or auranofin on PKG Iredox state in freshly isolated 
ARVMs.  
(A) ARVMs were treated with 0 - 750 μM cisplatin, DMSO vehicle or 0.5 mM diamide (30 
min) -/+ post-treatment with 5 µM diamide (5 min). Western blots were probed for PKG I 
and percentage PKG I disulfide dimer was presented graphically (n=5 ± SEM). (B) ARVMs 
were treated with 0 – 3 µM auranofin, ethanol vehicle or 0.5 mM diamide (30 min) -/+ post-
treatment with diamide (5 μM, 5 min). There was a trend towards an increase in PKG I 
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Effect of TrxR inhibition on Prx-1 redox state: Prx-1 is a known substrate for Trx-
catalysed reduction. I wanted to confirm that cisplatin and auranofin were indeed 
efficiently inhibiting TrxR under the treatment conditions used. Consequently, Prx-1 
oxidation to the disulfide dimer was monitored, serving as a positive control.  
Prx-1 was present basally as a disulfide dimer (50 kDa) in untreated ARVMs, as well as 
after 150 - 750 µM cisplatin treatment (Figure 6.19). No reduced monomeric Prx-1 (25 
kDa) was observed in untreated ARVMs, even after long film exposure times. This 
suggests that ARVMs were under substantive oxidative stress under basal conditions. 
However, there was also a band at ~150 kDa after 50 µM or 75 µM cisplatin treatment 
(Figure 6.19A) and this band increased in intensity as the concentration of cisplatin 
increased from 150 µM to 750 µM (Figure 6.19B). This band was present in the 
positive control (0.5 mM diamide, Figure 6.19A), and absent in the vehicle-only sample 
(Figure 6.19B). It may therefore indicate an oxidative modification of Prx-1 which is 
reduced by Trx, such that this oxidised form of Prx-1 accumulated when TrxR was 
inhibited. 
The redox state of Prx-1 was also analysed in freshly isolated ARVMs treated with 
auranofin (Figure 6.20). Again, in untreated and auranofin-treated ARVMs, Prx-1 was 
present only as dimer at 50 kDa suggesting that the ARVMs were already under 
significant oxidative stress. There was a faint band at ~150 kDa in 0.5 mM diamide-
treated ARVMs, but this was not seen in any other treatments. As shown in Figure 
6.20C, Prx-1 was not present as disulfide dimer under control conditions in other model 
systems such as Langendorff-perfused hearts. In these samples Prx-1 was predominately 
a reduced monomer at 25 kDa under basal conditions.  
Overall I was unable to determine whether cisplatin or auranofin inhibited TrxR, 
because Prx-1 was found to be basally oxidised (present as a disulfide dimer) in control 
ARVMs. However, a Prx-1 complex of ~150 kDa may be evidence for inhibition of 
TrxR in cisplatin-treated ARVMs.  























































































             (A) 
           (B) 
Figure 6.19 Effect of cisplatin on redox state of Prx-1.  
(A) ARVMs were left untreated or treated with 150 - 750 μM cisplatin or DMSO vehicle 
for 30 min -/+ post-treatment with diamide (5 μM, 5 min). Western blot was probed for 
Prx-1. (B) ARVMs from three different cell isolations (experiments 1 - 3) were treated 
with 20 - 75 μM cisplatin or 0.5 mM diamide for 30 min. Western blot was probed for 
Prx-1. Unexpectedly, Prx-1 was present as disulfide dimer in control conditions as well 
as treated cells. 
 








     (B) 
     (C) 
  
Figure 6.20 Effect of auranofin on redox state of Prx-1.  
(A) Freshly isolated ARVMs were left untreated or treated with 0.75 - 3 μM auranofin or 
ethanol vehicle (30 min) -/+ post-treatment with diamide (5 μM, 5 min) (B) ARVMs were 
treated with 0 - 500 nM auranofin or 0.5 mM diamide for 30 min. Redox state of Prx-1 in 
three different experiments was observed by Western blotting. Prx-1 was unexpectedly 
diimeric in untreated ARVMs as well as treated (C) Mouse hearts (heart 1 and 2) were 
Langendorff-perfused with K-HB for 40 min. Western blots were probed for Prx-1, which was 
present as monomer in both hearts. 
(A) 
















































































The aim of this chapter was to determine whether the Trx system reduces RI disulfide. 
If it does, it suggests that the RI disulfide is a reversible regulatory modification that 
potentially occurs physiologically. One approach was to determine if the Trx system 
reduces RI disulfide in vitro by measuring TrxR activity. This was indexed by 
measuring a decrease in NADPH absorbance, a common approach used by others.[411] 
When Trx reduces its substrate and becomes oxidised itself, it is then reduced by TrxR 
which in doing so becomes oxidised. Oxidised TrxR is then reduced by NADPH, 
causing NADPH to be oxidised to NADP
+
. NADPH absorbs light at 340 nm but 
NADP
+ 
does not. Pilot studies (results not shown) were carried out which measured 
NADPH absorbance when NADPH, Trx and TrxR were incubated with oxidised RI. 
However, by using GSSG and Prx-1 as positive controls, it was calculated that large 
amounts of RI would be required to drive the reaction and see a change in absorbance. 
RI is expensive to buy and the kinase concentration would not be physiologically 
relevant, so an alternative method was required.  
Instead, NADPH fluorescence was measured as fluorescence is more sensitive and so 
allows a smaller amount of RI to be used in the reaction assay. Fluorescence-
monitoring was carried out with the idea that TrxR activity would increase if the Trx 
system reduces RI disulfide. This would be demonstrated by a decrease in NADPH 
fluorescence, as NADPH is oxidised to the NADP
+
 form (during TrxR activity), which 
does not fluoresce. This method has been used by others to monitor TrxR activity.[412] 
Trx or TrxR alone altered NADPH fluorescence. The increased fluorescence with Trx 
was potentially due to Trx auto-fluorescence, and the decrease with TrxR addition may 
have been due to auto-oxidation of TrxR in air causing NADPH consumption. 
However, these possibilities were excluded as control assays without RI or Prx-1 were 
measured alongside the RI or Prx-1 assays for comparison, so RI or Prx-1-dependent 
changes could be identified.  




Oxidised Prx-1 and RI were used at a similar concentration in the fluorescence assays.  
Prx-1 is a well-known substrate for Trx,[410] and so the similarity in rate of NADPH 
consumption between Prx-1 and RI suggests the Trx system is involved in RI 
disulfide reduction. 
TrxR can alone reduce some low molecular weight proteins, as described in section 
6.1.2, but Trx1 has a wider range of substrates than TrxR (see section 6.1.1) and TrxR 
has not been shown to reduce any kinases directly. Consequently, it is unlikely that 
TrxR directly reduces RI disulfide but instead it‟s more likely to reduce oxidised Trx. 
However, I cannot be certain about this in these experiments. A control should have 
been carried out in which oxidised RI and NADPH and TrxR were incubated together 
and NADPH consumption monitored.  
Although the NADPH consumption assay suggests RI disulfide is reduced by the Trx 
system, this could not be corroborated by biochemical experiments in which RI redox 
state was measured by Western immunoblotting. RI was still disulfide dimer after 
incubation with components of the Trx system, and this may be because the interaction 
between Trx and its substrate (in this case RI) is only a transient one. This has been 
suggested by Hirota et al. when demonstrating the direct interaction between Trx and 
redox factor 1 (Ref-1) by immunoprecipitation.[357] So once RI is reduced and Trx 
released, RI may then be quickly re-oxidised by oxygen in air back to the disulfide, 
making it difficult to „catch‟ RI in its reduced form. However, it could be argued that 
if this is happening then the same would be expected for Prx-1. Clearly it does not, 
leaving this issue unresolved. 
Surprisingly, there was reduced monomeric RI present in some samples where only 
NADPH was also present. This is difficult to explain as NADPH is generally described 
as a reducing equivalent for reduction-catalysing enzymes such as TrxR (see 6.1.2), 
glutathione reductase,[45] and the enzyme NADPH-cytochrome P450 reductase, which 
accepts electrons from NADPH and transfers them to microsomal cytochrome 
P450s.[413] RI does not have any NADPH binding sites, the amount of reduced 




monomeric RI detected in these samples was relatively insignificant and the 
immunoblots had to be exposed for a long time for the monomer to be observed, so the 
observed reduced monomer is unlikely to be indicative of RI reduction by NADPH 
directly.  
cAMP binds to RI causing release of catalytic subunits and therefore PKA activation. 
Substrate can affect the sensitivity of PKA RI to cAMP (see Chapter 4). Viste et 
al.,[164] showed that for full activation of PKA ~1 µM cAMP was required which was 
approximately 200-fold excess cAMP compared to RI. I incubated RI with 100-fold 
excess cAMP, so consider this to be pertinent to physiology. I hypothesised that cAMP 
may modulate the ability of the Trx system to reduce oxidised RI because it causes a 
substantial conformational change in RIand this may affect access of Trx to the RI 
disulfide. In Chapter 4, Western immunoblotting revealed that cAMP increased H2O2-
induced RI disulfide. In this chapter, I found cAMP did not alter RI-modulated 
NADPH consumption, suggesting that the mechanism by which cAMP induces the 
increased disulfide formation does not involve inhibiting the regulatory reduction of 
RI disulfide by the Trx system. 
Another approach to assess whether RI disulfide is reduced by the Trx system 
involved treating ARVMs with the TrxR inhibitors auranofin or cisplatin and looking 
for an accumulation of RI disulfide. However, there are issues to consider when 
inhibiting TrxR. TrxR has other substrates apart from Trx (described in section 6.1.2) 
such as protein disulfide isomerase,[407] CaBP1 or CaBP2,[408] so when TrxR is 
inhibited these proteins may no longer be reduced and so their activity affected. In 
addition, because Trx is reduced by TrxR, inhibition of TrxR means that Trx may no 
longer be reduced and unable to reduce its downstream substrates, and so their activity 
may be altered. For example, ASK1 may not be activated and NF- B may not be 
inhibited (as described in section 6.1.1). 
Cisplatin is a Pt-containing compound (Figure 6.21A) that irreversibly inhibits 
TrxR.[414] Cisplatin is thought to target the SeCys in TrxR because cisplatin cannot 




inhibit glutathione reductase, a structurally related non-selenoprotein.[415] About 1 % 
of intracellular cisplatin reacts with DNA but cisplatin can also react with and form an 
adduct with GSH. The cell exports this adduct but when in the cell it can inhibit both 
the Trx system and the Grx system.[416] Cisplatin forms complexes with DNA 
resulting in DNA damage and cell death, and is therefore, used to treat a wide range of 
cancers.[415] Cisplatin has been shown to cause apoptosis at the concentrations used in 
my experiments, but the treatment time was a lot longer (48 hours) than the 30 min 
treatment used here and so perhaps apoptosis is not expected.[414]  
Auranofin is a compound used for the treatment of rheumatoid arthritis, inhibiting the 
reduced form of TrxR. Auranofin is also used in anti-cancer therapy where it inhibits 
DNA synthesis.[417] Auranofin contains gold (Figure 6.21B), which itself has a high 
affinity for thiols. Auranofin‟s mechanism of TrxR inhibition involves targeting the 
SeCys in TrxR, as demonstrated by its inability to inhibit glutathione reductase, a 
structurally related non-selenoprotein.[418] Auranofin also causes apoptosis, a LD50 of 
1.4 µM during 24 hours treatment,[419] which is at the top of the concentration range I 
treated ARVMs with, although this was only for 30 min. Thus it is unlikely that 






Figure 6.21 Structure of cisplatin and auranofin.  
(A) Cisplatin is a Pt containing compound. (B) auranofin is an Au containing compound.  
 
 
My experiments with TrxR inhibitors were initially carried out using overnight-cultured 
ARVMs; however the reduced monomeric RI was absent in control untreated ARVMs 




and RI protein abundance varied between treatments. These issues were considered in 
detail in Chapter 2.2. Fortunately, these problems did not occur in freshly isolated 
ARVMs. However, untreated cells still had the issue that RI disulfide dimer level was 
high basally. This high basal dimer is likely due to the stress of cell isolation because 
RI disulfide is low basally in control isolated hearts.  
I hypothesised that in some circumstances such as treatment with low concentrations of 
oxidant (e.g. 5 µM H2O2), RI disulfide formation is occurring but it‟s not detected by 
Western immunoblotting because the RI disulfide is rapidly reduced by the Trx 
system. There was evidence of this as auranofin and cisplatin both caused RI disulfide 
accumulation. At some concentrations of auranofin (1 µM and 2 µM) there also 
appeared to be a synergistic effect with diamide, i.e. RI disulfide formation was larger 
with diamide and auranofin treatment together than the sum of the amounts of disulfide 
formation for auranofin treatment alone and diamide treatment alone. This was not 
observed with cisplatin treatment however. It is difficult to compare effects of cisplatin 
with effects of auranofin because the concentrations of inhibitors I used were different. 
The concentrations of cisplatin were 250-fold higher than auranofin, yet auranofin 
synergised with diamide and cisplatin did not. However, others have compared cisplatin 
and auranofin and observed that auranofin is a more effective inhibitor than 
cisplatin.[420] This means that in my experiments, auranofin may be more effective at 
inhibiting TrxR than cisplatin, and so the effect of a low concentration of oxidant on 
RI disulfide would be greater in auranofin-treated cells than cisplatin-treated cells. 
This synergy may further support the hypothesis that RI is being recycled by the Trx 
system, such that RIdisulfide fails to accumulate at low concentrations of oxidant. 
Synergy was only observed at the highest concentrations of auranofin suggesting that it 
was necessary for TrxR activity to be inhibited to a large degree in order for the „real‟ 
percentage RI disulfide formation induced by 5 µM diamide to be observed i.e. to stop 
the Trx system recycling RI disulfide formed in response to 5 µM diamide back to the 
reduced state.      




PKG I oxidation was also assessed in ARVMs treated with TrxR inhibitors as this 
kinase can also be oxidised to a disulfide dimer.[60] There was a trend towards an 
increase in PKG I disulfide accumulation in control and diamide pre-treated ARVMs 
with increasing concentrations of auranofin or cisplatin. However, as observed for PKA 
RI, the increases in PKG I oxidation were relatively minor and non-significant. 
Again, a reason for this could be the significant background oxidant stress the ARVMs 
appear to be under.  
Unfortunately, I could not „prove‟ that the TrxR inhibitors were inhibiting TrxR activity 
at the concentrations used in my experiments, as assessed by monitoring Prx-1 
oxidation to the disulfide dimer. The ARVMs were already under oxidative stress under 
resting conditions as shown by presence of Prx-1 disulfide dimer only. No reduced 
monomer was present at all in control untreated ARVMs. In other systems such as the 
Langendorff-perfused rat heart, under resting conditions, Prx-1 is mainly present as 
reduced monomer although Prx-2 is 50:50 monomer:dimer,[309] and others have shown 
Prx-1 to be mostly present as a reduced monomer in untreated fresh ARVMs.[421] 
Again, the high basal Prx-1 dimer could be due to the stress of ARVM isolation. 
Another reason may be that the ARVM population used in the experiments does contain 
some dead and dying ARVMs (depending on the success of the ARVM isolation) which 
may release ROS, to elevate basal oxidative stress. Accumulation of a possible Prx-1 
complex at ~150 kDa was observed in cisplatin-treated ARVMs which may be 
indicative of TrxR inhibition. Typical 2-Cys Prxs such as Prx-1 have only been 
suggested to form decamers, and atypical 2-Cys Prxs have been suggested to form 
hexamers and a lower degree of polymerization compared to typical 2-Cys Prxs.[422] 
Therefore, formation of a Prx-1 complex at ~150 kDa (suggesting a hexamer) may not 
be possible. It may therefore, be interesting to look at the oxidation state of other Prx 
types such as the atypical 2-Cys Prxs in these ARVMs.  
Although I could not confirm that the inhibitors were inhibiting TrxR activity at the 
concentrations used, others have. Cox et al.,[419] showed that TrxR activity decreased 
to ~60 % of the control after 30 min of ~150 nM auranofin treatment. I observed an 




increase in RI disulfide in diamide-treated ARVMs at 250 nM auranofin, but this 
effect was not sustained when auranofin was increased to 500 nM in the first set of 
experiments. Cox et al. also showed that TrxR activity was reduced to ~15 % of the 
control with 750 nM auranofin treatment. I observed an increase in RI disulfide in 
ARVMs treated with 750 nM auranofin alone and treated with both 750 nM auranofin 
and diamide. Arnér et al. showed that 25 µM cisplatin for 30 min reduced TrxR activity 
to ~40 %, 50 µM cisplatin reduced TrxR activity to ~30 % and 100 µM cisplatin 
reduced activity to ~5 % of basal.[401] I failed to observe any effect on RI disulfide 
until 150 µM cisplatin was used, although in my experiments there was a jump from 75 
µM to 150 µM cisplatin treatments so the increase might have been observed at lower 
untested concentrations. It appears that TrxR activity needs to be inhibited to a high 
degree if RI disulfide accumulation is to be observed. Auranofin and cisplatin did not 
only increase RI disulfide in diamide-treated ARVMs, but also control ARVMs which 
supports the conclusion from the Prx-1 data that the ARVMs were under oxidative 
stress basally.   
Overall, the TrxR inhibitor results show a trend towards an increase in RI disulfide 
formation with increasing concentration of TrxR inhibitor. With more replicates, 
significant differences could potentially be unveiled and whether the Trx system is 
involved in RI disulfide reduction could be determined. Only small amounts of 
disulfide accumulation were caused by the TrxR inhibitors but the fact that the cells 
were under significant oxidative stress already means that there was less reduced RI 
available to form a disulfide dimer during oxidant treatment. Thus only small changes 
with the inhibitors may be anticipated.  
The methods used to determine if the Trx system reduces RI disulfide were „indirect‟. 
It would be useful to mutate the individual catalytic Cys residues in Trx1 and assess if 
accumulation of RI disulfide occurs in the presence of the mutants and oxidant. This 
would not only potentially help determine whether Trx1 specifically interacts with RI 
but would also confirm which Cys residues are involved.      




In conclusion, a significant decrease in NADPH fluorescence, i.e. increased NADPH 
consumption by the Trx system, occurred in the presence of oxidised RI suggesting 
that it is indeed reduced by the Trx system. Furthermore, a trend for an increase in RI 
disulfide formation in ARVMs after treatment with TrxR inhibitors also suggests that 
the Trx system is involved in RI reduction. The proposed mechanism for RI 
reduction by the Trx system is presented in Figure 6.22. If RI disulfide formation is a 
regulatory mechanism involved in redox signalling it is likely to be a reversible process 
to enable the signalling to be switched off. As far as I know, no other work has been 
carried out assessing the relationship between Trx and RI. H2O2 treatment has been 
reported to inhibit PKA, a process in which Trx-TrxR re-activated the kinase.[59] 
However, this occurred in Type II PKA which cannot form the disulfide that forms in 
RI as it does not contain the necessary N-terminal Cys residues. Further experiments 
investigating the direct interaction between Trx and RI would be a valuable 
supplement to the findings of this chapter. 
  
 
Figure 6.22 Proposed mechanism of RI reduction by the Trx system.  
Trx first forms an interprotein disulfide with RI which is then resolved by the other catalytic 
Cys in Trx, releasing reduced RI and forming an intraprotein disulfide in Trx. This is then 
reduced by TrxR using NADPH. Cisplatin and auranofin inhibit TrxR causing an 
accumulation of RI disulfide. 
 




7 GENERAL DISCUSSION 
Although a number of oxidative modifications of PKA have been reported,[58, 59] my 
research laboratory has only observed one such alteration, namely disulfide formation 
between the two RI subunits which was associated with kinase activation.[57] The 
main objective of my studies was to discover more about the regulation of PKA by 
RIdisulfide formation and the functional consequences of this event in the heart. A 
novel RI Cys17Ser knock-in (KI) mouse which cannot form disulfides in RI was 
generated on the basis that it would be a useful tool for discovering more about the role 
of RI disulfide formation in the heart.  
As outlined in Chapters 3-6, a series of hypotheses were postulated regarding the role of 
RI disulfide in PKA activation. Previous work showed that treatment of isolated rat 
hearts with H2O2 caused translocation of RI disulfide from cytosol to 
myofilament.[57] I also found that cytosolic disulfide RI translocated to the membrane 
and myofilament in response to H2O2 in isolated mouse hearts. RI translocation was 
most pronounced in the myofilament fraction, where after oxidant treatment RI was 
present in wild-type (WT) myofilament but completely absent in KI myofilament. In 
addition, it was only disulfide RI that was present in the WT myofilament after 
oxidant treatment; there was no reduced monomeric RI. These observations indicate 
that disulfide formation is a key event in RI translocation to myofilament. A-kinase 
anchoring proteins (AKAPs) target PKA to distinct subcellular locations in the cell. For 
example, Muscle-specific AKAP (mAKAP) can target PKA to the nuclear 
envelope,[238] and dual-specificity AKAP (D-AKAP) 1 can target PKA to the 
mitochondrial membrane.[259] Sarma et al. showed that disulfide increased 
RIaffinity for D-AKAP2,[119] which I hypothesised could also be applicable to other 
AKAPs because the disulfides that form in the dimerisation / docking (DD) domain of 
RI precisely flank the AKAP binding site. Thus RI disulfide formation may cause a 
conformational change that acts as a molecular structural switch to modulate AKAP 
binding to this region. I hypothesised that RI disulfide formation enhances the affinity 




of cytosolic RI for AKAPs in the membrane or myofilament inducing its translocation 
to these fractions of the heart (Figure 7.1). However, I failed to determine whether 
disulfide alters RI affinity for AKAPs using a 3′,5′-cyclic monophosphate (cAMP) 
affinity capture method, probing for the presence of AKAPs using specific antibodies or 
binding proteins generally using liquid chromatography-tandem mass spectrometry 
(LC-MS/MS). Consequently, I was unable to confirm an increase in affinity with 
AKAP(s) underlies RI translocation upon oxidation. This was disappointing but 
inconsistent results, most probably because of complexities with the cAMP affinity 
capture method, were a significant issue. These complexities include the non-
physiologically high concentration of cAMP on the affinity beads and capture of 
proteins other than PKA regulatory subunits. The antibodies used to identify captured 
AKAPs were unreliable also detecting non-specific proteins and in some cases not 
detecting the AKAP at all. Another confounding complexity was that incubation of RI 
with the cAMP agarose appeared to cause chemical reduction of RI disulfide to 
reduced monomer i.e. increased RI monomer abundance and total RI protein. This 
was highly unexpected as oxidising conditions prevail during the capture procedure 
(due to being carried out in air), so it was anticipated that RI disulfide would increase 
rather than decrease. The consequence of this chemical RI disulfide reduction may be 
that AKAP binding that occurred previous to the cAMP affinity capture protocol (i.e. 
because of oxidation) may be lost. This may be the major reason why this approach to 
investigating the role of disulfide in RI-AKAP interaction failed. At the outset of these 
studies, this could not have been foreseen. However, that cAMP can lead to reduction of 
RI disulfide is an intriguing observation worthy of future study. Nonetheless, LC-
MS/MS analysis did identify a number of candidate RI-binding proteins which warrant 
further investigation. These candidates include coiled-coil-helix-coiled-coil-helix 
domain-containing protein 3 (ChChd3) which is a PKA substrate important in 
maintaining mitochondria function and mitochondrial cristae structure.[295] LC-
MS/MS showed more ChChd3 bound to WT RIthan KI RI. ChChd3 has been shown 
to be associated with sphingosine kinase interacting protein (SKIP),[293] which 




interestingly is an RI-specific AKAP.[292] Similarly, the glycolytic enzyme, alpha-
enolase was identified by LC-MS/MS as a protein that bound more WT RIthan KI 
RI. Isoform 4 of myomegalin interacts with PKA RI and RII and also alpha-
enolase,[302] so there is potential for disulfide to alter the affinity of RI for 
myomegalin, which may recruit PKA to alpha-enolase. However, the function of this 
complex formation is unclear and alpha-enolase is not an established PKA substrate. I 
was unable to further investigate the interaction of RIwith SKIP or myomegalin (and 
whether this may be redox regulated) due to the lack of solubility of SKIP and 
myomegalin (both are in the Triton X-100 insoluble fraction), precluding cAMP affinity 









Figure 7.1 Schematic of substrate-induced PKA activation.  
RI disulfide may increase affinity of RI for AKAPs causing PKA translocation from the 
cytosol and targeting of PKA close to its substrates where substrate can sensitise PKA to 
cAMP. Upon cAMP binding to regulatory (R) subunits, catalytic (C) subunits are released 
and phosphorylate target substrates. 
 
Type I PKA is sensitised to cAMP by presence of substrate, whereas Type II is 
not.[164, 165] This is of particular note, given Type I can form disulfides but Type II 
cannot as it does not have the necessary Cys residues. Therefore, I hypothesised that the 
disulfide-induced increase in affinity of RIforAKAPs, as reported by Sarma et 
al.,[119] serves to position PKA close to its substrates to facilitate substrate-induced 
sensitisation of PKA to cAMP, resulting in kinase activation. Therefore, in adult rat 
ventricular myocytes (ARVMs) I expected to observe an increase in PKA activity (i.e. 
increased phosphorylation of PKA substrates) after oxidant treatment or increased 




sensitivity to a -adrenoceptor agonist (i.e. isoprenaline, generating cAMP) after 
treatment with an oxidant (Figure 7.1). I demonstrated that disulfide potentiated 
isoprenaline-induced cardiac troponin I (cTnI) phosphorylation in freshly isolated 
ARVMs, consistent with sensitisation of PKA to cAMP by disulfide. In addition, cAMP 
potentiated oxidant-induced disulfide formation suggesting a positive feedback system 
in which cAMP increases RI disulfide formation which then increases PKA sensitivity 
to cAMP. Treatment of ARVMs with H2O2 increased RI disulfide formation and this 
disulfide formation was associated with increased phosphorylation of cTnI, which is 
consistent with Brennan et al. showing that RIdisulfide was associated with PKA 
activation.[57] These results suggest that RI disulfide causes PKA to be sensitised to 
basal levels of cAMP, such that PKA is activated in the absence of increased -
adrenoceptor stimulation. However, I was unable to demonstrate a similar oxidant-
induced activation of PKA in isolated mouse hearts. In fact, oxidant-induced disulfide 
formation wasn‟t associated with altered phosphorylation of any substrate tested apart 
from the membrane-associated target phospholamban (PLB). However, PLB‟s 
phosphorylation was unexpectedly significantly reduced by H2O2 which I speculate 
could be because disulfide may in some cases decrease RI affinity for an AKAP such 
as that associated with PLB. In addition, LC-MS/MS analysis of cAMP affinity captures 
demonstrated significantly less binding of sarcoplasmic reticulum (SR) Ca
2+
 ATPase 
(SERCA) 2 to WT RI than KI RIPLB basally inhibits SERCA2, but when PLB is 
phosphorylated at Ser16 by PKA this relieves the inhibition to enhance Ca
2+
 uptake into 
the SR.[174, 175] The reduced SERCA2 binding to WT RI could be indicative of 
oxidant-induced RI disulfide translocation away from the membrane to the 
myofilaments. This translocation may result in decreased interaction of RI with a 
membrane-localised AKAP associated with PLB and SERCA2, AKAP7γ being a 
possible candidate.[226] This decreased AKAP interaction would reduce targeting of 
PKA close to PLB, so attenuating substrate-induced PKA activation and 
phosphorylation of PLB. Therefore I would expect RI disulfide formation to be 
associated with reduced phosphorylation of PLB which, as already stated, was found to 




occur in WT hearts after oxidant treatment. Again these observations highlight the 
possibility that disulfide may lower the affinity of RI for some AKAPs rather than 
enhance affinity, as occurs for D-AKAP2.[119] Whether oxidation increases 
RIbinding to AKAP and targets PKA close to substrate for substrate-induced cAMP 
sensitisation and substrate phosphorylation cannot readily be investigated in vitro with 
purified proteins, as the substrate and kinase will already be co-localised, lacking the 
compartmentalisation found in cells. However whether RI disulfide activates PKA 
could be determined in the future using in vitro kinase assays. For example, 
phosphorylation of the PKA substrate kemptide by gamma-
32
P-ATP (ATP in which 
radioactive phosphorus-32 has been incorporated into the triphosphate) can be used to 
assay activity of PKA with disulfide or dithiothreitol-reduced recombinant RI protein. 
A previous unpublished observation in my research laboratory found that monoamine 
oxidase (MAO)-catalysed metabolism of catecholamines induced PKG I disulfide 
formation as a result of generation of H2O2. It is known that the metabolic 
decomposition pathway of monoamines yields H2O2,[162, 163] and so it was logical 
that the oxidant generated may also target PKA RIto induce disulfide formationThis 
was indeed the case, RI was oxidised via this pathway. Treatment of freshly isolated 
ARVMs with the MAO inhibitor Clorgyline blocked monoamine-induced RI disulfide 
formation. This observation therefore provides a link between  adrenergic signalling 
(the classical mode of PKA activation) and potential oxidant-induced PKA activation 
(Figure 7.2). Monoamines may serve as dual inputs and may synergise to activate PKA, 
as considered further below.  
I also hypothesised that RI disulfide may be recycled back to the reduced state by the 
thioredoxin (Trx) system as outlined in Figure 7.2. Indeed evidence for redox cycling of 
RIwas identified, supporting the idea that PKA RI oxidation to disulfide and any 
associated alteration in kinase activity is reversible. NADPH fluorescence assays and 
experiments in which freshly isolated ARVMs were treated with TrxR inhibitors both 
provided strong evidence for recycling of RI disulfide by the Trx system. This is 




important as such reversal is an anticipated feature of a regulatory system. It has been 
reported that H2O2 treatment inhibits PKA, and the Trx-TrxR system re-activated the 
kinase.[59] However, this was for Type II PKA which does not contain the N-terminal 
Cys residues that enable the disulfides to form in RI.  
 
 
Figure 7.2 Redox regulation of PKA.  
Catecholamines classically activate  adrenergic signalling in which adenylate cyclase is 
activated, generating cAMP which activates PKA. However, these catecholamines and other 
monoamines are also transported into the cell and metabolised by MAO generating H2O2. 
This oxidises RI to the disulfide form, which may increase affinity of RI for AKAPs 
causing its translocation and positioning of PKA closer to substrates. This may facilitate 
substrate-induced sensitisation of PKA to cAMP and PKA activation. RI disulfide formation 
is also potentiated by cAMP and RI disulfide can be recycled back to the monomeric form 
by the Trx system. 
 
   
The studies reported in this thesis highlight inconsistencies between freshly isolated 
ARVMs and Langendorff perfused WT isolated hearts. For example H2O2 treatment 




increased phosphorylation of PKA substrates in freshly isolated ARVMs, but not in 
isolated mouse hearts. It may be that Langendorff perfusion is not an optimal model for 
studying the role of RI disulfide in regulating PKA activity because of presence of cell 
types other than ventricular myocytes. Perhaps myocytes isolated from WT and KI 
mouse hearts would be a good complementary model for future studies. In addition, 
perhaps in vivo studies would be a valuable next step for studying the RI Cys17Ser KI 
mouse in the context of furthering understanding of the oxidation of this kinase. 
Interestingly, the KI kidney expressed substantially more PKA RI than WT, which 
may be a compensatory mechanism for absence of RI disulfide. In the kidney, PKA 





exchanger 3,[141] which in turn effects cardiac function, and so this must be taken into 
consideration with future in vivo studies. It also has to be carefully considered whether 
the RI Cys17Ser KI mouse was the optimal mutation to use in generating a „redox-
dead‟ PKA mouse. One key consideration regarding the RI Cys17Ser KI mouse is that 
it is not known for certain whether Cys17 or Cys38 is the sensing thiol i.e. the thiol that 
is oxidised first. If Cys17 is the oxidant sensing thiol (which we think is the case, as 
discussed in Chapter 1) it is anticipated to be initially oxidised to a sulfenic acid before 
being resolved by Cys38 of the adjacent monomer to generate an interprotein disulfide. 
This potentially happens on Cys17 of both RI subunits, so a double disulfide is 
anticipated to form (Figure 7.3A). Therefore, if Cys17 is mutated to become a Ser17, 
neither disulfide can form, as shown in Figure 7.3B. If Cys38 is the sensing thiol, the 
outcome will be the same, namely no RI disulfides can form. However, if Cys38 reacts 
with the oxidant to form a sulfenic acid, as this cannot then be resolved by Ser17, there 
would be the potential for further stepwise oxidation to the sulfinic acid and then the 
sulfonic acid (Figure 7.3C) which are irreversible modifications and may themselves 
alter the activity of PKA. Future studies could determine whether Cys38 is indeed the 
sensing thiol by labelling sulfenic groups with dimedone,[423] a method established in 
our research laboratory. I would expect more dimedone labelling in the oxidatively 
stressed KI heart compared to the WT heart if Cys38 is the sensing thiol, as sulfenates 
in the WT would rapidly form disulfides. Perhaps, the double Cys mutant would have 




been the optimal mutant mouse to generate, as this would overcome the issues relating 
to thiol hyperoxidation discussed. However, the double mutation (albeit to Ala instead 
of Ser) abolished D-AKAP1 binding to RI,[116] and D-AKAP2 binding to RI[138] 
suggesting that the dual amino acid change caused a conformational change that itself 
altered normal PKA function. Perhaps, ideally but unlikely due to the high expense of 
generating and maintaining the mouse colonies, it would be best if the Cys17Ser, 
Cys38Ser and double Cys mutant mice were generated and comparisons made between 
all of these. 















Figure 7.3 Oxidation of WT and KI RI.  
(A) If Cys17 is the sensing thiol WT RI is oxidised to a sulfenic acid which is then resolved 
by Cys38 to form a disulfide. This also occurs in WT if Cys38 is the sensing thiol. (B) If 
Cys17 is the sensing thiol KI RI cannot be oxidised as it is mutated to a Ser17 and Cys38 
will not be reactive. Therefore, this KI RI is termed ‘redox dead’. (C) If Cys38 is the sensing 
thiol KI RI may be oxidised to a sulfenic which can’t be resolved by Cys17 as it is mutated 
to Ser17. The sulfenic acid may be further oxidised to a sulfinic or sulfonic acid which may 
alter PKA function. 
sulfenic acid reduced monomer 
reduced monomer 
reduced monomeric 
(A) WT RI 
(C) KI RI if Cys38 is sensing thiol 
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One of the obvious questions to consider is whether RI disulfide actually occurs in the 
„real world‟. The concentrations of oxidant required to observe RI disulfide in 
ARVMs are possibly higher than those that occur physiologically. However, if as my 
results suggest, the Trx system is recycling RIdisulfide, it is likely that RI disulfide 
forms continuously at low levels of oxidant, but I just don‟t observe it as it is quickly 
reduced back to monomeric RI. Low levels of oxidants causing disulfide formation 
may be important in basal, regulatory redox signalling, important for homeostatic 
maintenance. Such a regulatory role would be different than in oxidant-response 
pathways, such as that involving nuclear factor erythroid-derived 2 (Nrf2),[424] which 
predominately serves to combat oxidative stress by up-regulating antioxidant gene 
expression. I consider such adaptive signalling is a counter measure to injurious levels 
of oxidative stress, and that this is different to the oxidation of PKA which the evidence 
suggests occurs basally in healthy tissue. I am primarily interested in PKA oxidation in 
the heart as PKA plays a key role in the positive inotropic, lusitropic and chronotropic 
response to  adrenergic signalling,[146, 147] and is important in protein 
transcription.[425, 426] The cardiac phenotype of the Cys17Ser KI mouse perhaps 
provides the most insight into the role of RI disulfide under basal conditions. 
Echocardiography revealed that the KI heart had a slightly larger left ventricular volume 
than WT during diastole and systole. However, as the KI also had a reduced fractional 
shortening and ejection fraction than WT, this resulted in an essentially identical cardiac 
output as WT. As discussed in Chapter 3, this could be a chronic adaptive response to 
an inability to form RI disulfide or may represent a PKA-signalling difference that 
could potentially be reproduced in WT by removing all basal disulfide. These results 
suggest a subtle role for RI disulfide in basal heart contractility. In addition, I observed 
a reduced LVDP in the Langendorff perfused KI heart compared to WT. However, 
whether this reduction is significant enough to impact on cardiac function is arguable. 
The Langendorff heart is very sensitive to changes in EDP (which is determined by the 
volume in the balloon inserted into the left ventricle) according to the Frank-Starling 
mechanism. An increased volume in the balloon stretches the ventricular wall, causing 
cardiac muscle to contract more forcefully and so increase systolic and developed 
pressure. Therefore, a small difference in EDP between WT and KI hearts could result 
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in a potentiated difference in LVDP between genotypes so the difference in LVDP 
between WT and KI hearts may not be as a result of RI disulfide formation.  
The concentrations of monoamines that induced RI disulfide were well above the low 
nanomolar range occurring physiologically. However, RI disulfide may have been 
evident at lower physiological concentrations of monoamine if the Trx system wasn‟t 
recycling the disulfide. The prospect that monoamines (epinephrine and norepinephrine 
being catecholamines) not only classically activate PKA via  adrenergic signalling but 
also activate PKA via RI disulfide formation due to H2O production during their 
metabolism by MAO is interesting, but requires further study. At low concentrations of 
monoamine it is therefore possible that the PKA-mediated response to catecholamines is 
not just due to activation of  adrenoceptors and cAMP signalling but also due to H2O2-
induced RI disulfide formation.  
If oxidative stress occurs due to increased production of reactive oxygen species (ROS) 
or decreased antioxidant levels then RIdisulfide formation will most likely 
accumulate when a threshold oxidative stress level is exceeded, perhaps when the Trx 
system can‟t recycle the disulfide back to monomeric RI fast enough. The 
accumulation of RI disulfide may occur at the membranes and myofilaments of the 
heart, which my studies in ARVMs suggest may result in enhanced phosphorylation of 
PKA substrates. The mechanism for this potentiated phosphorylation likely being 
increased RI affinity for AKAPs after RI oxidation, leading to substrate-induced 
PKA activation. When flux through this pathway is persistently high, this may lead to 
disease such as heart failure. This condition is associated with abnormalities in Ca
2+
-
handling,[427] altered β adrenoceptor signalling,[428] and depressed cardiac 
contractility. For example, phosphorylation of ryanodine receptor (RyR) 2 by PKA is 
increased in the human failing heart,[429] and more specifically dilated 
cardiomyopathy.[430, 431] Although my findings with ARVMs suggest increased 
phosphorylation of PKA substrates with oxidant treatment, my observations with 
isolated hearts do not support this, although the phosphorylation status of RyR2 was not 
analysed.  
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In terms of PKA regulatory subunit-binding AKAPs, the literature is primarily focused 
on the RII isoform. Although, as considered throughout this thesis, RI-interacting 
AKAPs are being increasingly appreciated, the wealth of studies on RII is largely 
because early studies predominately identified AKAPs that only bound this isoform. 
Solid phase assays (such as blot overlay) generally failed to identify RI binding 
targets.  In addition, a peptide known as Ht31 (derived from a human thyroid AKAP) 
that binds to the RII subunit with high affinity to compete with AKAPs for RII has been 
a powerful tool in these studies. An equivalent selective peptide for studying 
RIAKAP binding has not been generated. In ARVMs expressing Ht31, reduced 
phosphorylation of PKA substrates and increased rate of amplitude of cell shortening 
and relaxation in response to isoprenaline were observed, with concomitant loss of RII 
compartmentalisation.[432] RII-AKAP interactions are also altered in the failing 
heart.[433] As already mentioned, sphingosine kinase interacting protein (SKIP) is an 
RI-specific AKAP,[292] associated with the PKA substrate ChChd3,[293] which I 
found bound more to WT RI than KI RIsuggesting disulfide may increase RI 
interaction with SKIP and so ChChd3. Interestingly, binding of PKA regulatory 
subunits (isoform not specified) to SKIP was increased in human failing hearts.[434] It 
would be therefore be fascinating to determine whether RI disulfide formation is 
increased in human failing hearts and then if so to assess whether more RI interacted 
with SKIP in these hearts to supplement the findings by Aye et al.[434]   
The potential for MAO-catalysed metabolism of monoamines to be a source of H2O2 for 
RI disulfide formation suggests that the associated enhanced PKA activity could be 
involved in conditions where MAO activity or levels of monoamines are increased. 
Kaludercic et al.,[435] showed that in pressure overloaded hearts, norepinephrine 
metabolism by MAO-A was increased as was ROS production and the hearts showed 
adverse remodelling and dysfunction. I hypothesise that RI disulfide may be highly 
abundant in these hearts. Mice expressing a dominant negative MAO-A were protected 
against pressure overload,[435] and I hypothesise that RI disulfide abundance may be 
lower in these hearts. Therefore, it may be interesting to assess whether Cys17Ser RI 
KI mice are protected against pressure overload-induced hypertrophy too. In contrast, 
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removal of MAO-A has been shown to increase serotonin-dependent ventricular 
hypertrophy in pressure overloaded hearts.[436] However, as discussed by Kaludercic et 
al.,[435, 437] the discrepancy between these two studies could be due to differences in 
the severity of the pressure overload or adaptive changes in the mice. Either way, the 
importance of RI disulfide in this model would be interesting to study.  
The transcription factor cAMP response element-binding protein (CREB) is an 
established substrate for PKA,[201, 202] and the monoamine phenylephrine has been 
shown to activate CREB in ARVMs via a number of signalling pathways involving 
PKA, extracellular signal-regulated kinase (ERK) 1/2, p38 mitogen activated protein 
kinase and mitogen- and stress-activated protein kinase 1 (MSK1). MSK1 was 
important in regulating expression of atrial natriuretic peptide messenger RNA 
(mRNA), which is a marker gene of cardiac hypertrophy.[438] Therefore, my results 
suggest that phenylephrine may also activate CREB via the following proposed 
mechanism. Phenylephrine is transported into the cell and metabolised by MAO 
generating H2O2 which induces RIdisulfide formation. This increases RI affinity for 
AKAPs which target PKA close to CREB for substrate-induced sensitisation to cAMP 
and therefore, upon cAMP binding to RI, catalytic subunits are released to 
phosphorylate and activate CREB. This mechanism may therefore contribute to 
hypertrophic growth. MAOs are also a source of H2O2 in ischaemia-reperfusion,[163] 
so RI disulfide abundance may also be interesting to analyse in this model, potentially 
contributing to the pathogenesis of ischaemia-reperfusion injury.  
Excessive amounts of catecholamines (e.g. norepinephrine or epinephrine) are secreted 
by tumours such as pheochromocytomas, which are most frequently formed from 
chromaffin cells in the adrenal glands, although they can also occur outside of these 
glands. Chromaffin cells can also be found along the aorta, blood vessel walls and in the 
heart, but primary pheochromocytomas of the heart are extremely rare.[439, 440] 
Patients with a pheochromocytoma can have a number of life-threatening cardiovascular 
complications and these can depend on which catecholamine the tumour is secreting. 
Epinephrine-secreting tumours are associated with episodic symptoms such as 
headaches, palpatations and hyperglycaemia whereas norepinephrine-secreting tumours 
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are associated with sustained hypertension. Other cardiovascular manifestations of 
pheochromocytomas are tachycardia, intermittent hypertension, orthostatic hypotension 
(occurs when standing up) and arrhythmias.[441] These symptoms are due to the 
excessive circulating concentrations of catecholamines which are well known to activate 
adrenoceptors but, as shown in my thesis, these catecholamines are also metabolised by 
MAOs generating H2O2 which then induces RI disulfide formation. Disulfide 
formation is associated with PKA activation and so increased PKA activity by this 
mechanism together with  adrenoceptor stimulation may play a role in the symptoms 
of pheochromocytomas.  
As already discussed in Chapter 3, Carney Complex is a multiple endocrine neoplasia 
characterised by spotty skin pigmentation typically on the face, schwannomas and 
myxomas, which occur anywhere in the body but those on the heart are the major cause 
of mortality. Most of the mutations identified in these patients are in the dimerisation / 
docking (DD) domain of PKA RI and result in inactivation of the regulatory 
subunit.[131] The effects of this mutation are due to excess PKA activity due to de-
regulation of the C subunit.[442] Therefore, the increased PKA activity associated 
with RI disulfide may also contribute to signalling leading to the myxomas in the 
heart. One study showed that, in tumours with these inactivating RI mutations, basal 
PKA activity was not altered but activity induced by cAMP was enhanced i.e. the 
tumours were more sensitive to cAMP.[135] Therefore, it could be that in Carney 
Complex, mutations cause PKA RIto have a heightened sensitivity to oxidation to 
disulfide making PKA more sensitive to cAMP via substrate-induced sensitisation. 
In summary, cardiac RI disulfide formation is an important post-translational 
modification that inter-relates with the classical mode of PKA activation by cAMP. 
Catecholamines which activate  adrenergic signalling to elevate cAMP and stimulate 
PKA are also transported into the cell and metabolised by MAO generating H2O2 which 
can then oxidise RI to disulfide. Disulfide formation causes translocation of RIto the 
membrane and myofilament. Whether this is as a result of increased affinity of RI for 
AKAPs is yet to be fully elucidated, but this event may serve to position PKA close to 
substrates to enable substrate-induced sensitisation of PKA to cAMP and PKA 
Chapter 7: General Discussion 
277 
 
activation. Therefore, catecholamines activate PKA by two pathways which potentially 
synergise. In addition, cAMP sensitises RI to disulfide formation which together with 
disulfide / substrate-induced sensitisation to cAMP forms a positive feedback loop. 
Importantly the oxidation of RI to disulfide may be reversed by the Trx sytem 
suggesting that RI disulfide formation is a regulatory mechanism. This mechanism is 
particularly important in the heart where PKA plays a prominent role in the positive 
inotropic, lusitropic and chronotropic response to  adrenergic signalling. Future work 
might assess whether disulfide directly activates PKA by in vitro kinase assays and 
whether RI-AKAP binding is modulated by disulfide. Ultimately, because of the major 
roles of PKA in the heart, experiments investigating the role of RI disulfide in diseases 
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Appendix A. Proteins identified in cAMP affinity capture capture samples by LC-
MS/MS. Capture samples were run on a gradient gel and the gel was stained with colloidal 
Coomassie. Selected stained bands were cut out of the gel and analysed by LC-MS/MS. 
The table shows the band ID in which the named protein was identified where A is control 
WT heart, B is 50 µM H2O2-perfused WT heart, C is control KI heart and D is 50 µM H2O2-
perfused KI heart and 1 – 6 is the different molecular weight levels on the gel. 
Band 
ID 
Protein name Protein 
accession no. 




















A1 Keratin, type II 
cytoskeletal 5 
K2C5_MOUSE 61,768.0 100.0 3 3 5 7.76 
 Protein KIAA0664 K0664_MOUSE 148,071.
4 
100.0 5 5 9 4.11 




100.0 4 5 8 3.46 












100.0 3 3 6 3.91 
 cAMP-dependent 
protein kinase type 
II-alpha regulatory 
subunit 
KAP2_MOUSE 45,389.4 100.0 3 3 5 8.23 
 ATP synthase 
subunit alpha, 
mitochondrial 
ATPA_MOUSE 59,754.1 100.0 7 8 14 15.90 
 Keratin, type II 
cytoskeletal 6A 
K2C6A_MOUSE 59,336.7 100.0 5 5 8 10.50 
 Cytoplasmic dynein 










IDHP_MOUSE 50,907.2 100.0 5 5 9 13.10 
 Superoxide 
dismutase [Cu-Zn] 
SODC_MOUSE 15,941.9 99.9 2 2 4 15.60 
 Filamin-C FLNC_MOUSE 291,111.
8 












100.0 18 19 34 13.90 
 A kinase anchor 
protein 1, 
mitochondrial 
AKAP1_MOUSE 92,164.5 100.0 6 6 8 13.10 
 Actin, alpha cardiac 
muscle 1 
ACTC_MOUSE 42,020.1 100.0 3 3 5 10.30 
 Trifunctional enzyme 
subunit alpha, 
mitochondrial 
ECHA_MOUSE 82,671.5 100.0 5 5 7 8.78 
 Keratin, type I 
cytoskeletal 10 






100.0 5 5 9 5.77 
 Aconitate hydratase, 
mitochondrial 
ACON_MOUSE 85,465.9 100.0 12 12 21 18.50 
 Vinculin VINC_MOUSE 116,719.
4 
100.0 5 5 7 5.72 
 Sarcoplasmic/endopl
asmic reticulum 
calcium ATPase 2 
AT2A2_MOUSE 114,860.
0 
100.0 13 15 26 14.10 
 ATP synthase 
subunit beta, 
mitochondrial 










PYGM_MOUSE 97,289.4 100.0 2 2 3 3.44 






99.9 2 2 3 2.90 
 Sarcalumenin SRCA_MOUSE 99,186.0 100.0 3 3 5 4.07 
 Carnitine O-
palmitoyltransferase 
1, muscle isoform 
CPT1B_MOUSE 88,220.0 100.0 4 4 6 5.31 
 cAMP-dependent 
protein kinase type I-
alpha regulatory 
subunit 
















100.0 17 18 30 17.90 
 Dystrophin DMD_MOUSE 425,816.
3 




THIM_MOUSE 41,858.2 100.0 2 2 3 8.06 
 Keratin, type I 
cytoskeletal 42 
K1C42_MOUSE 50,133.6 100.0 3 3 4 9.51 
 Keratin, type I 
cytoskeletal 16 

















100.0 17 17 29 10.30 
 ADP/ATP 
translocase 1 
ADT1_MOUSE 32,905.4 100.0 4 4 8 11.70 
 Myosin-6 MYH6_MOUSE 223,571.
2 
100.0 33 37 61 20.70 











100.0 19 19 34 23.40 
 cAMP-dependent 
protein kinase type 
II-alpha regulatory 
subunit 
KAP2_MOUSE 45,389.4 100.0 10 10 16 34.70 
 ATP synthase 
subunit alpha, 
mitochondrial 
ATPA_MOUSE 59,754.1 100.0 7 8 12 17.50 
 Keratin, type II 
cytoskeletal 6A 




























IDHP_MOUSE 50,907.2 100.0 6 6 11 17.70 
 Superoxide 
dismutase [Cu-Zn] 
SODC_MOUSE 15,941.9 99.9 2 2 3 15.60 
 LIM domain-binding 
protein 3 
LDB3_MOUSE 76,432.1 100.0 5 5 7 9.13 
 A kinase anchor 
protein 1, 
mitochondrial 
AKAP1_MOUSE 92,164.5 100.0 2 2 4 2.57 
 Actin, alpha cardiac 
muscle 1 
ACTC_MOUSE 42,020.1 100.0 5 6 12 15.90 
 Keratin, type I 
cytoskeletal 10 
K1C10_MOUSE 57,771.3 100.0 3 3 6 6.49 
 Aconitate hydratase, 
mitochondrial 
ACON_MOUSE 85,465.9 100.0 15 17 31 23.10 
 Trifunctional enzyme 
subunit beta, 
mitochondrial 
ECHB_MOUSE 51,388.0 100.0 3 3 6 6.95 
 Sarcoplasmic/endopl
asmic reticulum 
calcium ATPase 2 
AT2A2_MOUSE 114,860.
0 
100.0 23 27 49 24.40 
 ATP synthase 
subunit beta, 
mitochondrial 
ATPB_MOUSE 56,301.2 100.0 8 9 17 22.50 






70,877.0 100.0 4 4 6 7.62 
 Fumarate hydratase, 
mitochondrial 
FUMH_MOUSE 54,371.1 100.0 3 3 5 8.68 
 Trifunctional enzyme 
subunit alpha, 
mitochondrial 








PYGM_MOUSE 97,289.4 100.0 2 2 4 2.38 
 Sarcalumenin SRCA_MOUSE 99,186.0 100.0 2 2 3 2.86 
 Creatine kinase M-
type 














ODPB_MOUSE 38,937.0 99.9 2 2 4 6.41 
 cAMP-dependent 
protein kinase type I-
alpha regulatory 
subunit 












G3P_MOUSE 35,810.1 100.0 3 3 4 15.00 









100.0 3 3 3 3.10 
 Keratin, type I 
cytoskeletal 42 



































100.0 4 4 6 5.73 
 Hexokinase-2 HXK2_MOUSE 102,536.
6 
100.0 12 13 24 16.70 
 ADP/ATP 
translocase 1 
ADT1_MOUSE 32,905.4 100.0 3 3 5 10.10 
 Hexokinase-1 HXK1_MOUSE 108,304.
7 




A3 Keratin, type II 
cytoskeletal 5 
K2C5_MOUSE 61,768.0 100.0 3 3 5 7.93 
 Pyruvate kinase 
isozymes M1/M2 
KPYM_MOUSE 57,845.6 100.0 6 7 11 16.90 
 cAMP-dependent 
protein kinase type 
II-alpha regulatory 
subunit 
KAP2_MOUSE 45,389.4 100.0 18 27 58 48.10 
 ATP synthase 
subunit alpha, 
mitochondrial 
ATPA_MOUSE 59,754.1 100.0 14 17 33 32.20 
 Keratin, type II 
cytoskeletal 6A 







100.0 3 3 4 3.62 
 Tubulin beta-2C 
chain 





IDHP_MOUSE 50,907.2 100.0 13 15 30 32.70 










ALDH2_MOUSE 56,537.6 100.0 8 9 12 16.80 
 Actin, alpha cardiac 
muscle 1 
ACTC_MOUSE 42,020.1 100.0 3 4 6 13.30 
 Aconitate hydratase, 
mitochondrial 
ACON_MOUSE 85,465.9 100.0 3 3 5 4.10 
 Trifunctional enzyme 
subunit beta, 
mitochondrial 
ECHB_MOUSE 51,388.0 100.0 9 9 18 21.10 
 ATP synthase 
subunit beta, 
mitochondrial 
ATPB_MOUSE 56,301.2 100.0 15 20 35 43.30 
 Fumarate hydratase, 
mitochondrial 
FUMH_MOUSE 54,371.1 100.0 5 6 11 11.60 
 Trifunctional enzyme 
subunit alpha, 
mitochondrial 




 Sarcalumenin SRCA_MOUSE 99,186.0 100.0 7 7 12 10.40 
 Cytochrome b-c1 
complex subunit 1, 
mitochondrial 




alpha, somatic form, 
mitochondrial 
ODPA_MOUSE 43,232.5 100.0 2 2 8 5.13 




DLDH_MOUSE 54,272.4 100.0 6 7 10 16.10 
 Succinyl-CoA:3-
ketoacid-coenzyme 




55,990.2 100.0 5 6 10 15.00 
 cAMP-dependent 
protein kinase type I-
alpha regulatory 
subunit 




PCCB_MOUSE 58,394.5 100.0 3 3 5 8.13 
 Keratin, type I 
cytoskeletal 42 
K1C42_MOUSE 50,133.6 100.0 5 5 9 13.90 
 Keratin, type I 
cytoskeletal 16 
K1C16_MOUSE 51,607.7 100.0 2 3 5 9.59 
 Tubulin alpha-4A 
chain 
TBA4A_MOUSE 49,924.6 100.0 5 6 11 15.20 
 ADP/ATP 
translocase 1 












NFS1_MOUSE 50,001.8 100.0 3 3 5 8.65 






47,908.7 100.0 6 6 9 17.70 
 cAMP-dependent 
protein kinase type 
II-alpha regulatory 
subunit 




 ATP synthase 
subunit alpha, 
mitochondrial 
ATPA_MOUSE 59,754.1 100.0 5 6 11 11.20 
 Keratin, type II 
cytoskeletal 6A 












IDHP_MOUSE 50,907.2 100.0 17 22 50 39.80 









ODBA_MOUSE 50,371.5 100.0 3 4 7 11.10 
 Phosphoglycerate 
kinase 1 
PGK1_MOUSE 44,551.1 100.0 4 4 8 13.40 
 Elongation factor Tu, 
mitochondrial 




AT1B1_MOUSE 35,196.4 100.0 3 4 6 12.50 
 Citrate synthase, 
mitochondrial 
CISY_MOUSE 51,738.1 100.0 3 3 4 6.47 
 Aconitate hydratase, 
mitochondrial 
ACON_MOUSE 85,465.9 100.0 4 4 5 6.79 
 Trifunctional enzyme 
subunit beta, 
mitochondrial 
ECHB_MOUSE 51,388.0 100.0 7 8 14 16.20 
 ATP synthase 
subunit beta, 
mitochondrial 
ATPB_MOUSE 56,301.2 100.0 5 5 8 11.20 
 Fumarate hydratase, 
mitochondrial 
FUMH_MOUSE 54,371.1 100.0 6 7 12 17.80 
 Cytochrome b-c1 
complex subunit 1, 
mitochondrial 




alpha, somatic form, 
mitochondrial 




 Beta-enolase ENOB_MOUSE 47,025.9 100.0 9 13 27 29.70 
 Creatine kinase M-
type 
KCRM_MOUSE 43,045.6 100.0 3 3 5 9.97 
 Trifunctional enzyme 
subunit alpha, 
mitochondrial 






PDK1_MOUSE 48,926.8 100.0 2 2 3 8.06 
 Eukaryotic initiation 
factor 4A-I 




KAT3_MOUSE 51,127.9 99.9 2 2 3 5.27 
 cAMP-dependent 
protein kinase type I-
alpha regulatory 
subunit 
KAP0_MOUSE 43,185.8 100.0 8 9 14 23.10 






50,114.7 100.0 4 4 7 11.20 
 Keratin, type I 
cytoskeletal 42 






PDK2_MOUSE 46,070.1 100.0 5 5 5 15.20 
 Actin, alpha cardiac 
muscle 1 
ACTC_MOUSE 42,020.1 100.0 6 6 12 20.40 
 Cytochrome b-c1 
complex subunit 2, 
mitochondrial 
QCR2_MOUSE 48,236.0 100.0 9 9 14 25.60 
 ADP/ATP 
translocase 1 
ADT1_MOUSE 32,905.4 100.0 4 4 7 12.80 
 Creatine kinase S-
type, mitochondrial 








52,626.8 100.0 3 3 4 6.26 











protein kinase type 
II-alpha regulatory 
subunit 









ODP2_MOUSE 67,942.6 100.0 3 3 5 7.32 
 ATP synthase 
subunit alpha, 
mitochondrial 
ATPA_MOUSE 59,754.1 100.0 4 4 7 9.40 
 Keratin, type II 
cytoskeletal 6A 











46,482.4 100.0 4 6 12 12.40 
 Keratin, type II 
cytoskeletal 1 
K2C1_MOUSE 65,607.1 100.0 3 4 8 3.77 






46,841.0 100.0 3 3 4 9.01 
 Actin, cytoplasmic 1 ACTB_MOUSE,
ACTG_MOUSE 









MPI_MOUSE 46,575.9 100.0 3 3 5 10.20 
 Phosphoglycerate 
kinase 1 
PGK1_MOUSE 44,551.1 100.0 8 8 13 21.30 
 Aconitate hydratase, 
mitochondrial 
ACON_MOUSE 85,465.9 100.0 3 3 5 4.10 
 Elongation factor Tu, 
mitochondrial 
EFTU_MOUSE 49,508.9 100.0 4 5 9 10.40 
 NADH 
dehydrogenase 









 Actin, alpha cardiac 
muscle 1 
ACTC_MOUSE 42,020.1 100.0 16 20 40 54.10 
 Beta-enolase ENOB_MOUSE 47,025.9 100.0 3 4 5 10.10 
 Citrate synthase, 
mitochondrial 
CISY_MOUSE 51,738.1 100.0 4 4 8 11.40 
 Trifunctional enzyme 
subunit beta, 
mitochondrial 




THIL_MOUSE 44,816.4 100.0 8 13 22 26.40 
 ATP synthase 
subunit beta, 
mitochondrial 
ATPB_MOUSE 56,301.2 100.0 6 6 11 15.70 
 Trifunctional enzyme 
subunit alpha, 
mitochondrial 








alpha, somatic form, 
mitochondrial 
ODPA_MOUSE 43,232.5 100.0 3 3 6 8.97 
 Creatine kinase M-
type 
KCRM_MOUSE 43,045.6 100.0 4 4 8 13.10 
 Eukaryotic initiation 
factor 4A-I 
IF4A1_MOUSE 46,155.3 100.0 2 2 3 5.67 
 cAMP-dependent 
protein kinase type I-
alpha regulatory 
subunit 
KAP0_MOUSE 43,185.8 100.0 9 12 20 26.20 






50,114.7 100.0 11 13 23 24.00 
 Keratin, type I 
cytoskeletal 42 




IVD_MOUSE 46,326.5 100.0 5 6 11 13.70 
 Cytochrome b-c1 
complex subunit 2, 
mitochondrial 












ADT1_MOUSE 32,905.4 100.0 4 4 8 12.80 
 Creatine kinase S-
type, mitochondrial 
KCRS_MOUSE 47,474.7 100.0 7 7 9 20.00 
A6 Prohibitin PHB_MOUSE 29,820.6 100.0 4 4 7 15.80 
 ATP synthase 
subunit alpha, 
mitochondrial 











46,482.4 100.0 6 6 11 15.90 
 Keratin, type II 
cytoskeletal 1 





IDHP_MOUSE 50,907.2 100.0 4 4 7 11.10 
 Phosphoglycerate 
kinase 1 
PGK1_MOUSE 44,551.1 100.0 2 2 4 7.91 
 Sepiapterin 
reductase 
SPRE_MOUSE 27,883.8 100.0 4 4 6 23.80 
 Citrate lyase subunit 
beta-like protein, 
mitochondrial 
CLYBL_MOUSE 37,549.1 100.0 3 3 5 9.76 
 Electron transfer 
flavoprotein subunit 
alpha, mitochondrial 








MDHM_MOUSE 35,611.9 100.0 6 6 11 21.90 
 Actin, alpha cardiac 
muscle 1 
ACTC_MOUSE 42,020.1 100.0 6 6 10 19.60 
 Trifunctional enzyme 
subunit alpha, 
mitochondrial 
ECHA_MOUSE 82,671.5 100.0 3 3 4 4.72 
 Pyruvate kinase 
isozymes M1/M2 











30,149.4 100.0 4 6 10 15.20 
 Electron transfer 
flavoprotein subunit 
beta 
ETFB_MOUSE 27,623.2 100.0 3 3 3 14.10 
















26,334.4 100.0 7 8 13 18.90 
 Trifunctional enzyme 
subunit beta, 
mitochondrial 




THIL_MOUSE 44,816.4 100.0 4 4 8 13.20 
 ATP synthase 
subunit beta, 
mitochondrial 
ATPB_MOUSE 56,301.2 100.0 3 3 5 8.32 
 Prohibitin-2 PHB2_MOUSE 33,297.6 100.0 3 3 5 9.70 
 Aconitate hydratase, 
mitochondrial 




THIM_MOUSE 41,858.2 100.0 4 4 6 12.60 
 Cytochrome c1, 
heme protein, 
mitochondrial 
CY1_MOUSE 35,328.4 100.0 4 5 8 20.90 
 Mitochondrial 
carnitine/acylcarnitin
e carrier protein 




alpha, somatic form, 
mitochondrial 
ODPA_MOUSE 43,232.5 100.0 3 3 4 4.87 
 Cytochrome b-c1 
complex subunit 2, 
mitochondrial 












ODPB_MOUSE 38,937.0 100.0 5 5 9 17.50 
 Dihydropteridine 
reductase 
DHPR_MOUSE 25,570.2 100.0 3 3 5 17.80 
 ATP synthase 
subunit gamma, 
mitochondrial 
ATPG_MOUSE 32,887.4 100.0 4 4 11 15.80 
 cAMP-dependent 
protein kinase type I-
alpha regulatory 
subunit 














DHSB_MOUSE 31,815.0 100.0 5 6 11 19.50 
 Triosephosphate 
isomerase 
TPIS_MOUSE 26,712.2 100.0 7 8 16 36.10 
 Phosphate carrier 
protein, 
mitochondrial 




D3D2_MOUSE 32,079.2 100.0 5 5 10 21.50 
 NAD-dependent 
deacetylase sirtuin-5 
SIRT5_MOUSE 34,134.1 99.9 2 2 2 5.81 
 Voltage-dependent 
anion-selective 
channel protein 3 
VDAC3_MOUS
E 




MDHC_MOUSE 36,512.1 100.0 4 4 8 16.50 
 Myosin light chain 3 MYL3_MOUSE 22,422.2 100.0 5 6 10 38.20 
 Dehydrogenase/red










ADT2_MOUSE 32,932.6 100.0 4 4 7 20.80 
 14-3-3 protein 
zeta/delta 
1433Z_MOUSE 27,771.9 100.0 3 3 5 14.70 
 ADP/ATP 
translocase 1 
ADT1_MOUSE 32,905.4 100.0 14 15 28 39.30 
B1 Protein KIAA0664 K0664_MOUSE 148,071.
4 








100.0 3 3 5 3.32 




100.0 5 6 9 4.00 
 cAMP-dependent 
protein kinase type 
II-alpha regulatory 
subunit 
KAP2_MOUSE 45,389.4 100.0 4 4 6 13.50 
 ATP synthase 
subunit alpha, 
mitochondrial 







99.9 2 2 3 3.23 
 Fatty acid synthase FAS_MOUSE 272,429.
3 














ODP2_MOUSE 67,942.6 99.9 2 2 3 5.45 
 Superoxide 
dismutase [Cu-Zn] 
SODC_MOUSE 15,941.9 100.0 3 3 5 22.10 
 Filamin-C FLNC_MOUSE 291,111.
8 
99.9 2 2 2 0.95 








100.0 19 20 35 14.60 
 A kinase anchor 
protein 1, 
mitochondrial 








100.0 6 6 9 6.25 
 Actin, alpha cardiac 
muscle 1 
ACTC_MOUSE 42,020.1 100.0 3 3 6 10.30 
 Keratin, type I 
cytoskeletal 10 






100.0 8 9 15 9.08 
 Aconitate hydratase, 
mitochondrial 
ACON_MOUSE 85,465.9 100.0 12 13 24 18.50 
 Trifunctional enzyme 
subunit beta, 
mitochondrial 
ECHB_MOUSE 51,388.0 100.0 2 2 4 4.00 
 Sarcoplasmic/endopl
asmic reticulum 
calcium ATPase 2 
AT2A2_MOUSE 114,860.
0 
100.0 9 10 19 11.30 
 ATP synthase 
subunit beta, 
mitochondrial 
ATPB_MOUSE 56,301.2 100.0 8 9 16 23.60 
 Trifunctional enzyme 
subunit alpha, 
mitochondrial 
ECHA_MOUSE 82,671.5 100.0 6 6 10 9.96 
 Sarcalumenin SRCA_MOUSE 99,186.0 100.0 4 4 7 4.95 
 Cytochrome c1, 
heme protein, 
mitochondrial 
CY1_MOUSE 35,328.4 100.0% 3 3 5 17.20 
 Carnitine O-
palmitoyltransferase 
1, muscle isoform 
CPT1B_MOUSE 88,220.0 100.0% 3 3 6 4.27 
 cAMP-dependent 
protein kinase type I-
alpha regulatory 
subunit 








100.0 20 23 43 20.40 
 Vinculin VINC_MOUSE 116,719.
4 
100.0 2 2 3 2.25 
 A-kinase anchor 
protein 2 


























100.0 15 15 27 9.45 
 Myosin-6 MYH6_MOUSE 223,571.
2 
100.0 30 35 57 19.50 
 ADP/ATP 
translocase 1 
ADT1_MOUSE 32,905.4 100.0 4 4 8 11.70 
B2 cAMP-dependent 
protein kinase type 
II-alpha regulatory 
subunit 
KAP2_MOUSE 45,389.4 100.0 7 7 9 25.20 
 ATP-citrate synthase ACLY_MOUSE 119,731.
4 
100.0 3 3 4 3.76 
 ATP synthase 
subunit alpha, 
mitochondrial 














46,482.4 100.0 4 4 5 11.90 
 Heat shock 70 kDa 
protein 4 





IDHP_MOUSE 50,907.2 100.0 8 9 17 19.20 
 Long-chain-fatty-
acid--CoA ligase 1 
ACSL1_MOUSE 77,926.2 100.0 3 3 5 5.15 
 LIM domain-binding 
protein 3 
LDB3_MOUSE 76,432.1 100.0 4 4 6 6.92 





100.0 7 7 13 8.75 
 A kinase anchor 
protein 1, 
mitochondrial 
AKAP1_MOUSE 92,164.5 100.0 5 5 8 7.82 
 Actin, alpha cardiac 
muscle 1 
ACTC_MOUSE 42,020.1 100.0 3 4 7 9.81 
 Keratin, type I 
cytoskeletal 10 











100.0 3 3 4 3.07 
 Aconitate hydratase, 
mitochondrial 
ACON_MOUSE 85,465.9 100.0 14 17 30 21.20 
 Trifunctional enzyme 
subunit beta, 
mitochondrial 
ECHB_MOUSE 51,388.0 100.0 4 4 5 8.21 
 Sarcoplasmic/endopl
asmic reticulum 
calcium ATPase 2 
AT2A2_MOUSE 114,860.
0 
100.0 23 28 55 22.50 
 ATP synthase 
subunit beta, 
mitochondrial 
ATPB_MOUSE 56,301.2 100.0 9 10 18 26.10 






70,877.0 100.0 3 3 4 5.79 
 Trifunctional enzyme 
subunit alpha, 
mitochondrial 








PYGM_MOUSE 97,289.4 100.0 3 3 6 3.68 
 Carnitine O-
palmitoyltransferase 
1, muscle isoform 






100.0 4 4 8 4.73 
 cAMP-dependent 
protein kinase type I-
alpha regulatory 
subunit 
KAP0_MOUSE 43,185.8 100.0 16 18 43 41.70 

























 Keratin, type II 
cytoskeletal 1 

































100.0 4 4 7 5.24 
 Hexokinase-2 HXK2_MOUSE 102,536.
6 
100.0 14 16 25 19.00 
 Hexokinase-1 HXK1_MOUSE 108,304.
7 
100.0 3 3 6 5.13 
 ADP/ATP 
translocase 1 
ADT1_MOUSE 32,905.4 100.0 6 6 11 20.10 
B3 Succinyl-CoA:3-
ketoacid-coenzyme 




55,990.2 100.0 3 3 5 10.20 
 cAMP-dependent 
protein kinase type 
II-alpha regulatory 
subunit 
KAP2_MOUSE 45,389.4 100.0 19 27 46 50.60 
 ATP synthase 
subunit alpha, 
mitochondrial 
ATPA_MOUSE 59,754.1 100.0 15 18 33 34.20 
 Cytochrome b-c1 
complex subunit 1, 
mitochondrial 
QCR1_MOUSE 52,768.8 99.9 2 2 3 6.25 
 Fumarate hydratase, 
mitochondrial 
FUMH_MOUSE 54,371.1 100.0 4 5 9 11.20 
 cAMP-dependent 
protein kinase type 
II-beta regulatory 
subunit 




 ATP synthase 
subunit beta, 
mitochondrial 






MMSA_MOUSE 57,916.3 100.0 11 12 22 28.40 
 cAMP-dependent 
protein kinase type I-
beta regulatory 
subunit 




DLDH_MOUSE 54,272.4 100.0 4 4 5 9.82 
 Sarcalumenin SRCA_MOUSE 99,186.0 100.0 8 8 13 12.90 
 Tubulin beta-2C 
chain 
TBB2C_MOUSE 49,830.7 100.0 7 7 12 18.90 
 cAMP-dependent 
protein kinase type I-
alpha regulatory 
subunit 




alpha, somatic form, 
mitochondrial 
ODPA_MOUSE 43,232.5 100.0 5 5 8 13.10 
 Pyruvate kinase 
isozymes M1/M2 
KPYM_MOUSE 57,845.6 100.0 7 8 15 20.50 
 Epoxide hydrolase 2 HYES_MOUSE 62,516.8 100.0 3 3 5 6.50 
 Tubulin alpha-4A 
chain 
TBA4A_MOUSE 49,924.6 100.0 5 6 9 16.70 
 Aconitate hydratase, 
mitochondrial 
ACON_MOUSE 85,465.9 100.0 3 3 3 5.13 
 Actin, alpha cardiac 
muscle 1 

















 Trifunctional enzyme 
subunit beta, 
mitochondrial 








52,626.8 100.0 6 7 12 14.90 






47,908.7 100.0 3 3 5 7.67 
 cAMP-dependent 
protein kinase type 
II-alpha regulatory 
subunit 
KAP2_MOUSE 45,389.4 100.0 4 4 8 12.20 
 ATP synthase 
subunit alpha, 
mitochondrial 





IDHP_MOUSE 50,907.2 100.0 18 22 43 37.80 
 Alpha-enolase ENOA_MOUSE 47,141.7 100.0 5 6 11 27.60 
 Elongation factor Tu, 
mitochondrial 




AT1B1_MOUSE 35,196.4 100.0 3 4 7 12.50 
 Actin, alpha cardiac 
muscle 1 
ACTC_MOUSE 42,020.1 100.0 3 3 5 9.81 
 Keratin, type I 
cytoskeletal 10 
K1C10_MOUSE 57,771.3 100.0 3 3 5 5.96 
 Trifunctional enzyme 
subunit beta, 
mitochondrial 
ECHB_MOUSE 51,388.0 100.0 11 13 19 25.90 
 ATP synthase 
subunit beta, 
mitochondrial 
ATPB_MOUSE 56,301.2 100.0 5 5 8 15.10 
 Fumarate hydratase, 
mitochondrial 
FUMH_MOUSE 54,371.1 100.0 8 10 16 27.20 
 Elongation factor 1-
gamma 
EF1G_MOUSE 50,061.3 100.0 5 6 10 10.80 
 Cytochrome b-c1 
complex subunit 1, 
mitochondrial 







alpha, somatic form, 
mitochondrial 
ODPA_MOUSE 43,232.5 100.0 7 8 15 16.90 




KAT3_MOUSE 51,127.9 100.0 5 5 8 13.00 
 Elongation factor 1-
alpha 1 
EF1A1_MOUSE 50,114.2 100.0 3 3 4 7.58 
 cAMP-dependent 
protein kinase type I-
alpha regulatory 
subunit 
KAP0_MOUSE 43,185.8 100.0 12 15 26 28.30 
 Tetratricopeptide 
repeat protein 38 
TTC38_MOUSE 52,224.8 100.0 3 3 3 7.31 
 26S protease 
regulatory subunit 7 
PRS7_MOUSE 48,649.6 100.0 2 2 3 4.62 
 Lactation elevated 
protein 1 
LACE1_MOUSE 54,314.8 100.0 3 3 3 5.83 
 Creatine kinase S-
type, mitochondrial 
KCRS_MOUSE 47,474.7 100.0 2 2 4 5.49 
 ADP/ATP 
translocase 1 












NFS1_MOUSE 50,001.8 100.0 5 6 9 14.40 






47,908.7 100.0 8 9 15 24.70 
 cAMP-dependent 
protein kinase type 
II-alpha regulatory 
subunit 







46,482.4 100.0 6 8 13 17.10 
 Keratin, type II 
cytoskeletal 1 










46,841.0 100.0 5 5 8 14.10 
 Actin, cytoplasmic 1 ACTB_MOUSE,
ACTG_MOUSE 





IDHP_MOUSE 50,907.2 100.0 18 22 43 42.00 
 Phosphoglycerate 
kinase 1 
PGK1_MOUSE 44,551.1 100.0 11 12 18 31.40 
 Elongation factor Tu, 
mitochondrial 




AT1B1_MOUSE 35,196.4 100.0 3 4 6 12.50 
 NADH 
dehydrogenase 





40,604.7 100.0 3 3 5 8.73 
 Actin, alpha cardiac 
muscle 1 
ACTC_MOUSE 42,020.1 100.0 16 21 44 51.70 
 Beta-enolase ENOB_MOUSE 47,025.9 100.0 6 6 11 16.40 
 Citrate synthase, 
mitochondrial 
CISY_MOUSE 51,738.1 100.0 3 3 5 7.97 
 Trifunctional enzyme 
subunit beta, 
mitochondrial 














THIM_MOUSE 41,858.2 100.0 7 8 12 32.00 
 Cytochrome b-c1 
complex subunit 1, 
mitochondrial 




alpha, somatic form, 
mitochondrial 




 Creatine kinase M-
type 
KCRM_MOUSE 43,045.6 100.0 4 4 7 13.10 
 Eukaryotic initiation 
factor 4A-I 
IF4A1_MOUSE 46,155.3 100.0 5 5 9 14.30 
 cAMP-dependent 
protein kinase type I-
alpha regulatory 
subunit 




G3P_MOUSE 35,810.1 100.0 3 3 5 12.90 
 Phosphate carrier 
protein, 
mitochondrial 
MPCP_MOUSE 39,633.1 100.0 3 3 5 9.52 
















IVD_MOUSE 46,326.5 100.0 5 6 10 13.40 
 Cytochrome b-c1 
complex subunit 2, 
mitochondrial 
QCR2_MOUSE 48,236.0 100.0 9 13 25 29.60 
 ADP/ATP 
translocase 1 
ADT1_MOUSE 32,905.4 100.0 3 3 5 10.10 
 Creatine kinase S-
type, mitochondrial 
KCRS_MOUSE 47,474.7 100.0 9 10 18 23.90 




ECHM_MOUSE 31,475.3 100.0 9 12 20 37.20 
 ATP synthase 
subunit alpha, 
mitochondrial 







46,482.4 100.0 3 3 5 7.60 













IDHP_MOUSE 50,907.2 100.0 3 3 3 6.42 
 Sepiapterin 
reductase 
SPRE_MOUSE 27,883.8 100.0 3 3 4 18.80 
 Citrate lyase subunit 
beta-like protein, 
mitochondrial 
CLYBL_MOUSE 37,549.1 100.0 6 6 11 23.10 
 Electron transfer 
flavoprotein subunit 
alpha, mitochondrial 




LDHA_MOUSE 36,498.9 100.0 6 6 10 21.10 
 Actin, alpha cardiac 
muscle 1 
ACTC_MOUSE 42,020.1 100.0 6 7 13 20.20 
 NADH 
dehydrogenase 

















30,149.4 100.0 4 6 11 15.20 
 Electron transfer 
flavoprotein subunit 
beta 












26,334.4 100.0 6 7 13 18.50 
 Trifunctional enzyme 
subunit beta, 
mitochondrial 












BDH_MOUSE 38,286.0 99.9 2 2 3 6.12 
 Cytochrome c1, 
heme protein, 
mitochondrial 
CY1_MOUSE 35,328.4 100.0 4 5 8 20.90 
 Mitochondrial 
carnitine/acylcarnitin
e carrier protein 









ODPB_MOUSE 38,937.0 100.0 5 5 8 19.80 
 Dihydropteridine 
reductase 
DHPR_MOUSE 25,570.2 100.0 3 3 5 17.80 
 ATP synthase 
subunit gamma, 
mitochondrial 




















COQ5_MOUSE 37,336.0 100.0 4 4 7 13.10 
 Triosephosphate 
isomerase 
TPIS_MOUSE 26,712.2 100.0 4 5 9 21.30 
 Phosphate carrier 
protein, 
mitochondrial 




D3D2_MOUSE 32,079.2 100.0 5 5 9 21.50 
 Regulator of 
microtubule 
dynamics protein 1 







6PGL_MOUSE 27,255.3 100.0 3 4 5 18.70 
 Voltage-dependent 
anion-selective 
channel protein 3 
VDAC3_MOUS
E 




MDHC_MOUSE 36,512.1 100.0 4 4 8 16.50 
 Myosin light chain 3 MYL3_MOUSE 22,422.2 100.0 3 3 6 19.10 
 ADP/ATP 
translocase 1 
ADT1_MOUSE 32,905.4 100.0 14 15 28 35.90 
 ADP/ATP 
translocase 2 
ADT2_MOUSE 32,932.6 100.0 3 3 6 17.80 






47,908.7 100.0 4 4 6 11.40 
 cAMP-dependent 
protein kinase type 
II-alpha regulatory 
subunit 
KAP2_MOUSE 45,389.4 100.0 5 5 8 16.70 
 ATP synthase 
subunit alpha, 
mitochondrial 







46,482.4 100.0 4 5 6 10.90 
 Keratin, type II 
cytoskeletal 1 





IDHP_MOUSE 50,907.2 100.0 5 5 7 12.60 
 Filamin-C FLNC_MOUSE 291,111.
8 
100.0 3 3 6 1.47 
 LIM domain-binding 
protein 3 




MDHM_MOUSE 35,611.9 100.0 3 3 5 12.10 












 A kinase anchor 
protein 1, 
mitochondrial 
AKAP1_MOUSE 92,164.5 100.0 7 7 10 12.40 
 Actin, alpha cardiac 
muscle 1 







100.0 3 3 5 3.91 
 Keratin, type I 
cytoskeletal 10 
K1C10_MOUSE 57,771.3 100.0 3 3 6 5.96 
 Aconitate hydratase, 
mitochondrial 
ACON_MOUSE 85,465.9 100.0 13 15 26 19.90 
 ATP synthase 
subunit beta, 
mitochondrial 
ATPB_MOUSE 56,301.2 100.0 9 10 18 26.30 
 Trifunctional enzyme 
subunit alpha, 
mitochondrial 
ECHA_MOUSE 82,671.5 100.0 5 5 8 7.86 
 Sarcalumenin SRCA_MOUSE 99,186.0 100.0 3 3 5 3.74 
 Creatine kinase M-
type 
KCRM_MOUSE 43,045.6 100.0 3 3 6 9.45 
 cAMP-dependent 
protein kinase type I-
alpha regulatory 
subunit 








100.0% 13 14 23 13.90 
 Vinculin VINC_MOUSE 116,719.
4 
100.0 2 2 2 2.25 
 A-kinase anchor 
protein 2 






100.0 5 5 8 6.84 
 Fatty acid synthase FAS_MOUSE 272,429.
3 











100.0 15 16 26 12.70 
 Sarcoplasmic/endopl
asmic reticulum 
calcium ATPase 2 
AT2A2_MOUSE 114,860.
0 









100.0 4 4 5 2.94 
 Myosin-6 MYH6_MOUSE 223,571.
2 
100.0 33 40 71 19.00 
 ADP/ATP 
translocase 1 
ADT1_MOUSE 32,905.4 100.0 6 6 11 19.80 






47,908.7 100.0 3 3 6 8.14 
 cAMP-dependent 
protein kinase type 
II-alpha regulatory 
subunit 
KAP2_MOUSE 45,389.4 100.0 6 6 10 19.70 
 ATP synthase 
subunit alpha, 
mitochondrial 











46,482.4 100.0 3 3 3 9.03 
 Keratin, type II 
cytoskeletal 1 
K2C1_MOUSE 65,607.1 100.0 3 4 8 3.77 
 Heat shock 70 kDa 
protein 4 





IDHP_MOUSE 50,907.2 100.0 6 6 10 15.50 
 LIM domain-binding 
protein 3 
LDB3_MOUSE 76,432.1 100.0 5 5 8 7.75 









MDHM_MOUSE 35,611.9 100.0 3 3 5 12.10 
 ATP synthase 
subunit O, 
mitochondrial 
ATPO_MOUSE 23,364.4 100.0 2 2 2 11.70 
 A kinase anchor 
protein 1, 
mitochondrial 




 Actin, alpha cardiac 
muscle 1 







100.0 17 21 33 23.00 
 Keratin, type I 
cytoskeletal 10 
K1C10_MOUSE 57,771.3 100.0 4 4 6 5.79 
 Pyruvate kinase 
isozymes M1/M2 
KPYM_MOUSE 57,845.6 100.0 3 3 5 5.65 
 Heat shock protein 
HSP 90-beta 
HS90B_MOUSE 83,328.4 100.0 3 3 5 5.25 
 Aconitate hydratase, 
mitochondrial 
ACON_MOUSE 85,465.9 100.0 16 18 32 24.60 
 Trifunctional enzyme 
subunit beta, 
mitochondrial 
ECHB_MOUSE 51,388.0 100.0 4 4 7 8.00 
 Sarcoplasmic/endopl
asmic reticulum 
calcium ATPase 2 
AT2A2_MOUSE 114,860.
0 
100.0 20 22 37 21.20 
 ATP synthase 
subunit beta, 
mitochondrial 
ATPB_MOUSE 56,301.2 100.0 10 12 21 27.60 






70,877.0 100.0 7 7 11 13.00 
 Fumarate hydratase, 
mitochondrial 








PYGM_MOUSE 97,289.4 100.0 2 2 2 2.02 
 Sarcalumenin SRCA_MOUSE 99,186.0 100.0 2 2 4 2.31 
 Long-chain-fatty-
acid--CoA ligase 1 
ACSL1_MOUSE 77,926.2 99.9 2 2 2 3.15 
 Creatine kinase M-
type 
KCRM_MOUSE 43,045.6 100.0 3 3 6 9.45 
 Trifunctional enzyme 
subunit alpha, 
mitochondrial 


























100.0 3 3 5 2.99 




100.0 6 6 9 7.27 
 Heat shock cognate 
71 kDa protein 
HSP7C_MOUS
E 
70,872.8 100.0 3 3 3 6.19 
 cAMP-dependent 
protein kinase type I-
alpha regulatory 
subunit 









G3P_MOUSE 35,810.1 100.0 4 4 7 12.30 
 Cytochrome b-c1 
complex subunit 2, 
mitochondrial 











































 Myosin-6 MYH6_MOUSE 223,571.
2 
100.0 14 15 23 9.60 
 Hexokinase-1 HXK1_MOUSE 108,304.
7 
100.0 3 3 5 4.31 
 Hexokinase-2 HXK2_MOUSE 102,536.
6 
100.0 5 5 7 6.98 
 ADP/ATP 
translocase 1 




THIM_MOUSE 41,858.2 100.0 4 4 6 16.40 
 Pyruvate kinase 
isozymes M1/M2 
KPYM_MOUSE 57,845.6 100.0 8 8 13 20.50 
 cAMP-dependent 
protein kinase type 
II-alpha regulatory 
subunit 
KAP2_MOUSE 45,389.4 100.0 15 21 40 43.90 
 ATP synthase 
subunit alpha, 
mitochondrial 
ATPA_MOUSE 59,754.1 100.0 12 14 25 25.30 















AL1B1_MOUSE 57,553.5 100.0 2 2 3 4.62 
 Tubulin beta-2C 
chain 





IDHP_MOUSE 50,907.2 100.0 9 11 19 21.20 
 Long-chain-fatty-
acid--CoA ligase 1 
ACSL1_MOUSE 77,926.2 100.0 5 5 8 7.87 
 Calsequestrin-2 CASQ2_MOUS
E 













ALDH2_MOUSE 56,537.6 100.0 6 6 10 13.90 
 Actin, alpha cardiac 
muscle 1 




MDHM_MOUSE 35,611.9 100.0 3 3 3 9.47 
 Aconitate hydratase, 
mitochondrial 
ACON_MOUSE 85,465.9 100.0 10 12 22 14.10 
 Trifunctional enzyme 
subunit beta, 
mitochondrial 
ECHB_MOUSE 51,388.0 100.0 6 7 12 14.50 
 cAMP-dependent 
protein kinase type 
II-beta regulatory 
subunit 
KAP3_MOUSE 46,167.7 100.0 3 3 6 22.60 
 Sarcoplasmic/endopl
asmic reticulum 
calcium ATPase 2 
AT2A2_MOUSE 114,860.
0 
100.0 7 8 14 8.05 
 ATP synthase 
subunit beta, 
mitochondrial 
ATPB_MOUSE 56,301.2 100.0 13 17 29 38.80 
 Fumarate hydratase, 
mitochondrial 
FUMH_MOUSE 54,371.1 99.9 2 2 4 6.31 
 Trifunctional enzyme 
subunit alpha, 
mitochondrial 
ECHA_MOUSE 82,671.5 100.0 6 6 11 10.60 
 Sarcalumenin SRCA_MOUSE 99,186.0 100.0 6 6 10 8.90 
 Carnitine O-
palmitoyltransferase 
1, muscle isoform 




alpha, somatic form, 
mitochondrial 





















G3P_MOUSE 35,810.1 100.0 3 3 4 12.90 
 Succinyl-CoA:3-
ketoacid-coenzyme 








AT1B1_MOUSE 35,196.4 100.0 3 3 4 12.50 
 cAMP-dependent 
protein kinase type I-
alpha regulatory 
subunit 
KAP0_MOUSE 43,185.8 100.0 13 17 47 36.00 
 Phosphate carrier 
protein, 
mitochondrial 
MPCP_MOUSE 39,633.1 100.0 2 2 4 7.28 





ETFD_MOUSE 68,091.8 100.0 4 4 6 6.82 
 Vimentin VIME_MOUSE 53,688.8 100.0 2 2 3 4.94 
 Cytochrome b-c1 
complex subunit 2, 
mitochondrial 
QCR2_MOUSE 48,236.0 100.0 3 3 5 9.05 
 Tubulin alpha-4A 
chain 














100.0 4 4 6 2.70 
 ADP/ATP 
translocase 1 








52,626.8 100.0 3 4 7 6.05 











protein kinase type 
II-alpha regulatory 
subunit 
KAP2_MOUSE 45,389.4 100.0 4 4 6 12.20 
 ATP synthase 
subunit alpha, 
mitochondrial 







46,482.4 100.0 5 5 7 14.00 
 Keratin, type II 
cytoskeletal 1 





IDHP_MOUSE 50,907.2 100.0 16 20 43 36.90 
 Alpha-enolase ENOA_MOUSE 47,141.7 100.0 4 4 7 23.30 
 Phosphoglycerate 
kinase 1 
PGK1_MOUSE 44,551.1 100.0 3 3 4 10.60 
 Elongation factor Tu, 
mitochondrial 









AT1B1_MOUSE 35,196.4 100.0 2 3 4 9.87 
 Trifunctional enzyme 
subunit alpha, 
mitochondrial 
ECHA_MOUSE 82,671.5 100.0 5 5 9 9.04 
 Keratin, type I 
cytoskeletal 10 
K1C10_MOUSE 57,771.3 100.0 3 3 6 5.96 
 Aconitate hydratase, 
mitochondrial 
ACON_MOUSE 85,465.9 100.0 7 7 11 11.40 
 Trifunctional enzyme 
subunit beta, 
mitochondrial 
ECHB_MOUSE 51,388.0 100.0 7 8 15 16.40 
 Sarcoplasmic/endopl
asmic reticulum 
calcium ATPase 2 
AT2A2_MOUSE 114,860.
0 
100.0 2 2 3 2.20 
 Fumarate hydratase, 
mitochondrial 
FUMH_MOUSE 54,371.1 100.0 4 5 10 12.40 
 Elongation factor 1-
gamma 




 Cytochrome b-c1 
complex subunit 1, 
mitochondrial 




alpha, somatic form, 
mitochondrial 
ODPA_MOUSE 43,232.5 100.0 4 5 9 8.72 
 Beta-enolase ENOB_MOUSE 47,025.9 100.0 9 14 26 26.30 
 Creatine kinase M-
type 
KCRM_MOUSE 43,045.6 100.0 2 2 4 6.30 
 cAMP-dependent 
protein kinase type I-
alpha regulatory 
subunit 




KAT3_MOUSE 51,127.9 100.0 5 5 8 13.00 
 Keratin, type I 
cytoskeletal 42 
K1C42_MOUSE 50,133.6 100.0 3 3 6 6.64 
 Actin, alpha cardiac 
muscle 1 
ACTC_MOUSE 42,020.1 100.0 6 7 12 20.20 
 Cytochrome b-c1 
complex subunit 2, 
mitochondrial 
QCR2_MOUSE 48,236.0 100.0 3 3 5 9.05 
 Creatine kinase S-
type, mitochondrial 
KCRS_MOUSE 47,474.7 100.0 3 3 4 11.20 
 ADP/ATP 
translocase 1 












NFS1_MOUSE 50,001.8 100.0 3 3 5 8.65 






50,114.7 100.0 10 10 18 23.30 






47,908.7 100.0 7 7 11 22.10 
 cAMP-dependent 
protein kinase type 
II-alpha regulatory 
subunit 




 ATP synthase 
subunit alpha, 
mitochondrial 











46,482.4 100.0 5 6 11 14.00 
 Actin, cytoplasmic 1 ACTB_MOUSE,
ACTG_MOUSE 










ODBA_MOUSE 50,371.5 99.9 2 3 5 6.56 
 Phosphoglycerate 
kinase 1 




CMC1_MOUSE 74,571.8 100.0 3 3 4 4.87 
 Elongation factor Tu, 
mitochondrial 




AT1B1_MOUSE 35,196.4 100.0 3 4 6 12.50 
 Trifunctional enzyme 
subunit beta, 
mitochondrial 




THIL_MOUSE 44,816.4 100.0 6 7 12 23.30 
 Sarcoplasmic/endopl
asmic reticulum 
calcium ATPase 2 
AT2A2_MOUSE 114,860.
0 
100.0 5 5 9 6.51 
 ATP synthase 
subunit beta, 
mitochondrial 




THIM_MOUSE 41,858.2 100.0 6 7 13 23.40 
 Cytochrome b-c1 
complex subunit 1, 
mitochondrial 







alpha, somatic form, 
mitochondrial 
ODPA_MOUSE 43,232.5 100.0 7 7 16 19.00 
 Beta-enolase ENOB_MOUSE 47,025.9 100.0 5 5 8 15.70 
 Aconitate hydratase, 
mitochondrial 
ACON_MOUSE 85,465.9 100.0 10 10 19 17.60 
 Creatine kinase M-
type 
KCRM_MOUSE 43,045.6 100.0 4 4 8 13.10 
 Trifunctional enzyme 
subunit alpha, 
mitochondrial 
ECHA_MOUSE 82,671.5 100.0 3 4 7 4.59 
 Eukaryotic initiation 
factor 4A-I 




G3P_MOUSE 35,810.1 100.0 3 3 5 12.90 
 cAMP-dependent 
protein kinase type I-
alpha regulatory 
subunit 
KAP0_MOUSE 43,185.8 100.0 7 9 16 19.70 
 Keratin, type I 
cytoskeletal 42 




IVD_MOUSE 46,326.5 100.0 5 5 8 13.70 
 Actin, alpha cardiac 
muscle 1 
ACTC_MOUSE 42,020.1 100.0 10 15 32 30.80 
 Cytochrome b-c1 
complex subunit 2, 
mitochondrial 
QCR2_MOUSE 48,236.0 100.0 10 12 16 28.00 
 ADP/ATP 
translocase 1 
ADT1_MOUSE 32,905.4 100.0 4 4 7 12.80 
 Creatine kinase S-
type, mitochondrial 
KCRS_MOUSE 47,474.7 100.0 8 8 12 20.50 
C6 Prohibitin PHB_MOUSE 29,820.6 100.0 4 4 7 15.80 






47,908.7 100.0 3 3 5 8.37 
 cAMP-dependent 
protein kinase type 
II-alpha regulatory 
subunit 




 ATP synthase 
subunit alpha, 
mitochondrial 











46,482.4 100.0 4 4 7 11.40 





IDHP_MOUSE 50,907.2 100.0 8 8 10 20.80 
 Mitochondrial 
carnitine/acylcarnitin
e carrier protein 
MCAT_MOUSE 33,028.2 100.0 4 4 5 13.30 
 Citrate lyase subunit 
beta-like protein, 
mitochondrial 
CLYBL_MOUSE 37,549.1 100.0 5 5 8 16.90 
 Electron transfer 
flavoprotein subunit 
alpha, mitochondrial 




LDHA_MOUSE 36,498.9 100.0 5 5 9 16.60 
 Estradiol 17-beta-
dehydrogenase 8 
DHB8_MOUSE 26,645.3 100.0 3 4 6 15.40 
 Actin, alpha cardiac 
muscle 1 
ACTC_MOUSE 42,020.1 100.0 7 8 14 21.80 
 NADH 
dehydrogenase 

















30,149.4 100.0 3 4 8 14.80 
 Electron transfer 
flavoprotein subunit 
beta 







3HIDH_MOUSE 35,440.6 100.0 4 4 8 20.00 












26,334.4 100.0 3 3 5 12.80 
 Trifunctional enzyme 
subunit beta, 
mitochondrial 




THIL_MOUSE 44,816.4 100.0 5 5 8 17.70 
 Sarcoplasmic/endopl
asmic reticulum 
calcium ATPase 2 
AT2A2_MOUSE 114,860.
0 
100.0 3 3 5 4.02 
 Apolipoprotein O-like APOOL_MOUS
E 













alpha, somatic form, 
mitochondrial 









ODPB_MOUSE 38,937.0 100.0 5 5 10 16.20 
 Dihydropteridine 
reductase 
DHPR_MOUSE 25,570.2 100.0 3 3 5 17.80 
 ATP synthase 
subunit gamma, 
mitochondrial 
ATPG_MOUSE 32,887.4 100.0 6 7 14 20.50 
 cAMP-dependent 
protein kinase type I-
alpha regulatory 
subunit 

















DHSB_MOUSE 31,815.0 100.0 5 6 11 18.40 
 Triosephosphate 
isomerase 
TPIS_MOUSE 26,712.2 100.0 3 3 3 15.70 
 Phosphate carrier 
protein, 
mitochondrial 




D3D2_MOUSE 32,079.2 100.0 4 5 10 18.70 
 Cytochrome b-c1 
complex subunit 2, 
mitochondrial 














MDHC_MOUSE 36,512.1 100.0 4 4 7 16.50 
 Myosin light chain 3 MYL3_MOUSE 22,422.2 100.0 4 5 9 27.00 
 ADP/ATP 
translocase 2 
ADT2_MOUSE 32,932.6 100.0 2 2 4 17.80 
 ADP/ATP 
translocase 1 
ADT1_MOUSE 32,905.4 100.0 12 13 24 34.90 
D1 ADP/ATP 
translocase 1 
ADT1_MOUSE 32,905.4 100.0 5 5 9 15.80 
 Actin, alpha cardiac 
muscle 1 
ACTC_MOUSE 42,020.1 100.0 5 5 10 15.40 
 Aconitate hydratase, 
mitochondrial 











 A-kinase anchor 
protein 2 





IDHP_MOUSE 50,907.2 100.0 2 2 3 3.98 
 Sarcoplasmic/endopl
asmic reticulum 
calcium ATPase 2 
AT2A2_MOUSE 114,860.
0 
100.0 11 12 23 12.30 
 A kinase anchor 
protein 1, 
mitochondrial 
AKAP1_MOUSE 92,164.5 100.0 6 6 10 12.80 
 Creatine kinase M-
type 















46,482.4 100.0 3 4 6 9.50 






47,908.7 100.0 3 3 5 8.37 
 ATP synthase 
subunit beta, 
mitochondrial 
ATPB_MOUSE 56,301.2 100.0 10 11 17 28.20 
 Trifunctional enzyme 
subunit alpha, 
mitochondrial 
ECHA_MOUSE 82,671.5 100.0 7 7 10 12.30 








100.0 11 11 20 8.98 




100.0 5 5 8 6.54 
 Keratin, type II 
cytoskeletal 1 
K2C1_MOUSE 65,607.1 100.0 3 3 6 3.77 
 cAMP-dependent 
protein kinase type I-
alpha regulatory 
subunit 


























100.0 8 8 12 10.90 
 Vinculin VINC_MOUSE 116,719.
4 











100.0 13 14 23 8.88 
 Keratin, type I 
cytoskeletal 10 
K1C10_MOUSE 57,771.3 100.0 4 4 7 6.49 
 Superoxide 
dismutase [Cu-Zn] 
SODC_MOUSE 15,941.9 100.0 2 2 4 15.60 
 cAMP-dependent 
protein kinase type 
II-alpha regulatory 
subunit 
KAP2_MOUSE 45,389.4 100.0 4 4 7 11.70 
 ATP synthase 
subunit alpha, 
mitochondrial 
ATPA_MOUSE 59,754.1 100.0 8 9 15 19.20 
 Myosin-6 MYH6_MOUSE 223,571.
2 
100.0 32 39 63 18.40 




CMC1_MOUSE 74,571.8 100.0 3 3 5 4.87 
 Sarcoplasmic/endopl
asmic reticulum 
calcium ATPase 2 
AT2A2_MOUSE 114,860.
0 
100.0 21 25 45 22.10 




100.0 4 4 7 4.67 
 ADP/ATP 
translocase 1 




LDHB_MOUSE 36,572.4 100.0 3 3 4 10.50 
 Heat shock cognate 
71 kDa protein 
HSP7C_MOUS
E 






SODC_MOUSE 15,941.9 100.0 3 3 4 22.10 
 Trifunctional enzyme 
subunit beta, 
mitochondrial 
ECHB_MOUSE 51,388.0 100.0 5 5 8 10.10 
 Carnitine O-
palmitoyltransferase 
1, muscle isoform 

















79,749.6 100.0 4 4 6 6.60 
 A kinase anchor 
protein 1, 
mitochondrial 





















100.0 14 18 28 18.60 
 Long-chain-fatty-
acid--CoA ligase 1 
ACSL1_MOUSE 77,926.2 100.0 4 4 6 6.44 
 ATP synthase 
subunit beta, 
mitochondrial 
ATPB_MOUSE 56,301.2 100.0 11 12 22 31.20 
 Fumarate hydratase, 
mitochondrial 













 ATP synthase 
subunit alpha, 
mitochondrial 






100.0 3 3 3 2.05 
 Actin, alpha cardiac 
muscle 1 
ACTC_MOUSE 42,020.1 100.0 7 9 17 23.10 
 ATP synthase 
subunit gamma, 
mitochondrial 
ATPG_MOUSE 32,887.4 99.9 2 2 3 7.38 
 Keratin, type I 
cytoskeletal 10 
K1C10_MOUSE 57,771.3 100.0 3 3 6 5.61 




73,529.1 100.0 3 3 5 5.89 
 Hexokinase-2 HXK2_MOUSE 102,536.
6 
100.0 6 6 8 8.51 
 Creatine kinase M-
type 
KCRM_MOUSE 43,045.6 100.0 3 3 5 9.45 
 Heat shock protein 
HSP 90-beta 
HS90B_MOUSE 83,328.4 100.0 5 5 7 8.56 





100.0 4 4 5 5.16 
 LIM domain-binding 
protein 3 
LDB3_MOUSE 76,432.1 100.0 3 3 5 4.84 
 Hexokinase-1 HXK1_MOUSE 108,304.
7 
100.0 3 3 4 4.31 
 cAMP-dependent 
protein kinase type I-
alpha regulatory 
subunit 
KAP0_MOUSE 43,185.8 100.0 10 11 21 32.00 
































100.0 12 12 19 15.60 






70,877.0 100.0 4 4 6 7.62 
 Myosin-6 MYH6_MOUSE 223,571.
2 
100.0 14 15 21 8.82 
 Aconitate hydratase, 
mitochondrial 
ACON_MOUSE 85,465.9 100.0 15 19 36 23.60 
 Sarcalumenin SRCA_MOUSE 99,186.0 100.0 4 4 6 4.95 
 Citrate synthase, 
mitochondrial 
CISY_MOUSE 51,738.1 100.0 3 3 5 6.47 
 cGMP-dependent 
protein kinase 1 
















IDHP_MOUSE 50,907.2 100.0% 6 6 11 15.50 
 Trifunctional enzyme 
subunit alpha, 
mitochondrial 
ECHA_MOUSE 82,671.5 100.0 9 9 16 15.20 
 cAMP-dependent 
protein kinase type 
II-alpha regulatory 
subunit 
KAP2_MOUSE 45,389.4 100.0 7 7 11 24.40 
D3 ADP/ATP 
translocase 1 
ADT1_MOUSE 32,905.4 100.0 3 3 6 8.72 
 cAMP-dependent 
protein kinase type 
II-alpha regulatory 
subunit 
KAP2_MOUSE 45,389.4 100.0 15 22 41 43.90 
 Pyruvate kinase 
isozymes M1/M2 












MDHM_MOUSE 35,611.9 100.0 3 3 4 9.47 
 Actin, alpha cardiac 
muscle 1 















46,482.4 100.0 3 4 6 9.03 
 Succinyl-CoA:3-
ketoacid-coenzyme 

















ODP2_MOUSE 67,942.6 100.0 3 4 7 7.79 
 Long-chain-fatty-
acid--CoA ligase 1 
ACSL1_MOUSE 77,926.2 100.0 9 9 15 13.60 
 Sarcoplasmic/endopl
asmic reticulum 
calcium ATPase 2 
AT2A2_MOUSE 114,860.
0 
100.0 9 10 18 10.50 
 Sarcalumenin SRCA_MOUSE 99,186.0 100.0 6 6 11 8.90 
 ATP synthase 
subunit beta, 
mitochondrial 




ALDH2_MOUSE 56,537.6 100.0 4 4 6 8.67 
 cGMP-dependent 
protein kinase 1 
KGP1_MOUSE 76,353.9 100.0 3 3 4 5.51 
 Epoxide hydrolase 2 HYES_MOUSE 62,516.8 100.0 3 3 6 5.96 
 Phosphate carrier 
protein, 
mitochondrial 










47,908.7 100.0 3 3 4 7.91 









DLDH_MOUSE 54,272.4 100.0 5 6 9 11.40 
 Tubulin beta-2C 
chain 
TBB2C_MOUSE 49,830.7 100.0 6 6 10 14.40 
 Vimentin VIME_MOUSE 53,688.8 100.0 4 4 5 9.01 
 Trifunctional enzyme 
subunit alpha, 
mitochondrial 
ECHA_MOUSE 82,671.5 100.0 8 10 17 14.80 
 Fumarate hydratase, 
mitochondrial 






DHSA_MOUSE 72,585.6 100.0 5 5 8 9.34 
 cAMP-dependent 
protein kinase type 
II-beta regulatory 
subunit 
KAP3_MOUSE 46,167.7 100.0 3 3 6 22.60 
 cAMP-dependent 
protein kinase type I-
alpha regulatory 
subunit 
KAP0_MOUSE 43,185.8 100.0 14 18 40 34.10 
 Heat shock cognate 
71 kDa protein 
HSP7C_MOUS
E 








PCCB_MOUSE 58,394.5 100.0 6 6 11 14.40 
 Cytochrome b-c1 
complex subunit 1, 
mitochondrial 










 ATP synthase 
subunit alpha, 
mitochondrial 
ATPA_MOUSE 59,754.1 100.0 11 13 22 23.10 
 Aconitate hydratase, 
mitochondrial 
ACON_MOUSE 85,465.9 100.0 12 13 24 16.70 
 Tubulin alpha-4A 
chain 







79,749.6 100.0 2 2 2 3.58 
 Trifunctional enzyme 
subunit beta, 
mitochondrial 
ECHB_MOUSE 51,388.0 100.0 8 9 15 18.30 
 Acetyl-coenzyme A 
synthetase 2-like, 
mitochondrial 




CMC1_MOUSE 74,571.8 100.0 3 3 6 4.73 
 Carnitine O-
palmitoyltransferase 
1, muscle isoform 




alpha, somatic form, 
mitochondrial 
ODPA_MOUSE 43,232.5 100.0 3 3 6 7.18 





100.0 3 3 6 1.74 
 Adenylosuccinate 
lyase 
PUR8_MOUSE 54,809.3 100.0 2 2 2 4.13 
D4 ATP synthase 
subunit beta, 
mitochondrial 
ATPB_MOUSE 56,301.2 100.0 3 3 5 7.37 
 26S protease 
regulatory subunit 8 
PRS8_MOUSE 45,627.2 100.0 3 3 3 9.61 
 Creatine kinase S-
type, mitochondrial 
KCRS_MOUSE 47,474.7 100.0 7 8 11 17.40 
 Beta-enolase ENOB_MOUSE 47,025.9 100.0 8 10 17 23.00 
 Phosphoglycerate 
kinase 1 













THIM_MOUSE 41,858.2 100.0 2 3 5 8.31 
 Carnitine O-
palmitoyltransferase 
1, muscle isoform 
CPT1B_MOUSE 88,220.0 100.0 2 2 4 2.85 
 Sarcoplasmic/endopl
asmic reticulum 
calcium ATPase 2 
AT2A2_MOUSE 114,860.
0 
100.0 10 11 18 11.80 
 Cytochrome b-c1 
complex subunit 1, 
mitochondrial 
QCR1_MOUSE 52,768.8 100.0 6 6 11 15.40 
 Elongation factor Tu, 
mitochondrial 














52,626.8 100.0 3 3 6 6.05 
 Long-chain-fatty-
acid--CoA ligase 1 
ACSL1_MOUSE 77,926.2 100.0 5 5 8 7.01 
 Keratin, type I 
cytoskeletal 10 







46,482.4 100.0 4 5 9 11.60 






70,877.0 100.0 2 2 4 3.20 
 Fumarate hydratase, 
mitochondrial 
FUMH_MOUSE 54,371.1 100.0 3 3 5 10.50 
 Creatine kinase M-
type 
KCRM_MOUSE 43,045.6 100.0 3 3 6 9.45 

















LDHB_MOUSE 36,572.4 100.0 3 3 6 10.50 
 Citrate synthase, 
mitochondrial 
CISY_MOUSE 51,738.1 100.0 4 4 5 9.91 





ETFD_MOUSE 68,091.8 100.0 4 4 7 7.31 
 cAMP-dependent 
protein kinase type 
II-alpha regulatory 
subunit 











PDK2_MOUSE 46,070.1 100.0 5 5 5 16.50 
 Actin, alpha cardiac 
muscle 1 
ACTC_MOUSE 42,020.1 100.0 9 9 17 28.40 
 ADP/ATP 
translocase 1 
ADT1_MOUSE 32,905.4 100.0 6 6 10 20.10 






47,908.7 100.0 7 7 12 20.00 
 Aconitate hydratase, 
mitochondrial 





ODBA_MOUSE 50,371.5 99.9 2 2 4 6.56 
 Eukaryotic initiation 
factor 4A-I 
IF4A1_MOUSE 46,155.3 100.0 7 7 10 19.70 
 Cytochrome b-c1 
complex subunit 2, 
mitochondrial 
QCR2_MOUSE 48,236.0 100.0 8 8 15 22.30 
 Trifunctional enzyme 
subunit alpha, 
mitochondrial 






SAHH_MOUSE 47,689.1 99.9 2 2 3 5.56 
 ATP synthase 
subunit alpha, 
mitochondrial 
ATPA_MOUSE 59,754.1 100.0 8 8 13 18.40 
 cAMP-dependent 
protein kinase type I-
alpha regulatory 
subunit 




alpha, somatic form, 
mitochondrial 
ODPA_MOUSE 43,232.5 100.0 5 5 8 13.80 
 Trifunctional enzyme 
subunit beta, 
mitochondrial 
ECHB_MOUSE 51,388.0 100.0 7 7 11 16.20 










CMC1_MOUSE 74,571.8 100.0 6 6 10 10.90 
D5 cAMP-dependent 
protein kinase type 
II-alpha regulatory 
subunit 









AATM_MOUSE 47,412.3 100.0 3 3 5 6.28 
 Aconitate hydratase, 
mitochondrial 




THIL_MOUSE 44,816.4 100.0 9 12 19 29.50 





ETFD_MOUSE 68,091.8 100.0 3 3 6 5.52 
 Actin, alpha cardiac 
muscle 1 
ACTC_MOUSE 42,020.1 100.0 16 21 46 55.70 












ADT1_MOUSE 32,905.4 100.0 5 5 8 15.80 
 Trifunctional enzyme 
subunit alpha, 
mitochondrial 
ECHA_MOUSE 82,671.5 100.0 3 3 6 5.37 
 ATP synthase 
subunit beta, 
mitochondrial 




G3P_MOUSE 35,810.1 100.0 3 3 6 12.90 
 Creatine kinase M-
type 
KCRM_MOUSE 43,045.6 100.0 4 4 7 13.10 
 Sarcoplasmic/endopl
asmic reticulum 
calcium ATPase 2 
AT2A2_MOUSE 114,860.
0 
100.0 5 6 9 6.32 
 Citrate synthase, 
mitochondrial 








MPI_MOUSE 46,575.9 100.0 3 3 5 10.20 
 Elongation factor Tu, 
mitochondrial 
EFTU_MOUSE 49,508.9 100.0 3 3 3 8.41 
 NADH 
dehydrogenase 





40,604.7 100.0 5 5 7 20.00 
 Actin, cytoplasmic 1 ACTB_MOUSE,
ACTG_MOUSE 
41,737.8 100.0 3 4 7 37.90 










NFS1_MOUSE 50,001.8 100.0 2 2 3 4.66 
 Phosphate carrier 
protein, 
mitochondrial 
MPCP_MOUSE 39,633.1 100.0 2 2 4 7.28 
 Creatine kinase S-
type, mitochondrial 
KCRS_MOUSE 47,474.7 100.0 5 5 5 14.80 
 Long-chain-fatty-
acid--CoA ligase 1 




 ATP synthase 
subunit alpha, 
mitochondrial 


















DHSA_MOUSE 72,585.6 100.0 4 4 8 7.23 
 cAMP-dependent 
protein kinase type I-
alpha regulatory 
subunit 















IDHP_MOUSE 50,907.2 100.0 7 8 12 19.20 
 Cytochrome b-c1 
complex subunit 2, 
mitochondrial 
QCR2_MOUSE 48,236.0 100.0 11 16 27 30.50 
 Phosphoglycerate 
kinase 1 





ODPB_MOUSE 38,937.0 100.0 3 3 4 10.00 
 cAMP-dependent 
protein kinase type I-
alpha regulatory 
subunit 











alpha, somatic form, 
mitochondrial 



























BDH_MOUSE 38,286.0 100.0 3 3 4 11.40 
 ADP/ATP 
translocase 2 
ADT2_MOUSE 32,932.6 100.0 3 3 4 22.50 
 Electron transfer 
flavoprotein subunit 
alpha, mitochondrial 
ETFA_MOUSE 35,009.8 100.0 6 8 14 27.30 
 Actin, alpha cardiac 
muscle 1 












M2OM_MOUSE 34,156.3 100.0 6 6 10 22.30 
 Triosephosphate 
isomerase 




MDHM_MOUSE 35,611.9 100.0 4 4 7 13.30 
 ATP synthase 
subunit alpha, 
mitochondrial 
ATPA_MOUSE 59,754.1 100.0 7 8 16 17.40 
 ADP/ATP 
translocase 1 
ADT1_MOUSE 32,905.4 100.0 14 15 26 40.30 
 Sepiapterin 
reductase 
SPRE_MOUSE 27,883.8 100.0 3 4 6 18.00 
 Sarcoplasmic/endopl
asmic reticulum 
calcium ATPase 2 
AT2A2_MOUSE 114,860.
0 




 Citrate lyase subunit 
beta-like protein, 
mitochondrial 
CLYBL_MOUSE 37,549.1 100.0 3 3 5 9.76 





100.0 3 3 4 2.28 
 ATP synthase 
subunit gamma, 
mitochondrial 
ATPG_MOUSE 32,887.4 100.0 4 5 12 15.80 
 Aconitate hydratase, 
mitochondrial 
ACON_MOUSE 85,465.9 100.0 3 4 6 5.26 
 Cytochrome b-c1 
complex subunit 2, 
mitochondrial 












D3D2_MOUSE 32,079.2 100.0 3 4 7 13.50 
 cAMP-dependent 
protein kinase type 
II-alpha regulatory 
subunit 














DHSA_MOUSE 72,585.6 100.0 3 4 7 5.27 
 Trifunctional enzyme 
subunit alpha, 
mitochondrial 
ECHA_MOUSE 82,671.5 100.0 4 5 7 7.08 
 Trifunctional enzyme 
subunit beta, 
mitochondrial 
ECHB_MOUSE 51,388.0 100.0 6 6 10 14.30 










 Electron transfer 
flavoprotein subunit 
beta 








LDHA_MOUSE 36,498.9 100.0 3 3 5 8.73 
 ATP synthase 
subunit beta, 
mitochondrial 








THIM_MOUSE 41,858.2 100.0 7 9 14 25.70 
 Estradiol 17-beta-
dehydrogenase 8 
DHB8_MOUSE 26,645.3 100.0 3 4 6 15.40 
 Phosphate carrier 
protein, 
mitochondrial 
MPCP_MOUSE 39,633.1 100.0 10 13 19 23.80 

















Appendix B. Proteins of which abundance increased or decreased with H2O2 in WT 
capture but not KI capture. cAMP affinity capture samples were run on a gradient gel and 
the gel was stained with colloidal Coomassie. Selected stained bands were cut out of the 
gel and analysed by LC-MS/MS. The table lists identified proteins in which abundance 
increased or decreased between control and H2O2-treated WT hearts but not between KI 
control and H2O2-treated hearts. The accession no., molecular weight (Mw) and no. of 
assigned spectra for each capture sample are also shown. 
   
    
Displaying: no. of assigned spectra 
  
WT WT KI KI 
Identified proteins Accession no. 
Mw 
(kDa) control H2O2 control H2O2 
Aspartate aminotransferase, mitochondrial AATM_MOUSE 47 11 8 17 17 
Medium-chain specific acyl-CoA dehydrogenase, 
mitochondrial ACADM_MOUSE 46 44 28 41 45 
Very long-chain specific acyl-CoA dehydrogenase, 
mitochondrial ACADV_MOUSE 71 8 4 17 16 
ATP-citrate synthase ACLY_MOUSE 120 0 4 0 0 
A kinase anchor protein 1, mitochondrial AKAP1_MOUSE 92 12 23 18 18 
A-kinase anchor protein 2 AKAP2_MOUSE 99 0 13 6 8 
ATP synthase subunit alpha, mitochondrial ATPA_MOUSE 60 90 74 99 98 
Citrate lyase subunit beta-like protein, mitochondrial CLYBL_MOUSE 38 5 11 8 5 
Ubiquinone biosynthesis methyltransferase COQ5, 
mitochondrial COQ5_MOUSE 37 3 7 1 3 
Estradiol 17-beta-dehydrogenase 8 DHB8_MOUSE 27 6 3 6 6 
Dihydrolipoyl dehydrogenase, mitochondrial DLDH_MOUSE 54 10 5 10 13 
Fatty acid synthase FAS_MOUSE 272 1 15 2 4 
Lactation elevated protein 1 LACE1_MOUSE 54 0 3 0 0 
NADH dehydrogenase [ubiquinone] 1 alpha 
subcomplex subunit 9, mitochondrial NDUA9_MOUSE 43 0 10 4 0 
Dihydrolipoyllysine-residue acetyltransferase 
component of pyruvate dehydrogenase complex, 
mitochondrial ODP2_MOUSE 68 14 7 15 14 
Pyruvate dehydrogenase E1 component subunit 
beta, mitochondrial ODPB_MOUSE 39 16 12 20 19 
Phosphoglycerate kinase 1 PGK1_MOUSE 45 25 19 26 36 
26S protease regulatory subunit 7 PRS7_MOUSE 49 0 3 0 0 




Valyl-tRNA synthetase SYVC_MOUSE 140 4 9 1 0 
Tetratricopeptide repeat protein 38 TTC38_MOUSE 52 0 3 0 0 
Voltage-dependent anion-selective channel protein 










































Appendix C. Proteins of which abundance was significantly (p<0.05) different 
between WT and KI capture samples. cAMP affinity capture samples were run on a 
gradient gel and the gel was stained with colloidal Coomassie. Selected stained bands were 
cut out of the gel and analysed by LC-MS/MS. The table lists identified proteins in which 
abundance was significantly (p<0.05) different between WT (control and H2O2-treated) and 
KI (control and H2O2-treated) hearts. The accession no., molecular weight (Mw) and no. of 
assigned spectra for each capture sample are shown as well as the p-value from a Fishers 
Exact Test. 
    
    
Displaying: no. of assigned 
spectra 
  
WT vs KI WT WT KI KI 





value) control H2O2 control H2O2 
Aspartate aminotransferase, 
mitochondrial AATM_MOUSE 47 0.033 11 8 17 17 
Long-chain specific acyl-CoA 
dehydrogenase, mitochondrial ACADL_MOUSE 48 0.038 40 25 35 51 
Very long-chain specific acyl-CoA 
dehydrogenase, mitochondrial ACADV_MOUSE 71 0.00039 8 4 17 16 
Aconitate hydratase, mitochondrial ACON_MOUSE 85 2.5E-11 74 61 116 127 
Acetyl-coenzyme A synthetase 2-
like, mitochondrial ACS2L_MOUSE 75 0.018 0 2 2 9 
Long-chain-fatty-acid--CoA ligase 1 ACSL1_MOUSE 78 0.000000033 4 8 15 38 
Actin, alpha cardiac muscle 1 ACTC_MOUSE 42 0.0044 85 83 98 118 
Aldehyde dehydrogenase X, 
mitochondrial AL1B1_MOUSE 58 0.03 0 0 3 3 
Sarcoplasmic/endoplasmic 
reticulum calcium ATPase 2 AT2A2_MOUSE 115 0.0000037 81 74 97 122 
ATP synthase subunit alpha, 
mitochondrial ATPA_MOUSE 60 0.028 90 74 99 98 
Coiled-coil-helix-coiled-coil-helix 
domain-containing protein 3, 
mitochondrial CHCH3_MOUSE 26 0.024 13 13 5 8 
Clathrin heavy chain 1 CLH_MOUSE 192 0.042 8 9 2 4 
Calcium-binding mitochondrial 
carrier protein Aralar1 CMC1_MOUSE 75 0.0000059 3 6 13 25 
Ubiquinone biosynthesis 
methyltransferase COQ5, 
mitochondrial COQ5_MOUSE 37 0.041 3 7 1 3 
Carnitine O-palmitoyltransferase 1, 




Cytochrome c1, heme protein, 
mitochondrial CY1_MOUSE 35 0.00031 11 14 4 2 
Dehydrogenase/reductase SDR 
family member 4 DHRS4_MOUSE 28 0.02 4 5 0 2 
Succinate dehydrogenase 
[ubiquinone] flavoprotein subunit, 
mitochondrial DHSA_MOUSE 73 0.0000068 11 9 23 35 
Cytoplasmic dynein 1 heavy chain 1 DYHC1_MOUSE 532 0.011 7 3 0 1 
Trifunctional enzyme subunit alpha, 
mitochondrial ECHA_MOUSE 83 0.00000069 38 26 50 75 
Elongation factor Tu, mitochondrial EFTU_MOUSE 50 0.049 22 25 16 18 
Alpha-enolase ENOA_MOUSE 47 0.013 12 12 9 3 
Beta-enolase ENOB_MOUSE 47 0.034 41 37 36 22 
Electron transfer flavoprotein 
subunit alpha, mitochondrial ETFA_MOUSE 35 0.043 13 14 21 22 
Electron transfer flavoprotein-
ubiquinone oxidoreductase, 
mitochondrial ETFD_MOUSE 68 0.0000032 5 7 20 24 
Stress-70 protein, mitochondrial GRP75_MOUSE 74 0.0029 0 1 5 7 
Heat shock protein HSP 90-beta HS90B_MOUSE 83 0.036 4 3 7 9 
Heat shock cognate 71 kDa protein HSP7C_MOUSE 71 3.5E-10 0 0 11 21 
Hexokinase-2 HXK2_MOUSE 103 0.00011 24 25 7 8 
Isocitrate dehydrogenase [NADP], 
mitochondrial IDHP_MOUSE 51 0.022 127 133 121 95 
Uncharacterized protein KIAA0564 
homolog K0564_MOUSE 213 0.00000053 33 38 9 9 
Protein KIAA0664 K0664_MOUSE 148 0.022 9 7 3 2 
cAMP-dependent protein kinase 
type I-alpha regulatory subunit KAP0_MOUSE 43 0.00045 144 179 131 112 
cAMP-dependent protein kinase 
type I-beta regulatory subunit KAP1_MOUSE 43 0.0000017 3 10 6 2 
cGMP-dependent protein kinase 1 KGP1_MOUSE 76 0.00066 0 4 6 12 
L-lactate dehydrogenase B chain LDHB_MOUSE 37 0.0033 6 8 15 19 
Methylmalonate-semialdehyde 
dehydrogenase [acylating], 
mitochondrial MMSA_MOUSE 58 0.029 16 22 10 15 
Myosin-6 MYH6_MOUSE 224 0.00000042 61 57 94 84 




NADH dehydrogenase [ubiquinone] 
1 alpha subcomplex subunit 9, 
mitochondrial NDUA9_MOUSE 43 0.041 0 10 4 0 
NADH-ubiquinone oxidoreductase 
75 kDa subunit, mitochondrial NDUS1_MOUSE 80 0.0065 3 4 9 12 
NADH dehydrogenase [ubiquinone] 
iron-sulfur protein 2, mitochondrial NDUS2_MOUSE 53 0.032 17 16 13 7 
Phosphoglycerate kinase 1 PGK1_MOUSE 45 0.036 25 19 26 36 
Presequence protease, 
mitochondrial PREP_MOUSE 117 0.021 2 8 1 0 
Pyruvate carboxylase, mitochondrial PYC_MOUSE 130 0.0000063 9 15 0 1 
Cytochrome b-c1 complex subunit 
1, mitochondrial QCR1_MOUSE 53 0.0033 30 34 21 17 
Valyl-tRNA synthetase SYVC_MOUSE 140 0.0034 4 9 1 0 
3-ketoacyl-CoA thiolase, 
mitochondrial THIM_MOUSE 42 0.012 33 31 39 53 
Triosephosphate isomerase TPIS_MOUSE 27 0.011 16 9 3 7 
 
 
 
 
 
